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Abstract 
Streptococcus pneumoniae (the pneumococcus) is an important human pathogen responsible for 
life threatening invasive diseases such as pneumonia, septicaemia and meningitis, as well as less 
severe but highly prevalent infections. Despite the availability of antibiotics and a vaccine, 
pneumococcal infection contributes significantly to human mortality worldwide. There is a need 
for a greater understanding of the molecular mechanisms of pathogenicity of this pathogen, 
which will enable the development of novel therapeutic targets and vaccine candidates. 
This thesis aimed to evaluate the contribution of several pneumococcal two-component systems 
to virulence by analysis of null mutants in a murine model of infection. In addition, a putative 
zinc metalloprotease, ZmpB, located immediately downstream of one of the TCS, was analysed 
for its role in virulence. 
Data indicated that one of the systems studied, TCS08, does not contribute significantly to 
virulence in serotype 2 pneumococcus, but may have a slightly more important role in a serotype 
3 background. A second two-component system, TCS09, was found to be essential for virulence 
in a serotype 2. Despite the completely avirulent phenotype of the mutant, no difference in 
expression of many of the previously identified pneumococcal virulence-associated genes was 
detected in the mutant compared to its isogenic parental strain. Microarray analysis indicated that 
in serotype 2, TCS09 may be involved in nutrient perception. TCS09 was found to be required 
for full virulence in a serotype 3 strain. In this strain, mutants appeared to be impaired in their 
ability to disseminate from the lungs to the blood in a pneumonia model of infection, but were 
not attenuated in virulence following direct inoculation into the systemic circulation. These data 
provide evidence that virulence determinants can behave differently based on the genetic 
background of the parental strain. 
ZmpB was found to contribute significantly to pneumococcal virulence in a serotype 2 strain. 
Further analysis of the contribution of this protein to infection found that ZmpB appears to have 
a role in promoting inflammation. Thus this work has identified ZmpB as being a novel 
pneumococcal virulence factor. The role of this protein in inflammation is being investigated 
further. 
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This thesis has thus identified several genes important in the virulence of S. pneumoniae and 
work is currently ongoing to assess the potential of these genes as future vaccine or drug 
candidates. Data presented within this work also provides evidence that virulence determinants 
can behave differently based on the genetic background of the parent bacterial strain. This 
important observation could have significant implications for the future characterisation of 
pneumococcal virulence factors and may apply to other bacterial pathogens. 
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Part 1: Streptococcus pneumoniae 
Chapter 1 Introduction 
1.1 Overview of Streptococcus pneumoniae 
Streptococcus pneumoniae (the pneumococcus) is a Gram-positive, facultatively anaerobic 
bacterium, that is an important human pathogen. The bacterium was first identified in 1880 
independently by Pasteur and Sternberg (Davis et at., 1990), and since has been studied 
extensively which has led to important scientific discoveries. The principle of transformation 
was first identified in the pneumococcus and this led to the discovery of nucleic acid as the 
hereditary material (Avery et at., 1944). Initial studies with penicillin and bacterial 
polysaccharide capsules were also carried out with the pneumococcus (Alonso De Velasco et at., 
1995). 
There are several tests available for identifying S. pneumoniae (Gillespie, 1994 and Kellogg et 
at., 2001). When grown on blood agar, colonies display a characteristic draughtsman-like 
appearance and produce a zone of a-haemolysis. Staining with Gram's stain reveals dark, 
coccoid cells that are present singly, in pairs or in short chains. Sensitivity of S. pneumoniae to 
optochin (hydro cupreine hydrochloride) can be used to distinguish the pneumococcus from other 
viridans Streptococcus (Gardam and Miller, 1998). Solubility in bile / deoxycholate and several 
biochemical tests are often used in diagnostic laboratories for the identification of S. 
pneumoniae. Generally, several tests are used in combination as individual tests may result in 
erroneous identification. For example, optochin sensitivity is thought to be over 98 % sensitive 
with a specificity of 100 % (Kellogg et at., 2001), but atypical isolates have been identified that 
are resistant to optochin (Borek et at., 1997). peR using known S. pneumoniae genes, such as 
pneumolysin, may be used, but pneumolysin has been identified in other Streptococcal species 
(Keams et at., 2000). 
Over 90 different serotypes of S. pneumoniae exist and these are classified by differences in the 
chemical structure of the polysaccharide capsule that surrounds the organism (Kalin, 1998). The 
capsule serotype can have a large influence on the virulence of the organism, and certain 
serotypes are more frequently associated with clinical disease than others. Thus, it is necessary to 
be able to distinguish between serotypes. The Quellung reaction is a simple test that involves 
mixing serotype-specific anti-capsule antisera with bacterial cultures. The presence of capsule is 
detected by swelling and clumping of organisms which is attributed to the binding of capsule-
specific antibody. Recently, multilocus sequence typing (MLST) has been applied to the typing 
of S. pneumoniae (Enright and Spratt, 1998). This technique involves sequencing seven selected 
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housekeeping genes and analysing results using a database to obtain an allelic profile. The 
method can distinguish between pneumococcal strains and has been useful for identifying 
virulent and antibiotic resistant clones ofthe pneumococcus (Enright and Spratt, 1999). 
1.2 S. pneumoniae as a human pathogen 
1.2.1 Carriage 
S. pneulnoniae is primarily a human pathogen, although horses may also become infected 
(Benson and Sweeney, 1984). The situation with equine infection is interesting as, unlike in 
human infection, all isolates are serotype 3 and appear to form a clonal group. These isolates are 
virtually identical to each other but genetically distinguishable from human type 3 isolates which 
suggests that they may have been acquired from humans relatively recently (Whatmore et at., 
1999). Furthermore, equine isolates appear to lack pneumolysin and autolysin activities, two 
virulence factors thought to be important in human pneumococcal infection (Whatmore et at., 
1999). It is not known if equine isolates can infect humans, and vice versa, but studies have 
shown that farmworkers are usually colonised with pneumococcal serotypes distinct from that 
found in horses, suggesting that cross-infection does not occur (Burrell et at., 1986). 
In humans, S. pneulnoniae asymptomatic ally colonises the upper respiratory tract (UR T) of 
healthy individuals. Virtually all individuals are thought to be colonised at some stage and 
carriage rates may exceed 70 % in some areas. Carriage rates are higher in young children or in 
environments where crowding is present (Obaro and Adegbola, 2002). Carriage generally results 
in an antibody-mediated immune response that is capable of eliminating the organism, and this 
response is serotype-specific. However, in some individuals, carriage can result in infection and 
this is thought to be due to a recently acquired serotype rather than one that has been present 
asymptomatic ally for some time (Obaro and Adegbola, 2002). Infection and carriage is spread by 
aerosols and is acquired via the respiratory tract. 
1.2.2 Human disease 
S. pneumoniae can cause a range of illnesses and these can be grouped into upper respiratory 
tract infections (URTI) , lower respiratory tract infections (LRTI) and disseminated / invasive 
infection. Of these otitis media, pneumonia, septicaemia and meningitis are the most prevalent. 
Table 1.1 lists other disease states that have been attributed to pneumococcal infection. Many of 
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these result from complications following systemic infection and although they are generally rare 
they can dramatically increase the seriousness of the disease. Nevertheless, 4 % of all cases of 
septic arthritis and osteomyelitis in children are attributed to S. pneumoniae (Tan, 2000). 
Infection Disease state Ref. 
URT Otitis media Tuomanen, 2001 
Sinusitis Conrad and Jenson, 2002 
LRT Pneumonia Kayhty and Esko1a, 1996 
Invasive Septicaemia Kayhty and Eskola, 1996 
Meningitis Meli et al., 2002 
Haemolytic uremic syndrome Brandt et al., 2002 
Osteomyelitis Tan, 2000 
Cellulitis Parada and Maslow, 1999 
Pericarditis Tan, 2000 
Endocarditis Tan, 2000 
Septic arthritis Peters et al., 2000 
Table 1.1 Diseases caused by S. plleunloll;ae 
Pneumonia, otitis media, septicaemia and meningitis are the most common infections caused by S. 
pneumoniae. Other infections generally arise following bloodstream infection and often occur as isolated 
cases. 
1.2.3 Factors predisposing to infection 
Invasive pneumococcal disease is rare in immunocompetent individuals. The immune system is 
very efficient in clearing pneumococcal infection, so those most at risk have underlying 
conditions that weaken the immune system. Infants under the age of 2 years and elderly persons 
over 65 years of age have an increased risk of pneumococcal infection and these are the groups 
in which pneumococcal disease is most prevalent (figure 1.1). Other at-risk groups include 
splenectomised patients or those with a spleen defect, HIV -infected patients and other 
immunocompromised individuals (Parsons and Dockrell, 2002). Patients with sickle-cell 
anaemIa are particularly susceptible to pneumococcal infections, possibly due to the 
accumulation of sickle cells in the liver and spleen, which may inhibit normal functioning 
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(Kumar and Clark, 1998). IgG2 deficiencies are frequently associated with infections with 
encapsulated bacteria, such as S. pneumoniae and Haemophilus injluenzae as this is the 
predominant antibody class produced in response to polysaccharide antigens (Escobar-Perez et 
ai., 2000). Alcoholism and smoking may also predispose to pneumococcal infection. There also 
appears to be a genetic basis for susceptibility to infection as some ethnic groups such as black 
Americans, Alaskan natives and certain American-Indian populations are at higher risk than 
others for developing pneumococcal disease (Schoenmaker et ai., 2002). However, this could 
also be due to socio-economic factors such as alcoholism, low education/health care, higher 
incidence of AIDS, sickle-cell disease. 
A recent episode of viral infection, particularly with adenovirus or influenza virus, is another 
factor predisposing to disease. In such circumstances it is thought that prior infection exposes 
hosts ligands that can enhance adhesion of the pneumococcus (Hakansson et ai., 1994). 
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Figure 1.1 Incidence of pneumococcal invasive disease with age 
The figure shows that the incidence of invasive disease is highest at the extremes of age. Data is taken from 
mean annual incidence in England and Wales between 1995 and 1997. Modified from Sleeman et al., 2001. 
1.2.4 Epidemiology 
Epidemiology of pneumococcal disease is complicated, varying both geographically and within 
populations. Exact figures for disease may depend on differences in identification and reporting 
strategies and is further complicated by the range of other pathogens with the ability to induce 
similar symptoms to those observed in pneumococcal infection and the difficulty in obtaining 
appropriate samples for microbiological diagnosis. 
S. pneumoniae causes significant morbidity and mortality world wide, particularly among young 
children and the elderly. Disease is largely endemic, although epidemics may occur in conditions 
of crowding and institutional settings, such as military camps (Gray et ai., 1999). The 
pneumococcus is the major cause of acute bacterial pneumonia, otitis media and sinusitis, and is 
a significant cause of meningitis (Kalin, 1998). It is estimated that over 1 million deaths occur 
each year in children under the age of 5 due to S. pneumoniae (Hausdorff et ai., 2000a). A large 
proportion of these deaths occur in developing countries. In the United States, pneumococcal 
infection causes approximately 40,000 deaths each year, making it one of the top 10 causes of 
death. A significant proportion of these deaths are thought to be preventable by the 23-valent 
vaccine. Meningitis and bacteraemia have the highest case fatality rates, especially in those most 
susceptible to disease. Pneumococcal meningitis, when not fatal, can result in serious 
neurological sequelae such as loss of hearing in up to 50 % of survivors (Meli et ai., 2002). 
Although non-invasive infections are associated with lower mortality, these infections still 
contribute significantly to morbidity and are a huge burden for health trusts due to the costs 
involved in treating such infections. It is estimated that 30 % of all children under the age of 5 
years are seen annually by general practitioners in the UK, with the majority of these infections 
being caused by S. pneumoniae (Choo and Finn, 2001). 
Within the UK, case fatality may be as high as 38 % (with pneumococcal meningitis), despite the 
use of appropriate antimicrobial agents (Kyaw et ai., 2002a). In Scotland an increase in the 
annual incidence of invasive disease was reported between 1988 and 1999, together with an 
increase in the prevalence of antibiotic non-susceptible isolates (Kyaw et ai., 2002a). This 
highlights the clinical impact of this human pathogen, despite the availability of antibiotics and 
vaccmes. 
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Although most, if not all, capsular serotypes have been associated with clinical infection, some 
serotypes are more commonly associated with infection than others. Furthermore, serotypes 
prevalent in invasive disease vary geographically, may depend on age, and also have been shown 
to change over time. Studies have shown that types 1, 2 and 3 accounted for up to 75 % of 
bacteraemic cases in the US and Europe during the beginning of the 20th century (Kalin, 1998). 
However, serotypes 1 and 2 are now rarely isolated from clinical infections, with type 2 being 
uncommon in all geographical regions for several decades. The reason for alterations in serotype 
prevalence over time are not fully understood but could be due to different socioeconomic 
circumstances, availability of antimicrobials, underlying medical conditions or the prevalence of 
other pathogens. Capsule switching between strains has also been reported and could contribute 
to infections with strains previously thought to have low incidence of infection (Coffey et al., 
1998). In the United States, types 6B, 14, 18C and 19F are prevalent in young children, but 
serotype distribution in adults tends to be more evenly spread and includes a greater number of 
serotypes (Kalin, 1998). Despite having similar populations, the serotypes causing disease in the 
UK differ to those prevalent in the United States. A wider range of serotypes causing disease is 
present in developing countries than in developed countries. The virulent serotype 3 that is often 
found to be associated with fatal illness predominates in Spain and the United States (Wuorimaa 
and Kayhty, 2002). One study even highlights the contribution of specific serotypes to different 
disease manifestations (Haustdorff et al., 2000b). 
1.3 Vaccines 
1.3.1 Polysaccharide vaccine 
The pneumococcal polysaccharide capsule is a major virulence determinant and anti-capsular 
immunoglobulin (Ig) G2 antibodies are an important host response in clearing pneumococcal 
infection (Catterall, 1999). The immunogenicity of a vaccine preparation depends on the 
antibody titres and antibody affinity induced, although the levels of antibody required for 
protection against pneumococcal disease are yet to be determined. As only a small proportion of 
the 90 pneumococcal serotypes cause disease in humans, current vaccines contain preparations 
of capsular material from disease-associated serotypes. A pneumococcal vaccine comprising 
purified polysaccharide preparations from 14 serotypes was first licensed in the United States in 
1977. This was soon replaced, in 1983, with the 23-valent polysaccharide vaccine that is now 
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widely in use (Pneumovax II, Pnu-Immune 23). This vaccine contains purified polysaccharide 
antigens from 23 serotypes implicated in the majority of invasive disease in the developed world 
(1,2, 3,4,5, 6B, 7F, 8, 9N, 9V, lOA, l1A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 
33F). It is recommended for those at risk of pneumococcal infection and has been shown to be 
highly cost effective when used for vaccinating elderly persons (Ament et al., 2000). Protection 
conferred is serotype specific so it does not protect against serotypes not included in the vaccine. 
Although effective in adults, this vaccine fails to induce a good response in children younger 
than 2 years, the age group with the highest incidence of invasive and non-invasive infection 
(Wuorimaa and Kayhty, 2002). This is because polysaccharide cannot associate with major 
histocompatability complex (MHC) class II on antigen presenting cells and is thus classed as a 
T -cell independent antigen. The mechanism by which polysaccharide does induce an immune 
response (via induction of interferon-gamma [IFN -y] which can enhance antibody production by 
B cells and induce class switching) is not fully developed in infants. This may explain why T-
independent antigens fail to induce an immune response, immunological memory and are unable 
to prime for subsequent boosting in this high-risk group. 20 % of the elderly population also 
respond poorly to polysaccharide antigen due to a weak IgG response (Wuorimaa and Kayhty, 
2002). The polysaccharide vaccine does not provide any protection against carriage of the 
organism and does not protect against mucosal infections or prevent the spread of invasive or 
resistant strains (Wright et al., 1981; Obaro and Adegbola, 2002). Protection is severely reduced 
in other groups at high risk from pneumococcal infection, including those who are HIV -positive. 
1.3.2 Conjugate vaccine 
Due to the ineffectiveness of the polysaccharide vaccines in infants, conjugate vaccines were 
developed. These vaccines covalently link polysaccharide antigens to a carrier protein to convert 
the immune response to a thymus-dependent one. The protein component in such preparations 
has the ability to elicit aT-cell dependent response and induce B cell memory, so that immunity 
is longer lasting. However T-cell memory is not induced. A conjugate vaccine developed against 
Haemophilus injluenzae (Hib) has been hugely successful and is routinely used in many 
countries (Scheifele, 2001). Several conjugate vaccines have been developed and are in various 
stages of testing. One of these preparations, a 7-valent conjugate (Prevnar™ I Prevenar®, Wyeth 
Lederle Vaccines), was licensed in the United States in February, 2000 and since, over 17 
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million doses have been administered. The polysaccharides included in this vaccine comprise 
serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. These are conjugated to the non-toxic CRM197 
diphtheria carrier protein. Other conjugate vaccines in trials include 9- and II-valent 
preparations. Studies with Prevnar™ have shown it to be protective against otitis media, 
pneumonia and invasive disease caused by vaccine serotypes (Black et at., 2000; Eskola et at., 
2001). Serogroup cross protection may also be achieved. The vaccine has been shown to be 
immunogenic in infants under 2 years of age and other high-risk groups. The vaccine has also 
been shown to induce mucosal IgA responses in infants (Choo et at., 2000). The conjugate has 
not yet been licensed for use in the UK. 
Despite the success of the 7-valent vaccine, conjugate vaccines have several drawbacks. The 
manufacturing process involved means they are considerably more expensive than the 23-valent 
polysaccharide vaccine and that fewer serotypes can be included within each preparation. This 
will have a huge impact on the suitability of the vaccine to provide protection for all those who 
require it. Natural changes in serotype distribution, which have been discussed above, may have 
important implications for the use of pneumococcal conjugate vaccines. Although the 7 
serotypes included in the vaccine currently account for over 80 % of invasive pneumococcal 
disease in the United States, during the beginning of the 20th century the same 7 serotypes 
accounted for as little as 15 % and 53 % of disease in adults and children, respectively (Feikin 
and Klugman, 2002). The use of the vaccine itself may also result in serotype replacement, 
through its ability to reduce colonisation of vaccine serotypes. Alternatively other pathogens may 
be able to colonise the URT resulting in new or increased infections due to such organisms. 
Indeed S. pneumoniae has been shown to inhibit the growth of H injluenzae, another respiratory 
tract pathogen) through production of hydrogen peroxide (Pericone et at., 2000) and can 
desialylate the lipopolysaccharide of H injluenzae and Neisseria meningitidis (Shakhnovich et 
at., 2002). Furthermore, although providing high coverage against disease in North America and 
some European countries, the vaccine will not provide sufficient protection for those in Africa, 
Asia and Oceania where a different set of serotypes are responsible for serious pneumococcal 
infections (Wuorimaa and Kayhty, 2002). One study in Finland demonstrated that the vaccine 
reduced 57 % of pneumococcal acute otitis media (AOM) due to vaccine-related serotypes 
(Eskola et at., 2001). This is in contrast to the predicted 84 % protection against AOM in the 
United States with the same vaccine (Joloba et at., 2001). The former study also reported an 
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increase in AOM due to non-vaccine serotypes (Eskola et al., 2001), eluding to the risk of 
serotype replacement. This could be a potentially serious problem with the conjugate vaccines as 
it is not desirable to have a vaccine that increases the risk of infection against other organisms or 
strains. 
1.3.3 Future vaccines 
The inefficiency of the 23-valent vaccine in infants and the problems with cost and serotype 
coverage discussed with the conjugate vaccines increase the need for a new pneumococcal 
vaccine with increased serotype coverage and at a lower cost. Intense epidemiological 
investigations may increase our understanding of disease causing serotypes and their 
geographical prevalence but it would not be practical to tailor-make conjugate vaccines to suit 
individual populations, and those in developing countries would not be able to afford such 
vaccines. Much research is currently focussed upon identifying suitable candidates for a new 
pneumococcal vaccine. An ideal vaccine would induce IgA and IgG antibodies with high affinity 
and would ideally contain a pneumococcal protein with the ability to induce a good antibody 
response that is cross protective against the majority of serotypes. Currently there is debate as to 
whether an ideal vaccine would reduce / prevent carriage of the organism. A vaccine able to 
prevent carriage would have the advantage of interfering with infection at the earliest possible 
stage, could reduce the spread of highly virulent and resistant organisms and could eventually 
induce herd immunity. Such a vaccine could, however, allow for the colonisation and subsequent 
infection by non-vaccine serotypes, although the inclusion of a pneumococcal protein antigen 
should help prevent this. Elimination of S. pneumoniae from the nasopharynx could, however, 
allow other pathogens to occupy this niche. A vaccine that was to include several protein 
antigens important at various stages of infection would significantly increase immunogenicity 
and efficacy and could remove the need to include any polysaccharide antigens. Several 
pneumococcal proteins, including pneumolysin and pneumococcal surface protein A (PspA), are 
currently being investigated as potential vaccine candidates (Alexander et al., 1994; Paton 2001). 
Many new techniques have been applied to the identification of virulence factors and putative 
vaccine candidates of S. pneumoniae, including signature tagged mutagenesis (STM), differential 
fluorescence induction (DFI) and motif searches for surface expressed molecules (Pearce et ai, 
1993; Polissi, et al., 1998; Lau et ai, 2001; Wizemann et ai, 2001; Hava and Camilli, 2002; 
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Marra et at., 2002). These studies have identified a huge number of genes that are potential 
candidates, although detailed analysis of these must be performed to assess their suitability for 
inclusion in a future vaccine. 
1.4 Antibiotics and resistance 
At the beginning of the 20th Century, Dr. William Osler, an influential physician, described the 
pneumococcus as the 'captain of the men of death', due to its prevalence and the high mortality 
associated with infection. This situation changed dramatically with the introduction of 
sulphonamides in the late 1930s, followed by penicillin in 1945. The use of antibiotics at this 
time was so successful in treating pneumococcal infection that vaccine development was halted 
for many years. The first report of a pneumococcal strain showing resistance to penicillin was in 
Papua, New Guinea in 1969 (Tomasz, 1999). An editorial at the time evaluated this case and 
described the possibility of the spread of resistant S. pneumoniae as being extremely remote. 
This editorial could not have been further from the truth. Reports of penicillin non-susceptible 
strains in Spain were seen with increasing frequency and this progressed to an increase in 
resistant strains worldwide. Since the late 1980s, penicillin resistant strains have been 
increasingly isolated from infections in the United States (Figure 1.2) and other countries, and 
may be present in up to 80 % of isolates (Low 2000; Normark et at., 2001). A recent study found 
that 61 % of clinical strains isolated in Scotland between 1992 and 1999 were not susceptible to 
penicillin. In the same study 14 % of isolates were resistant to erythromycin (Kyaw et at., 
2002b). The highly resistant penicillin isolates are also invariably resistant to other ~-lactam 
antibiotics, including the third generation cephalosporins, cefotaxime and ceftriaxone (Linares et 
at., 1992). Vancomycin tolerance in S. pneumoniae has also been reported (Novak et at., 1999b; 
Normark et at., 2001). Prescribing of antibiotics is thought to have played a major role in 
antibiotic resistance, although other factors may also be involved. Some serotypes are more 
frequently associated with antimicrobial resistance than others and include 6A, 6B, 9V, 14, 19F 
and 23F (Wuorimaa and Kayhty, 2002). These serotypes are included in the Prevnar™ 7-valent 
conjugate vaccine. Capsular switch has also been reported in highly resistant clones and may 
facilitate the spread of multi-resistant determinants to other serotypes (Tomasz, 1999). 
Resistance to antibiotics may be achieved through several mechanisms and is thought to be 
transferred between bacterial strains by horizontal gene transfer and homologous recombination 
35 
Chapter 1 Introduction 
(Dowson et at., 1997). This transfer is largely facilitated by the natural transformability of the 
pneumococcus. The alarming increase in multi-resistant strains, together with the problems 
associated with the vaccines, requires the design of new therapeutic agents or the introduction of 
a more effective vaccine to prevent pneumococcal infection. 
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Figure 1.2: Emergence of penicillin resistance in S. plleulllolliae in the United States, 1988-1997 
The figure shows the increase of penicillin intermediate or resistant isolates in the United States over 10 
years. Data was compiled by the Centre for Disease Control and Prevention and is modified from a 
presentation by The National Foundation for Infectious Diseases and the National Coalition for Adult 
Immunisation (http://www.nfid.orgllibrary/pneumococcal). 
1.5 Host response to disease 
1.5.1 Defences in the upper airways 
The immunocompetent host has a series of innate defences that are highly effective in protecting 
against S. pneumoniae and other respiratory pathogens. Airway defences include intact epithelial 
membranes, mucociliary clearance, antimicrobial peptides, local IgA production and the cough 
and sneeze reflexes. IgA is able to agglutinate microbial particles to promote mucociliary 
clearance but has no opsonic activity (Canto et at., 1994). However, its role in preventing 
pneumococcal infection is unclear as human IgA deficiencies do not appear to have increased 
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susceptibility to infection (Kaliner, 1992). Small amounts of IgG may be present in the upper 
airways, although concentrations of this immunoglobulin are greater in the lower airways and 
lung tissue and also increase following changes in vascular permeability. IgG is a good opsonin 
and can thus fix complement. Lymphoid tissue in the URT includes tonsils, adenoids and 
bronchus-associated lymphoid tissue (BALT). Ig-bearing cells may be sampled by BALT and 
migrate to the lamina propria in the respiratory tract to produce local antibody for the mucosal 
surface. 
1.5.2 Defences within the lung 
The human lungs are usually sterile, so bacterial infection in this environment requires a more 
vigorous immune response to control microbial invasion and promote clearance. Resident 
alveolar macrophages are abundant in the lung environment and have an important role in 
clearing pneumococci (Gordon et at., 2001). These cells are the first line of phagocytic defence 
and are also efficient immune effector cells, having the ability to release a range of mediators. 
Released mediators include pro-inflammatory cytokines interleukin I-beta (IL-l P), interleukin 6 
(lL-6), IFN-y and tumour necrosis factor-alpha (TNF-a), enzymes (including lysozyme), 
biologically active lipids, oxygen metabolites and proteins (Roitt et at., 1996a). The release of 
chemotactic factors attracts polymorphonuclear leukocytes (PMN)s, such as neutrophils, to the 
site of infection. Neutrophils are a major defence against microbial invasion via phagocytosis. 
They have cell surface receptors for IgG Fc region. Following phagocytosis, microbes are killed 
by the respiratory burst and through release of potent enzymes within the neutrophil. Certain 
complement components can also attract neutrophils. 
Within the lung environment, the invading microbes may be coated with opsonins, such as 
surfactant (secreted by Type II pneumocytes), complement components (generated by the 
classical and alternative complement pathways) or antibody. This opsonisation greatly facilitates 
phagocytosis (Gordon et at., 2000). Cytokines produced by T cells within the lung can enhance 
the phagocytic and bactericidal capabilities of macrophages. Figure 1.3 summarises some of the 
major host defences present within the lung environment. 
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Figure 1.3: Host mechanisms involved in clearing pneumococcal infection 
Some of the mechanisms detailed are specific for certain regions of the respiratory tract only. For example 
IgA tends to predominate in the upper airways whilst IgG is found in higher concentrations in the lower 
airways. Mucociliary clearance operates in the upper respiratory tract and intact epithelial barriers are 
important throughout the respiratory h·act. Complement, cytokines, IgG and neutrophils are also important 
in systemic infection. Different aspects of the host immune response may be required at different sites of 
infection and for different disease states. The alTOW indicates the general route of infection. 
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1.5.3 The inflammatory response 
If the mechanical and immune defence barriers fail, an appropriate inflammatory response is 
generated, the initiation of which involves the release of cytokines and other mediators described 
above. The nature of this response is complex, multifactorial and requires careful regulation to 
prevent potentially damaging effects. A massive inflammatory response is a key element of 
certain pneumococcal infections (meningitis and pneumonia) and has been associated with the 
tissue destruction and pathology that results from such infection (Meli et at., 2002). Cell wall 
components and other bacteria products, such as pneumolysin, have been identified as important 
pneumococcal inflammatory mediators (Tuomanen, 2000). Several key cytokines involved in the 
response following infection with S. pneumoniae have been studied and are discussed below. 
The cytokines described represent only a small proportion of the mediators likely to be involved 
in the host inflammatory response to pneumococcal infection, but represent those best studied. 
1.5.3.1 Cytokines 
Cytokines are soluble molecules produced by a range of cell types that mediate interactions 
between cells. They are usually small proteins with low molecular mass, and help regulate many 
biological processes such as cell growth, cell activation, immunity, inflammation and tissue 
repair. Members of the cytokine family include interleukins (IL), interferons (IFN) , tumour 
necrosis factors (TNF) and colony stimulating factors (CSF). Cytokines are extremely potent 
molecules, often capable of exerting their effect at femtomolar concentrations. Locally produced 
cytokines can act in autocrine and paracrine fashion, integrating signals over short cellular 
distances. Cytokines rarely, if ever, act in isolation and cytokine networks are dynamic and 
complex, with individual cytokines being pleiotropic in their functions. 
Cytokines can broadly be subdivided into those that are pro-inflammatory and those that are able 
to down regulate host responses or anti-inflammatory, and the balance between such molecules is 
crucial in determining the outcome of infection. Perturbation of this balance, either by microbial 
products and interactions, or intervention using immunomodulatory therapies, could have serious 
consequences for the ability of the host to cope with infections. 
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1.5.3.2 Pro-inflammatory cytokines and pneumococcal infection 
IL-I~ 
Introduction 
IL-I ~ is a pro-inflammatory cytokine secreted by many cells, although most abundantly by 
macrophages. Virtually all cells on the body have receptors for IL-I~, but the main targets are T 
and B cells where it induces inflammatory responses. During pneumococcal infection, IL-l ~ 
does not appear to be important early in infection but in an experimental model was found to be 
important for survival after 5 days (Benton et al., 1998). The presence of pneumococci within the 
lung tissue causes alveolar macrophages to secrete TNF -a and IL-l ~, and this is the start of the 
host inflammatory response. 
IL-6 
Although generally classed as pro-inflammatory, IL-6 can have both pro and anti-inflammatory 
activities. Within the lung environment, interstitial fibroblasts, alveolar macrophages, endothelial 
cells and bronchial epithelial cells produce IL-6. Serving an inflammatory role, IL-6 is able to 
activate monocytes and can increase the respiratory burst of neutrophils in combination with 
TNF-a (Mullen et al., 1995). However, several studies have indicated that IL-6 serves to down-
regulate the inflammatory response within the lung environment. It has been found to inhibit IL-
l and TNF production from macrophages (Ulich et al., 1991). One study found that IL-6 plays 
an anti-inflammatory role in lipoteichoic acid-induced pulmonary inflammation but had a pro-
inflammatory role in lung inflammation induced by peptidoglycan from the Gram positive 
organism S. aureus (Leemans et al., 2002). IL-6 deficient mice (IL-6-/-) are more susceptible to 
intranasal (i.n.). challenge with pneumococcus, displaying a more pronounced inflammatory 
response when compared to control mice. Within the lung environment, these IL-6-/- mice had 
elevated levels ofTNF-a, IL-l~, IFN-y and IL-I0 (van der Poll et al., 1997). Such data indicates 
a regulatory role for IL-6 in the control of the inflammatory response induced by pneumococcal 
infection. IL-6 levels have been shown to increase in children with septic shock and are 
predictive for the isolation of bacteria, including S. pneumoniae, from the blood (Saladino et al., 
1992). Stimulation of whole blood from infants and adults with live and heat-killed S. 
pneul1loniae and other pathogens results in increased levels of IL-6 but stimulation of whole 
blood from pre-term infants was shown to result in significantly lower levels of IL-6 (Yachie et 
al., 1992). As pre-term infants are more susceptible to bacterial infections, these findings suggest 
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that IL-6 may have a role in protection against infection. However, the immune response as a 
whole will be underdeveloped in pre-term infants and susceptibility to infection in this group 
should not be attributed to a single cytokine. In contrast, a study in pigs showed that high levels 
of IL-6 in the blood resulted in increased mortality from pneumococcal infection, suggesting IL-
6 is non-beneficial (Ziegler-Heitbrock et al., 1992). Other published data have indicated that IL-6 
concentrations increase during pneumococcal infection. For example, serum levels of IL-6 were 
significantly higher during episodes of pneumococcal AOM than AOM caused by other bacteria 
(Heikkinen et al., 1998). Increased levels of IL-6 in the serum have also been shown to be 
associated with community acquired pneumonia (CAP) caused by the pneumococcus compared 
with infections caused by Mycoplasma pneumoniae (Lieberman et al., 1997). These studies 
illustrate that AOM, CAP and invasive infection with S. pneumoniae all result in increased serum 
concentrations of IL-6, although the role that this cytokine has during infection is unclear. 
TNF-a 
TNF - a and IL-l P have multiple overlapping activities. TNF - a is a potent pro-inflammatory 
cytokine that has both beneficial and toxic effects. TNF -a can have detrimental effects during 
infection. Increased levels of TNF-a have been detected in the central nervous system (eNS) 
during infections such as meningitis and brain injury, and high levels in the CSF during bacterial 
meningitis are predictive of poor outcome. TNF-a, however, has also been shown to be a critical 
inflammatory mediator in the control of numerous microbial infections using experimental 
animal models (Blanchard et al., 1988; Mastroeni et al., 1991). 
Many groups have studied the role of TNF-a in pneumococcal infection in vivo. Following 
intranasal challenge, the levels of TNF -a in lung tissue increase over a period of 48 hours and 
can reach very high levels (Bergeron et al., 1998). In bronchi-alveolar lavage fluid (BALF), 
TNF-a concentration increases up to 12 hours post-infection, after which time concentrations 
return to normal levels, despite progression of the infection. Serum TNF -a levels also increase, 
albeit at a later stage (2-3 days post infection) and at lower levels than those present in the lung. 
These increases in lung and serum TNF -a concentrations appear to correlate with bacterial loads 
in the lung tissue and migration of bacteria into the bloodstream respectively (Takashima et al., 
1997; Bergeron et al., 1998). Several studies have shown the importance of the TNF-receptor-l 
(TNFRI) in pneumococcal infection and the benefits of early production of TNF -a in protection 
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(0' Brien et ai., 1999; Kerr et ai., 2002). Kerr and colleagues also showed that neutralisation of 
TNF- a with polyclonal anti-TNF antibody significantly increased bacterial loads in the BALF 
and lung tissue of MFI mice following intranasal infection, although this had no effect on levels 
of bacteraemia (Kerr et ai, 2002). Intraperitoneal administration of anti-TNF-a antibodies have 
also been shown to produce higher levels of bacteraemia, lower counts of neutrophils in the 
blood and acceleration of death in CBAlJ mice challenged with type 19 pneumococcus 
(Takashima et ai., 1997). As neutrophils are crucial for the phagocytosis of S. pneumoniae, it 
was suggested that this decrease in neutrophil count was allowing for accelerated access of 
bacteria into the bloodstream. Furthermore, as TNF -a can potentiate the bactericidal activities of 
neutrophils, any of these cells present during infection may not be as efficient at phagocytosing 
bacteria in the absence of TNF-a. However, O'Brien and colleagues found the number of 
neutrophils recruited to the site of infection over 3 days post infection did not differ from control 
mice, despite a more severe infection with TNF-a receptor knock out mice (O'Brien et ai., 
1999). This could illustrate differences in the effects of TNF-a at different sites of infection or 
between different mouse strains and supports the idea that neutrophils were less bactericidal. 
Indeed work within our own laboratory has implicated TNF -a in protection against bacterial 
challenge. A reduced ability to induce rapid TNF -a within the airways of CBAlCa mice was 
proposed to render such mice susceptible to pneumococcal challenge with type 2, D39, when 
compared to the resistant BALB/c mouse model (Kerr et ai., 2002). 
The mechanisms by which TNF - a is able to elicit protection may be the same mechanisms that 
could be non-beneficial to the host. TNF- a is thought to attract neutrophils by up-regulating 
vascular and neutrophil adhesion molecules. It can also up-regulate the release of chemokines, 
such as macrophage inflammatory potentiator I-alpha (MIP-la) and MIP-2, which are 
chemoattractant for inflammatory cells (Standiford et ai., 1996). Once at the infection site, 
neutrophils can be activated by TNF - a by direct stimulation of the respiratory burst and 
modulation of lysosomal enzyme release. Such activities are likely to be protective against 
infection at low levels but at higher levels could cause injury to host tissue and subsequently 
provoke a detrimental inflammatory response. TNF - a and IL-l P have been shown to stimulate 
nitric oxide (NO) production, which can also be protective, but overproduction has been 
associated with a high histopathology score and rapid death in pneumococcal models of 
infection. Blocking NO is able to delay such mortality (Bergeron et ai., 1998). 
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TNF- a is one of the first inflammatory mediators detected early in pneumococcal infection in 
both BALF and lung tissue (Bergeron et ai., 1998), and this early release is thought to be 
necessary to afford protection (O'Brien et ai., 1999 and Kerr et ai., 2002). It is possible that 
mast cells within the lung environment are responsible for this early appearance of TNF - a, 
being the only cells to possess the cytokine pre-synthesised (Gordon et ai., 1990). Indeed a 
correlation between increased numbers of mast cells and TNF - a levels has been shown (Kerr et 
ai., 2002). Following this initial release, TNF- a concentrations may increase through its release 
from other stimulated cells within the site of infection, as well as cells recruited to the infection 
site. TNF - a can up-regulate its own expression resulting in a vigorous immune response which 
must then be controlled through anti-inflammatory cytokines and other regulatory factors to 
prevent it becoming detrimental to the host. 
The role of TNF - a depends on its location and when present in the systemic circulation, has 
been associated with sepsis. High levels ofTNF- a are detected in the blood of patients suffering 
Gram-negative sepsis, although elevated TNF - a levels are also detected during infection with 
Gram-positive organisms, including S. pneumoniae (Cohen and Abraham, 1999). Although 
sepsis is often initiated by microbial infection, the resulting tissue injury and organ failure is due 
to host mediators rather than bacterial products (Sriskandan and Cohen, 1995). TNF - a is central 
in this injury and can cause a range of systemic effects. When recombinant human TNF- a was 
injected intravenously into experimental animals, shock, tissue injury, capillary leakage, 
hypoxia, pulmonary oedema and multiple organ failure associated with high mortality ensued 
(Tracey and Cerami, 1994). Thus, TNF- a may have both beneficial and detrimental effects both 
in human and experimental murine infection, depending on where it is produced and the levels 
present. 
IFN-y 
IFN-y is a potent pro-inflammatory cytokine that contributes to immunity by inducing a range of 
physiologically significant responses (Shtrichman and Samuel, 2001). It is the main T cell 
product that activates macrophages. Although there is much data on the importance of this 
cytokine in the innate immune response to many microbial pathogens, the evidence of its role in 
pneumococcal infection is conflicting. IFN-y -/- mice have been used in two independent studies, 
but resulting data are conflicting. Rubins and Pomeroy (1997) used IFNy-/- mice on a C57BLl6 
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background and found that such mice were more susceptible to intranasal challenge with type 2 
pneumococcus compared to wild type C57/BI mice. Rijneveld and co-workers however, found 
no difference in mortality of IFNy-/- mice on a BALB/c background when challenged 
intranasally with type 3 pneumococcus (Rijneveld et al., 2002). Evidence indicates that T cells 
from C57BLl6 mice produce significantly higher amounts of IFN-y in response to pathogens 
than lymphocytes from other murine models, including BALB/c (Shtrichman and Samuel, 2001). 
This illustrates how genetic background of both mouse and bacterial strains used in such studies 
can influence the data obtained and that care must be taken when interpreting and extrapolating 
data from experiments. 
1.5.3.3 Anti-injlammatory cytokines and pneumococcal infection 
IL-10 
IL-10 is a potent regulatory cytokine that down-regulates the synthesis of pro-inflammatory 
cytokines by macrophages, neutrophils and mast cells. It also suppresses free oxygen radical 
release and NO-dependent microbicidal activity of macrophages. Various cell types, including T 
cells, B cells and macrophages can produce IL-10. Following challenge with S. pneumoniae, IL-
10 levels within lung tissue increase and remain sustained throughout infection (van der Poll et 
at., 1996). Administration of anti-IL-10 antibody has demonstrated that IL-10 can reduce the 
pro-inflammatory response during experimental pneumococcal pneumonia. Abolishing IL-10 
resulted in increased levels of TNF-a and IFN-y in lungs and blood and caused early lethality 
(van der Poll et al., 1996). Similarily, in patients with sepsis, a high TNF-a to IL-lO ratio has 
been associated with fatal outcome (van Dissel et at., 1998). 
1.5.4 Defence in the systemic circulation 
Antibody or complement mediated phagocytosis provide the major clearance mechanisms for 
pneumococcal infection and the spleen is the major organ involved. The IgG2 class of antibody 
is the predominant form produced in response to the pneumococcal polysaccharide capsule 
(Escobar-Perez et al., 2000). Deficiencies in this class of antibody can predispose to infection 
with S. pneumoniae and other encapsulated bacteria such as H injluenzae (Escobar-Perez et al., 
2000). Complement is a series of over 30 serum proteins that have multiple roles in host defence. 
It is part of the innate immune system and can be activated by antibody/antigen complexes 
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(classical pathway) or by the deposition of complement component C3b on the surface of 
invading microbes (alternative pathway). Complement components may also be produced as 
acute phase proteins by the liver. Complement can result in bacterial killing either directly by its 
ability to form pores in bacteria membranes (membrane attack complex) or indirectly by 
opsonising bacterial surfaces (C3 & C3b) and targeting them for phagocytosis. Some 
complement components are also chemotactic or have the ability to activate lymphocytes or 
increase vascular permeability. 
The complement membrane-attack complex is unable to penetrate the rigid cell wall of S. 
pneumoniae so deposition of opsonic C3b on the surface is the principle mediator of 
pneumococcal clearance in the non-immune host (Hostetter 2000). C3 can bind to the 
polysaccharide capsule and to teichoic acid within the cell wall. In the immune host, anti-
capsular antibodies recognise and bind to the capsule and this further facilitates the deposition of 
complement C3b. Bound C3b can be cleaved by serum proteases to the smaller fragments iC3b 
and C3d. These are recognised by receptors on phagocytes and the organisms are subsequently 
rapidly cleared. The importance of complement in the host response to pneumococcal infection 
can be demonstrated by the use of complement knock-out mice which are highly susceptible to 
infection compared to their isogenic parental strains (our laboratory, unpublished data). The Fc 
gamma receptors also have an important role in phagocytosis of pneumococcal cells. Antibody 
mediated phagocytosis by FcyRIIa can occur even in the absence of complement, although 
opsonisation by C3 greatly enhances phagocytosis. In children and adults, activity of FcyRIIa 
largely depends on anti-capsular IgG2 antibody. However, IgG2 levels are slow to mature and 
children under the age of 2 years are unable to produce this immunoglobulin subclass. 
It is known that some pneumococcal serotypes are more virulent than others and this has often 
been attributed to differences in the chemical structure of the capsule. Different cleavage patterns 
of deposited C3b by pneumococcal serotypes can explain why some are more resistant to 
opsonophagocytosis than others. Studies have shown that with serotypes 3 and 4, which are 
resistant to phagocytosis but potent immunogens, C3d is the predominant C3 fragment on the 
surface. This component is recognised by CR2 receptors on B cells but not by phagocyte 
receptors. In contrast, serotypes 6A and 14 display iC3b on their surface and this is recognised 
by CR3 on phagocytes but not by B cell receptors. The reasons for these differences are unclear. 
These serotypes are poor immunogens but readily phagocytosed (Hostetter, 2000). Surface-
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bound C-reactive protein (CRP) is also able to induce opsonic activity, possibly through its 
ability to activate complement by the classical pathway (Volanakis and Kaplan, 1974), although 
macrophages themselves have surface receptors with the ability to bind CRP (Tebo and 
Mortensen, 1990). This would enhance phagocytosis of opsonised bacteria. 
S. pneumoniae is capable of phase variation whereby two variants, opaque and transparent are 
found. Opaque variants have increased amounts of capsule and decreased levels of several 
surface components such as autolysin (LytA) , choline binding protein A (CbpA) and teichoic 
acid compared to transparent variants. The opaque variants tend to predominate in systemic 
infection, whilst transparent variants are more adapted for colonisation (Weiser, 2000). One 
study has demonstrated that more C-reactive protein (CRP) binds to the transparent form of 
pneumococci than the opaque form and that opsonophagocytosis occurs only in the former (Kim 
et at., 1999). This may explain why the transparent variants are less virulent in systemic 
infection. 
1.6 Pneumococcal pathogenicity and virulence factors 
As with any bacterial pathogen, the ability of S. pneumoniae to cause disease depends on several 
important stages, namely colonisation of host surfaces, damage to host tissue and evasion of the 
host immune response. Although a variety of pneumococcal virulence factors have been 
identified that contribute to each stage of infection, the molecular details of pathogenicity are not 
yet fully understood. Some of the known mechanisms that contribute to virulence are described 
below. Although these will be discussed with particular reference to pneumococcal pneumonia, 
many will apply to other disease states caused by S. pneumoniae, including meningitis. The 
following section does not aim to discuss all of the S. pneumoniae virulence factors identified to 
date, as these are too numerous to include in this thesis. Instead, it aims to discuss several 
virulence factors associated with different aspects of infection to provide an overview of the 
intricate nature of bacterial pathogenicity and gene regulation. Some virulence factors, such as 
pneumolysin, may play a role in many stages of infection, such as adhesion, tissue damage, 
nutrient acquisition and evasion of the host response. Again, this demonstrates the complex 
issues involved in studying bacterial pathogens. 
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1.6.1 Colonisation and adhesion 
The first step in pneumococcal infection is colonisation of the nasopharynx. This site is the 
natural niche of the pneumococcus and colonisation is generally asymptomatic. However, 
colonisation with a newly acquired isolate may result in infection if the host is 
immunocompromised or at high-risk. The success of S. pneumoniae to inhabit this niche may be 
partly due to its ability to inhibit other URT bacteria such as H injluenzae, Moraxella 
catarrhalis and N meningitidis, via the production of extracellular products such as hydrogen 
peroxide (Pericone et ai., 2000). The neuraminidase (NanA) from S. pneumoniae can also 
desialylate the lipopolysaccharide from H injluenzae and N meningitidis (Shakhnovich et ai., 
2002). S. pneumoniae can bind to sugar receptors on resting host cells and host cell ligands that 
are induced through activation with cytokines, for example (Tuomanen, 1997). On resting cells, 
bacteria are able to adhere to nasopharyngeal cells through recognition of at least 2 specific host 
disaccharides (Anderson et ai., 1983). These sugars include N-acetyl-o-galactosamine Pl-3 
galactose (GalNAcp 1-3Gal) and N-acetyl-o-galactosamine p 1-4 galactose (GalNAcp 1-4Gal) 
(Cundell et ai., 1995b). S. pneumoniae has also been shown to bind to the human polymeric 
immunoglobulin receptor found in the URT (Zhang et ai., 2000) although this appears to be 
strain-specific (Brock et ai., 2002). It has been proposed that this binding may facilitate 
translocation of bacteria across nasopharyngeal epithelial cells. Surface-located CbpA has a role 
in this binding (Zhang et ai., 2000). 
Spread to the lungs probably occurs by aspiration and is enhanced by impaired defences such as 
the cough reflex or mucociliary activity. Pneumococci have been shown to adhere to and invade 
human or other bronchial epithelial cells (Talbot et ai., 1996; Adamou et ai., 1998; Kadioglu et 
at., 2001). Platelet activating factor receptor (P APr), on cytokine-activated cells, has been shown 
to act as a host ligand for this interaction and it is thought that this binds phosphorylcholine 
present on the pneumococcal cell wall (Cundell et ai., 1995a). Phosphorylcholine also serves to 
anchor the Cbps to the pneumococcal cell wall. Cbp comprise a set of at least 12 surface-located 
proteins that have a variety of functions, many of which are thought to be important in adhesion 
and colonisation (Paton, 1998; Gosink et ai., 2000). CbpA, discussed above for its role in 
nasopharangeal adhesion, also appears to be able to bind to cytokine-activated type II 
pneumocytes and endothelial cells (Paton 1998). Due to its conservation across pneumococcal 
serotypes and its role in adhesion, this protein may be a good vaccine candidate. Inhibition of 
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choline mediated adhesion by dimyristoylphosphatidlcholine (DMPC) was demonstrated to 
reduce binding of several pneumococcal strains to lung cells by up to 80 % (Berube et al., 1999). 
This could be a potential therapeutic approach to treating early stages of pneumococcal infection. 
S. pneumoniae has also been shown to bind to another glycoconjugate receptor that is expressed 
on human epithelial cells following stimulation with pro-inflammatory cytokines (Cundell et al., 
1995b). 
Pneumococcal phase variation also influences adhesion and colonisation. The transparent 
pneumococcal variants (see section 1.5.4) are thought to be better adapted for colonisation 
compared to the opaque variants (Weiser, 2000). This is attributed to different expression of 
surface proteins between the variants, where transparent forms have increased amounts of CbpA, 
a pneumococcal protein previously shown to be involved in adhesion to cytokine-stimulated type 
II pneumocytes (Rosenow et al., 1997; Weiser, 2000). Furthermore, transparent variants 
demonstrate increased production of hydrogen peroxide (Overweg et al., 2000b) which has been 
shown to inhibit the growth of other pathogens that may be present in the nasopharynx (Pericone 
et al., 2000). This could confer a competitive advantage upon pneumococcal cells, allowing for 
increased colonisation of this niche. 
Adhesion / colonisation is a complex process and involves many other pneumococcal 
components too numerous to discuss here e.g. pneumolysin (pIn) and PavA (Rub ins et al., 1998; 
Holmes et al., 2001). Environmental factors may influence this process, such as previous viral 
infection and / or activation of host cells by cytokines and other mediators. These may serve to 
reveal new or up-regulate existing host ligands that the pneumococcal can than adhere to. 
Cigarette smoking has also been shown to increase susceptibility to respiratory pathogens by 
inhibiting mucociliary clearance and coating the airways with smoke components which may 
facilitate bacterial adhesion (Ahmer et al., 1999). 
1.6.2 Environmental sensing and expression of virulence factors 
Regulation of bacterial genes in response to environmental signals is an essential yet complex 
mechanism used by bacteria to adapt to their surroundings. The ability to induce or repress gene 
expression at different sites and in response to a whole range of stimuli has allowed bacteria to 
evolve as highly successful pathogens, both in their ability to colonise and damage host tissue 
and in the evasion of host immune responses. Many bacterial virulence factors are likely to be 
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tightly regulated according to environmental signals. A single regulatory element may control 
the expression of numerous, unrelated genes (global regulation) (Finlay and Falkow, 1997). 
Examples include the Bordetella pertussis BvgA/S and Staphylococcus. aureus AgrC/ A two-
component systems (TCS) (Uhl and Miller, 1996; Lyon et al., 2000). mRNA transcripts for 
several known pneumococcal virulence factors have been shown to be up-regulated during in 
vivo infection (Orihue1a et al., 2001; Ogunniyi et al., 2002). Further studies, including 
microarray analysis, should allow the identification of a whole range of virulence genes that are 
differentially regulated at different stages of S. pneumoniae infection. 
Two-component systems (TCS) have a central role in the sensing of environmental conditions 
and in subsequent gene regulation. These systems are ubiquitous among bacteria where they 
control a whole range of cellular functions. Thirteen of these systems have been identified in the 
pneumococcus and these are discussed in further detail in section 1.14. 
Other components that may be involved in gene regulation include DNA topology, alternate 
sigma factors including heat shock proteins, and other transcriptional regulators such as the Fur 
protein involved in gene regulation in response to iron (Finlay and Falkow, 1997). 
1.6.3 Damage to host tissue and dissemination of infection 
Many pneumococcal factors are thought to play a role in tissue destruction. Direct destruction 
may be achieved through the action of enzymes or toxins. PIn, for example, is a potent toxin 
released upon pneumococcal cell lysis. It has multiple activities at a range of different sites and 
many studies have identified it as an important virulence factor directly involved in the 
pathogenesis of pneumococcal infections (Berry et al., 1989; Canvin et al., 1995; Paton, 1996). 
This toxin is able to lyse many eukaryotic cells with cholesterol in their membrane in vitro by the 
formation of transmembrane pores (Alonso De Velasco et al., 1995). A second haemolysin has 
also been identified in S. pneumoniae (Canvin et al., 1997). Both haemolysins could contribute 
to tissue destruction. 
Two enzymes, neuraminidase and hyaluronidase may also contribute to tissue damage. 
Neuraminidase cleaves terminal sialic acid residues from a variety of cell surfaces (Paton et al., 
1993). This could also expose host ligands that can be utilised by the invading bacteria for 
attachment. It is thought that more than one form of the neuraminidase enzyme exists in 
pneumococcal strains (Berry et al., 1996). Hyaluronidase is secreted by S. pneumoniae during 
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exponential growth and is able to break down hyaluronic acid (Paton et at., 1993), a component 
of mammalian connective tissue. This could facilitate bacterial dissemination in host tissues. 
Indirect tissue destruction may occur though the ability of pneumococcal components to induce a 
vigorous inflammatory response within host tissue. The natural response to invading organisms 
within lung tissue will result in the release of inflammatory cytokines from resident alveolar 
macrophages and / or mast cells or other sources. However several pneumococcal components 
are known to potentiate this response. PIn has been shown to increase the production of pro-
inflammatory cytokines TNF-a and IL-1~ from monocytes (Houldwsorth et at., 1994) and to 
induce nitric oxide production from macrophages (Braun et at., 1999). The cell wall is also a 
potent inducer of inflammation, via the activation of complement and the induction of pro-
inflammatory cytokines (Catterall, 1999). Peptidoglycan and teichoic acids are the active 
components in the cell wall. 
A range of uncharacterised surface molecules, secreted or intracellular bacterial components, 
such as CpG motifs on DNA, may also contribute to the inflammatory response. Autolysin, is an 
enzyme that IS involved in maintaining cell surface integrity and can induce lysis of 
pneumococcI in vitro. This enzyme may be indirectly involved in activating the host 
inflammatory response by its ability to release pro-inflammatory cell wall components and 
intracellular pneumolysin into the host tissue. 
Damage to host tissue may also occur through the action of bacterial proteases. Several proteases 
have been identified in S. pneu7noniae and many of these are thought to be involved in virulence. 
Pneumococcal strains possess at least one IgA1 protease, thought to be involved in cleaving 
secretory IgA (discussed below). Proteases may contribute to the dissemination of bacteria or 
expose potential host ligands for binding / colonisation. An pneumococcal enolase, capable of 
binding and activating plasminogen, may facilitate degradation of the extracellular matrix and 
enhance dissemination of bacteria through host tissues. Two serine proteases have been 
identified in the pneumococcus, HtrA, shown to be important in nasopharyngeal colonisation 
(Sebert et at., 2002) and PrtA, shown to be important in systemic infection (Bethe et at., 2001), 
although the exact function of these proteases is unknown. 
Within this work, a putative zinc metalloprotease has been characterised. This protease is >5.5Kb 
(approximately 1800 amino acids) and has a molecular weight of ~210 KDa. This protein was 
identified in a search for putative adhesion molecules and was designated ZmpB to distinguish it 
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from a second ZInC metalloprotease in the pneumococcus (Novak et al., 2000). It was 
characterised as a putative zinc metalloprotease based on a HEXXH-E motif that is conserved in 
other zinc metalloproteases (Rawlings and Barrett, 1995). A mutation in the zmpB gene 
demonstrated a marked in vitro phenotype, leading the authors to propose an involvement of 
ZmpB in the translocation of certain proteins to the bacterial cell surface via a proteolysis based 
mechanism (Novak et al., 2000). However, a second study could not reproduce any of the 
phenotypes observed by Novak and colleagues, and subsequently demonstrated that the zmpB 
mutant used within the first study was a not S. pneumoniae but was one of the viridans group of 
Streptococcus (Berge et al., 2001). Thus the role ofZmpB remains unknown. 
ZmpB is one of the few proteins in S. pneumoniae which demonstrates extensive sequence 
variation between the serotypes for which a sequence has been published. There is a region of 
approximately 300-400 amino acids at the start of the protein which are approximately 99 % 
homologous between serotypes. This region contains a potential signal peptidase site, followed 
by two hydrophobic regions of alpha helices and an LPXTG motif (Berge et al., 2001). The 
remainder of the protein is highly variable, with the TIGR4 strain showing 40 % and 41 % 
identity with the R6 and G54 sequences respectively. The G54 and R6 sequences are more 
closely related but still only show 67 % identity within the variable region. Although the 
HEXXH-E motif is situated within the variable region, this motif is conserved between serotypes 
for which sequence data are available. Figure 1.4 is a schematic diagram of the ZmpB protein. 
Sequence alignments of this protein from TIGR4, G54 and R6 are provided in the appendix 
(appendix 6a and 6b). 
The LPXTG motif is one often found in proteins of Gram positive bacteria, where it serves to act 
as a cell-surface anchor, through the action of sortase enzymes (Pallen et al., 2001). However, 
the position of this LPXTG motif is usually found near the C-terminus end of the protein. As the 
LPXTG motif lies near the N-terminus region of ZmpB, it is not known if it serves as a true 
surface anchor. The cellular location of ZmpB is thus unknown. 
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Figure 1.4 Schematic diagram of ZmpB 
The figure illustrates the 1800 amino acid ZmpB protein of S. pneumoniae. The LPXTG motif, followed by 
the hydrophobic region (represented by dark swirling lines) at the N-terminal region of the protein are 
shown. The putative signal peptidase site is situated before the LPXTG motif (not shown on the 
diagram).This region appears to be -99 % homologous between serotypes (amino acids 1-300, shown by 
the red bar) . The remainder of the protein sequence is highly variable between the serotypes for which 
sequence data are available (shown by the blue bar) . The HEXXH-E motif, characteristic of zinc 
metalloproteases is found near the C-terminus. This motif is also conserved between serotypes. The entire 
protein has a molecular weight of approximately 210 KDa. 
1.6.4 Acquisition of nutrients and growth factors 
The ability to acquire essential nutrients and growth factors in host tissue is crucial for bacterial 
pathogens, so mechanisms involved in this process may also be classed as virulence factors. The 
virulence factors discussed above that result in damage to host tissue may also serve to release 
nutrients required for growth of invading bacteria. Other factors may also be used in combination 
with the above to obtain specific nutrients. For example, iron, an essential co-factor required for 
growth of most bacterial pathogens, is not freely available in the host and must be sequestered 
from mammalian iron-binding or haem-containing proteins. Several putative mechanisms for 
obtaining iron in the human host have been identified in the pneumococcus. PspA, a choline 
binding protein, has been shown to bind human lactoferrin, an iron-binding protein found in 
mucosal secretions (Hakansson et ai., 2001). However in iron-deficient medium, lactoferrin does 
not support the growth of S. pneumoniae (Brown and Holden, 2002), although this could indicate 
that environmental factors specific to the infected host may be required to induce certain iron 
uptake mechanisms. One group has shown that haemin binds to the pneumococcus in vitro and 
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used affinity chromatography to identify a putative haemin binding protein (Tai et ai., 1997). A 
S. pneumoniae pathogenicity island has been identified that has 2 genetic loci encoding ATP-
binding cassette (ABC) transporters required for iron uptake (Brown et ai., 2001a). Mutations in 
either of these transporters only moderately affected the ability of the bacteria to use 
haemoglobin as an iron source. A double mutation in both ABC transporters markedly reduced 
growth in iron deficient media and was highly attenuated in a murine model of pneumonia and 
septicaemia (Brown et ai., 2001a). Recombinant proteins from these transporters were shown to 
elicit protective immunity against sepsis when used to immunise mice (Brown et ai., 2001 b). 
These data also suggested that loss of one locus could be compensated for by the other functional 
locus. A third ABC transporter involved in iron uptake has also been identified (Brown et ai., 
2002). The identification of several loci utilising different mechanisms for the acquisition of iron 
in S. pneumoniae suggests that these systems could be important at different sites of infection 
and are likely to be regulated accordingly. Indeed TCS may be involved in the regulation of 
some of these systems. Siderophores, microbial iron transporters, have not been identified in S. 
pneumoniae. 
1.6.5 Evasion of the host immune response 
The pneumococcus has many strategies for evading the host responses to infection. In the upper 
airways, pneumolysin is able to inhibit the ciliary beat, which is an important mechanism in 
preventing bacteria from reaching the LR T. S. pneumoniae also possesses an IgA 1 protease that 
is able to cleave human, but not murine, IgAl (Poulsen et ai., 1996; Wani et ai., 1996), and 
could prevent clearance by this immunoglobulin. A pneumococcal protein, CbpA is also able to 
bind the secretory component of IgA that may serve to sequester this immunoglobulin 
(Hammerschmidt et ai., 1997). However, the role of IgA in protecting against pneumococcal 
infection is unclear as human IgA-deficiencies do not appear to result in increased susceptibility 
to infection. 
Phagocytosis is a major mechanism involved in clearing pneumococcal infection, both within the 
lungs and in the blood. This host defense mechanism is enhanced through opsonisation by 
complement, antibody or other components. Several pneumococcal proteins are thought to playa 
role in modulating host phagocytic and opsonisation functions. Pneumolysin is able to inhibit the 
bactericidal activity of PMNs, inhibit lymphocyte proliferation and inhibit antibody synthesis 
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(Paton et at., 1993; Mitchell and Andrew, 2000). Pneumo1ysin has been reported to have 
complement activating activity (Paton et at., 1993 ; Alcantara et at., 2001). It is thought that 
continuous activation of complement at a site distant from the invading bacteria may serve to 
deplete complement resources and remove opsonic complement components away from intact 
bacterial surfaces, thus reducing opsonophagocytosis (Alcantara et at., 2001). Other 
pneumococcal proteins, such as PspC and PspA, have the ability to bind complement 
components and this may inhibit complement activity (Alonso De Velasco et at., 1995; 
Janulczyk et at., 2000; Duthy et at., 2002). 
The polysaccharide capsule surrounding pneumococcal cells is essential for the virulence of S. 
pneumoniae. The capsular material itself is inert and has no inflammatory or tissue-destroying 
activities but it has a major role in the ability of pneumococci to resist phagocytosis. The amount 
of polysaccharide capsule surrounding invading organisms increases greatly following transition 
from the respiratory tract to the bloodstream and this is thought to promote survival of the 
bacteria systemically where phagocytosis is of major importance in controlling infection. This 
process of phase variation also involves differential expression of other surface-located 
components thought to have roles at different sites of infection (Overweg et at., 2000). Some 
capsular serotypes are more virulent than others. This has generally been attributed to differences 
in chemical structures resulting in variation in the ability to resist phagocytosis and / or 
opsonisation, or having different levels of immunogenicity (Hostetter, 2000). However it is now 
becoming apparent that genetic background may also have an important role in how virulent any 
particular serotype is (Kadiog1u et at., 2002). The ability of the capsule to resist opsonisation by 
complement components has been discussed elsewhere (section 1.5.4). 
1.7 Manipulation of the pneumococcal genome 
The genomes of 3 pneumococcal serotypes (2, 4 and 19F) (Dopazo et at., 2001; Hoskins et at., 
2001; Tette1in et at., 2001) have been sequenced. The genomes for type 2 and 4 have been 
completely annotated and are publicly available (http://www.tirg.org/). The 19F sequence has not 
yet been assembled and annotated Availability of this sequence information has been of 
enormous benefit to those involved in pneumococcal research as it has enabled the development 
of sophisticated techniques such as micro array analysis. Furthermore, large scale techniques to 
identify putative new virulence factors have made use of the availability of annotated sequence 
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data to provide lists of previously uncharacterised genes that are involved in virulence (Pearce et 
at, 1993; Polissi, et at.1998; Lau et at, 2001; Wizemann et at, 2001; Hava and Camilli, 2002; 
Marra et at., 2002). 
Although microarray analysis and other techniques have the potential to generate vast amounts 
of data previously unattainable using conventional techniques, genes of interest must still be 
analysed in further detail to determine their role within the pneumococcus or for their suitability 
as vaccine candidates I drug targets. There are currently several techniques available for creating 
mutations within target genes, some of which are discussed below. All of these techniques make 
use of the natural ability of S. pneumoniae to take up DNA from its environment and incorporate 
it into its genome. By using a peptide (competence stimulating peptide, CSP) to stimulate this 
DNA uptake (competence), target genes which have been manipulated or mutated within 
plasmids or other constructs can be introduced into the bacterium with relative ease. Regions of 
homology within the introduced DNA combine with homologous sequences within the 
chromosome and can result in a stable genomic mutation. Sequence information has allowed the 
refinement of mutagenesis techniques such that single amino acids can now be mutated within 
genes of interest. 
1. 7.1 Insertion-duplication mutagenesis 
This was one of the first techniques used to create mutations in pneumococcal genes. A small 
region with homology to the target gene is cloned into a suicide plasmid containing an antibiotic 
resistance marker and introduced into the target cell by transformation (Lee et at., 1998). The 
region of homology combines with the homologous sequence in the target gene via a single 
cross-over event and the whole plasmid integrates into the bacterial chromosome. During the 
process, the homologous region is duplicated, hence the name insertion-duplication. Potential 
mutants are selected in media or agar containing the appropriate antibiotic marker. The plasmid 
vector used is such that it can replicate in Escherichia coli (for propagation) but is unable to 
replicate within the pneumococcal cell and will be eliminated unless it is able to insert into the 
genome. This process is illustrated schematically in figure 1.5, and is based on the vector, pAS1, 
used within this work to create insertion-duplication mutants. The problems associated with this 
technique include the integration of a large amount of foreign DNA into the gene of interest that 
could have polar effects on downstream genes. Furthermore, the homologous region should be 
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designed to be at the start of the gene to prevent translation of a truncated protein that could have 
some functional activity. Plasmid excision and potential reversion back to wild-type has also 
been demonstrated with this form of mutagenesis (Yother, 2000). 
1.7.2 Allelic replacement mutagenesis 
This technique is similar to insertion duplication mutagenesis but an antibiotic cassette is used to 
replaces the entire gene or a large region of the target gene using a double cross-over event. This 
prevents the integration of large regions of 'foreign' DNA and ensures that the whole gene is 
replaced. No gene duplication occurs and mutants can be selected using antibiotics as described 
above. Mutants created using this technique are usually more stable than those made by insertion 
duplication, although care must be taken to ensure no polar effects result. Mutations are easily 
confirmed by using peR across the whole mutated region and sequencing the peR product to 
ensure the gene is absent and to check for polar effects. The process of creating mutants using 
this technique is given in figure 1.6. 
1.7.3 Mariller mutagenesis 
This technique uses transposon mutagenesis (Akerley et at., 1998; Berge et at., 2001). The peR 
product of the target gene is mutated in vitro by the random insertion of the mariner 
minitransposon encoding antibiotic resistance. Transposition products are used as donor DNA in 
the transformation of S. pneumoniae and double cross-over events occur between DNA regions 
flanking the transposon integration as described for allelic replacement mutagenesis. As above, 
mutants are selected by their ability to grow in the presence of antibiotic and are confirmed by 
peR. The technique has the advantage that it can create a series of integrations along the length 
of the gene and these can be analysed simultaneously. This may help identify regions of 
importance, and may be especially useful for large genes. 
1.7.4 Gene replacement through negative selection (Janus) 
This is a new mutagenesis technique based on the Janus cassette constructed by Sung and co-
workers (Sung et at., 2001). Using two transformations, this cassette can be used to insert DNA 
of arbitrary sequence at any chosen site. The technique is extremely versatile, allowing complete 
inactivation of genes by the insertion of stop codons, or more subtle mutations such as amino 
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acid changes, or epitope tagging. The resultant mutations do not possess any antibiotic-selection 
markers that may interfere with further investigation. This also allows for the construction of 
multiple mutations in different genes without the need for various antibiotic selection markers. 
The technique allows for the transfer of large regions of DNA between different strains. 
Furthermore, polar effects on downstream genes are avoided. 
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A short region homologous to the target gene is cloned into a suicide vector, PAS I, within the multiple 
cloning site (MCS). The vector, containing a gene conferring erythromycin resistance (ery) is transformed 
into S. pneumoniae. Unable to replicate in the pneumococcal cells, the plasmid (shown in light blue) is 
eliminated or integrates into the genome via homologous recombination with the target gene (shown in 
dark blue). This integration results in a duplication of the homologous region and mutants can be selected 
for their growth on erythromycin. Successful integration into the target gene can be determined by PCR 
across the chromosome / plasmid junctions. Primer pairs PI + PB and P A + P2 would confIrm the 5' and 3' 
integration sites, respectively, where one primer of each set is specifIc for genomic DNA (PI and P2) and 
one primer for each set is specifIc for the integrated plasmid DNA (P A and PB). 
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Figure 1.6: Allelic-replacement mutagenesis 
Null mutations are made in target genes by replacing the gene with an cassette encoding antibiotic 
resistance. Primer pairs PI + P2 and P3 + P4 are used to create PCR products flanking the gene of interest. 
Primers erml and erm2 are used to amplify up the erythromycin resistance (ery) cassette. Primers P2 and 
P3 have short sequences at the 5' end that are homologous to the 5' regions of erml and erm2, respectively. 
The two flanking regions are mixed with the ery cassette in a cross over PCR to generate an ery cassette 
with flanking regions homologous to the target gene or regions immediately outwith the target gene. When 
transformed into S. pneumoniae, double cross-over events occur at each flanking region and the cassette 
replaces the target gene. Mutants can be selected on erythromycin and confirmed using primers PI and P4. 
Figure modified from Tluoup et at., 2000. 
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1.8 Overview of two component systems (TCS) 
The TCS of bacteria generally comprise two protein modules; a transmembrane receptor also 
known as a sensor protein, or histidine protein kinase (HK / hk), due to its ability to 
autophosphorylate a histidine residue, and its cognate, intracellular signalling component 
commonly known as a response regulator (RR / rr). The various histidine kinases and response 
regulators can be organised in a number of different ways to assemble a variety of signal 
transduction circuits. For instance, such couples, including hybrid histidine kinases that contain 
additional response regulators or histidine-containing pho sphotrans fer domains can be 
conjugated to constitute a complex phosphorelay pathway (Dutta et al., 1999). Bacterial TCS 
were first described in the mid-late eighties when the amino acid sequence of CheY, a response 
regulator involved in chemotaxis in E. coli, and other Gram-negative bacteria, was shown to be 
related to regulatory proteins of other cellular processes (Stock et al., 1985). The dual component 
nature of such systems was then recognised (Nixon et al., 1986) and since, these systems have 
been found to be ubiquitous in bacteria. Indeed, over three hundred have been identified in 
approximately one hundred different bacterial genera (Goudreau and Stock, 1998). The only 
bacteria studied to date in which multiple TCS have not been identified are Borrelia burgdorferi 
and Mycoplasma genitalium (Barrett et al., 1998). The small genome and limited metabolic 
capacities of the two pathogens suggest they may not require or be able to respond to their 
environment via gene regulation. TCS have been shown to respond to a very wide range of 
environmental signals (such as pH, temperature, nutrient availability and oxygen/carbon dioxide 
levels) and control a range of activities, including the regulation of virulence factors, sporulation, 
chemotaxis and competence. Table 1.2 illustrates the diversity of cellular processes controlled by 
bacterial TCS in a large range of different bacteria. This table represents a range of bacteria, 
including Gram-positive and Gram-negative organisms, human and plant pathogens, swarming 
bacteria, photosynthetic bacteria and spores-forming organisms. Most bacteria will contain 
multiple TCS and these can be involved in the regulation of a large number of genes or sets of 
genes. Indeed anyone TCS may interact with one or more other TCS, and activation of a single 
TCS can induce both negative and positive regulation of different sets of genes. The S. aureus 
agr system and other TCS involved in regulation of virulence genes in this organism are 
examples of the complex nature of bacterial gene regulation. 
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Study of the control of virulence factors in response to environmental stimulus by a pathogenic 
organism is obviously an important area in terms of understanding bacterial pathogenicity and in 
the development of novel therapies (Magasanik, 1995). Many bacterial TCS are recognised for 
their role in the regulation of genes important for different stages of the infection process. This 
regulation of virulence genes varies greatly and includes control of secreted toxins and toxic 
products, alteration of membrane / cell wall proteins, control of capsule synthesis, motility and 
nutrient utilisation. The contribution to virulence includes damage to host tissue, evasion of the 
immune response and resistance or tolerance to antibiotics. Some of the TCS recognised to be 
important in the control of virulence factors in bacterial and plant pathogens are listed in table 
1.3. Only selected TCS from individual organisms are shown and often homologues of the 
described systems are present in other bacteria. TCS important in the virulence of S. pneumoniae 
are discussed under a separate section (introduction, section 1.14.5). The list of TCS represented 
in tables 1.2 and 1.3 is by no means exclusive. Indeed most bacteria will possess more than one 
TCS and therefore can detect and respond to several different environmental stimuli. At least 
thirty TCS have been identified so far in E. coli on the basis of sequence homology. Mutants in 
all of these have recently been analysed using micro arrays (Oshima et al., 2002). Given the large 
number of TCS in individual organisms, interactions between individual TCS within a cell 
(,cross-talk') are likely to occur. Indeed several TCS interact in S. aureus to regulate different 
sets of virulence factors (Lyon et al., 2000; Fournier et al., 2001; Yarwood et al., 2001). One of 
these systems, Agr, is very well characterised and acts as a global regulator capable of inducing 
and repressing different groups of virulence-associated genes depending on the site of infection 
(Lyon et al., 2000). 
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Organism TCS(HK/RR) Function 
B. subtilis VanSIVanR Vancomycin tolerance 
B. subtilis KinA/SpoOF Sporulation regulation 
B. subtilis ComP/ComA Competence regulation 
B. subtilis DegS/DegU Regulation of many cellular processes e.g. exoprotease production, 
catabolism, competence development and motility 
C. crescentus CckA/CtrA Co-ordination of cell cycle progression and polar morphogenesis 
E. coli CheAlChe Y,B Chemotaxis 
E. coli EnvZ/OmpR Adaptation to environmental osmotic changes by controlling expression of 
major outer membrane proteins 
Enteric bacteria PhoRIPhoB Phosphate regulation 
R. sphaeroides PrrAIPrrB Expression of photosynthesis and Calvin cycle CO2 fixing operons 
Rhizobium spp. FixLlFixJ Nitrogen fixation 
S. aureus SrhS/SrhR Regulation of energy transduction in response to changes in oxygen 
availability 
S. aureus YycFNycG Regulation of bacterial cell wall / membrane composition. 
S. coelicoior AbsAliAbsA2 Antibiotic synthesis 
V.fischeri LuxIILuxR Quorum sensing and induction of bioluminescent genes 
Table 1.2 Diversity of bacterial processes controlled by TCS 
Legend on following page 
Reference 
Evers and Courvalin, 1996 
Wang et ai., 2001 
Weinrauch et ai., 1990 
Ogura et ai., 2001 
Jacobs et ai, 1999 
Wheeler and Shapiro, 1999 
Hess et ai., 1988 
Egger et ai., 1997 
Lee et ai., 1989 
Emmerich et ai, 2000 
Weinstein et ai., 1992 
Throup et ai., 2001 
i 
Martin et ai., 1999 
Brian et ai, 1996 I 
Anderson et ai, 2001 
. 
Salmond et ai., 1995 
I --_ .. -
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Table 1.2 Diversity of bacterial processes controlled by TCS 
Bacillus subtilis is a sporulating Gram-positive organism. Caulobacter crescentus represents a swarming bacterium. Escherichia coli is a commensal of 
humans and mammals and can also be pathogenic, causing a range of diseases. The Enterobacteriaceae are Gram-negative commensals of the digestive 
tract, although they can be important pathogens. Rhodobacter sphaeroides is a purple photosynthetic, symbiotic bacteria. Rhizobium spp. are Gram-
negative bacterium common in soil and can induce nodule formation for nitrogen fixation in leguminous plants. Staphylococcus aureus is an important 
pathogen of humans and animals. Streptomyces coelicolor is a Gram-positive bacterium found within the environment and commonly associated with 
antibiotic production. Vibrio fischeri is a Gram-negative aquatic organism capable of bioluminescence. 
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Organism TCS Function Reference 
(HK/RR) 
A. tumefaciens VirAlVirG Crown gall tumour formation Dziejman and Meka1anos, 1995 
B. pertussis BvgSlBvgA Activation and repression of a range of virulence factors Akerley et aI., 1992 
E·faecium VanRJVanS Vancomycin resistance Arthur et aI., 1992 
K. pneumoniae NtrAlNtrC Urease production Collins et al., 1993 
M tuberculosis PrrBlPrrA Involved in early intracellular multiplication during macrophage Ewann et aI., 2002 
infection 
N gonorrhoeae PilAlPilB Pilus production 
P aeruginosa PirSlPirR Iron acquisition 
PilSlPilR Pilus production 
FleSlFleR Adhesion 
AlgR21 AlgR1 Alginate synthesis 
S. aureus AgrCIAgrA Expression of a range of extracellular proteins and toxins 
involved in various aspects of virulence (global expression) 
ArlS/ArlR Interacts with other systems to modulate virulence factor 
regulation 
S. pyogenes CsrS/CsrR Negative regulation of hyaluronic acid production and several 
toxins 
Salmonella spp. PhoQlPhoP Required for survival in macrophages 
Salmonella, E. EnvZ/OmpR Outer membrane protein expression for nutrient acquisition 
coli, Shigella 
V. cholerae ToxS/ToxR Expression of virulence factors e.g. pilus and toxins 
Table 1.3: Bacterial TCS involved in the regulation of virulence determinants 
Legend on following page. 
Taha et aI., 1991 
Rumbaugh et aI., 1999 
Rodrigue et aI., 2000 
Dziejman and Mekalanos, 1995 
Balaban et aI., 1998 
Yarwood et aI., 2001 
Fournier et aI., 2001 
Bernish and Rijn, 1999 
Engleberg et aI., 2001 
Groisman 2001 
Bernardini et aI., 1989 
Barrett and Hoch, 1998 
DiRita, 1992 
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Table 1.3: Bacterial TCS involved in the regulation of virulence determinants 
The examples given in the table generally represent pathogens important in human infection, although Agrobacterium tumefaciens is a plant pathogen 
able to induce tumour formation in its host. The human pathogens are responsible for a range of disease processes, some capable of causing many 
different infections. Bordetella pertussis is the causative agent of whooping cough. Enterobacter faecium, Klebsiella pneumoniae, Salmonella, 
Escherichia and Shigella are all members of the Enterobacteriaceae (see table 1.2). Mycobacterium tuberculosis causes tuberculosis. Pseudomonas 
aeruginosa is a prominent pathogen in cystic fibrosis patients. Staphylococcus aureus and Streptococcus pyogenes are both Gram-positive organisms 
that can cause a range of diseases at different sites within the body. S. aureus has become a pathogen of particular significance due to strains that are 
now resistant to virtually all licensed antibiotics (MRSA). Vibrio cholerae is the causative agent of cholera. 
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1.9 Signal Transduction 
The mechanism of converting an extracellular signal into gene expreSSIOn III bacterial TCS 
occurs via reversible protein phosphorylation (Wurgler-Murphy and Saito, 1997), hence the 
reason such systems are also classified as phosphorelay systems (figure 1.7). It is believed that 
on sensing its stimulus the histidine kinase undergoes a conformation change that results in auto-
phosphorylation within a single, conserved histidine residue. The y-phosphate of ATP is utilised 
as the high-energy phosphate source. Subsequently the phosphoryl group is then transferred to an 
aspartate residue on a cognate response regulator, resulting in activation of the regulator in 
question (Perego and Hoch, 1996). Frequently histidine kinases and response regulators are 
organised within an operon and often, though not exclusively, these proteins are members of a 
cognate pair. 
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Figure 1.7: Overview of bacterial TCS 
The figure shows the phosphoryl transfer process occurring between the histidine kinase (HPK) and its 
cognate response regulator (RR) (reproduced from Barrett and Hoch, 1998). Following detection of its 
environmental stilulus, the HPK autophosphorylates on a histidine residue. The phosphoryl group is 
transferred from the HPK to its cognate RR protein, found in the cytoplasm. The phosphorylated RR 
protein can control gene regulation by binding to promoter regions upstream of its target genes .. 
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The majority or regulators to date appear to act as transcriptional activators of a gene or set of 
genes although phosphorylated response regulators that also act to repress genes are a common 
feature. Such systems have also been described as sensory-recognition and signal transduction 
systems, although the term 'two-component systems' will be used throughout this report for 
convemence. 
1.10 Histidine kinases 
Histidine kinases are generally made up of an extracellular sensmg domain, two or more 
hydrophobic transmembrane helices traversing the cell membrane, and a cytoplasmic domain 
containing the histidine residue that is autophosphorylated. Several conserved regions or boxes, 
which are used for identifying members of the histidine protein kinase superfamily, are also 
located within the cytoplasmic domain (Grebe and Stock, 1999). Such conserved sequences 
extend for approximately 200 amino acid residues and are located at the C-terminal end of the 
protein. All histidine kinases share 20-30 % sequence homology within this region (Hakenbeck 
and Stock, 1996). The hydrophobic, transmembrane regions are situated toward the N-terminus 
of the protein (Stock et at., 1995). Histidine kinases can thus be divided into two different 
functionally and structurally distinct regions or domains, the extracellular portion that senses 
stimuli, and the cytoplasmic domain involved in autophosphorylation and phosphotransfer to the 
cognate response regulator. Due to the range of stimuli that can be detected by histidine kinase 
proteins, it is not surprising that the regions involved in sensing show the greatest diversity 
within the family. In contrast the functionally conserved boxes are associated with 
autophosphorylation and phosphoryl transfer. Histidine kinase sensing proteins tend to be found 
as homodimers that operate in trans, with the kinase domain of one subunit catalysing the 
phosphorylation of a second subunit (Stock et at., 1995; Lau et at., 1997; Dutta et at., 1999; 
Surette et at., 1999). Histidine kinases may also be assigned into either of two classes (ClassI or 
ClassII), depending on various structural differences (Bilwes et at., 1999). Figure 1.8 shows a 
schematic diagram of a typical histidine kinase EnvZ. 
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Figure 1.8: Schematic representation of a histidine kinase, EnvZ, from E. coli 
The figure shows the various regions associated with bacterial histidine kinase sensors. This particular 
sensor senses osmolarity and regulates porin expression accordingly. Homology boxes (H, X, N, G 1, DIF, 
G2) and their relative positions to one another in the primary amino acid sequence are illustrated. Only one 
member of the homodimer pair is shown for convenience and the periplasm would be covered by a further 
membrane in E. coli and other Gram-negative cells (reproduced from Hsing et al., 1998). 
Initially it was believed that the sensory region of histidine kinase sensors was an essential 
component, being the region that sensed the environmental signal (Stock et at., 1990). However, 
one study found no change in the ability of the EnvZ histidine kinase to regulate the expression 
of the outer membrane porins, OmpF and Ompe following deletion or replacement of the 
periplasmic sensing domain (Leonardo and Forst, 1996). Following these observations, the 
authors proposed that osmolarity changes are sensed directly through the transmembrane regions 
of EnvZ and that the periplasmic domain may be required for correct positioning of the 
transmembrane helices for signalling or could detect some other, as yet unidentified, signal. This 
may not be the case, however, for all histidine kinase proteins. 
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Although it is rare to have kinases that naturally lack the periplasmic / extracellular sensing 
domain, several have been identified, one example being the chemotaxis kinase CheA (Grebe 
and Stock, 1999), which senses chemical gradients using a distinct class of chemoreceptors 
known as methyl-accepting chemotaxis proteins (MCPs). This HK protein is a cytoplasmic 
protein. Other cytoplasmic HK proteins have also been identified, the NtrB nitrogen-regulating 
kinase of E. coli being an example (Stock et al., 2000). Genomic sequencing projects may assist 
in identifying other examples where sensing modules can be found to deviate from the general 
model. 
A role for the transmembrane spanning regions beyond surface anchoring is not yet clear 
although it has been proposed that they undergo a conformational change following activation, 
which results in autophosphorylation within the cytoplasmic domain. It is possible that, in E. coli 
EnvZ and similar systems, one transmembrane helix moves relative to the other during signalling 
(Hugson and Hazelbauer, 1996), but different systems may not exhibit such movement. Not all 
histidine kinases possess two transmembrane domains as described for the E. coli EnvZ sensor. 
The sensor kinase KdpD of E. coli has four predicted transmembrane helices (Zimmann et al., 
1995) and at least eight transmembrane regions are present in UhpB, a histidine kinase within the 
same organism. The histidine kinases ComD (S pneumoniae) and AgrC (S aureus), which show 
homology to TCS 13 of S pneumoniae, have 5-7 potential transmembrane segments that are 
characteristic of this group. Although most members of the histidine kinase protein family do 
display transmembrane stretches of hydrophobic amino acids, thought to be essential for correct 
functioning (Stock et al., 1990), this region may be indispensable in some members. Several 
soluble histidine kinases have been identified and were discussed above. Otterman and Koshland 
demonstrated that signalling via the Tar receptor (a signalling molecule involved in E. coli 
chemotaxis) was still functional when the transmembrane domains were deleted and the 
periplasmic and cytosolic domains were directly linked, thus creating a soluble protein 
(Ottermann and Koshland, 1997). 
1.10.1 Homology Boxes 
Members of the histidine kinase superfamily can be identified based on five conserved 
regions/motifs of similarity, named the H, N, Gl, F (D) and G2 boxes respectively (figure 1.8), 
(Alex and Simon, 1994; Grebe and Stock, 1999). These cytoplasmic sequences are arranged in 
the same order but variably spaced within kinases (Parkinson and Kofoid, 1992). As these motifs 
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display highly conserved residues they are presumed to play crucial roles in substrate binding, 
catalysis and/or structure, and have also been used to classify the histidine kinases into 
subfamilies. In some bacteria, most of the histidine kinase proteins belong to the same family but 
other bacteria have histidine kinases that represent members of many families (Foussard et ai., 
2001). From the descriptions below it can be seen that most of the conserved sequences playa 
role in nucleotide binding, implying that they are in close proximity to one another within the 
tertiary structure of the mature protein. 
Hbox 
This region contains the site of histidine phosphorylation and is the most variable of the five 
motifs. It can be found within the N-terminus of the cytoplasmic region of the histidine kinase 
and the phosphorylated histidine is usually located approximately 110 amino acids N-proximal to 
the N-box (Stock et ai., 1995). Although generally present in most histidine kinase members, 
there are examples where the phospho-accepting histidine is replaced by other residues, namely 
aspartate, tyrosine or arginine. Wu and colleagues have shown experimentally that a tyrosine 
residue in a Cauiobacter crescentus histidine kinase, DivL, is phosphorylated (Wu et ai., 1999). 
However, in most systems, if this phospho-accepting histidine residue is substituted, 
autophosphorylation and phosphatase activity are both lost (Kanamaru, 1990), although the 
region surrounding the conserved histidine residue is also likely to influence the ratio of these 
two activities. 
Nbox 
Mutations within the N region of E. coli EnvZ suggest it is critical for kinase activity. A 
mutation within this region did not bind ATP as well as the wild type, which infers that the N 
region has an involvement in nucleotide binding (Hsing et ai., 1998). 
Gland G2 boxes 
These glycine-rich regions and are also thought to be involved in nucleotide binding as they form 
an ATP-binding cavity, along with the Nand F boxes (Foussard et ai., 2001). They may also be 
associated with autokinase activity. Substitution of certain glycine residues in Gland G2 with 
alanine in the CheA HK of E. coli resulted in a reduced affinity for ATP and no detectable 
autokinase activity (Stewart et ai., 1998). Kinase and phosphatase activities may also be 
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associated with the G boxes as they playa critical role in phosphotransfer (Stewart et at., 1998). 
The G boxes, if both present, are separated by a variable sequence in which block F (also known 
in some of the literature as block D) is located. Nucleotide binding may still occur, however, 
with only one of the G boxes present, as some functional transmitters have been identified that 
lack one of these blocks. 
F(D) box 
This motif is part of the nucleotide binding domain and probably interacts with the a-group of 
the adenine ring (Grebe and Stock, 1999), although its exact function is as yet unknown. Hsing et 
at., 1998, created a mutant, in EnvZ, within this region that resulted in a porin negative 
phenotype. In eukaryotic kinases, a conserved aspartic acid/phenylalanine/glycine (DFG) motif 
is believed to be involved in chelating the Mg2+ that bridges the p and y phosphates of ATP. This 
helps to orient the phosphate moiety facilitating its transfer (Taylor et at., 1992). Thus, F(D) and 
G boxes are thought to be important in positioning of ATP for optimal phosphoryl transfer. 
X box 
One further region of potential importance in the cytoplasmic domain of histidine kinases was 
recently identified through various mutations that affected kinase or phosphatase activity (Hsing 
et at., 1998). Most of these mutations mapped to the aforementioned regions, but a novel motif, 
weakly conserved in other bacterial TCSs, was also discovered. Mutations within this region 
were found to alter the conformation of EnvZ, resulting in a significant decrease in phosphatase 
activity. This region was found to be N-terminal to the H-box and appears to be important in the 
de-phosphorylation ofOmpR~P (the cognate response regulator) in E. coli. 
Linker Region 
The region between the transmembrane hydrophobic segments and the cytoplasmic signalling 
domain of histidine kinases may also be classed as an important domain in its own right 
(Goudreau and Stock, 1998). A role for this cytoplasmic linker region has been implicated in 
signalling in the EnvZ/OmpR pathway of E. coli (Park and Inouye, 1997), and has been shown to 
adopt a closer juxtapositioning between subunits of a histidine protein kinase sensor upon 
binding of a ligand (Chen and Koshland Jr, 1997). In histidine kinases the linker regions are not 
usually well conserved (Lange et at., 1999). Lange et at., 1999, identified a region of low, but 
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significant, level of sequence similarity within the linker region in five of the histidine kinases 
identified in S. pneumoniae. This was termed the 'E box' since in all of the sequences a 
glutamate residue ('E' in the one-letter amino acid code) was present. This motif was used to 
screen databases, and several histidine kinases, including EnvZ, MCPs were found to have 
homologous regions. 
1.10.2 Unorthodox bacterial histidine kinases 
Several bacterial HK exist that do not phosphorylate on a single histidine residue as described 
above. Instead, such sensor proteins have 3 phosphorylation sites and are thus referred to as 
tripartite or unorthodox. An example of such a sensor is the TorS kinase of E. coli (Ansaldi et al., 
2001). The HK detects thimethylamine N-oxide and once activated, its cognate RR activates 
transcription of the genes encoding the thimethylamine N-oxide anaerobic system. This HK has 
two histidine phosphorylation sites and one aspartate phosphorylation site and the multi-step 
phosphorelay progresses from His(HK)-Asp(HK)-His(HK)-Asp(RR). The reason for the 
existence of such systems is unclear but it may enable additional regulation of expression. Other 
unorthodox sensors include the HK BvgS of Bordetella species. 
1.10.3 Structure of histidine kinases 
The three-dimensional structures of several response regulator proteins have now been 
elucidated but, being membrane-located proteins, the structures for histidine kinases have been 
harder to characterise. Recently, the 2.6 A resolution crystal structure of part of the CheA 
histidine kinase of Thermotoga maritima has been determined, CheA~289, (Bilwes et al., 1999), 
which possesses a chemotaxis system similar to that found in mesophilic bacteria. The two 
subunits of the CheA dimer were each found to contain separate dimerisation, kinase and 
regulatory domains with no contact occurring between the latter two (figure 1.9) 
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Figure 1.9: Structure of part of the CheA dimer from T. maritima (CbeM289) 
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The figure shows the three functionally different domains; the kinase domain, regulatory domain and 
dimerisation domain. Two monomers of CheA associate via a centrally located four-helix bundle which 
places the two ATP-binding sites (G-boxes) 90 A away from each other to form a dimer (taken from 
Bilwes et ai., 1999). 
The domain showing kinase activity is a two-layered a-p sandwich with a five-stranded p sheet 
and six a-helices, which produces a cavity presumed to be the ATP-binding site. This catalytic 
domain was found to have completely distinct topology to that of serine/threonine or tyrosine 
kinases, but did show similarity to two functionally different ATPases; the N-terminal of gyrase 
B (a type II topoisomerase) and the N-terminal of Hsp90 (a chaperone protein). The NMR 
structure of EnvZ of E. coli ,a class I kinase, was also found to show similarity to gyrase Band 
Hsp90 (Tanaka et al., 1998). However, CheA belongs to the class II group of histidine kinases 
(Bilwes et al., 1999) which show structural differences to those in class I (the latter of which 
most of the bacterial TCS concerning us are grouped), and variation in three-dimensional 
structure may thus be expected. Through sequence alignment around the H box, Bilwes and co-
workers proposed that class I histidine kinases are likely to share a similar dimerisation motif 
with CheA. This demonstrated several conserved hydrophobic residues indicative of two 
amphipathic helices preceding the kinase domain. The phosphorylated histidine residue may be 
located within this dimerisation motif for class I but is at a distant region for class II histidine 
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kinases. Dimerisation may be important for the regulation of signalling and would therefore be 
critical for histidine kinase activity. 
Hinge regions within histidine protein kinase structures may allow for movement and 
transphosphorylation to the phospho-accepting histidine residue. In multi-domain histidine 
kinases, relative movement between the domains is likely to be an essential feature of signalling, 
as mutation of a hinge residue in the CheA histidine kinase of E. coli (Arg354-Cys) reduces 
autophosphorylation and suppresses chemotaxis. In class I histidine kinases a hinge region would 
be required to allow the kinase domain to reach the histidine substrate on the dimer interface and 
then to release this region to allow for subsequent transfer of the phosphoryl group from the 
His~P to an aspartate residue on the response regulator. The availability of the crystal structure 
for CheA~289 provides an opportunity for further study into the interactions between 
domains/modules within histidine kinases and also provides a focus for drug design. 
1.11 Response regulators 
Response regulators are generally cytoplasmic proteins that associate with a cognate histidine 
kinase sensor by an unknown mechanism. This protein family share a conserved N-terminus 
sequence of approximately 125 amino acids, termed the 'receiver' domain which contains the 
aspartic acid residue that accepts the phosphoryl group from the phosphorylated histidine kinase 
in a Mg2+-dependent reaction (Goudreau and Stock, 1998). Like the C-terminus of histidine 
kinases, the conserved N-terminus of any response regulator exhibits 20-30 % amino acid 
sequence homology to other response regulators, and also contains several invariant residues. 
These include an aspartate residue near the N-terminus border of the domain, one near the centre 
and a lysine residue near the C-terminus border. These conserved residues cluster within an 
acidic pocket that serves as the site for aspartyl phosphorylation. The gain of a phosphate group 
within the receiver domain is assumed to activate the DNA-binding/transcriptional regulatory 
domain located at the C-terminus, which consequently results in activation and/or (Lange et ai., 
1999) repression of a given set of genes (Hakenbeck and Stock, 1996). A schematic structure of 
a response regulator is shown in figure 1.10. 
76 
Chapter 1 
receiver I input 
domain output domain 
Figure 1.10: Schematic diagram of a typical bacterial response regulator 
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The response regulator is phosphorylated on an aspartate (D) residue within the receiver / input domain by 
its cognate histidine kinase (not shown). Phosphorylation is thought to result in a conformation change 
allowing the activation or repression of genes by the output domain located at the C-terrninus region of the 
response regulator. 
The majority of response regulators are multi-domain proteins that are very diverse, with the 
exception of the receiver domain (Volz, 1995). These proteins have been divided into 
subfamilies based on various similarities in their C-terminal sequences, and the families are often 
named by their founder member, for example, OmpR, AraC, CheY, NtrC and FixJ (Stock et ai., 
1990; Egger et ai., 1997). Within each subfamily members associate with a different set of 
promoters, and almost identical response regulators can regulate different responses in different 
species (Hakenbeck and Stock, 1996). The response regulator of S. pneumoniae TCS08 belongs 
to the OmpR family of response regulators (Lange et ai., 1999) which contain a conserved DNA-
binding domain of approximately 150 amino acids, linked to the C-terminus of a receiver 
domain. Members are able to activate and/or repress target genes depending on features of the 
promoters with which they interact. OmpR proteins appear to function through direct contact 
with the C-terminus of the a-subunit of RNA polymerase (Pratt et ai., 1994). When these 
response regulators are not in the phosphorylated state the N-terminus receiver domains appear 
to interfere with DNA binding and/or transcriptional control by blocking the access of the C-
terminus domain. It has been proposed that phosphorylation of the receiver domain could then 
result in a conformational change which allows the active site to be exposed and thus reverses 
the inhibitory effect. This is just one possible mechanism of action of response regulators. 
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Phosphorylated receiver domains have also been shown to act in a positive manner in the 
activation process, by providing additional surfaces for intermolecular interactions (Djordjevic et 
at., 1998), or to act to enhance oligomerisation between response regulators, which in tum could 
enhance DNA binding properties. Indeed, when purified OmpR is phosphorylated in vitro, it 
dimerises and shows increased ability to bind specific target DNA sequences (Nakashima et at., 
1991). 
1.11.1 Structure of response regulators 
Che Y of E. coli was the first member of the response regulator family for which a three-
dimensional, X-ray crystallographic structure was determined (Stock et at., 1989) and from 
which further studies helped to elucidate mechanisms of phosphoryl transfer and identify 
important residues in this process (Volz and Matsumura, 1991; Stock et at., 1993). In this 
particular response regulator it was found that the signalling ability is modulated by the 
movement of the phenolic side chain of tyrosine, position 106, between the inside and outside 
positions within the CheY structure (Zhu et at., 1997). Within the receiver domain residues D-
B, D-57 and K-109 (aspartic acid and lysine residues respectively) have been implicated as 
having important roles in the phosphorylation active site (Lukat et at., 1990). Within this site, the 
presence of a hydroxyl containing amino acid (serine or threonine) is thought to be crucial for 
proper functioning. All members of the Che Y family appear to share a doubly-wound, five-
stranded, alP motif with a hydrophobic core. Until recently it was assumed that all response 
regulator domains shared this a/~ structure (Guillet et at., 2002; Im et at., 2002), but the crystal 
structure of the OmpR DNA binding domains defined a new structure for transcriptional 
activators which have been termed 'winged helix-turn-helix' motif (Martinez-Hackert and Stock, 
1997). These helix-turn-helix consensus sequences have been identified in many members of the 
OmpR families, and function in both the binding of specific DNA sequences and in the 
interaction with RNA polymerases. This provides evidence that response regulators of other 
families could have different structural features that are, as yet, unidentified. Over half of the 
response regulators identified in S. pneumoniae belong to this OmpR family, and the ones 
studied so far contain the helix-turn-helix consensus. 
A crystal structure is also available for a member of the NarL family of response regulators 
bound to DNA (Maris et at., 2002). 
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1.11.2 Phosphorylation reactions 
The chemistry of phosphorylation at histidine and aspartate residues that predominates as the 
signal transducing mechanism in bacteria is very distinct from eukaryotic phosphorylation which 
generally occurs at serine, threonine and tyrosine side chains (Stock et ai., 1990). 
The intrinsic free energies of phosphorylation of amino acids alone often differs from when these 
amino acids are residues within a protein. When isolated histidine and aspartate amino acids are 
phosphorylated, they are high-energy molecules with the equilibrium well in favour of the un-
phosphorylated state (figure 1.11). 
His 
Asp 
Figure 1.11: Phosphorylation reaction 
The phosphorylation of histidine and aspartate residues of HK and RR, respectively, lies with the 
equilibrium in favour of the un-phosphorylated form. 
When a phospho-histidine residue (his~P) within a protein is de-phosphorylated, the energy 
released is very similar to the isolated amino acid, which indicates that de-phosphorylation of 
this particular amino acid does not depend on the protein of which it is a part. This is important 
in the context of histidine-aspartate phospho transfer signal transduction where the 
phosphorylated histidine residue functions as a catalytic phosphate donor with the ability to drive 
phosphorylation of its substrate. However, the free energy of phosphorylation of aspartate within 
a protein depends on the rest of the protein structure and explains why phosphorylation of this 
residue may trigger a conformational change within the protein or response regulator in which it 
is located (Stock et ai., 1990). 
Response regulators have been shown to autophosphorylate themselves in vitro using small, low 
molecular weight phosphodonors, including phosphoramidate or acetyl phosphate (Parkinson 
and Kofoid, 1992), so a small amount of phosphorylation of these modules may occur within the 
cell without input from the cognate histidine kinase. However, the in vivo significance of this 
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phenomenon is unclear and, until recently (Throup et al., 2000), no evidence has been found in 
which a response regulator exists independently of a cognate histidine kinase. 
The phosphorylated receiver of response regulators is unstable so is readily converted to its un-
phosphorylated form. This de-phosphorylation process may be autocatalytic, although it has been 
proposed, and generally accepted, that the cognate histidine kinase protein plays a major role in 
this action (Hakenbeck and Stock, 1996; Mizuno, 1998). Thus the absolute level of 
phosphorylation of a response regulator may be determined by the ratio of kinase to phosphatase 
activities of its kinase and the autophosphatase activity of the response regulator. Systems have 
been identified whereby the kinase does not function as a phosphatase and this role is served by a 
completely distinct protein. This occurs in the Che system of chemotaxis in E. coli, where de-
phosphorylation of Che Y ~p response regulator is catalysed, independently of the CheA kinase, 
by the CheZ protein. In EnvZ, a histidine kinase involved in sensing osmolarity in E. coli, the G2 
box has been implicated as having a role in phosphatase activity (Zhu and Inouye, 2002). 
However, in NtrB, a histidine kinase involved in nitrogen regulation in E. coli, the phosphatase 
activity has been attributed to the H-box (Weiss et al., 2002). 
The half life of the phosphorylated receiver can vary from only a few seconds, as in the case of 
phospho-CheY, to several hours, as in the case of phospho-OmpR and this may play an 
important role in the type of response generated. In the case of Che Y phosphorylation, which is 
involved in the chemotactic response of E. coli, a very short half life is necessary to allow the 
bacteria to respond quickly to changes in chemotactic gradients which could occur over a very 
short time period. Such systems may thus be harder to study and elucidate than those in which 
the phosphorylated response regulator persists for longer time periods. 
1.11.3 Orphan response regulators 
Although response regulators are usually part of a TCS with a cognate HK protein, there are 
examples of 'orphan' rr genes found in the absence of a hk gene. Examples or organisms having 
unpaired response regulators in their genomes include S. pneumoniae, Listeria monocytogenes, 
Helicobacter pylori, Streptococcus agalactiae, Streptococcus suis and Campylobacter jejuni 
(Throup et al., 2000; Glaser et ai, 2001; Delany et al., 2002; Glaser et al., 2002; de Greeff et al., 
2002). Most of these rr retain the conserved active-site residues of other rr genes, with the 
exception of the orphan regulators in H pylori (Delany et al., 2002). Two studies in 
Streptococcus species have demonstrated that these RR proteins are active (Throup et al., 2000; 
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de Greeff et al., 2002). The pneumococcal unpaired rr gene (RR14) will be described elsewhere 
(introduction, section 1.14) and a null mutation in this gene was found to be highly attenuated in 
its ability to colonise the lungs in a murine model of pneumonia (Throup et al., 2000). A second 
unpaired rr gene has been described in S. suis, a pig pathogen, and a mutation within this gene 
was also found to be impaired in virulence compared to wild-type (de Greeff et al., 2002). H. 
pylori has 2 orphan response regulators, which is surprising considering that only three complete 
TCS have been identified in the genome of this Gram-negative pathogen. One of these RR 
proteins has been shown to bind to specific DNA sequences in response to growth phase. 
Phosphorylation of this RR is not a prerequisite for its activity. This RR appears to be 
autoregulatory and it is thought that this protein is tightly regulated at the post-transcriptional 
level. Interestingly, analysis of phosphotransfer reactions between purified proteins has 
illustrated that one of the complete TCS of this organism comprises hk and rr genes but these 
are encoded at distant loci (Beier and Frank, 2000). 
1.11.4 Autoinduction of bacterial TCS 
Auto-induction of the genes involved in regulation is a common feature in many bacterial TCS, 
whereby expression of the histidine kinase and response regulator genes is increased upon 
activation of the response regulator. Examples include the BvgA/S system of Bordetella species 
and the PhoPQ system of Salmonella species. Where auto-induction is present, genes other than 
the regulatory components are also regulated. Hoffer and colleagues describe an auto-
amplification system in genes of the phoRiphoB TCS of E. coli and hypothesise that such a 
mechanism can help induce a more rapid response when sensing the same conditions on 
subsequent occasions (Hoffer et al., 2001). Autoinduction is often a feature in bacterial quorum 
sensing systems to ensure that gene regulation only occurs at a certain quorum or cell density of 
bacteria. 
1.11.5 Cross regulation in bacterial TCS 
Cross regulation has been described by several researchers and is likely to play an important role 
in global control (co-ordination of several systems), linking response regulators of TCS to one 
another and/or to other general regulatory systems. The complex issues of cross regulation in 
vivo in E. coli and Salmonella typhimurium have been raised (Wanner, 1992). It appears that 
there are three separate TCS that act on the phosphate (PHD) regulon in E. coli. The histidine 
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kinase sensor, PhoR and the response regulator, PhoB, pair sense extracellular inorganic 
phosphate levels and respond accordingly. Usually, extracellular phosphate is the preferred 
phosphate source for the PHO system and is transported into the cell via the PstSCAB 
transporter. In contrast two other controls associated with expression of the PHO regulon act 
independently of inorganic phosphate. These involve metabolic pathways and are regulated by 
carbon source in different ways. The CreC sensor can be involved in regulating PhoB and is 
induced by growth on glucose while the other sensor is induced during growth on pyruvate but 
not on glucose, and is CreC independent. This regulation occurs between non-cognate partners I 
proteins not part of the same TCS. 
A recent study used micro array analysis to examine gene expression in vitro in mutants in all 
TCSs in E. coli strain K-12. This study indicated that cross regulation and cascade regulation 
have important roles in cell physiology for co-operative functioning between multiple TCSs 
(Oshima et at., 2002). Other studies have also provided evidence that sensor proteins may have 
the ability to phosphorylate non-partner regulators as well as their cognate partners. However, 
much larger amounts of the non-partner protein are required for this level of regulation, and the 
phosphorylation rates between non-partner proteins are much slower than that which occurs 
between partner proteins. For instance, Fisher et at produced evidence, again involving the PhoB 
response regulator of E. coli, whereby in vitro and in vivo activation of this response regulator 
was achieved using the cytoplasmic domain of the VanS histidine kinase from E. faecium (Fisher 
et at., 1995). This was shown to occur in the absence of the cognate kinase of PhoB (PhoR), 
CreC or acetyl phosphate synthesis, which were eliminated by mutation. The VanSN anR TCS 
of E. faecium (histidine kinase and response regulator respectively) is involved in activating 
genes that are responsible for vancomycin resistance in this Gram-positive organism. The 
resistance is achieved through activation, by VanR, of several structural genes that encode 
enzymes involved in modifying the peptidoglycan structure that ultimately results in a one 
thousand-fold decrease in the affinity for the glycopeptide antibiotic. The activation levels of the 
non-cognate response regulator, PhoB, by VanS were high with approximately ninety percent 
transfer of the phosphate group to PhoB within five minutes. However, the rate of transfer was at 
least one hundred-fold lower than that occurring between VanS and VanR. Similar studies have 
also reported on cross-regulation between non-cognate components of TCS, often demonstrating 
phosphorylation between proteins of different genera as illustrated above, demonstrating that 
histidine kinases and response regulators may be involved in very complex pathways. 
82 
Chapter 1 Introduction 
The ability to induce gene expression by a response regulator in the absence of its cognate 
histidine kinase is demonstrated by the study of Ogura and colleagues. Plasmids expressing RR 
protein were introduced into cells where the cognate HK was deleted, yet expression of the target 
genes could still be induced (Ogura et at., 2001). The mechanism behind this is not known but 
could indicate that the RR proteins were being phosphorylated by other, non-cognate HK 
proteins. It has also been observed that a deletion in a hk gene often does not result in a 
phenotypic change that is as pronounced as when the cognate rr gene is deleted. For example a 
null mutation in S. pneumoniae RR02 is lethal, whereas a null mutation in the cognate HK gene 
is not lethal (Throup et at., 2000). This suggests that RR proteins may still be able to function in 
the absence of their HK partner, possibly through cross-regulation by other HK proteins. 
1.12 Eukaryotic signalling systems 
The two-component signal transduction systems described above are abundant in, and originally 
thought to be unique to, prokaryotes. However, recent studies have reported the existence of 
homologous systems in eukaryotes. Similarly eukaryotic-type signalling domains involving 
serine, threonine and tyrosine kinase cascades have been found in bacteria through sequence 
similarity (Goudreau and Stock, 1998). However, bacterial TCS homologues have not been 
identified in mammals or other vertebrates. 
1.12.1 EUkaryotic-type signalling systems in bacteria 
Eukaryote-type systems in bacteria are classed as those that do not conform to the general 
mechanism of two-component signalling as described above, and/or involve phosphorylation of 
residues other than histidine. Several such systems have now been recognised, including a 
system in the Gram-negative gliding bacterium, Myxococcus xanthus, which uses soluble and 
transmembrane serine and threonine kinases combined with changes in tyrosine phosphorylation 
for some developmental processes (Hanlon et at., 1997). A second example occurs in the 
complex signalling cascades involved in sporulation in B. subtilis. Here, phosphorylation of a 
serine residue within the regulator for sigma factor <l occurs together with de-phosphorylation 
performed by a protein phosphatase, SpoIIE, that is a member of one of the subfamilies of 
eukaryotic serine/threonine phosphatases (Adler et at., 1997). 
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1.12.2 Prokaryote-type systems in eukaryotic organisms 
One of the first discoveries of a 'bacterial' histidine kinase within a eukaryotic orgamsm 
occurred when Popov and colleagues cloned a kinase gene from rat mitochondria and found that 
the closest homologues to this enzyme were within the protein histidine kinase family of bacteria 
(Popov et al., 1992). Although this protein has a putative catalytic histidine residue, it appears to 
phosphorylate its substrate on a pair of serine residues rather than on an aspartate residue, as is 
the case for 'typical' prokaryotic signal transduction. Subsequently, systems resembling bacterial 
TCS have been discovered in other eukaryotes, including the fungus, Neurospora crassa (Alex et 
al., 1996), and the yeast, Saccharomyces cerevisiae (Maeda et al., 1994). These results raise 
intriguing evolutionary questions as to how similar protein kinases and/or protein phosphatases 
occurred within different domains of life. For instance it is interesting to speculate on whether 
they were inherited directly from a universal ancestor or acquired through gene transfer. 
The discovery of prokaryote-like signalling proteins in eukaryotes, and vice versa, provides 
further data to support the concept that within different systems there appears to be extensive 
variation and ways in which different components of signalling systems are arranged and operate 
to create complex information processing pathways. Even within the prokaryotes themselves, a 
variety of signalling mechanisms may occur where periplasmic, transmembrane and cytoplasmic 
domains are all required for a response, or a combination of these can suffice. Sensor dimers and 
conformational changes mayor may not be required. 
1.13 Targeting TCS for therapeutic purposes 
Bacterial TCS are attractive targets for anti-microbial therapy for a number of reasons. Firstly, 
multiple TCS have been identified in most bacteria. TCS are often essential for viability (Volz 
1995; Azoulay-Dupuis et al., 1998; Lange et al., 1999) and I or virulence (Roychoudhury et al., 
1993; Dziejman and Mekalanos 1995; Rumbaugh et al., 1999 and table 1.1). Homology exists 
between TCS of different bacteria, which could facilitate the design of a broad-spectrum drug. 
Similarily, regions unique to individual TCS could be targeted to produce drugs specific for a 
given bacterium. Furthermore, homologous systems have not been identified in vertebrates so 
any drug specific for TCS should show low toxicity to the host cells (Hilliard et al., 1999). A 
drug targeting several different regions within TCS would have the additional benefit of 
overcoming the 'target-alteration' mechanism utilised by microbes to confer resistance In 
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response to antibiotics that possess a very specific mechanism of action against one target only. 
The emergence of resistance to such drugs could also be minimised as most bacteria will contain 
multiple TCS with different functions, and the ability to mutate one of these to develop 
resistance will still leave the remaining systems susceptible to the drug in question. The crystal 
structure for several response regulators and the CheA histidine kinase have now been elucidated 
(Bilwes et al., 1999; Guillet et al., 2002; Maris et al., 2002), providing a framework for rational 
drug design. Furthermore, with the increasing plethora of genome sequences that are now 
available in public databases, it is now possible to identify most/all TCS within an organism. 
Mutants can then be created within each individual system to evaluate their putative role in the 
viability / pathogenicity of the bacterium in question. 
The therapeutic approach may not necessarily need to kill the pathogenic agent to be effective, as 
a bacteriostatic effect may be desirable and easier to achieve. S. pneumoniae infection is a prime 
example where it may be desirable to inhibit growth and virulence whilst avoiding death of the 
organism, as the latter would release the inflammation inducing cell wall products and the potent 
intracellular toxin, pneumolysin. Furthermore, this would block disease rather than carriage and 
would prevent niche replacement by other potential pathogens. 
1.13.1 Potential sites for targeting TCS 
Various sites of TCS could be targeted for intervention depending on whether the drug was 
required to be broad-spectrum and thus active against both Gram-positive and Gram-negative 
organisms, or if the therapy was to be targeted against a specific pathogen. In the former case, 
sequences conserved against all TCS in bacteria would be investigated. These sequences are 
found within the autophosphorylating sites of histidine kinases and the phosphoryl-accepting 
regions of response regulators. Residues specific to a single TCS within a bacterium are located 
in the sensory region involved in stimuli detection of histidine protein kinases, and the C-
terminal of response regulators responsible for DNA binding and gene activation and/or 
repreSSIOn. 
Ideally it would be desirable to target drugs against surface components, i.e. the histidine kinase 
sensory region to avoid difficulties of drug entry into cells. In that regard, one possible obstacle 
in targeting TCS is that the histidine kinases are generally situated in the cell membrane. In 
Gram-positive bacteria this membrane will be covered by a thick layer of peptidoglycan that 
must first be penetrated. Gram-negative organisms have a thin layer of peptidoglycan but the 
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presence of an additional outer membrane. Cross regulation may also pose a problem as any 
particular set of genes controlled by a specific TCS could also be under the control of other 
systems, and thus the effect of inhibiting a given component may not be observed if the functions 
of this system can be complemented by other systems. 
1.13.2 Natural inhibitors ofTCS 
Several natural inhibitors of TCS have been described. Strauch and co-workers reported that 
oleic acid, an unsaturated fatty acid, acted to inhibit the phosphorylation of a histidine kinase in 
B. subtilis (Strauch et ai., 1992). This inhibition was non-competitive, occurred independently of 
the presence/absence of the cognate response regulator and did not inhibit bacterial growth. 
Bromoacetosyringone, another natural compound, was shown to completely inhibit expression of 
genes required for crown-gall tumour formation in the pathogenic plant bacterium A. 
tumefaciens. These genes are under the control of a two-component system and could be 
completely inhibited at concentrations that did not affect bacterial growth (Barrett and Hoch 
1998). 
1.13.3 Chemical inhibitors ofTCS 
Roychoudhury and colleagues screened approximately 25,000 natural and synthetic compounds 
for their ability to inhibit the TCS which partially controls alginate production in the Gram-
negative bacterium P. aeruginosa, an important pathogen in cystic fibrosis (Roychoudhury et ai., 
1993). Alginate is thought to promote adherence of the organism and help resist phagocytosis. 
Out of all the compounds screened, fifteen were identified as inhibitory to in vivo alginate 
production in whole cells. Four of these chemicals showing significant inhibition were studied 
further. 
Two of the chemicals (A and A') inhibited phosphorylation of the response regulator AlgRI, 
involved in alginate production, and had significant inhibitory effect on autophosphorylation of 
the cognate histidine kinase, AlgR2, above a concentration threshold of ~ 0.5 ).!g mrl. They also 
affected histidine kinase autophosphatase activity. Chemicals A and A' had no significant effect 
on the DNA-binding properties of the response regulator, AlgRl, but chemical B did inhibit 
DNA binding of this protein. These compounds appear to act at different stages in the signalling 
pathway that partially controls alginate production and so could be used in combination to help 
avoid the selection of resistant strains. However, alginate synthesis is a complex process 
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involving many genes that could be under the control of multiple systems with the ability to 
compensate for the loss of one. 
The effect of these compounds on other bacterial histidine kinases; CheA & NRII involved in 
bacterial chemotaxis and nitrogen assimilation respectively in E. coli, and the KinA histidine 
kinase involved in B. subtilis sporulation, were investigated. Chemicals Band B' appeared to 
show significant to potent inhibition of all the kinase activities tested at low concentrations and 
could therefore be general inhibitors of many bacterial kinases, whilst compounds A and A' 
showed varying degrees of inhibition depending on the system being studied. This was one of the 
first reports of inhibitors of prokaryotic kinases or phosphatases. 
A senes of diphenol-methane compounds were found to inhibit two-component systems in 
Gram-positive organisms, through high-throughput screening, with MICs of 1-4 flg mrl. 
(Domagala et at., 1997). Several other chemical groups with inhibitory activity against TCS, and 
in particular histidine kinases, have also been reported. These include benzoxazines, 
benzimidazoles, bis-phenols, cyclohexenes, trityls, salicylanilides and a family of hydrophobic 
tyramines tenned RWJ-49815 (Barrett et at., 1998; Hlasta et at., 1998; Hilliard et at., 1999; 
Kanojia et at., 1999), the latter of which were found to inhibit growth of MRSA, vancomycin-
resistance E. faecium and penicillin-resistant S. pneumoniae. Like many of the other compounds 
described with 'anti-kinase' activity, RWJ-49815 was found to be a potent inhibitor of the 
autophosphorylation reaction of the histidine kinase and is competitive with respect to ATP, 
causing a bactericidal effect. This suggests that the compound is active against the ATP binding 
site common to all two-component kinases. RWJ-49815 has also been reported to have 
antifungal properties, although the mode of action in this case appears to be independent of HK 
inhibition (Deschenes et at., 1999). An inhibitor of bacterial HK-phosphorylation has also been 
shown to have an inhibitory effect on the succinyl Co-A synthase enzyme of the parasite 
Trypanosoma brucei (Hunger-Glaser et at., 1999), and illustrates the potential of therapeutic 
compounds against a range of microbial infections. Some studies have examined the mechanisms 
of action of some of the inhibitory compounds described above in further detail (Barrett et at., 
1998; Stephenson et at., 2000). These compounds may also be of interest as basic research tools 
to probe the mechanisms of TCS signalling. 
87 
Chapter 1 Introduction 
1.13.4 Potential problems in targeting TCS 
The chemical agents described above are generally inhibitory to Gram-positive bacteria, with 
MICs ranging from 0.5-16 Ilg mrl. However, at higher concentrations than the MIC, many of the 
compounds tested affected the integrity of the bacterial cell membrane, indicating that inhibition 
by some, or all, of the chemicals may not be specific against the two-component systems 
themselves. The toxicological properties of most of the agents described have also yet to be 
established, and several that have been analysed in studies were shown to have acute in vivo 
toxicity in mice when given alone (Melton et at., 1997). Many known inhibitors are also very 
hydrophobic compounds so are not suitable as therapeutic agents (Barrett et at., 1998). 
Furthermore, many of the chemicals examined were not effective against Gram-negative 
bacteria, unless these organisms were first treated with a membrane-permeabilising compound, 
highlighting the problem posed by the Gram-negative outer membrane. Many of the chemicals 
described seem to target the ATP-binding site of histidine protein kinases and this type of site 
has been found in the serine protein kinases of anti-a factors in B. subtilis (Min et at., 1993). As 
a family of serine protein kinases possessing similar characteristics have been found in 
mitochondria (Harris et at., 1997), consideration must therefore be given to the potential 
inhibition of these mitochondrial enzymes by such chemicals. 
1.13.5 Global inhibitors of TCS 
Global regulators of virulence factors have been identified in several bacterial pathogens. The S. 
aureus AgrC/ AgrA system is such an example of global regulation which is activated in a 
quorum-sensing fashion through binding of secreted autoinducing peptide (AIP) to the HK AgrC 
protein (Ji et at., 1995). Activation of this system ultimately results in the expression of RNAIII, 
which in tum is able to activate the expression of several secreted virulence factors and down-
regulate expression of some surface proteins. Inhibition of a single global regulator thus has the 
potential to disrupt many cellular processes that could be important for survival or virulence. 
Several inhibitors of the S. aureus Agr system have been described (Matsushita and Janda, 
2002). However there is much sequence diversity between the AIP/AgrC receptor pair between 
strains, such that AlP structures that activate the AgrC HK of some strains may inhibit that of 
other strain (Lyon et at., 2000; Dufour et at., 2002). A similar phenomenon has been found with 
inhibitors of the Agr system (Matsushita and Janda, 2002). Similarly an agr-like locus is present 
in S. epidermidis and a synthetic AIP from this organism has been found to inhibit virulence 
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factor expression from the S. aureus Agr (van Wamel, 1998; Otto et at., 1999). Vaccination with 
the peptide auto inducer of the S. aureus Agr system has been shown to protect mice from S. 
aureus pathology (Balaban et at., 1998), and could be an alternative approach for targeting 
similar TCS in other pathogenic bacteria. 
A second TCS, the sae locus, demonstrating global regulation of S. aureus virulence genes has 
been described (Giraudo et at., 1997). It is thought this system controls expression of a and ~ 
haemolysins and coagulase independently of the agr system, although the latter system is also 
thought to be involved in the control of these genes. Another global regulation system in S. 
aureus, also mediated by a RRlHH pair (SrrAlSrrB) has recently been identified (Yarwood et at., 
2001). This system appears to repress virulence factor expression under low oxygen conditions 
and it is thought that regulation of this system is partly mediated by the agr system. Several other 
less well characterised systems are also involved in regUlating S. aureus virulence factors 
(Fournier et at., 2001), illustrating the highly complex nature of bacterial gene regulation in 
response to environmental stimuli. 
1.13.6 Non-bactericidal therapy 
As already mentioned, a potential therapy against bacterial TCS may not necessarily have to be 
bactericidal to be effective. Many TCS have been described that play some role in the emergence 
of antibiotic resistance or tolerance, and inhibition of these systems without killing the host cell 
may render the bacterium sensitive to antibiotics again. S. pneumoniae, for example, has several 
such systems, including a TCS involved in vancomycin tolerance and one with a role in 
penicillin resistance. The former system, VncSNncR, is required in a fully functional form to 
render the pneumococcus susceptible to the antibiotic vancomycin. The antibiotic is the stimulus 
for the histidine kinase (VncS) and resulting activation of this sensor results in de-
phosphorylation of the cognate response regulator (compared to other histidine kinases which 
tend to phosphorylate their cognate response regulator when activated). This de-phosphorylation 
reaction undoes the repression of autolysin activity controlled by the phosphorylated response 
regulator. As a result, this enzyme is free to partake in the disruption of the cell wall, leading to 
eventual cell death due to the presence of vancomycin. In S. pneumoniae, insertion-duplication 
mutagenesis to create a knock-out mutant in VncS resulted in tolerance both to vancomycin and 
other classes of antibiotic, including beta-Iactams, cephalosporins, aminoglycosides and 
quinolones (Novak et at., 1999b). Activation of this system could therefore help in the 
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susceptibility of the pneumococcus to vancomycin. This is in contrast to the situation in E. 
faecalis where high level vancomycin resistance is regulated by the VanRIVanS TCS, the 
inhibition of which should render a resistant organism sensitive to vancomycin again. 
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RR TIGR4 R6 gene Common Possible function Tigr4/R6 Orientation Reference 
gene name name protein 
name homology 
RROI /480 SPl633 Spr1474 Unknown 100% RRIHK (-) Lange et al 
Throup et al 
RR02 /492 SPI227 Spr1107 MicA Redox / energy sensing. Essential for 100% RRlHK (-) Lange et al 
viability. Competence? Throup et al 
Homologous to B. subtilis yycFG Echenique et aI, 2001 
RR03 /474 SP0387 Spr0344 Homologous to B. subtilis yvqCE 100% HKIRR(+) Lange et al 
Throup et al 
RR04/481 SP2082 Spr1893 PnpR Phosphate metabolism? 100% RRIHK(+) Novak et al (1999a) 
Homologous to B. subtilis phoPR 
RR05 /494 SP0798 Spr0707 CiaR Involved in competence and penicillin 100% RRlHK(+) Giammarinaro et aI, 
susceptibility 1999 
RR06 / 478 SP2193 Spr1998 CbpA regulation? 99% RRIHK (-) Our laboratory, 
unpublished data 
RR07 / 539 SP0156 Spr0154 Unknown 98% HKIRR(+) Lange et al 
Throup et al 
RR08 /484 SP0083 Spr0076 Unknown 99% RRlHK(+) Lange et al 
Throup et al 
RR09 / 488 SP0661 Spr0578 Role in virulence. Nutrient perception? 100% RRIHK(+) This work 
RRlO / 491 SP0603 Spr0528 VncR Vancomycin tolerance 100% RRlHK(+) Novak et al (199b) 
RR11 /479 SP2000 Spr1814 Homologous to B. subtilis yvITU 93% HKIRR (-) Lange et al 
Throup et al 
RR12 / 498 SP2235 Spr2041 ComE Competence regulation / quorum sensing 100% HKIRR(-) Lacks and Greenberg, 
2001 
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RR13 /486 SP0526 Spr0463 BlpR/ Bacteriocin production / quorum sensing 97% RRIHK(+) De Saizieu et aI., 
RR14 
2000 
SpiR Reichmann and 
Hakenbeck, 2000 
SP0376 Spr0336 Unknown 99% RR(+) Throup et al 
Table 1.4: Response regulators of S. pneumoniae 
RR detailed are those detected in the TIGR4 sequence of S. pneumoniae identified by Hoffmann-La-Roche and SmitbKline-Beecham (Lange et al., 
1999, Throup et aI., 2000). The nomenclature TCS01-TCS13 (designated by Lange et aI., 1999) by which the TCS are referred to in this work are given 
in the first column. The corresponding names given by Throup et aI., are also provided in this column. The official gene names as given by the two 
sequencing projects for strains TIGR4 (serotype 4) and R6 (serotype 2) are provided for reference. Several of the systems have been studied previously 
and thus are known by more common names, often with reference to the processes the systems control. These are also provided. Putative functions still 
to be confirmed are followed by a question mark. Homology between the RR proteins ofTIGR4 and R6 sequences is indicated. The orientation of the 
HKIRR pairs on the bacterial chromosome are given. A plus sign (+) indicates genes encoded on the positive strand. The minus (-) symbol represents 
gene pairs encoded on the negative/complementary strand. 
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1.14 TCS in Streptococcus pneumoniae 
Groups at Hoffmann-La-Roche and SmithKline-Beecham (now GlaxoSmithKline) have used 
genomic analysis to identify all the TCS in a virulent serotype 4 pneumococcus (Lange et ai., 
1999; Throup et ai., 2000), of which thirteen HKIRR pairs were found. Throup et ai identified a 
further, unpaired response regulator (Throup et ai., 2000). All thirteen HKIRR pairs have been 
identified in all the pneumococcal genomes that have been sequenced to date (Dopazo et ai. 
2001; Hoskins et ai., 2001; Tettelin et ai., 2001). All TIGR4 TCS genes had a median G + C 
content of approximately 42 %, with the exception of TCS 12 (ComDIE) which had a G+C 
content of 31 %, which is comparatively low. The median G+C content for S. pneul110niae is 
42.2 % (TIGR4) / 39.1 % (R6) (http://www.tigr.org/), suggesting that the ComD/E system may 
have been acquired from an external source. Indeed the comelDIE operon is flanked by 2 tRNA 
loci which are the preferred integration sites for other bacterial pathogenicity islands (Ohlsen et 
ai.,1999). The coding sequences of individual gene pairs of pneumococcal TCS were found to 
overlap or were spaced by no more than 11 base pairs suggesting that, for many systems, the 
histidine kinase/response regulator genes are transcribed as a single transcriptional unit. Table 
1.4 summarises the pneumococcal TCS. 
1.14.1 Response regulators of S. plleu11lolliae 
Fourteen putative response regulator genes were identified in the pneumococcus, thirteen of 
which are found paired to a histidine kinase gene. The receiver domains of the pneumococcal 
response regulators were all shown to contain the three invariant residues corresponding to D-13, 
D-S7 and K-I09 of the CheY phosphorylation / active site (Lukat et ai., 1990), together with a 
conserved threonine thought to be important for function. All thirteen RR also display 
hydrophobic regions that correspond to the ~-sheets 1, 3 and 4 present in the hydrophobic inner 
core of Che Y. This indicates that the S. pneul110niae receiver domains adopt a similar tertiary 
fold to the Che Y response regulator in S. typhil11urium. Alignments of the receiver domain 
sequences of the response regulators studied in detail in this work, RR08 and RR09, compared to 
CheY are shown in figure 1.12. Lange et ai., (Lange et ai., 1999) provide alignments of other 
pneumococcal RRs. 
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Figure 1.12: Alignments of pneumococcal RR08 and RR09 receiver domains compared to S. 
typltilllllrilllll CheY 
Sequences from TIGR4 and R6 genomes are given. Homologous amino acids are highlighted. The three 
conserved aspartic acid/lysine residues impOltant in the receiver domain active site are indicated with an 
asterix (*). The conserved threonine residue important for function is indicated by \jI . 
The response regulators of S. pneumoniae fall into four major families (OmpRIPhoB, 
AraC/XyIS, LuxRlFixJ and CornEl ArgA) when grouped on both similarities within the receiver 
domain and homologies within the output domain. Three-dimensional crystal structures are 
available for members of the families with the exception of CornEl ArgA. The two response 
regulators in the AraC family (RR07 & RR09) are the first response regulator representatives of 
this family to be identified. The AraC-type DNA binding domain of this family comprises 
seventeen highly conserved positions extending over 99 amino-acids, and has a different three-
dimensional structure to other response regulators previously described. Seven of the thirteen 
response regulators, including TCS08, were identified as being in the OmpR family, where the 
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output domain comprises three a -helices flanked on either side by anti-parallel p-sheets and two 
C-terminal p-sheets. This forms the 'winged-helix-tum-helix' motif described previously 
(Martinez-Hackertand and Stock, 1997). TCS13 has been grouped, along with the previously 
characterised response regulator ComE, into the ArgNComE class of DNA binding proteins. 
Although no structural data are available on this family, a cluster of basic amino-acid residues 
has been identified within the C-terminal (Pestova et aI., 1996). This charged region may have a 
role in DNA binding. 
1.14.2 Histidine kinases of S. plleulIlolliae 
The histidine kinases of S. pneumoniae were identified on the basis of their paired association to 
response regulators on the chromosome and on the homology boxes. All of the histidine kinases 
were found to have the linker region (E box) and H, Nand G boxes, although histidine kinases 
from TCS03 , TCS07 and TCS 11 were found to have unusual G boxes that were different to the 
typical GXGL motif (see Figure 1.13). HK06, HK10, HK12 and HK13 all lack a D box. HK03 , 
HK07 and HK09-13 do not possess an F-box, suggesting that D and F boxes are not essential for 
activity in these systems. 
S~ . YLSKKl HKOI G tl SlAKEl HK02 
DLS · RNlKER HK03 
~i · AlVKEL HK04 YlVNNl HK05 SS · YlVNNl HK06 
RQSl lVNVHER HK07 
AlAREL HK08 
QNVDQR HK09 
FVVKSL HKIO 
HTVRNR HKll 
NNVKEL HK12 
E YTVMKl HK13 
Figure 1.13: Alignment of the G-box sequences of S. pllellmolliae histidine kinases 
Sequences were taken from the published sequence for a serotype 4 pneumococcus (Tettelin et al., 2001). 
The GxGL motif characteristic of the G-box is conserved in all but three of the pneumococcal HKs; HK03, 
HK07 and HK 11. 
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Transmembrane segments within the N-terminus of the histidine kinases were predicted and 
results revealed 1, 5 or 7 potential transmembrane segments. All the histidine kinases are thus 
predicted to be membrane-bound. The pairs of histidine kinases and response regulators were 
predominantly arranged with the response regulator gene first, followed by the histidine kinase 
gene (TCS01, TCS02, TCS04, TCS05, TCS06, TCS08, TCS09, TCS10, TCS13), although in 
some cases the kinase gene occurred first (TCS03, TCS07, TCS11, TCS12). 
1.14.3 Functions of TCS in S. plleulIlolliae 
Several of the pneumococcal two-component systems identified have been characterised 
previously and their functions are known. Of these, the ComDIE system (TCS12) involved in the 
regulation of competence is probably the best characterised. Competence refers to the ability of 
certain bacteria to take up DNA from their external environment. In S. pneumoniae, DNA uptake 
is regulated, in part, by a quorum sensing mechanism. The regulation of the early competence 
genes is thought to be in response to oxygen availability (Echenique and Trombe, 2001). The 
bacteria secrete a competence stimulating peptide (CSP) (Havarstein et at., 1995) which, at a 
certain cell density, serves to activate a membrane bound HK, ComD. HK~P subsequently 
transfers its phosphoryl group to its cognate RR, ComE. Activated ComE serves to regulate 
genes involved in the uptake of DNA. The ComD/E TCS is also an example of an auto-
regulatory system and the process is summarised in figure 1.14. Creation of a null mutant within 
comE results in bacteria that are unable to respond to CSP and a subsequent loss in competence 
(Pestova et at., 1996). However, one study created a single amino-acid change in the C-termina1 
region of comE that resulted in cells becoming constitutively competent, even in the absence of 
CSP (Lacks and Greenberg, 2001). Other systems thought to playa role in the regulation of 
competence in the pneumococcus are PnpSIR (TCS04), CiaRIH (TCS05) and MicAiB (TCS02) 
(Guenzi et at., 1994; Giammarinaro et at., 1999; Novak et at., 1999; Echenique et at., 2000, 
Martin et at., 2000; Echenique and Trombe, 2001). The PnpS/R system has recently been 
described as a potential phosphate-sensing system with a possible role in competence (Novak et 
at, 1999). MicBI A (TCS02) is a TCS that may be involved in the negative regulation of 
competence under limiting oxygen concentrations (Echenique and Trombe, 2001). The hk and rr 
genes of TCS02 form a single transcriptional unit, together with a third gene encoding a putative 
protein of unknown function (Wagner et at., 2002). It is the only TCS in S. pneumoniae that 
contains a PAS domain. PAS domains are widely distributed and can monitor changes in light, 
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redox potential, oxygen and the overall energy levels of a cell (Taylor and Zhulin, 1999). PAS 
domains are commonly involved in sensing intracellular signals, so the activating signal for 
TCS02 may reside within the bacterial cell (Wagner et al., 2002). Several groups have reported 
the inability to create mutations in the response regulator gene of this TCS, indicating that the 
system is essential for viability, and presumably regulates cellular functions other than 
competence (Lange et al., 1999; Throup et al., 2000; Echenique and Trombe, 2001). 
Furthermore, homologues of this system exist in other Gram-positive bacteria, including B. 
subtilis and S, aureus, where the systems also appear to be essential for cell viability (Fabret and 
Hoch, 1998; Wagner et al., 2002), although the exact function of these systems is unknown. A 
mutation in the hk02 gene was found to have a 400-fold reduction in transformation frequency 
compared to the parental wild-type strain (Wagner et al., 2002). A mutation over-expressing 
HK02 was shown to result in longer murine survival times compared to wild-type parental strain 
when administered by intraperitoneal injection, suggesting the system may have a role in 
virulence (Wagner et al., 2002). 
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Figure 1.14: Competence regulation in S. pllelllllolliae 
Competence is a complex series of events that eventually lead to the uptake of DNA from the external 
environment. It is mediated by CSP, which is encoded, as a pre-cursor, by the come gene. The peptide 
precursor is cleaved during export through the ATP-binding cassette (ABC), encoded by comAIB. Mature, 
secreted CSP accumulates in the external medium and, upon reaching a critical cell density, is able to bind 
to and activate the membrane-located HK protein, encoded by comD. Phosphoryl transfer proceeds from 
the activated HK protein to the intracellular RR protein, encoded by comE. Phosphorylated RR can auto-
regulate expression of the comelDIE and comAIB operons and also activates transcription of cornX / early 
competence genes which encode a SigH-like transcription factor (not shown). This then serves to activate 
genes involved in DNA uptake apparatus, together with other genes involved in competence (late 
competence genes). Development of competence is extremely complex, involving activation and repression 
of different genes or sets of genes at different stages of the process and this diagram represents a simplified 
overview of the events. Indeed other pneumococcal TCS, CiaHIR (TCS05) and TCS02 are also involved in 
the mechanism (Giammarinaro, et ai, 1999,and Echenique and Trombe, 2001). The comelDIE system is 
autoregulated. Genes other than the comelDIE operon are also regulated by activated RR (RR-P). (Lee and 
MOlTison, 1999, Lacks and Greenberg, 2001 and Berge et al., 2002). Phosphorylated ComE-P may also 
regulate expression of the comAB operon as a ComE binding site upstream of this operon has been 
identified (Martin et al., 2000). 
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A further system involved in competence regulation is the CiaRH system (TCS05). This system 
appears to function as a pleiotropic regulator, controlling several diverse functions within the 
cell. Much of the characterisation of this system to date has resulted from experiments into the 
mechanism of ~-lactam resistance in the pneumococcus. Until recently it was thought that 
resistance to this class of antibiotics was solely attributed to the alteration of penicillin binding 
proteins (PBPs), cell wall enzymes involved in peptidoglycan synthesis. These proteins are the 
cellular targets for ~-lactams and accumulations of point mutations in their structure can result in 
decreased affinity for the binding of ~-lactam antibiotics. However, laboratory experiments 
designed to isolate mutations that resulted in increased resistance to antibiotics detected a point 
mutation in ciaR that resulted in resistance to cefotaxime (a third generation cephalosporin / ~­
lactam) in the absence of any alteration in PBPs (Guenzi et at., 1994). This mutation (CiaH*) 
appears to result in constitutive expression of ciaRH through the inability of the CiaH* mutant to 
de-phosphorylated activated CiaR. The kinase activity of CiaH* was not affected by the 
mutation. This mutant could not be transformed and it was demonstrated that mutants were 
unable to express CSP, indicating that activation of the CiaRH system is involved in repressing 
the early stages of competence in pneumococcal cells. Regulation of expression of competence-
related genes other than CSP were suspected as the addition of exogenous CSP failed to abolish 
the defective transformation phenotype (Guenzi et at., 1994). Null mutations in the ciaH and 
ciaR genes were created and were not found to be attenuated in transformation ability. Of these 
mutants, only the ciaH null mutation (and CiaH*) was resistant to cefotaxime indicating that the 
CiaR protein is required for resistance to this ~-lactam, but this requirement is independent of the 
phosphorylation state of the response regulator (Guenzi et at., 1994). Alternatively, in the 
absence of the CiaH histidine kinase, CiaH may be phosphorylated by other means. Another 
study showed that inactivation of ciaR affects expression of the comCDE operon more 
drastically than inactivation of ciaH, providing further evidence that the non-phosphorylated 
response regulator / phosphorylation by other proteins can repress competence (Martin et at., 
2000). It is not known if the CiaRH system controls the competence-related genes directly or if 
the negative regulation of transformation is indirect. A 24 bp long sequence within the promotor 
region of comCDE and ciaRH has been shown to exhibit 83 % identity, indicating that CiaR~P 
could directly regulate expression of the comCDE operon. Other phenotypes that were attributed 
to the CiaH* mutant included resistance to lysis by deoxycholate (DOC), penicillin and several 
other antibiotics, indicating a role for this system in regulation of cell wall biosynthesis 
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(Giammarinaro et at, 1999). Indeed one group have reported preliminary data demonstrating that 
the CiaRH system controls the level of the lipid carrier, bactoprenol, involved in cell wall / 
peptidoglycan synthesis (Hakenbeck et at., 1999). The link between the regulation of 
competence and resistance to ~-lactams is not understood, the system may sense disruption of 
cell wall integrity, which is important for both competence and resistance to ~-lactam antibiotics. 
Several studies have eluded to the possible sensory signals to which the CiaRH system responds. 
The development of competence requires several cations, including Ca2+, Mg2+ and Zn2+, 
phosphate, oxygen and other environmental factors. One group has demonstrated that low Ca2+ 
activates transcription of the ciaRH operon and that this activation is also increased upon 
increasing phosphate concentration. It was thus proposed that low Ca2+ was required for CiaH 
activation and that the addition of phosphate served to decrease Ca2+ levels further by reacting 
with this cation to remove it from the system (Giammarinaro et at., 1999). A second study, 
examining the requirement of oxygen for development of competence, isolated mutants in ciaH 
that enabled transformation when cells were grown in low oxygen environments and thus 
proposed that competence development in aerobic cultures was a result of the lifting of CiaRH-
mediated repression of competence genes (Echenique et at., 2000). Thus low oxygen 
concentrations may also activate the CiaRH system. 
Several studies have indicated a role for the CiaRH system in pneumococcal virulence. A ciaRH 
mutant was highly attenuated in a systemic model of infection (Marra et at., 2002) and had 
reduced counts in the lungs following intranasal infection (Throup et at., 2000). In another study, 
mutations in ciaRH were significantly impaired in their ability to colonise the nasopharynx using 
an infant rat model of colonisation (Sebert et at., 2002). This study subsequently used micro array 
analysis to compare the gene expression between the ciaRH mutant and its isogenic parental 
strain and found 24 genes that had significantly altered regulation in the mutant strain. These 
genes were specific to the CiaRH TCS and not altered in other pneumococcal TCS mutants. The 
study identified one gene in particular, htrA, that had a 27-fold reduction in expression in the 
ciaRH mutant compared to the wild-type strain. A null mutation was created in this gene and the 
resulting mutant was significantly impaired in colonisation (Sebert et at., 2002). The htrA gene is 
thought to encode a serine protease and homologues of this gene have been identified in other 
bacteria. Of the genes with altered expression levels in the ciaRH mutant, 12 were significantly 
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down-regulated and 12 were significantly up-regulated. Many of these genes were not linked to 
competence or any of the other phenotypes thought to be associated with this system. This 
highlights the complex nature of gene regulation by the CiaRH system and indicates that the 
system may be involved in regulating a plethora of cellular functions not yet identified. Figure 
1.15 summarises the data available on the CiaRH TCS. 
CiaR 
Activates htr A 
(required for coloni sation) 
Penici llin / cefotaxime 
resistance 
Represses competence 
genes 
Other function s '?? 
Regulates cell wall 
synthesis 
Figure 1.15 Summary of the S. pllellmolliae CiaRH system (TCS05) 
The signals to which the CiaH protein responds are not well understood, but low Ca 2+ and low oxygen 
may both have a role in activating this system. Other environmental factors may also be involved. The 
activated system has been shown to result in resistance to p-lactam antibiotics in laboratory mutants and its 
role in repressing the development of competence is well recognised. The system appears to regulate cell 
wall synthesis and is required for nasopharyngeal colonisation in an animal model. MicroalTay data also 
implies a role for this system in the regulation of many other genes. The figure is based on published data 
discussed within the text. 
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Several pneumococcal TCS have been implied to have a role in resistance or tolerance to 
antibiotics. CiaRfH, as discussed above has a role in penicillin I ~-lactam resistance. VncS/R 
(TCSI0) has been proposed to have a role in vancomycin tolerance (Novak et al., 1999b; Novak, 
et al., 2000) and has been described above (section 1.13.6). 
One other pneumococcal TCS that has been characterised is TCS 13. This system has been shown 
to be a quorum sensing system activated by a auto-induced peptide and it appears to regulate the 
production of an ABC transporter and a set 16 of bacteriocin-like genes (de Saizieu et al., 2000; 
Reichmann and Hakenbeck, 2000). Bacteriocins are potent proteins produced by bacteria that 
can inhibit the growth or kill closely related bacterial species. They have been well characterised 
in many lactic acid bacteria so their presence in S. pneumoniae is not surprising. However, 
bactericidal activity for these putative bacteriocins has not been identified to date. 
Some of the systems also showed homology to the yvfTU, yycFG, yvqCE and phoPR TCS pairs 
of B. subtilis. Of these, only the phoPR and yycFG systems have been previously studied and are 
responsible for phosphate regulation and in vitro growth respectively. Both Lange and co-
workers and Throup and co-workers (Lange et al., 1999; Throup et al., 2000) attempted to 
created a mutant in the response regulator that showed homology to yycFG (TCS02), but were 
not successful. This response regulator thus appears to be essential for growth and viability of S. 
pneumoniae and is a possible drug target. Only three other bacterial RR had previously been 
identified as being essential for viability, the B. subtilis yycF with the other two being in 
Caulobacter crescentus (Hecht et al., 1995; Quon et al., 1996). Homologues of the yycFG 
system have been identified in many Gram-positive bacteria through genome data base analysis, 
which suggests that this TCS may have an essential role in such bacteria (Throup et al., 2000). 
1.14.4 S. pneu11lo11iae TCS studied in this work 
TCS08 
This system was first identified by researchers at Hoffmann-La-Roche (Lange et al., 1999) and 
later by SmithKline Beecham (Throup et al., 2000). The environmental signal to which this TCS 
responds is unknown and the function of this system has not been determined, although it may 
have a role in virulence (discussed in section 1.14.5). Hoffmann-La-Roche have done 
preliminary array experiments with this TCS using a custom designed Affymetrix array based on 
the TIGR4 sequence. This work indicated that the activated response regulator appears to induce 
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the expression of a single surface protein, designated Sp0082, which is located immediately 
upstream of TCS08 (unpublished data) (figure 1.16). This clear-cut correlation between a TCS 
and a surface protein was one of the reasons we chose to study this system. 
spOOB2 rrOB hkOB rpS4 
Figure 1.16: S. plleumoll;ae TCS08 locus and surrounding genes 
rrOB and hkOB designate genes for the response regulator and histidine kinase proteins respectively. spOOB2 
encodes a surface protein and the rpS4 gene encodes ribosomal protein S4. Genes are not drawn to scale 
but represent approximate relations in size between genes shown. The closed circle represents a rho-
independent transcriptional terminator. 
The response regulator of TCS08 belongs to the OmpR family of regulators, and levels within 
the cell have been shown to vary from between 100-200 molecules per cell. RR08 expression is 
thought to be auto-regulated (Hoffmann-La-Roche, personal communication). The histidine 
kinase possesses all the conserved regions/boxes characteristic of other HK proteins and is 
predicted to have 2 transmembrane helices (Lange et at., 1999). 
Mature Sp0082 is a 83 KD protein with 857 ammo acids, and its expression appears to be 
induced in stationary phase or when pneumococcal cells are grown as a biofilm (Lange et at., 
1999). The sp0082 gene codes for a typical surface protein precursor with a LPXTG cell wall 
anchor motif at the C-terminus region. The N-terminal has a unique domain of ~100 amino-
acids. The function of the protein is unknown and it shows homology to other bacterial proteins 
including those in S. agatactiae, Lactococcus tactis and S. aureus. A knock-out in the sp0082 
gene does not affect the expression ofTCS08 (Lange et at., 1999). 
TCS09 
As for TCS08, this system was identified based on sequence homology to other bacterial TCS 
(Lange et at., 1999; Throup et at., 2000). The function of this system is unknown, although 
Lange and colleagues proposed a role for nutrient perception. This was on the basis of some 
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homology between HK09 and two proteins involved in nutrient sensing and chemotaxis in B. 
subtilis (McpA and McpB). No further data exist to provide evidence for this putative role. The 
TCS09 locus and surrounding genes are illustrated in figure 1.17. 
0.94Kb 5.65 Kb 
msrA rr09 hk09 chp zmpB 
Figure 1.17: S. plleUmOIl;ae TCS09 locus and surrounding genes 
The rrlhk genes make up S. pneumoniae tcs09. Downstream of the tcs09 locus is a conserved hypothetical 
protein (chp) and a gene, zmpB, encoding a putative zinc metalloprotease (Berge et aT., 2001; Novak et aT., 
2000). Immediately upstream of tcs09 is the msrA gene, encoding a methionine sulphoxide reductase, also 
important in virulence (Wizemann et aT., 1996). The closed circles represent rho-independent 
transcriptional terminators. 
Although this TCS has been referred to as ZmpR/ZmpS in recent studies (Novak et at., 2000; 
Hava and Camilli, 2002), it is not known if any of the genes surrounding S. pneumoniae tcs09 
are actually regulated by this system. One group investigated this hypothesis but did not obtain a 
similar phenotype in a knock-out mutation of this system compared to a zmpB-deficient mutant 
(Novak et at., 2000). This, however, does not eliminate the possibility of regulation of zmpB, as 
mutating one single TCS may not be sufficient to expose any regulatory links. The same group 
found a single transcript for the chp and zmpB genes, indicating that these genes form an operon 
(Novak et at., 2000), as indicated by the transcriptional terminators shown on figure 1.17. 
1.14.5 III vivo role of TCS in S. plleulIlolliae 
Lange and colleagues and Throup and colleagues created mutant S. pneumoniae strains by 
inactivating each of the 12 response regulators that would not result in cell death (Lange et at., 
1999; Throup et at., 2000). Lange and colleagues used insertional mutagenesis to disrupt all rr 
genes. Throup and colleagues used the technique of allelic replacement to delete either the rr 
genes or the whole hklrr pair. The former group inoculated mice intraperitoneally with each of 
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these mutants and found no significant difference in the ability to cause bacteraemia in vivo 
compared to wild-type. The latter group, however, used intranasal infection of mice and 
enumerated bacterial load from lung tissue samples. Eight response regulator mutants showed a 
dramatic decrease in in vivo lung counts 48 hr post infection compared to wild-type (RR01, 
RR04, RR05-08, RR13 and the fourteenth unpaired response regulator identified by this group 
[RR14]). However such mutants had little detrimental effect on in vitro bacterial growth in 
nutrient-replete conditions. (RR12 was not studied in vivo). A time-course study followed the 
growth of mutants within the lung tissue at pre-selected time points. This identified three TCS 
that had similar counts to wild-type parental strain at earlier time points but a significant 
reduction was observed at later time points (TCS06, TCS13 and the un-paired RR14, Throup et 
at, 2000). This indicates that TCS may contribute differently to various stages of infection. 
The eight TCS that showed reduced virulence in the lung in the work by Throup and colleagues 
were analysed in a separate study for their ability to colonise the nasopharynx in an infant rat 
model (Sebert et at., 2002). Only one system (CiaHIR I TCS05) was found to have reduced 
colonisation in this model of infection (the system was determined to be essential for 
colonisation), indicating the importance of TCS for sensing different environments and 
expressing their genes accordingly. 
Other studies using techniques for the large-scale identification of pneumococcal virulence 
factors have identified several pneumococcal TCS as having a role in virulence (Lau et at., 2001; 
Marra et at., 2002; Hava and Camilli, 2002). Three groups have used signature tagged 
mutagenesis (STM) screens using serotype 19, 3 and 4 pneumococcus, respectively (Polissi et 
at., 1998; Lau et at., 2001; Hava and Camilli, 2002). The first STM study identified 126 different 
genes that were attenuated in virulence and were subsequently analysed individually in a murine 
model. However, none of the TCS genes were included in the detailed analysis, although not all 
attenuated genes were listed (Polissi et at., 1998). Lau and colleagues used the same serotype 3 
strain (0100993) used for the identification of all pneumococcal TCS and their virulence studies 
within the lungs (Throup et at., 2000) and found HK07 to be highly attenuated in a competitive 
model of pneumonia (lung counts 48-72 hr post i.n. challenge). ComDIHK12 was also attenuated 
in a competitive model of pneumonia and bacteraemia (bacterial load in the spleen 16-24 hr post 
intraperitoneal [i.p.] challenge) (Lau et at., 2001). The most recent STM screen used a derivative 
of the TIGR4 sequenced pneumococcal strain and found no detectable hybridisation signal for 
the output pools of rrOl, rr07, rr09 and hk12 mutants following i.n. challenge with subsequent 
105 
Chapter 1 Introduction 
recovery of pools from lung tissue 44 hr post challenge (compared to output pools) (Hava and 
Camilli, 2002). A BlpA mutant, a transporter thought to be linked to the quorum sensing TCS13, 
also failed to produce a detectable output signal in this pneumonia model. RR01, RR07 and 
RR09 were analysed further in competition studies in combination with WT parental strain using 
three models of infection (pneumonia, bacteraemia and nasopharyngeal colonisation). The RR07 
mutant was not attenuated in any of the models tested. This does not agree with the attenuated 
phenotype seen in the lung tissues by Throup and co-workers (Throup et at., 2000) but does 
agree with the bacteraemia model described by Lange and co-workers (Lange et at., 1999) where 
no reduction in virulence following i.p. challenge was demonstrated. RR01 was found to be 
attenuated in all three models which is in agreement with Throup and colleagues but not with the 
data presented by Lange and colleagues. The RR09 mutant was found to be highly attenuated in 
lung counts only following i.n. infection. This is in agreement with the bacteraemia data of 
Lange and others, who found no difference for any of the TCS mutants following i.p. challenge. 
Throup and co-workers did find that the mean lung count of the RR09 mutant was lower than 
that of WT but this was not deemed to be 'highly attenuated'. This final discrepancy could 
merely highlight differences in the way data is interpreted between studies. 
Differential fluorescence induction (DFI) has also been used to identify promoters that are 
induced over two-fold under a variety of environmental conditions (Marra et at., 2002). This 
study used a serotype 2 pneumococcus (D39) and found a 4.8 fold increase in expression of 
TCS05 (CiaH/R) and a mutation in this operon resulted in attenuation in systemic infection (i.p., 
LD50 dose) but not in a RTI model (lung counts and bacteraemia following i.n. challenge). 
These data are in complete disagreement to published data from other studies (Lange et at., 1999 
and Throup et at., 2000). TCS04 (PnpSIR) was identified in a RTI model as having increased 
expression but attempts at making a mutation within this system were unsuccessful. Genes 
within tcs03 were induced greater than two-fold under conditions where temperature was altered, 
although the role in virulence of this system was not determined. 
The differences seen in the in vivo experiments described may be attributed to different routes of 
administration, different pneumococcal strains/ serotypes or use of different animal models. 
Alternatively the different methods of mutagenesis used to create the mutants (insertional 
duplication, allelic replacement and STM) may contribute to the differences in observed 
phenotypes. It was also noted that disruption of the hk gene often resulted in substantially less 
attenuation compared to disruption of the cognate rr gene (Throup et at, 2000). This could 
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indicate that cross-regulation could be occumng, where the HK of one system is able to 
compensate for the loss of a HK sensor in a different system. Furthermore individual studies 
define their parameters of virulence differently, some using single analysis, others using 
competitive studies, so the significance of results may be interpreted in various ways. The 
definitions of infection models also vary. For example, separate studies defined bacteraemia as 
counts in the blood (Hava and Camilli, 2002) or spleen following i.p. challenge (Lau et at., 2001) 
and another study defined it as the challenge dose that resulted in 50 % mortality of animals 
following i.p. injection (Marra et at., 2002). Bacteraemia may also refer to counts in the blood 
following i.n. challenge (Kerr et at., 2002). Caution must therefore be used when comparing data 
from individual studies. 
A response regulator, RevS, that appears to have a role in virulence in the pig pathogen S. suis 
has been shown have 61 % similarity to pneumococcal RR13, a system proposed to have a role 
in regulating a set of bacteriocin-like genes (Lange et at., 2000; Reichmann and Hakenbeck, 
2000; de Greeff et at., 2002; de Greeff, personal communication). Upstream of revS is an 
incomplete open reading frame that shows homology to a conserved hypothetical protein of 
several organisms, including S. pneumoniae. In the pneumococcal genome, this conserved 
hypothetical protein does not appear to be in close proximity to any of the TCSs or the unpaired 
RR14. The S. suis RevS protein was initially selected under iron-restricted conditions (Smith et 
at., 2001). A mutation in the revS gene had identical in vitro growth rate compared to the 
parental strain, but infected less organs and had lower counts in organs that were infected in a 
piglet model of infection (de Greeff et at., 2002). 
The contribution of various TCS to the virulence of S. pneumoniae to date has been summarised 
in tables 1.5. Data for RR08 and RR09, the two systems studied in this work, are displayed in a 
separate table to the other systems (table 1.6). 
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RR 
RR01 
RR04 
RR05 
RR06 
RR07 
RRll 
RR12 
RR13 
RR14 
Attenuation 
Reduced lung counts, 48 hr (i.n.) 
Highly attenuated in nasopharyngeal and lung counts (i.n.). Highly attenuated in bacteraemia (i.p) (Using competitive 
studies) 
Reduced lung counts, 48 hr (i.n.) 
Gene expression induced> 2 fold in RTI but attempt to construct mutant was unsuccessful (unlike [aJ) 
Reduced lung counts, 48 hr (i.n.) 
Attenuated in systemic infection (i.p., LD5o) but not in RTI (lung and bacteraemia i.n., 24 & 48 hr) 
Impaired in ability to colonise nasopharynx 
Reduced lung counts, 48 hr (i.n.) 
Reduced lung counts, 48 hr (i.n.) 
Highly attenuated in lung counts (i.n.) (competitive studies). No attenuation in bacteraemia (I/P) 
Attenuated in lung counts (i.n.) (but no attenuation when examined using a competitive study) 
Putative attenuation in lung infection and bacteraemia (i.n. & i.p.) (based on mutation in upstream gene that may have 
polar effects) 
Attenuated in lung counts (i.n.) and bacteraemia (i.p.) using competitive studies 
Attenuated in lung counts (HK) (i.n.) (not tested in competitive studies) 
Reduced lung counts, 48 hr (i.n.) 
A transporter linked to TCS13, BlpA, was attenuated in lung counts 
Reduced lung counts, 48 hr (i.n.) 
Table 1.5 S. pneumoniae response regulators involved in virulence 
Legend on following page 
Ref 
a 
d 
a 
c 
a 
c 
e 
a 
a 
b 
d 
d 
b 
d 
a 
d 
a 
108 
Chapter 1 Introduction 
Table 1.5: S. pneumoniae response regulators involved in virulence 
The table gives details of TCS (in particular RR) found to be important in virulence in several published studies (a; Throup et a!., 2000, b; Lau et a!., 
2001, c; Marra et aI, 2002 d; Hava and Camilli, 2002 e; Sebert et a!., 2002). RR03 and RR10 have not been reported to have any role in virulence to 
date and RR02 is essential for viability, so these have been removed from the analysis. RR08 and RR09 have been summarised in a separate table (6). 
Three of the published studies (b; Lau et a!., 2001, c; Marra et aI, 2002 d; Hava and Camilli, 2002), involved various screening techniques which would 
not identify every gene involved in virulence. Thus the absence of data for individual TCS is not evidence that they are not involved in virulence in any 
particular study. Differences in mutagenesis technique, bacterial strains, challenge doses and animal models may account for any discrepancies seen in 
the data between individual studies. Routes of infection were either intranasal (i.n.) or intraperitoneal (i.p). LD50 represents the dose that can kill 50 % 
of infected animals. Where studies examined virulence using competitive infections with wild-type parental strain and infections with single strains, the 
conditions in which attenuation was found are indicated. Individual studies have different ways of determining the significance of an attenuated 
phenotype and data included within this table are based on the definitions provided in the literature reviewed, not on my own interpretations. Lange et 
al., 1999, created mutants in all rr genes and found no attenuation in virulence following i.p. challenge. 
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Reference Strain I serotype Mutagenesis Murine I animal 
of bacteria techuique strain 
TCS08 
Lange et at., Sp.l (type 22) Insertion C57BL6/J (I) 
1999 duplication Females 
Lange et aI., Sp.1711 (type 3) Insertion C57BL6/J (I) 
1999 duplication Females 
Throup et a!., 0100993 (type 3) Allelic CBAlJ (I) 
2000 replacement Males, 5 wk 
Sebert et aI., 0100993 (type 3) Allelic Sprague-Dawley 
2002 replacement infant rats (0) 
TCS09 
Lange et at., Sp.1 (type 22) Insertion C57BL6/J (I) 
1999 duplication Females 
Lange et aI., Sp.1711 (type 3) Insertion C57BL6/J (I) 
1999 duplication Females 
Throup et aI., 0100993 (type 3) Allelic CBAlJ (I) 
2000 replacement Males, 5 wk 
Hava and TIGR4 (type 4) STM Swiss Webster 
Camilli, 2002 (streptomycin mice, 6-10 wk, 
resistant males (0) 
derivative) 
Table 1.6 Role of S. pneumoniae TCS08 and TCS09 in virulence 
Legend on following page 
Introduction 
Route of Inoculum Measure of Role iu Virulence 
infection virulence 
i.p. (NP) 4 X lOb Mean survival time None 
i.p. (NP) 1 x 10j Mean survival time None 
i.n.(NP) 1 x 101 Mean lung counts, 48 > 1000 fold decrease in lung 
hr counts compared to WT 
i.n. 4 x 10b - Colonisation of None 
1.6 x 107 nasopharynx 
i.p. (NP) 4 X lOb Mean survival time None 
i.p. (NP) 1 X 103 Mean survival time None 
i.n. (NP) 1 x 10' Mean lung counts, 48 10-100 fold decrease in lung 
hr counts compared to WT, not 
significant 
i.n. (NP) 1 x 101 Lung counts, 44 hr Highly attenuated in lung counts 
i.p. (NP) 5 X 105 Bacteraemia, 20 hr but not bacteraemia 
(competition 
experiments) 
! 
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Table 1.6 Role of S. pneumoniae TCS08 and TCS09 in virulence 
The table gives details of several published studies examining the contribution ofTCS08 or TCS09 to virulence. All mutations were created in the 
response regulator component. The techniques used for creating mutants are given, where signature-tagged mutagenesis is represented as STM. The 
murine strain used is provided, together with details of whether the strain was inbred (I) or outbred (0). Routes of infection were either intranasal (i.n) 
or intraperitoneal (i.p). Wild-type is represented as WT. NP designates strains that were non-passeged. 
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1.14.6 Identification of genes regulated by pneumococcal TCS 
For many of the TCS identified in S. pneumoniae and other bacteria, the signals that they 
respond to and the genes they regulate are largely unknown. Until recently, creating null 
mutations in the genes and looking for possible phenotypes in a range of assays or animal models 
was perhaps the only way to assign putative functions. However, the availability of several S. 
pneumoniae genome sequences and the introduction of exciting technologies such as 
mlCroarrays, proteomics and DNA footprinting should now enable researchers to perform 
detailed analyses of microbial TCS (Throup et ai., 2001; Dietz et ai., 2002). 
Microarrays 
Microarrays are powerful tools for studying gene regulation or to compare genomes. Microarray 
chips comprise gene-specific probes immobilised on a nylon membrane, glass or silicon platform 
(chip). Chips can contain probes to detect as many as 60,000 different genes (Affymetrix Human 
Genome U95 set, Affymetrix) on an area the size of a microscope slide. Nucleotide probes 
synthesised onto the chip are hybridised to sample cDNA labelled with fluorescent dyes. The 
micro array is then scanned to measure the fluorescent intensity of individual spots and data is 
analysed using appropriate software. 
Arrays may allow the discrimination between genes that are up to 90 % identical and technology 
is progressing such that very high sensitivity and specificity are possible with micro array 
experiments. Many arrays are available commercially, although researches can choose to have 
arrays custom made to contain desirable genes or sets of genes. Microarrays are excellent 
research tools for many scientific disciplines and microbiology has benefited greatly from such 
technology. Whole microbial genomes can be printed onto a single array allowing gene 
expression to be characterised using a variety of different parameters. For examples, microbial 
arrays have been used to study microbial response to stress and environmental change, cell 
cycle-associated gene expression and characterisation of regulatory pathways (Ye et ai., 2000; 
Lucchini et ai., 2001; Stephens, 2001; Yarwood et ai, 2002). Certain arrays (e.g. Affymetrix 
oligonucleotide arrays) can also be used to detect point mutations or polymorphisms, deletions 
and insertions, to serotype bacteria and to compare gene profiles between bacterial strains 
(Chizhikov et ai., 2001; Murray et ai, 2001). The effects of chemical agents and antibiotics on 
microbial gene expression can also be characterised. Human or murine arrays are also of huge 
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benefit to microbiology research, allowing the study of the expression of host genes in response 
to microbes or microbial products. They are also useful for the identification of drug or vaccine 
targets (Belcher et at., 2000; Detweiler et at., 2001; Diehn and ReIman, 2001; Yowe et at., 2001; 
Grifantini et at., 2002). Microarrays are useful to TCS research as they can aid in the 
characterisation of complex processes expected to involve many genes. 
The role of a single gene in inducing gene expression can be studied through the use of null or 
over-expression mutations, and this is where micro arrays are useful, and have been applied, for 
the study of bacterial TCS (Ye et at., 2000; Detweiler et at., 2001; Ogura et at., 2001; Sebert et 
at., 2002). This method is particularly useful for target gene identification where the signals 
required for TCS induction are unknown, or hard to simulate. One such study has been used to 
confirm known, and identify unknown, targets for three response regulator genes of B. subtilis 
(Ogura et at., 2001). IPTG-inducible rr genes cloned into plasmids were introduced into cells 
and gene expression compared in bacterial cells with and without IPTG induction. Experiments 
were performed in bacterial strains where the cognate hk gene had been mutated, indicating that 
the identified candidate genes were expressed in the absence of signal transduction, and that the 
over-expressed regulators were behaving as if phosphorylated. Many genes previously identified 
as being regulated by the RRs used in this study were detected by micro array analysis. This helps 
validate the identification of genes previously unknown to be under the control of individual 
TCSs. Many genes previously unknown to be regulated by the individual RR proteins were also 
identified. A recent study used micro array analysis to examine gene expression in mutations in 
all TCSs of E. coli, strain K-12 (> 30 TCS). Gene expression at one time point during in vitro 
growth was studied and showed that over half the mutants had significant alterations in a small 
number of genes. Unknown functions of several TCSs were discovered, along with evidence for 
the control of several genes by other TCSs in a cascade-type regulation. Furthermore, this 
analysis showed that cross regulation plays an important role in cell-physiology of E. coli 
(Oshima et at., 2002). Microarray analysis has also been used to show that a response regulator 
in group A Streptococcus, CovR, can influence the transcription of over 250 genes (Graham et 
at., 2002). Although direct regulation of all of the identified genes is unlikely, this data indicates 
how powerful microarrays can be at identifying complex gene regulatory networks. Indeed, some 
of the genes that had altered expression in a covR mutant were regulators themselves (Graham et 
at., 2002). 
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In S. pneumoniae, micro arrays have been used in two studies to identify genes involved in 
competence (Peterson et at., 2000; Rimini et at., 2000). Many genes are known to playa role in 
this complex mechanism of DNA uptake that proceeds via several stages, although the timing of 
their expression is largely uncharacterised. The process is under the control of a TCS, ComD/E 
(TCS12), although several other TCS may playa role, and is induced by a peptide, CSP, in a 
cell-density dependant manner. The system can be analysed in a variety of ways using 
microarrays. Expression of groups of genes at different stages of competence, via the induction 
of CSP, can be studied using time-scale experiments (Peterson et at., 2000 and Rimini et at., 
2000). Alternatively, individual genes can be mutated to determine their influence on other genes 
(Peterson et at., 2000). The arrays used for both studies were not full genome arrays. Peterson 
and colleagues used 3 mini arrays of 40, 68 and 99 genes respectively. Rimini and co-workers 
spotted 4301 clones from a pneumococcal library onto a nylon membrane and used this array for 
subsequent analysis. This array was thought to represent most of the genome of a type 19F(G54) 
strain. 
The above studies identified known and unknown genes induced by CSP and provided data on 
the timing of expression of certain sets of genes. One further study with the CiaH/R (TCS05) 
system has also identified genes involved in competence and is discussed below (Sebert et at., 
2002). 
Microarrays have been used with TCS 13 (BlpHIR or SpiHIR) to identify a group of bacteriocin-
like genes and their immunity proteins that appear to be regulated by the system in response to a 
peptide signal. This system shares many features with the ComD/E system. A time course 
analysis was performed to monitor the expression of genes over time in cultures treated with the 
synthetic peptide. 16 genes were found to be up-regulated over eight-fold. Most of these genes 
were located in close proximity to the TCS locus itself. The microarray analysis also indicated 
that expression of the system is auto-induced, as is the case for ComD/E. A deletion in this 
system was found to have reduced growth in the lung environment (Throup et at., 2000), 
suggesting it is important in virulence. However, as the lungs are normally sterile, the 
requirement for bacteriocins that inhibit the growth of closely related bacteria in this 
environment is doubtful. These pore-forming toxins may thus function to damage host cells in 
some way and could constitute the second, as yet, unidentified haemolysin of S. pneumoniae 
(Canvin et at., 1997). Alternatively the bacteriocins could act on inhabitants of the nasopharynx, 
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the site of initial pneumococcal colonisation, although a recent study has demonstrated that a 
mutation within this system is not impaired in its ability to colonise the nasopharynx in an infant 
rat model (Sebert et ai., 2002). However colonisation could be a human-specific effect. 
Recently another pneumococcal TCS, CiaHIR (TCS05) has been analysed using micro arrays 
(Sebert et ai., 2002). A mutation within this system was found to have greatly reduced virulence 
in an infant rat model of nasopharyngeal colonisation and was studied using micro arrays to 
determine genes that could contribute to this phenotype. Expression of genes in the ciaHIR 
mutant were compared with those of wild type from in vitro cultures grown to an OD 600 nm of 
0.3. The mutation resulted in the up-regulation of genes involved in the later stages of 
competence (the contribution of this TCS to competence has been discussed elsewhere in this 
chapter) but the down-regulation of two other genes htrA and spoJ. Mutations were made in both 
of these genes and tested for their ability to colonise the nasopharynx. Only a mutation in htrA 
was impaired in colonisation. This appears to encode a serine protease, although its substrate has 
not been identified. HtrA is located in close proximity to the comelDIE locus so could too be 
involved in competence. 
1.15 TCS Summary 
Two component systems are ubiquitous in bacteria where they control a wide range of processes 
in response to various environmental stimuli. Research into these systems is revealing the 
complex nature of gene regulation in bacteria in response to their environment. These systems, 
therefore, are unlikely to be solely 'two-components' as their name suggests, but rather two-
components functioning as part of a more global and highly intricate network of systems capable 
of a range of functions. A vast amount of work remains to be done before we can begin to 
comprehend how these systems function in the context of the whole bacterial cell and in 
combination with other systems. Advanced technology, such as microarrays and proteomics 
should help to determine genes regulated by these systems, and structure function studies will be 
of benefit in the identification of active sites and design of therapeutic targets. 
Thirteen HKIRR pairs have been identified in S. pneu111oniae, together with a single, unpaired 
RR. One of these systems appears to be essential and many seem to have a role in virulence, 
albeit at different stages or at different sites of infection. More comprehensive analysis of 
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virulence will enable researchers to identify the precise roles of these systems in infection. 
However, bacterial TCS may respond to signals present solely in the human host that may 
require more sophisticated analyses to enable complete characterisation. This project aims to 
characterise two pneumococcal TCS and putative related genes for their role in virulence using a 
well-characterised murine model of infection. 
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2. Materials and methods 
Prior to use, all heat stable reagents were sterilised by autoc1aving. 
A table of all strains and mutants used in this work is given in the appendix (Al) 
Details of vectors (supplied by Hoffman-La-Roche) used for creating insertion-duplication 
mutants in TCS08 are provided in A2 
Details and sequences of all primers used in this thesis are given in A3. All sequences for S. 
pneumoniae specific primers were blasted against the TIGR4 and R6 pneumococcal genome 
sequences (http://www.tigr.org/) to ensure binding only to the required region. 
Preparation of common solutions and buffers is detailed in A4. 
2.1 Confirming organisms as Streptococcus pneumoniae 
2.1.1 Bacterial cell culture 
All S. pneumoniae strains were grown on Blood Agar Base, number 2 (BAB, Oxoid Ltd. 
Basingstoke) supplemented with 5 % defibrinated horse blood (E&O Laboratories, Bonnybridge, 
Scotland), or maintained in Brain Heart Infusion media (BHI, Oxoid Ltd., Basingstoke). Mutants 
were maintained with appropriate selection: erythromycin (1.0 Ilg mrl) or spectinomycin (200 
Ilg mrl). Plates /cultures were incubated statically at 37 0 C and colonies were examined for their 
appearance and production of a-haemolysis on blood agar. These conditions were maintained 
throughout experimental procedures, unless stated otherwise. 
2.1.2 General confirmation of strains 
All strains used within this work were confirmed by colony morphology, production of a-
haemolysis on blood agar, Grams stain and optochin sensitivity (5 Ilg 
optochiniethylhydrocupreine hydrochloride). Quellung reaction was used to confirm capsular 
serotype. Multilocus sequence typing (MLST) was also performed to confirm strains. Analysis 
was performed at the Scottish Meningococcal and Pneumococcal Reference Laboratory 
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(SMPRL), Stobhill Hospital, Glasgow, Scotland and clarified usmg the MLST data-base 
(http://fi-srvmlstl-ide.sm.med.ic.ac.uklnew/). 
2.1.3 peR for pneumolysin gene 
Following preparation of genomic DNA from bacterial strains (see below), primers specific for 
pneumolysin (PlyF & PlyR, A3) were used to confirm the presence of pneumolysin. PCR 
reaction mixtures were as follows (in a 100 fll reaction); 65 - 150 flg mrl genomic DNA (gDNA) 
template, 1 flM of each primer (desalted, Sigma Genosys, UK), 10 fll buffer (10 x, no Mg2+), 1-2 
mM MgS04, 50 flM dNTP's and 1-2 units Taq polymerase (all reagents from Promega). PCR 
conditions; Stage 1: 94 0 C (5 min), repeat x 1. Stage 2: 94 0 C (30 sec), 62 0 C (30 sec), 72 0 C 
(1 min, 30 sec), repeated x 30. Stage 3: 72 0 C (10 min), repeated x 1. Products were 
electrophoresed on a 1 % agarose gel (Gibco BRL Life Technologies, Scotland, UK) containing 
ethidium bromide (0.5 flg mrl, Sigma-Aldrich, UK) in TAE buffer. DNA was visualised using 
an UV transilluminator (Spectroline, TVC-312A) and images were captured using a UVP 
GelDoc and analysis system (UVP Laboratories). 
Conditions for all PCRs were optimised for each new primer pair using a temperature gradient 
(50-65 0 C) and a range ofMg2+ concentrations (1-4 mM). 
2.1.4 Glycerol stock preparation 
Glycerol stocks of all confirmed S. pneumoniae strains and mutants were prepared by growing a 
bacterial culture from a single, pure colony to mid-exponential phase (OD6oo nm 0.5-0.6). 
Glycerol was added to a final concentration of 12 % (v/v). 1 ml aliquots were prepared and 
frozen at - 70 0 C in cryotubes. Viability of stocks was determined 24 hr after freezing by the 
method described below (section 2.4.1). 
119 
Chapter 2 Materials and Methods 
2.2 Construction of mutants 
2.2.1 Construction of mutants by insertion-duplication mutagenesis 
2.2.1.1 Transformation of plasmid constructs into E. coli competent cells 
Plasmid constructs used to create mutants were based on the pAS 1 vector and were supplied by 
R. Lange, Hoffmann-La-Roche (see A2). Plasmids were transformed into NovaBlue Singles ™ 
competent cells (Novagen), following manufacturer's instructions. Following overnight 
incubation, transformed cells were selected by their ability to grow on erythromycin selection 
(Img mrl). Single colonies were inoculated into LB media supplemented with erythromycin, 
grown to an optical density (OD6oo nm) of 0.5-0.6 and used for the preparation of glycerol 
stocks (section 2.1.7). Preparations were stored at - 70 0 C. Plasmid pVA838 (a kind gift from J. 
Paton), a positive control for pneumococcal transformation was also transformed into NovaBlue 
Single cells as described above. This plasmid also carries a gene encoding erythromycin 
resistance. 
2.2.1.2 Plasmid isolation and purification 
Purified plasmid constructs were isolated from transformed NovaBlue Single cells usmg a 
commercially available plasmid isolation kit, according to manufacturer's instructions 
(QIAprep® Spin Miniprep Kit, Qiagen). This technique uses alkaline lysis of bacterial cells. 
Released DNA is adsorbed onto a silica gel from which plasmid DNA can be eluted in a low salt 
buffer. Plasmid DNA concentration and purity was determined by OD26o nm and OD28o nm 
readings (Unicam UV2, UV/Vis spectrometer), where an OD26o nm of 1.0 corresponds to 50 flg 
mrl DNA and OD26o nmlOD28o nm is 1.8 for pure DNA. 
2.2.1.3 Confirmation of isolated plasmid by restriction digest 
Purified plasmid constructs based on the pAS 1 vector were cut using EcoRl and BamHl 
restriction enzymes (Promega, IOU fll-1). Each mixture comprised IOU of each enzyme in 
Multicore buffer (Promega, 10 x) and 3 fll plasmid DNA in a 10 fll reaction. Samples were 
incubated for 2-12 hr at 37 0 C. DNA loading buffer was added and samples were 
electrophoresed on a 1 % agarose gel as described in section 2.1.3. This yielded bands of ~ 0.3 
Kb and 7.4 Kb, representing the cloned region with homology to the target gene and empty 
vector respectively. Plasmid pVA838 (Macrina et aI., 1983) was also cut using EcoRl and 
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BamHl enzymes as described above to yield expected bands of approximately 2.3 Kb and 6.9 
Kb. 
2.2.1.4 Transformation ofS. pneumoniae 
A transformation protocol based on previously described methods was developed to enable the 
construction of mutants in S. pneumoniae. 50 fll of thawed pneumococcal stock was used to 
inoculate 30 ml BHI supplemented with 1 mM CaCh (Sigma-Aldrich, UK). Cultures were 
grown to an OD6oo nm of 0.1-0.3. For each transformation 1 ml of culture was added to a sterile 
bijoux. CSP-1 (Havarstein et al, 1995) (Sigma Genosys, UK) was added to a final concentration 
of 100 ng mrl, and samples were incubated at 37 0 C for 15 min. Plasmid/sample DNA was 
added to a final concentration of 8-10 flg mrl. Total volume of DNA added was kept to a 
maximum of 50 fll. For each transformation, a positive (p V A838) and a negative (no sample 
DNA) control was set up. Samples were incubated for 75 min at 37 0 C. Following incubation, 
450 fll aliquots of transformation mixture were plated onto blood agar plates containing 
appropriate antibiotic selection. Plates were air dried under a bunsen burner and incubated OIN 
at 37 0 C. Potential transformants were selected by their ability to grow on antibiotic-selective 
plates. Single colonies were sub-cultured into BHI containing antibiotic, from which glycerol 
stocks were prepared as described above (section 2.1.4). p V A838 is able to replicate in S. 
pneumoniae and thus does not require chromosomal integration. The efficiency of transformation 
using this plasmid is therefore greater than using a suicide vector or PCR fragment (used to 
create mutants) which require chromosomal integration to prevent elimination. 
2.2.2 Construction of mutants by allelic-replacement and Mariner mutagenesis. 
2.2.2.1 a Allelic replacement; amplification of DNA from existing mutants 
Our laboratory was supplied with mutants in RR and HK genes in a serotype 3 background 
(M.K. Burnham, GlaxoSmithKleine). To create isogenic mutants in serotype 2 D39, PCR was 
used to amplify DNA encoding desired mutation from the type 3 mutants. This was carried out 
using PCR with primers designed 5' and 3' to the mutated region (primers described below and 
in A3). PCR reactions were carried out and DNA was visualised as described above (section 
2.1.3) replacing Taq polymerase with Vent polymerase (New England Biolabs®, Inc.) for 
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proofreading activity. Primers used and optimised conditions for PCR are provided in the table 
below. 
Mutation Primers (forward, Annealing I 
reverse) elongation 
conditions 
L1rr08 SKB484P1 58 0 C, 30 sec 
SKB484P4 72 0 C, 1 min 30 sec 
L1rr09 SKB488P1 62 0 C, 30 sec 
SKB488P4 72 0 C, 1 min 20 sec 
2.2.2.1 b Allelic replacement,' DNA purification 
Following PCR, the desired DNA product was excised from the agarose gel and purified using a 
commercially available kit (QIAquick® Gel Extraction Kit, Qiagen). The purified product was 
re-analysed on an agarose gel and then transformed into D39 as described below. 
2.2.2.2 Mariner mutagenesis 
PCR products, designed to create two mutations in the zmpB gene, were supplied by lean-Pierre 
Claverys (Toulouse, France). Mutation L1zmp739 results in a more truncated version of the 
L1zmp738 mutation. Both mutants were created by Mariner cassette insertion into the zmpB gene 
(Berge et. aI, 2001). 
2.2.2.3 Transformation of D39 
S. pneumoniae, strain D39, was transformed using the purified tcs08, tcs09 and zmpB PCR 
products as described in section 2.2.1.4. For mutants created by allelic replacement, potential 
transformants containing the desired mutation were selected on erythromycin plates (1 f.t,g mr1). 
Mutations in zmpB were selected on spectinomycin plates (200 f.t,g mrl). 
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2.3 Confirming mutant genotypes 
2.3.1 Confirming knock-out mutants created by insertion-duplication mutagenesis 
2.3.1.1 Preparation o/Genomic DNA 
A sweep of 4-5 bacterial colonies from a blood plate was used to inoculate 10 ml BHI. Following 
OIN incubation at 37 0 C, cultures were centrifuged for 15 min, 5,000 rpm at RT (Hereus 
Sepatech medifuge). The pellet was re-suspended in 1 ml extraction buffer and incubated for 1 hr 
at 37 0 C. Proteinase K (Sigma-Aldrich, UK) was added to a final concentration of 100 Ilg mrl 
and the mixture was incubated for 3 hr at 50 0 C. RNase (Sigma-Aldrich, UK) was added to a 
final concentration of 20 Ilg mrl and incubated at 37 0 C for 30 min. Resultant mixture was 
gently mixed with an equal volume of phenollchlorofonnlisoamylalcohol (25 :24: 1 vlv, BDH & 
Fisher Scientific UK. Ltd.) and centrifuged at 13,000 rpm for 3 min (Sigma 113 microfuge). The 
aqueous layer was removed and added to 0.2 volumes of 10M ammonium acetate (Sigma-
Aldrich, UK). Ethanol (100 %) was added to precipitate the DNA and the mixture was 
centrifuged at13,000 rpm for 30 min. The DNA pellet was left to air dry for 10 min, re-
suspended in TE buffer, pH 7.4, and stored at 4 0 C or - 20 0 C. DNA concentration and purity 
was determined as described above (section 2.2.1.2). 
2.3.1.2a peR to confirm chromosome/ plasmid junctions 
PCR was used to confirm the plasmid integrations for mutants created by insertion duplication 
mutagenesis. For each mutation, a primer specific for the inserted DNA was used in combination 
with a primer specific for the D39 genomic DNA. The resulting PCR fragment thus spanned the 
chromosome I plasmid junction. All PCR reactions were carried out in 100 III volumes as 
described in section 2.1.3. PCR mixtures were denatured at 94 0 C, 5 min., followed by 30 cycles 
of denaturation (94 0 C, 30 sec.), annealing and elongation (conditions vary, see table below). 
Samples were then held at 72 0 C for 10 min. The table below shows conditions, optimised for 
individual reactions. Genomic DNA prepared from strains as described in section 2.3.1.1 was 
used for PCR reactions. 
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Mutation Primers (forward, Annealing I 
reverse) elongation 
conditions 
LlpRPL7, 5' region HK8PFW, RPL22 53 0 C, 1 min 
72 0 C, 45 sec 
LlpRPL7, 3' region AP70,HK8PR 54 0 C, 30 sec 
72 0 C, 1 min 
LlpASl, 5' region URR8F, RP122 54 0 C, 30 sec 
72 0 C, 1 min 
LlpASl, 3' region AP70,RR08R 55 0 C, 30 sec, 
72 0 C, 1 min 
LlpRPL50, 5' region RPL102, RPL22 56 0 C, 1.5 min, 
72 0 C, 30 sec 
LlpRPL50, 3' region AP70, RPL109 56 0 C, 1.5 min, 
72 0 C, 30 sec 
2.3.1.2b Sequencing to confirm insertions 
Several PCR fragments from the PCRs described above were selected for sequencing to further 
ensure mutations were correct. Sequencing was performed in-house (MBSU DNA Sequencing 
Service, University of Glasgow, UK) using primers specific for individual PCR reactions 
described above. Primers were used at 3.2 )lM for sequencing reactions. Sequences were 
analysed using Edit View ASI Automated DNA Sequence Viewer (ABI Prism™) and 
DNAST AR software. Sequence homology searches were performed to confirm mutations using 
BLAST (Altschul et at., 1990) and The Institute of Genomic Research's Comprehensive 
Microbial Resource (TIRG CMR, http://www.tigr.org/). 
2.3.1.2c peR to confirm absence of wild-type gene in mutants 
Primers were also designed flanking the target genes. PCR was performed using these primers to 
demonstrate the absence of the wild-type gene in mutant DNA (the inserted plasmids were too 
big to give a detectable PCR product for mutants using the primers described and under the 
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conditions stated). This experiment also enabled checking for any gene duplications that may 
have been present on the chromosome. 
Mutation Primers (forward, Annealing / elongation 
reverse) conditions 
LJpAS1 RR08F 51°C,30sec 
RR08R 72 ° C, 1 min 
LJpRPL7 HK08F 51.4 ° C, 30 sec 
HK08R 72 ° C, 1 min 
LJpRPL50 Sp0644F 53 ° C, 30 sec 
Sp0644R 72 ° C, 3 min, 30 sec 
2.3.2 Confirming mutants created by allelic-replacement 
2.3.2.1 PCR 
PCR using primers out-with the mutated region was performed using the primers and PCR 
conditions described in section 2.2.2.1 a. Reactions were set up as previously described, section 
2.1.3., using Vent polymerase (New England Biolabs® Inc.) to provide proofreading activity to 
ensure high fidelity. 3' adenine overhangs were subsequently added onto PCR products by the 
addition of 1 U Taq polymerase to the reaction mixture and further incubation at 72 ° C for 10 
min. This enabled direct cloning using the TOPO TA cloning Kit at a later stage (described 
below). PCR products were electrophoresed on a 1 % agarose gel as described in section 2.1.3. 
Genomic DNA prepared from strains as described in section 2.3.1.1 was used for PCR reactions. 
Insertion of mutated DNA resulted in a detectable increase in PCR product size for mutants 
when compared to wild type DNA. 
2.3.2.2 Cloning of PCR fragments into a plasmid vector (TOPO) for sequencing 
PCR products were excised from the agarose gel and purified using a commercially available 
DNA purification kit (QIAquick® Gel Extraction Kit, Qiagen) according to manufacturer's 
instructions. The size of the purified PCR product was confirmed by electrophoresis and cloned 
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into the vector pCR®4-TOPO® (Invitrogen™ life technologies). This was then used to transform 
TOPI0 chemically competent E.coli cells (Invitrogen™ life technologies) according to 
manufacturer's instructions. Transformation mixture was plated onto LB plates containing 
ampicillin (75 f!g mr\ for selection of cells containing pCR®4-TOPO®. 
2.3.2.3 Restriction digest to confirm insert in TOPO 
pCR® 4-TOPO® containing insert was purified using a commercially available plasmid isolation 
kit (QIAprep® Spin Miniprep Kit, Qiagen) according to manufacturer's instructions. Isolated 
plasmid vector was digested with EcoRl (Promega, 10 U f!rl) as described previously (section 
2.2.1.3). Products were electrophoresed on a 1 % agarose as described previously. 
2.3.2.4. Sequencing of cloned products 
Following confirmation of DNA insert into pCR®4-TOPO®, purified plasmid was sequenced in-
house as described in section 2.3.1.2b, using primers T3 and T7 specific for the pCR®4-TOPO® 
vector. This confirmed replacement of the target gene with an erythromycin cassette. 
2.3.3 Confirming mutants created by mariner mutagenesis 
Mutants were confirmed by PCR as described in section 2.1.3. Due to the large size of the zmpB 
gene, expand polymerase (Expand Long Template PCR System, Roche Diagnostics), a 
polymerase for the amplification of large DNA fragments, was used in replacement of Taq 
polymerase. This polymerase has proof-reading activity. Primers used and optimum PCR 
conditions are shown below. 
Mutation Primers (forward, Annealing / 
reverse) elongation conditions 
Both iJzmp mutants ZmpUp, ZmpDo 55 ° C, 30 sec 
nOC,10min 
Both iJzmp mutants ZmpUp, MP128 55 ° C, 30 sec 
n° c, 10 min 
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2.4 In vitro characterisation of bacterial strains 
2.4.1 Determining number of viable organisms 
To enumerate number of CFU in frozen stocks, an aliquot of culture was rapidly thawed in a 37 0 
C water bath. 900 fll was removed and cells pelleted by centrifugation, 13,000 rpm. (Sigma 113 
microfuge). Bacterial pellets were re-suspended in 900 fll PBS. Serial 10-fold dilutions were 
carried out in a 96-well round-bottomed tissue culture plate (Nunclon™ surface, Nalge Nunc 
IntemationaFM) to a final concentration of 10 -6 in PBS. 6 x 20 fll of each dilution were plated 
onto blood agar and plates were incubated for at least 16 hr, 37 0 C. Following incubation the 
dilution of culture giving counts of 60 - 200 CFU per 20 fll spot were counted. CFU mr! was 
calculated. This method is based on that of Miles and Misra (1938). 
2.4.2 Growth curves 
15 ml BHI was inoculated with 1.0 x 10 6 CFU bacterial strains and incubated at 37 0 C. OD600 
nm readings were taken at 2-hourly intervals for at least 14 hr post inoculation. Growth of 
mutant strains was monitored in both selective and non-selective media. 
2.4.3 Viability curves 
The viability of bacterial strains was monitored during the growth described above. At 2-hourly 
intervals, samples removed for OD600 nm data were used for viable cell enumeration as described 
in section 2.4.1. 
2.4.4 Lysis with deoxycholate 
15 ml BHI, without antibiotic selection, was inoculated with 1.0 x 106 CFU bacterial strains. 
Cultures were incubated at 37 0 C until mid-log phase (OD 600 nm 0.5-0.6) was reached. A 10 % 
(w/v) solution of deoxycholate (DOC) (Sigma-Aldrich, UK) was prepared in PBS and added to 5 
ml aliquots of each culture to a final concentration of 0.04 % (w/v). Samples were removed for 
viable cell enumeration immediately prior to and following treatment with DOC at pre-
determined time points for up to 60 min. Viability counts of untreated culture were used as a 
control. 
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2.4.5 Stability of mutants 
To assess the ability of mutant strains to retain antibiotic resistance, cultures were grown in the 
absence of erythromycin or spectinomycin selection. BHI was inoculated with 1 x 10 6 CFU 
bacterial strains and incubated at 37 0 C. At predetermined time points viability was determined 
using BAB plates both with and without appropriate antibiotic selection. 
2.4.6 Haemolytic assay 
Bacterial strains were grown to mid log phase (OD 600 nm 0.5-0.6). Samples were removed and 
treated for 5 minutes with 0.04 % (w/v) deoxycholate (Sigma-Aldrich, UK) to lyse all cells and 
release haemolysins. Lysed cultures were diluted two-fold across a 96-well round bottomed plate 
(Nunclon™ surface, Nalge Nunc IntemationaFM) in PBS in a final volume of 50 fll. Control 
wells were set up containing PBS alone, cultures of iJptn (a pneumolysin null mutant created by 
allelic replacement in our laboratory, unpublished data), BHI with 0.04 % deoxycholate and non-
deoxycholate-lysed bacterial cultures. 50 fll of a 2 % (w/v) suspension of sheep red blood cells 
(E&O Laboratories, Bonnybridge, UK) was added to each well. Plates were incubated at 37 0 C 
for 30 min then room temperature for 30 min. Haemolysis of sheep red blood cells was assessed 
visually by the absence of a compact pellet following incubation. partial haemolysis was 
recorded when a very small pellet was visible. 
2.4.7. Transformation efficiency 
To determine the transformation efficiency of strains, the transformation procedure was carried 
out, as described in section 2.2.1.4. p V A838 plasmid was used as a marker for erythromycin 
resistance to determine transformation rates in strains not possessing erythromycin resistance. 
For strains already resistant to erythromycin, S. pneumoniae chromosomal DNA containing a 
marker for streptomycin resistance (rpsL41 allele with a change from lysine (AAA) to threonine 
(ACA) at position 56 of the S12 protein, Salles et at., 1992) was used to determine the 
transformation efficiency. The transformation mix was plated out on BAB both with and 
without antibiotic selection (erythromycin, 1 flg mrl or streptomycin, 150 flg mrl) for viable 
cell enumeration. Efficiency was calculated based on number of transformants per flg 
plasmid/chromosomal DNA. 
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2.4.8 Carbohydrate utilisation 
Thioglycollate medium (without dextrose or indicator) (4.8 g) containing purple broth base (3.2 
g) (both from DifcolBecton Dickinson), was made up in 200 ml dH20 and autoc1aved. 
Carbohydrate solutions (10 % [w/v], all from Sigma-Aldrich, UK) were made up in dH20 and 
filter sterilised using 0.2 ~M filters (Sartorius Minisart, Germany). Carbohydrate was added to 
the sterilised thioglycollate/purple media to a final concentration of 1 % (w/v). Bacterial cultures 
were grown in Todd-Hewitt broth (Oxoid Ltd., Basingstoke, UK) OIN at 37 0 C. 75 ~l of 
carbohydrate solution was mixed with 25 ~l of overnight culture in a 96-well, flat bottomed 
micro titre plate (Nunc1on™ surface, Nalge Nunc InternationaFM), placed into an anaerobic bag 
(BBLTM GasPak Pouch™, Becton Dickinson, USA) and incubated at 37 0 C for 24 hr. Addition 
of 25 ~l Todd-Hewitt broth alone to the carbohydrate solution was set up as a negative control. 
Ability to ferment the carbohydrate was demonstrated by a colour change from purple to yellow, 
due to the production of acid, and was determined by visual inspection. 
2.5 In vivo experiments 
All S. pneumoniae strains used were mouse passaged (intraperitoneally, see below) prior to use 
in the animal model, unless stated otherwise. This enhances virulence of the bacterial strains and 
is a technique commonly applied to many S. pneumoniae studies. 
2.5.1 Animal models 
Adult female MFI mice aged 9-13 wk and weighing 28-35 g were used as the standard model of 
pneumococcal pneumonia and sepsis. Male CBAlJ mice, aged 5 wk and weighing 14-16 g were 
used to repeat the work of Throup et. at. and were housed in filter top cages to reduce 
environmental infection. Female CBAlJ mice were purchased for breeding purposes and were 
also housed in filter top cages. Complement studies were carried out using C3-/- mice (Wessels 
et at., 1995), bred in-house. Adult male and female C57/Bl mice, aged 9-13 wk were purchased 
as wild type controls for the C3-/- experiments. All mice, with the exception of C3-/- mice, were 
purchased from Harlan Olac, Bicester, UK. All mice were provided with sterile pelleted food 
(B&K Universal, North Humberside, England) and water ad libitum throughout the experiments. 
Mice were housed at the Central Research Facility, University of Glasgow, UK. All animal work 
was carried out under appropriate licensing and with approval from the Home Office and the 
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University of Glasgow. CBAlJs with endemic infections were treated with Borgal (a 
sulphonamide), to a final concentration of 0.01 % in drinking water. 
2.5.2 Preparation of standard inoculum / intraperitoneal challenge 
Bacterial strains were re-suspended in sterile PBS to give approximately 1.0 x 10 6 CFU mrl. 
200 III was injected into the peritoneal cavity of MFI mice using a 1 ml insulin syringe (Micro-
fine, 12,7 mm, Becton Dickinson). 24 hr following injection, mice were sacrificed by cervical 
dislocation and the chest cavity opened. Blood was collected from the heart using a 23 gauge 
needle inserted into the right ventricle. 50 III of removed blood was inoculated into 10 ml BHI 
and grown OIN, statically at 37 0 C. Bacteria were harvested by centrifugation at 3,000 rpm. 
(Heraeus Sepatech medifuge) and re-suspended in 1 ml BHI. 100 III of this suspension was used 
to inoculate 20 ml BHI containing 20 % (v/v) heat inactivated FBS (Gibco BRL, Life 
Technologies, u.K.) and then incubated at 37 0 C until mid-exponential phase was reached 
(OD6oo nm 0.5 - 0.6). Culture was stored at - 70 0 C in 1 ml aliquots until required. Viability of 
stocks was determined 24 hr following freezing as described in section 2.4.1. Appropriate 
antibiotic selection was added to BHI to sustain the growth of all mutant strains. 
2.5.3 Intranasal challenge 
900 III of standard inoculum were rapidly thawed and centrifuged at 13,000 rpm. for 3 min 
(Sigma 113 microfuge). The pellet was re-suspended in 900 III PBS and diluted to give 2.0 x 10 7 
CFU mrl (unless stated otherwise). Mice were lightly anaesthetised with 2.5 % (v/v) halothane 
(Zeneca Pharmaceuticals, Macclesfield, UK.) over oxygen (1.5 L min -1) using a calibrated 
vaporiser. Confirmation of anaesthesia was determined when mice failed to produce a reflex 
reaction when gently pinched. 50 III of bacterial suspension was administered, drop-wise, to the 
nares using a Proline® Pipette (Biohit). Individual mice were thus given 1.0 x 106 CFU. Mice 
were laid on their backs until they recovered. Viable counts of the bacterial suspensions were 
determined prior to and immediately after challenge, by viable cell enumeration, as described in 
section 2.4.1. 
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2.5.4 Intravenous challenge 
900 III of standard inoculum was rapidly thawed and centrifuged at 13,000 rpm. for 3 mm 
(Sigma 113 microfuge). The pellet was re-suspended in 900 III PBS and diluted to give 2.0 x 10 6 
CFU mrl (unless stated otherwise). Mice were placed in a ventilated, heated perspex box for 5 
min and restrained in appropriate apparatus. 100 III of bacterial suspension was administered 
directly into the bloodstream via the lateral tail vein using a 1 ml insulin syringe (Micro-fine, 
12,7 mm, Becton Dickinson). Blood was sampled from a different tail vein 1 min following 
challenge to ensure all mice were administered equal bacterial counts. At pre-determined time 
points, blood was sampled from the lateral tail vein as described above and used for viable cell 
enumeration, as described in section 2.4.1. Viable counts of the bacterial suspensions were 
determined prior to and immediately after challenge. 
2.5.5 Determining levels of bacteraemia 
Blood was sampled at pre-determined intervals following challenge via removal of blood from 
peripheral veins. Mice were placed in a ventilated, heated perspex box for 5 min and restrained 
in appropriate apparatus. A 1 ml insulin syringe (Micro-fine, 12,7 mm, Becton Dickinson) was 
used to remove a maximum of 100 III blood from the lateral tail vein. Blood was immediately 
diluted 1: lOin PBS and stored on ice until viability counts were carried out, as described in 
section 2.4.1. 
2.5.6 Determining bacterial loads in lung tissue 
At pre-determined time points following intranasal challenge, as described in section 2.5.3, mice 
were culled by cervical dislocation and the thoracic cavity opened up to expose the lungs. Lungs 
were aseptically removed, rinsed with dH20 and placed in 5 ml sterile PBS. Weight of the lungs 
was recorded. Lungs were homogenised for 10 sec using an electric hand-held tissue 
homogeniser set at high speed (IKA®-Ultra-Turrax® T25, JanIce Kunkel Laboratories). Samples 
of homogenised lung tissue were used for viable cell enumeration, as described section 2.4.1. 
2.5.7. Preparation of lung tissue for cytokine analysis 
At pre-determined time points following intranasal challenge, as described in section 2.5.3, mice 
were culled by cervical dislocation and the thoracic cavity opened up to expose the lungs. Lungs 
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were aseptically removed, wrapped in aluminium foil and snap frozen in liquid nitrogen. Prior to 
use, lungs were weighed and homogenised as described in section 2.5.6. Based on the protocol 
by van der Poll et al (van der Poll et al. 1996) homogenates were centrifuged at 1600 g for 30 
min at 4 0 C. to pellet cell debris. Supernatants were then centrifuged at 5000 g for 30 min at 4 0 
C (Sigma 4K15 centrifuge). The supernatant was removed and filter sterilised through 0.20 IlM 
filters (Sartorius Minisart, Germany). Cell free supernatant was aliquoted into cryovials and 
stored at - 70 0 C until required for cytokine analysis. 
2.5.8 Bronchi-alveolar lavage 
Mice were killed by cervical dislocation. The skin and muscles surrounding the trachea were 
exposed and the thoracic cavity opened up to allow expansion of the lungs. The trachea was 
clamped using Spencer-Wells forceps (Fisher Scientific Ltd. UK) to prevent backflow of fluid up 
the trachea. A 16-gauge non-pyrogenic angiocath (F. Baker Scientific) was inserted into the 
trachea immediately above a ring of cartilage to hold the catheter in place. Lavage was 
performed using 2 x 1 ml volumes of PBS. Recovery volume was between 1.6 1.8 ml per 
mouse. A small aliquot ofBALF was retained for viable cell enumeration and the remainder was 
snap frozen in liquid N2 in cryovials for cytokine analysis. BALF was stored at - 70 0 C until 
required. 
2.5.9 Murine survival and pain scoring 
Mice were monitored frequently throughout the infection by a pain scoring system devised 
within this laboratory. Symptoms progressed from normal to severe with mice showing starry 
coat/piloerection, hunched posture and lethargy. Severe infection resulted in the mice eventually 
becoming moribund. Mice were sacrificed, by cervical dislocation, when showing signs of 
severe lethargy or upon becoming moribund. Where animals were actively culled, the time of 
reaching a moribund state was taken as the time of death (,mortality') / experimental end point 
for survival data. Mice that survived the course of infection (7 days, unless stated otherwise) 
were assigned an arbitrary survival time of 168 hr for statistical analysis. 
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2.5.10 Stability of mutants 
On removing blood samples for bacterial load determination, viable counts for all the mutant 
strains were plated onto BAB plates with and without antibiotic selection to ensure the mutation 
conferring antibiotic resistance was maintained throughout infection. Viable cell enumeration 
was determined as described in section 2.4.1. 
2.5.11 Confirming mutants following ill vivo infection 
DNA was isolated from all mutants retrieved from the blood of infected mice at least 24 hours 
post challenge as described in section 2.3.1.1. PCR as detailed in previous sections was then used 
to re-confirm the individual mutations. 
2.6 Immunological techniques 
For ELISAs, standards were run in duplicate and samples in triplicate. A set of standards was 
included on every plate. Measurements were determined from the standard curve specific for 
individual ELISAs using Biolinx 2.21 ™ software. 
2.6.1 Detection ofTNF-a by ELISA 
TNF-a was detected using an OptEIATM Mouse TNF-a Set (Pharmingen, USA), optimised prior 
to use. Batch-specific recombinant mouse TNF- a standard was re-suspended in dH20 as directed 
and stored in aliquots at - 70 0 C. Plastic, flat bottomed 96-well maxisorb™ plates (Nalge Nunc 
IntemationaFM) were coated OIN at 4 0 C with anti-mouse TNF- a capture antibody, diluted 
1 :350 in coating buffer. Wells were washed x 3 in wash buffer, and blocked with 200 III assay 
diluent for 1 hr at RT. Standards were prepared in assay diluent, using 1:2 dilutions to produce a 
standard curve ranging from 15.6 - 1000 pg mrl. Assay diluent served as the zero standard. 
Wells were washed, as above. 100 III samples and standards were added to wells and plates were 
incubated, sealed, for 2 hr at RT. Wells were washed (x 5) in wash buffer and 100 III working 
detector was added (biotinylated anti-mouse TNF-a detection antibody I :350). Plates were 
sealed and incubated for 1 hr at RT. Wells were washed (x7) in wash buffer and 100 III substrate 
solution was added. Plates were incubated, unsealed, in the dark for 30 min. Reaction was 
stopped with 50 III stop solution and absorbance read at A450 nm with A570 nm correction using a 
Dynatech MRX ELISA reader and Biolinx 2.21 ™ software. 
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2.6.2 Detection of IL-1 0 by ELISA 
IL-IO was detected using an OptEIA ™ Mouse IL-IO Set (Pharmingen, USA), following the 
protocol described above for TNF -u. Capture antibody, biotinylated anti-mouse IL-IO detection 
antibody and avidin horseradish peroxidase conjugate were all used at 1 :250 dilutions. Standard 
curve values ranged from 32.25-2000 pg mrl. 
2.6.3 Detection of IL-6 by ELISA 
IL-6 was detected using an OptEIA ™ Mouse IL-6 Set (Pharmingen, USA), optimised prior to 
use and following the protocol described above for TNF-u. Capture antibody and avidin 
horseradish peroxidase conjugate were used at 1 :350 dilutions. Biotinylated anti-mouse IL-6 
detection antibody was diluted 1 :500 in assay diluent prior to use. Standard curve values ranged 
from 32.25-2000 pg mrl. 
2.6.4 Detection of IFN-y by ELISA 
IFN-y was detected using an OptEIATM Mouse IFN-y Set (Pharmingen, USA), optimised prior to 
use and following the protocol described for TNF -u. Capture antibody and avidin horseradish 
peroxidase conjugate were all used at 1 :350 dilutions. Biotinylated anti-mouse IFN-y detection 
antibody was diluted 1 : 1000. Standard curve values ranged from 32.25-2000 pg mrl. 
2.7 Tissue culture 
2.7.1 Recovery ofL929 cells from liquid nitrogen storage 
The L929 mouse fibroblast cell line was purchased from the European Collection of Animal Cell 
Cultures (ECACC no. 85011425). A vial of L929 cells was removed from liquid nitrogen 
storage. The lid was loosened and cells were thawed rapidly by immersion in a 37 0 C water bath. 
The tube was swabbed with 70 % ethanol to ensure sterility. Cells were re-suspended in 10 ml 
growth media and centrifuged at 1000 rpm for 10 min (Sigma 4K15 centrifuge). The pellet was 
re-suspended in 5 ml growth media, transferred to a 25 cm2 tissue culture flask (IW AKI, Scitech) 
and incubated at 37 0 C with 5 % C02. 
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2.7.2 Passage of L929 cells 
Upon reaching confluency, cells were left for a further 24 hr. The growth media was removed 
and the cell layer was gently washed with 10 ml sterile PBS. The PBS was removed and 1 ml 
trypsinJEDTA (Gibco, Life Technologies) was added to digest junctions between cells. Flasks 
were incubated at 37 0 C with 5 % CO2 for 5 min, or until the cell layer had become detached 
from the bottom of the flask. Cells were re-suspended in fresh medium and mixed by gentle 
pipetting to separate cell clumps. 2 ml of the resulting suspension was used to inoculate 18 ml 
fresh medium. Caps were loosely replaced and flasks were incubated at 37 0 C with 5 % CO2. 
2.7.3 TNF bioassay 
This assay was optimised by Dr. A.R. Kerr within our laboratory, based on a procedure run by 
AstraZeneca pharmaceuticals and published cytotoxicity assays. The bioassay measures levels of 
active TNF (both TNF-a and TNF-~) through its ability to induce fibroblast cytotoxicity. 
Resulting cell death is measured by the inability of fibroblast mitochondria to breakdown MTT 
(3-[ 4,5-cimethylthiazol-2yl]-2-5, diphenyltetrazolium bromide), a yellow substrate to formazan 
product (dark blue). MTT cleavage is detected by colorimetrically following solubilisation of 
formazan product by addition of DMSO (dimethyl-sulphoxide) + HCl. TNF activity within the 
sample is determined using a standard curve. 
During late afternoon (to prevent over-proliferation of cells), cells were trypsinised as described 
above. Live cells were counted in a haemocytometer using trypan blue staining (500 III trypan 
blue (Sigma-Aldrich, UK), 300 III medium and 200 III re-suspended cells). The number of live 
cells were adjusted to 3.0 x 105 mrl in growth medium and 200 III of this suspension was added 
to each well of a 96-well, flat-bottomed tissue culture plate (Nunclon™ surface, Nalge Nunc 
InternationaFM). Following OIN incubation at 37 0 C with 5 % CO2, medium was removed from 
wells and replaced with 50 III of a 20 III mrl solution of Actinomycin D (Sigma-Aldrich, UK) in 
PBS, to prevent further multiplication of cells. TNF-a standard (Sigma-Aldrich, UK) was diluted 
in medium to produce concentrations ranging from 0.014 - 2500 U mrl. 25 III of standard and 
samples were added in triplicate to appropriate wells. Samples were applied neat and in 1 in 3, 1 
in 6 and 1 in 9 dilutions. Medium alone was used as a 0 % kill control. 
Following OIN incubation at 37 0 C with 5 % CO2, 100 III MTT in PBS (1 mg mrl) was added to 
each well. Plates were incubated for 4 hr at 37 0 C with 5 % CO2. 100 III ofDMSOI0.04N HCI 
was added to wells to solubilise any formazan product. Plates were tapped gently to mix contents 
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and AS40 run read with the correction set at A630 run, using a Dynatech MRX plate reader and 
Biolinx 2.21 ™ software. A logarithmic standard curve was used to determine the TNF activity in 
samples using 50 % kill measurements. 
2.8 ZmpB protein expression 
2.8.1 peR to amplify desired regions of zmpB for expression 
2.8.1.1 Primer design 
Primers were designed to amplify up the central and 3' regions of zmpB (ZmpB itself is thought 
to be too large to express whole [>5 Kb D. Primers were designed with restriction sites (BamHI 
and Sac!) to enable subsequent in-frame cloning of the PCR product into pET33b (see below) 
downstream of the T7 promoter. The reverse primer for the central region amplification was also 
designed to contain a stop codon to prevent read-through during transcription. 6 random bp were 
added onto the 5' ends of all primers to aid restriction enzyme digestion and enable direct 
cloning into an expression vector. 
2.8.1.2 peR and restriction digest offragmentsfor cloning and expression 
PCR reactions were set up as previously described, section 2.1.3., using Vent polymerase (New 
England Biolabs® Inc.) to provide proofreading activity. 
Region of ZmpB for Primers Annealing / 
expreSSIOn (forward, elongation conditions 
reverse) 
Central (600 ammo ForBamZmp 62 0 C, 30 sec 
acids) RevSacZmp 72 0 C, Imin 40 sec 
C-terminal (530 ForBamZmp2 62 0 C, 30 sec 
amino acids) RevSacZmp2 72 0 C, Imin 40 sec 
PCR products were electrophoresed on a 1 % agarose as previously described. D39 WT genomic 
DNA prepared as described in section 2.3.1.1 was used for PCR reactions. PCR products were 
excised from the agarose gel and purified using a commercially available DNA purification kit 
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(QIAquick® Gel Extraction Kit, Qiagen) according to manufacturer's instructions. PCR product 
was digested with BamHI and Sac! (Promega, IOU /-Lr1) as described in section 2.2.1.3. 
2.8.2 Cloning into pET33b and transformation into expression host 
2.8.2.1 Vector preparation 
3 /-Ll of pET33b expression vector (Novagen, UK) was digested with BamHI and Sac! as 
described in section 2.3.1.1. 2 /-Ll of digested product was electrophoresed on a 1 % agarose gel to 
check vector had linearised. The vector preparation was heated at 65 0 C for 10 min to inactivate 
enzymes. Vector was incubated at 37 0 C for 4 hr with alkaline phosphatase (Prom ega 1 U /-Lr1) 
and 10 x buffer (Promega) to prevent ligation of the removed fragment back into the vector (1 /-Ll 
alkaline phosphatase per 10 ul reaction mixture). The vector preparation was purified using a 
commercially available gel extraction column (QIAquick® Gel Extraction Kit, Qiagen), without 
prior electrophoresis on a gel. 
2.8.2.2 Ligation of peR product into pET vector 
For each zmpB insert, 7 /-Ll PCR product was mixed with 1 /-Ll prepared pET33b vector, 1 III T4 
ligase (Promega, 3 U Ilrl) and 1 III 10 x ligation buffer (Promega). The ligation reaction was 
allowed to proceed OIN at 16 0 C. A control ligation was set up without insert. 
2.8.2.3 Transformation into DH5a cells for sequencing 
E. coli DH5a cells were used to enable sequencing of the insert prior to transformation into E. 
coli BL21 cells, due to the increased transformation efficiency of the former. One vial of 
competent DH5a-Library efficiency cells (Invitrogen™ Life Technologies) was thawed on ice 
and divided into 3 x 100 III aliquots. 3 III of ligation mixture was added to each (one 
transformation for each zmpB ligation and one control to check for self ligation). Cells were 
incubated on ice for 30 min then heat shocked at 42 0 C for 30 sec. Tubes were placed back on 
ice for a further 2 min. 450 III SOC media was added and cells were incubated for 1 hr at 37 0 C, 
with shaking. Transformation mixtures were spread onto LB agar plates containing kanamycin 
(30 /-Lg mrl) to select for pET33b. Plates were incubated OIN at 37 0 C. Several colonies from 
each transformation were selected and grown to OD 600 nm 0.5-0.6. Glycerol stocks were made as 
described in section 2.1.4. 
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2.8.2.4 Restriction digest and sequencing to confirm inserts 
pET33b vector was purified from DH5a stocks using a commercially available plasmid isolation 
kit (QIAprep® Spin Miniprep Kit, Qiagen) according to manufacturer's instructions. Isolated 
plasmid vector was digested with BamHI and Sac! as described above. Products were 
electrophoresed on a 1 % agarose gel. Confirmation of the insert was indicated by two DNA 
bands of 1.6-1.85 Kb and 5.4 Kb. These bands represented insert and empty vector respectively. 
Following confirmation of DNA insert into pET33b, purified plasmid was sequenced in-house as 
described in section 2.3.1.2b. T7 promoter and T7 terminator primers, specific for pET33b were 
used for sequencing. Following confirmation that insert was present and in frame, the middle 
region of the cloned fragment was sequenced using primers specific for zmpB (ZmpseqgF, 
ZmpseqgR) to ensure sequence homology with the R6 genome sequence. The sequence of the 
entire insert could thus be checked for amino acid changes. 
2.8.2.5 Transformation of BL21 cells for zmpB expression 
Following confirmation of zmpB insert in pET33b by sequencing, purified vector was used to 
transform BL21 (DE3) competent cells (Stratagene) according to manufacturer's instructions. 
Transformants were selected on kanamycin plates (30 ftg mrl) and glycerol stocks were prepared 
as described previously. 
2.8.3 ZmpB protein expression 
2.8.3.1 Protein expression 
BL21 (DE3) cells (Stratagene) were used for the expression of protein as these cells have the T7 
polymerase and its lacUV5 promoter on a bacteriophage, DE3. Addition of IPTG induces T7 
polymerase transcription from lacUV5. T7 polymerase then acts to induce protein expression 
from the T7 promoter on pET33b. BL21 (DE3) cells transformed with pET33b vector 
containing zmpB insert were streaked onto an L-agar plate containing kanamycin (30 ftg mrl) 
and plates were incubated OIN at 37 0 C. Single colonies were used to inoculate 100 ml LB 
media supplemented with kanamycin. Cultures were incubated OIN at 37 0 C with shaking. 10 
ml of overnight culture was used to inoculate 1 L fresh media containing kanamycin selection. 
Cultures were incubated at 37 0 C, with shaking, until an OD 600 nm of 0.6 was reached. Protein 
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expression from the T7 promoter was induced by the addition of 1 ml of 1M IPTG (Melford 
Laboratories Ltd, Ipswich, UK). Cultures were placed back into the shaking incubator for a 
further 3 hr to allow protein expression to proceed. Cells were then pelleted by centrifugation at 
5000 rpm for 15 min (Sigma 4K15 centrifuge). The pellet was re-suspended in 10 ml PBS and 
lysed as described below. 
2.8.3.2 Cell disruption to release protein 
Re-suspended cell pellets were passed (x 2) through a One Shot Benchtop Cell Disrupter 
(Constant Systems Ltd., Warwick, UK) at 12 KPSI to ensure complete disruption. A small 
aliquot was retained for analysis on a SDS-PAGE gel (described below in section 2.9.5). The 
remainder of the lysed cell pellet was centrifuged at 14,000 rpm for 1 hr (Sigma 4K15 
centrifuge). A small aliquot of the supernatant was retained for analysis on a SDS-P AGE gel and 
the remainder was discarded. The pellet was frozen at - 70 0 C until required. 
2.8.3.3 Detection 0/ expressed protein by SDS-PA GE 
Detection of expressed protein in soluble and insoluble cell fractions was determined by SDS-
PAGE with Coomassie staining, as described in section 2.9.5. 
2.8.3.4 Preparation o/protein/rom inclusion bodies 
The majority of expressed protein was in the insoluble fraction and had to be released from the 
inclusion bodies. The frozen cell pellet from section 2.8.3.2 was thawed at room temperature and 
re-suspended in PBS containing 30 % (w/v) sucrose and 10 mM EDT A (Fisher Scientific). An 
electronic hand-held tissue homogeniser set at high speed (IKA®-Ultra-Turrax® T25, Janke 
Kunkel Laboratories) was used to aid re-suspension of the hard cell pellet. The resulting 
suspension was centrifuged at 14,000 rpm for 1 hr. The pellet was washed in PBS containing 1 
% Triton-X-100 (Sigma-Aldrich, UK) and centrifuged as described above. Following each 
centrifugation stage, a small aliquot of the supernatant was retained for gel analysis and the 
remainder discarded. The pellet was re-suspended in 100 ml of 7 M urea (Sigma-Aldrich, UK) 
made up in PBS to re-solubilise the released protein. Mixtures were kept on ice for 2 hr, with 
frequent mixing. The re-solubilised protein solution was poured into dialysis tubing with a 
molecular weight cut off of between 6-8 KDa (SpectraiPor 1 ®, Fisher Scientific) and dialysed 
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against PBS for 1 hr at 4 0 C. Used PBS was discarded and replaced with fresh PBS, and dialysis 
was continued for 4 hr, changing the PBS once during this time. Finally the protein solution was 
dialysed OIN at 4 0 C in fresh PBS. Following OIN dialysis, large precipitates of protein were 
formed within the tUbing. This precipitate was retained and the supernatant passed down a nickel 
column (Ni-NTA superflow column, Qiagen) using a Pharmacia FPLC machine (purification 
step performed by Crystallography Department, University of Glasgow). The column was 
washed in PBS with 4 mM imidazole (Sigma-Aldrich, UK). His-tagged protein bound to the 
column was eluted with PBS containing 250 mM imidazole. Eluted protein was electrophoresed 
on a 10 % SDS PAGE gel as described above. 
The protein precipitate from the overnight dialysis was re-solubilised in 100 ml of 7 M urea in 
order to measure the protein concentration. Re-solubilised protein was scanned using a Unicam 
UV2, UV Nis spectrophotometer (Sigma) between A220 nm and A320 nm. Absorbance was 
determined and used to estimate the total protein concentration using the equation C=AIE.L, 
where C = concentration, A = absorbance E = extinction co-efficient and L = pathlength of cell 
used to read absorbance. E was calculated using the ExP ASy molecular biology server with the 
ProtParam programme (http://ca.expasy.org/tools/protparam.html). The protein was precipitated 
once more, following the dialysis procedure described above. The protein concentration in the 
supernatant was calculated in order to determine the total protein concentration in the remaining 
precipitate. This precipitate was suspended in sterile, LPS-free NaCl to give a final concentration 
of 2.2 mg mrl and used as the source of crude ZmpB protein for vaccination. The suspension 
was aliquoted and stored at - 20 0 C until required. 
2.9 ZmpB antibody production 
2.9.1 Preparation of ZmpB protein for vaccination 
For each vaccination with Freunds complete and incomplete adjuvant (FCA and FIA 
respectively, Sigma-Aldrich, UK), frozen protein aliquots, see above, were thawed on ice. 
Sterile, LPS-free NaCl was then added to give a final concentration of 1 mg mrl protein. Protein 
suspension was added to an equal volume ofFCA / FIA and the mixture was vortexed vigorously 
for 15-25 min, or until a thick emulsion was formed. 
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2.9.2 Vaccination schedule 
The vaccination schedule was as follows: 
Day -1: Pre-vaccination bleed 
Day 1: Vaccinate subcutaneously with 50 Ilg mrl ZmpB in FCA 
Day 13: Pre-boost bleed 1 
Materials and Methods 
Day 14: Boost # 1, vaccinate subcutaneously with 50 Ilg mrl ZmpB in FIA 
Day 27: Pre-boost #2 bleed 
Day 28: Boost # 2, vaccinate subcutaneously with 50 Ilg mrl ZmpB in FIA 
Day 41: Pre-boost #3 bleed 
Day 42: Boost # 3, vaccinate intravenously with 50 Ilg mrl ZmpB in sterile NaCI 
Day 44: Terminal bleed 
Vaccinations were given in 100 III volumes. 
2.9.3 Vaccination of mice 
A small group of MF1 mice were vaccinated subcutaneously with 50 Ilg mrl of ZmpB (central 
region) protein using a 21 gauge needle. Mice were scruffed and held firmly to restrict 
movement. 100 III of protein emulsified in FCA / FIA was injected into the layer of skin around 
the neck. Successful vaccination was evident by the formation of a granuloma beneath the top 
layer of skin, 24 hours post vaccination. Mice were monitored frequently to ensure granulomas 
did not become exposed to the surface or cause the mice any evident distress. A control 
vaccination of one mouse was set up using PBS with FCAIFIA. 
2.9.4 Bleeds to obtain sera 
Blood was taken from mice as described in section 2.5.5. 100 III was removed and placed on ice. 
Blood was allowed to clot OIN at 4 0 C. Clotted blood was pelleted by centrifugation at 10,000 
rpm and the sera was decanted off and stored at 4 0 C or - 20 0 C until required. For the terminal 
bleeds, mice were sacrificed by cervical dislocation and the thoracic cavity opened up to expose 
the heart and lungs. A 23-gauge needle was inserted into the right ventricle of the heart and 
blood was collected into an attached syringe. Blood was processed as described for the tail 
bleeds. 
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2.9.5 Analysis of immune sera for antibodies by Western blot 
2.9.5.1 SDS-PAGE 
Materials and Methods 
A 12 % SDS polyacrylamide gel was prepared as described below using standard protein gel 
apparatus (Bio-Rad). An aliquot of frozen ZmpB protein was thawed at RT and mixed with the 
appropriate volume of 5 x sample buffer. Protein was denatured by heating to 100 0 C for 2 -3 
min. 25 III of sample was added to wells and the gel was electrophoresed at 200 V for 1 hr 30 
min. A standard was included with each gel (Kaleidoscope Pre-stained Standards, Bio-Rad). 
Total concentration of protein loaded per well was 44 Ilg. For each group of immune sera to be 
analysed, duplicate gels were set up. One of each gel was used for Western blot and the other 
was stained with Coomassie Blue to ensure presence of ZmpB protein. 
Separating gel: 
Stock solution Volume added for 12 % gel 
1.5M Tris-HCI, pH 8.8 (Sigma-Aldrich, UK), 2.5 ml 
10 % SDS (Fisher Scientific UK. Ltd.), 100 III 
30 % acrylamide-bis (Bio-Rad Laboratories) 4.0ml 
10 APS (Sigma-Aldrich, UK) 50 III 
TEMED (Sigma-Aldrich, UK) 5 III 
dH20 3.35 ml 
Stacking gel: 
Stock solution Volume added for 10 % gel 
0.5M Tris-HCI, pH 8.8 (Sigma-Aldrich, UK), 1.25 ml 
10 % SDS (Fisher Scientific UK. Ltd.), 50 III 
30 % acrylamide-bis (Bio-Rad Laboratories) 665 III 
10 APS (Sigma-Aldrich, UK) 25 III 
TEMED (Sigma-Aldrich, UK) 5 III 
dH20 3.05 ml 
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2.9.5.2 Coomassie Blue staining 
Gels were immersed in Coomassie Blue stain for 1-3 hr on a shaking platform (Edmund Buhler 
KM-2 shaker). Gels were subsequently rinsed several times in dH20, immersed in destain for 1-2 
hr, rinsed in dH20 and dried between cellophane support sheets on a GelAir dryer (BioRad). 
2.9.5.3 Western Blot 
Transfer buffer was cooled to 4 0 C prior to use. The gel was placed in the cooled transfer buffer 
for 30 min and set up with HybondTKC super membrane (Nitrocellulose, 0.45 /-LM, Amersham 
Life Science) with filter paper and fibre pads within a standard Western blot gel tank (BioRad 
Mini Protein WM). The tank was filled with cold transfer buffer and the gel blotted at 30 V OIN. 
The nitrocellulose membrane was subsequently blocked with Tris N aCI, pH 7.4, containing 
skimmed milk (3 % w/v, Marvel) for 1 hr. Primary antibody (mouse sera) was diluted 1:1000 in 
Tris NaCI, pH 7.4, containing 3 % skimmed milk, and incubated with the membrane with gentle 
shaking at 37 0 C for 3 hr. The membrane was washed several times in Tris NaCI, pH 7.4, and 
transferred to Tris NaCI, pH 7.4, containing 3 % skimmed milk and secondary antibody (sheep 
anti-mouse, horseradish peroxidase-linked whole antibody, Amersham Life Science) diluted 
1: 1 000. Following incubation with gentle shaking at 37 0 C for 1 hr, the membrane was washed 
thoroughly in Tris NaCI, pH7.4, and developed in the dark using 4-chloro-1-napthol. Sera 
samples that were positive for antibody production were pooled, aliquoted and stored at - 20 0 C. 
2.10 Expression analysis 
Powder-free gloves were worn at all times when preparing RNA or working with micro arrays to 
prevent RNA degradation by RNases present on the skin and to avoid contamination of arrays 
with dust particles. All glassware used for RNA / microarray work was washed thoroughly with 
diethyl pyrocarbonate (DEPC)-treated dH20 prior to use and filter tips were used for pipetting all 
liquids during this work. 
2.10.1 Culture of bacterial strains for RNA isolation 
Bacterial strains were grown in BHI, in the absence of antibiotic selection, to mid-log phase (OD 
600 nm 0.6-0.7). 2 ml aliquots were removed and rapidly frozen in liquid N2. This was to preserve 
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the cellular RNA profile as quickly as possible. Frozen cultures were stored at - 70 0 C until 
required. 
2.10.2 Isolation ofbacferial RNA 
Bacterial RNA was isolated using a commercially available kit (Rneasy® Mini Kit, Qiagen) with 
minor modifications to manufacturer's instructions. All reagents described in this section were 
provided with the kit, unless stated otherwise. 
Aliquots of frozen bacterial cultures (described above) were removed and 8 ml sterile, RNase-
free dH20 was added to each. Once the bacterial stock had thawed in the dH20, suspensions 
were centrifuged at 5000 rpm for 10 min (Sigma 4K15 centrifuge). The supernatant was gently 
removed and tubes were inverted on a paper towel to remove all final traces of supernatant. 200 
~l of freshly-prepared TE buffer, pH 8.0 (see appendix, A4) containing 15 mg mrl lysozyme 
(Sigma-Aldrich, UK) was used to re-suspend the bacterial pellet. The suspension was gently 
mixed by pipetting for 1 min. The resultant mixture was incubated at RT for 10 min with brief 
vortexing every 2 min. 700 ~l of Buffer RLT containing ~-mercaptoethanol (10 ~l ~­
mercaptoethanol per 1 ml buffer, added immediately prior to use) was added to lyse the bacteria 
and mixed by vortexing vigorously. 500 ~l of 100 % ethanol was added and mixed by pipetting. 
Solutions were applied to RNeasy® mini spin columns and centrifuged at 10,000 rpm for 15 sec 
(Sigma 113 microfuge). 350 ~l wash Buffer RWI was applied to each column and tubes were 
centrifuged at 10,000 rpm for 15 sec. The flow-through was discarded. DNA was removed by 
DNase treatment (70 ~l Buffer RDD with 1 0 ~l DnaseI stock per column Qiagen ). DNase was 
applied directly onto the RNeasy® membrane and left to incubate at RT for 15 min. The 
membrane was washed by the addition of 350 ~l Buffer RWI followed by centrifugation of 
columns at 10,000 rpm for 15 sec. The RNeasy® columns were transferred to new collection 
tube. 500 ~l Buffer RPE was added and columns centrifuged at 10,000 rpm for 15 sec. The flow-
through was discarded. 500 ~l Buffer RPE was added and columns centrifuged at 10,000 rpm for 
2 min. The flow-through was discarded and columns were centrifuged at 10,000 rpm for an extra 
1 minute. Columns were transferred to new RNase-free collection tubes and RNA was eluted by 
the addition of 50 ~l sterile, RNase-free dH20 followed by centrifugation at 10,000 for 1 min. 
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2.10.3 Determination of RNA concentration 
The concentration of isolated bacterial RNA was quantified by electrophoresing 5 /-il RNA 
sample with 1 /-il DNA sample buffer on a 1 % agarose gel containing ethidium bromide as 
described previously. Commercially available RNA of a known concentration (E. coli 16S and 
23S RNA, 4 U /-irI, Boehringer) was diluted as appropriate and used as a reference for RNA 
concentration. 
2.10.4 Printing of S. plleu11lolliae microarrays 
The array was designed based on the 2 pneumococcal genome sequences currently available 
publicly (TIGR4 and R6, http://www.tigr.org/). Probes were initially designed based on the 
TIGR4 sequence (as part of a collaboration between T.J. Mitchell, J. Hinds and J. Wells). The 2 
genomes were compared to each other using the BLAST algorithm to identify genes present in 
R6 but absent in TIGR4. These genes were also included on the array to produce a composite 
array representative of both genomes (2238 TIGR4 genes, 116 R6 genes). Probes were designed 
using the Primer 3 software. One probe per gene was used and probes were designed to be 
specific to target genes and to have hybridisation / annealing temperatures as close as possible. 
This resulted in probes of different lengths, binding to random regions of the target genes. All 
oligonucleotide sequences were analysed for specificity using the BLAST algorithm. 
S. pneu1110niae micro arrays were printed by the Bacterial Microarray Group at St. Georges 
Hospital (BbLG@S, http://www.sghms.ac.ukldepts/medmicro/bugs/ 
London, UK). 
2.10.5 Hybridisation of RNA to arrays 
cDNA hybridisations were performed following the protocols optimised at B/-iG@S. 
2.10.5.1 Cy3/Cy5 labelling of eDNA 
One Cy3 and one Cy5 labelled cDNA sample were prepared per micro array slide. 
RNA samples were adjusted to equal concentrations by the addition of sterile, RNase-free dH20 
where appropriate. RNA samples containing less than 7 /-ig /-ir1 were not used for microarray 
hybridisation. 
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10 J..LI each RNA sample was mixed with 2 J..LI random primers (3 J..Lg J..Lrl, Gibco BRL, Life 
Technologies), heated at 95 0 C, snap cooled on ice and briefly centrifuged. The following were 
added to each reaction; 5 J..L15 x First Strand Buffer (Gibco BRL, Life Technologies), 2.5 J..LI DTT 
(l00 mM, Buffer, Gibco BRL, Life Technologies), 2.3 J..LI dNTPs (5 mM dA/G/TTP, 2 mM 
dCTP, Gibco BRL, Life Technologies), 1.7 J..LI Cy3 OR Cy5 (dCTP Fluorolink:, Amersham 
Pharmacia Biotech) and 2.5 J..LI Superscript II Reverse Transcriptase (200 U J..Lrl, Gibco BRL, Life 
Technologies). Reactions were incubated at 25 0 C, for 10 min, followed by 42 0 C for 90 min. 
Both incubations were carried out in the dark. 
2.10.5.2 Pre-hybridisation 
The pre-hybridisation solution was equilibrated at 65 0 C in a Coplin jar (Fisher Scientific) 
during the labelling reaction described above. The micro array slide was incubated in the pre-
heated pre-hybridisation solution at 65 0 C for 20 min. The slide was then rinsed in 400 ml dH20 
for 1 min, followed by a rinse in 400 ml propan-2-01 (BDH Laboratories) for 1 min (using slide 
staining troughs and racks, Fisher Scientific). The slide was placed into a 50 ml falcon tube and 
dried by centrifugation at 1500 rpm for 5 min. 
2.10.5.3 Purification ojCy3/Cy5 labelled cDNA 
Following labelling of cDNA with Cy3/Cy5 as described above, reaction mixes were combined 
into a singe tube and purified using a commercially available kit (MinElute PCR Purification Kit, 
Qiagen) according to manufacturer's instructions. Labelled cDNA was eluted in 15 J..LI sterile, 
RNase-free dH20. 
2.10.5.4 Wash preparation 
Wash A was placed in a sealed Duran and incubated OIN at 65 0 C, together with an empty 
staining trough (Fisher Scientific). 
2.10.5.5 Microarray hybridisation with Cy3/Cy5 labelled cDNA 
The freshly prepared microarray slide was placed into a hybridisation cassette (Telechem 
International). 15 J..LI aliquots of water were added to the wells at either end of the cassette. 4.6 J..LI 
of filter sterilised 20 x SSC (0.2 J..LM filters, Sartorius Minisart, Germany) and 3.5 J..LI filter 
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sterilised SDS (20 %) was added to the purified Cy3/Cy5 labelled eDNA. The mixture was 
heated at 95 0 C for 2 min, allowed to cool slightly and briefly centrifuged. The solution was 
gently pipetted onto the array and covered with a glass coverslip (BDH Laboratories). The 
hybridisation cassette was sealed and immersed in a water bath at 65 0 C in the dark for 16-20 hr. 
2.10.5.6 Final washing of arrays 
Following hybridisation, the micro array slide was removed for the hybridisation cassette and 
immersed into pre-heated Wash A to remove the coverslip. The array was then washed for 2 min 
by gentle agitation in Wash A using the staining troughs and slide racks (Fisher Scientific). 
Arrays were transferred to new racks and washed in Wash B (x2) for 2 min each. The slide was 
placed into a 50 ml Falcon tube and dried by centrifugation at 1500 rpm for 5 min. Array slides 
were stored in a dark, dust-free box. 
2.10.6 Scanning micro arrays 
Arrays were scanned using a dual-laser scanner (Affymetrix). Individual arrays were scanned x 
2. 
2.10.7 Data analysis 
Scanned images were imported into Imagene™ (BioDiscovery) for examination and 
optimisation ofraw data. Data analysis was performed using GenespringTM version 4.2.1 (Silicon 
Genetics) with the S. pneumoniae array template installed. Each gene's measured intensity was 
divided by its control channel value in each sample. 
2.10.8 Normalisation of data 
The GenespringTM default settings were used for normalisation for the array experiment 
performed in this thesis. 
2.10.9 RT-PCR 
2.10.9.1 eDNA synthesis 
Reverse transcription reactions were carried out using the ThermoScript™ RT-PCR System 
(Invitrogen Life Technologies). This system utilises a reverse transcriptase that has high thermal 
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stability and can increase specificity of reactions. Prior to use, RNA was treated with DNase 
(RQ1, Promega) according to manufacturer's specifications. cDNA synthesis using random 
hexamers was performed using the recommended Thermoscript ™ R T -PCR System protocol. 
This proved more efficient than using gene-specific primers. Control reactions were performed 
in the absence of reverse transcriptase. Resulting cDNA was treated with 1 III RNase H (E. coli, 
2 U Ilr1, Invitrogen Life Technologies) at 37 0 C for 20 min, and stored at - 20 0 C until required. 
2.10.9.2 peR 
PCR reactions were performed using 2 III of the cDNA from the reverse transcription reaction 
described above. This was incorporated into a general PCR reaction as described in section 2.1.6 
using PCR conditions optimised to suit individual primer pairs. Negative control reactions were 
set up using cDNA synthesis reactions carried out in the absence of reverse transcriptase and 
PCR reactions where cDNA was substituted with dH20. A genomic DNA PCR was included as 
a positive control. Details of all primers used for RT-PCR analysis are provided in the appendix 
(A3). 
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2.11 Statistics 
2.11.1 Overview 
Much of the data presented in this work is based on in vivo experiments using a murine model of 
pneumococcal infection, where the behaviour of selected mutants is compared to that of isogenic 
parental strain. The model used for the majority of this data is an outbred strain of mouse and 
thus variation is expected. Statistical analysis is used to determine if any differences observed are 
significant. This section aims to highlight the parameters that have been applied to allow for the 
appropriate presentation of data and analysis of the significance of such data. A data set 
comprising bacterial counts in the blood of mice 24 hours post challenge with a virulent, type 2 
strain of S. pneumoniae (D39) was selected to demonstrate the variation typically seen and how 
this was analysed. The data set comprises 50 mice selected at random from the experiments 
performed during the course of this project and is representative of all data sets obtained in this 
work. The time point selected represents one in which mice would be expected to be showing 
symptoms and have detectable bacterial counts within the blood. 
2.11.2 Normally distributed measurements 
A data set has normal/parametric distribution when a symmetrical histogram is produced. The 
tip of this plot should correlate approximately with the mean value and +/- 1 SD around the mean 
should encompass 68 % of the population. Normal data sets can be analysed statistically using 
tests that take into account mean values, such as t-tests. A histogram-based analysis was applied 
to 50 MF1s challenged intranasally with 106 CFU D39 (following intraperitoneal challenge), to 
determine if the in vivo data sets produced in this work had normal distribution. Mice included in 
this analysis all became bacteraemic during the course of infection. 
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Figure 2.1: D39 bacteraemia, 24 hr post challenge 
Materials and Methods 
7.5 8.5 9.5 
Histogram showing the spread of bacterial counts in the bloodsh'eam of mice following inh'anasal challenge 
with 106 CFU D39 bacteria, A normal dish'ibution curve has been superimposed onto the data set using 
Minitab Software, Release 13,1. 
The mean value of LoglO 5.4 CFU mr!, as calculated using basic statistical tests, lies within the 
peak of the normal distribution curve. 1 +/- SD of the mean (LOglO 1.78) includes 69 % of the 
population, indicating normal distribution. To determine if these data were representative of a 
normal distribution set a specific test for normality was applied. This test converts the bell 
shaped normal distribution curve into a straight line. The data points can be observed visually for 
exactness of fit to this line. Altematively, and more accurately, a statistical test can be applied to 
determine if the individual points are significantly different from the normal curve (P<0.05) . The 
vertical axis of this plot represents a probability scale and the horizontal axis represents the data 
scale. A reading of 0.5 on the probability scale should correspond to the mean value of the data 
set if the data has normal distribution. 
Several variations of these normality tests are available and these depend on the shape of the 
histogram described above. For example, the Ryan-Joiner test is based on curved distributions 
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whilst a second test, the Anderson-Darling test, is based on a flatter distribution. As the D39 data 
shown above (figure 2.1) appears to represent a curved distribution, it was analysed for normality 
using the Ryan-Joiner test. The results of this normality plot are shown below (figure 2.2). 
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Figure 2.2: The Ryan-Joiner normality test 
This test was applied to the D39 data set described in the text to determine normality. Spots represent 
counts from the blood of individual mice, 24 hr post challenge with 106 CFU bacteria. The data is normally 
distributed. 
The Ryan-Joiner normality test showed that the D39 data set was normally distributed as the P 
value was greater than 0.05 (a P value of <0.05 is indicative of data that are not normally 
distributed). Furthermore, a value of 0.5 on the probability scale correlated to a value of IOglO 
~5.3-5.4 CFU mrl which is in agreement with the mean value of the data set (lOglO 5.40 CFU mr 
I). This provides further evidence that this data set is normally distributed. This data set also 
demonstrated normal distribution using the Anderson-Darling test (data not shown). 
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2.11.3 Non-parametric measurements 
The normality test used above demonstrated that the D39 data sets have normal distribution and 
that mean values can be used to represent these data. However, the data set included only mice 
that became bacteraemic, and working with an outbred murine model means that this may not 
always be the case. Outliers in data sets can distort the results, especially when working with 
small populations (n=5-10) and being an outbred, biological system, outliers are to be expected 
with our model. Similarily, in comparing two groups of data such as wild-type verses mutant 
data sets there may be significant differences in the standard deviations between the two groups, 
making t-tests invalid (this tests relies on the standard deviations between groups being very 
similar). Non-parametric statistical analysis can overcome these differences by using the median 
value as the measure of central tendancy. The Mann-Whitney Test is a non-parametric statistical 
test that can be used to examine differences between 2 random populations. It does not require 
that the data have a normal distribution or that populations have similar standard deviations. It is 
based on the null hypothesis that the medians of the two populations are equal. Even if data do 
show normal distribution, this test of statistical significance can be applied to provide a more 
stringent basis for detecting differences. 
2.11.4 Summary 
Since non-parametric analysis is a more stringent determination of significant difference between 
2 populations, this statistical analysis will be applied to all in vivo data sets used in this work, 
where mutant behaviour is compared to that of wild type. Mann Whitney Tests will be performed 
for all data sets and a P value of <0.05, represented by a single asterix (*) will be considered 
statistically significant. A P value of <0.005 will be considered highly significant and will be 
respresented with a double asterix (**). Graphical presentation of all data (in vitro and in vivo) 
will be based on mean values for all experiments with error bars representing +/- 1 standard error 
of the mean (SEM). Where logarithmic values are involved the geometric mean will be used to 
represent data. This will allow the reader to appreciate the error associated with experiments as 
median values do not have the equivalent of a SD or SEM as measures of variabilityl. This 
1 SEM refers to the estimation of the significance in the deviation of the mean of a sample from the true mean ofthe 
population. SD is a measure of variance in a sample. Approximately 68 % of the sample population should lie within 
+/- 1 SD of the mean 
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method of presentation should represent results accurately as median values were rarely found to 
differ substantially from mean values during the course of this work. However, should mean and 
median values differ for any particular set of data, such that the chosen form of presentation does 
not accurately represent the results, this will be highlighted and discussed as appropriate2• 
Furthermore, mean values are represented to allow for comparison of results obtained within this 
thesis concerning the rr08 and rr09 mutants with that of published data which also used mean 
values (Throup et al., 2000). 
All statistics were performed using Minitab™ Statistical Software (Release 13, Minitab Inc.). 
Mann-Whitney Tests were used for the analysis of all in vivo data. For all animal work, a 
minimum of 5 mice were used for all bacterial strains for each time point / measurement 
examined and experiments were repeated on at least 2 separate occasions. Therefore n = at least 
10 for each data point displayed for animal work. Measurements of bacteraemia were 
continuous, using the same group of infected mice for successive time points. Such mice were 
also used for analysis of survival. Analysis of bacterial loads in the lung tissue or BALF required 
that the mice be culled first, and such measurements at different time points are thus from 
different mice. 
2-sample t-tests were used to analyse in vitro data and for all micro array analysis of statistical 
significance. For all in vitro work (growth curves, transformation efficiencies etc) assays were 
performed in replicates of at least 2, and repeated on at least one separate occasion, unless stated 
otherwise. Therefore n = at least 4 for all in vitro analysis. 
Data points on individual figures represent the mean value of all repetitions and error bars 
represent 1 +/- SEM, unless stated otherwise. 
2 Evaluation of statistical tests and methods discussed in this section was obtained from 'Practical Statistics for 
Experimental Biologists' by A. C. Wardlaw, John Wiley & Sons Ltd, Second Edition 
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3 Results; S. pneumoniae TCS08 
The study of this system for its role in virulence of S. pneumoniae was chosen based on 
preliminary data that suggested that the system may be important in respiratory tract infection 
(Hoffmann-La-Roche, personal communication, Throup et al., 2000). Furthermore, expression 
analysis indicated that the system controls the expression of a single gene of unknown function, 
sp0082, located immediately upstream of the rrlhk08 locus, indicative of a relatively simple 
system of gene regulation (Hoffmann-La-Roche, personal communication). Thus the aim of this 
section was to create mutations in the sp0082, hk08 and rr08 genes and to analyse the mutants 
individually for virulence using a murine model of infection. Mutations in the rr08 gene in 2 
different serotypes were created and analysed. The effect of the mutagenesis technique on 
phenotype was compared. 
3.1 Transformation of S. pneumoniae and its effect on virulence 
The natural ability of the pneumococcus to obtain DNA from the extracellular environment and 
incorporate it into its genome (transformation or competence), and the availability of several 
pneumococcal genome sequences can be exploited to create mutations in virtually any gene of 
choice in S. pneumoniae. Much of the experimental data presented in this thesis are based on the 
construction of different mutations using several mutagenesis techniques, all of which rely on the 
transformation of parental S. pneumoniae cells with different DNA constructs. Resulting mutants 
are compared with isogenic parental strains to characterise any differences in phenotypes, both in 
vitro and in vivo. To ensure that any differences observed in the mutant strains are due to the 
mutation itself and not the transformation procedure, the virulent, encapSUlated serotype 2 
pneumococcal strain D39 was transformed with a control plasmid pVA838 and compared to a 
non-transformed strain for in vitro growth and virulence. pVA838 contains an erythromycin-
resistance gene, which acts as a selection marker for transformants, and is able to replicate in S. 
pneumoniae. 
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3.1.1 lit vitro growth 
Growth of the pVA838-transformed D39 strain (tD39) in BHI was compared to that of non-
transformed D39 (D39) for a period of 20 hr. During this time, no differences in growth were 
observed between the 2 strains. The tD39 strain also retained its erythromycin resistance when 
grown in culture in the absence of antibiotic selection for up to 20 hr (data not shown). 
3.1.2 lit vivo characterisation 
Mice were challenged intranasally with 106 CFU of both tD39 and D39 and monitored for 
survival. Levels of bacteraemia in the blood were measured at pre-determined time points 
following challenge. No significant differences were observed between tD39 and D39 for murine 
survival or levels ofbacteraemia in the blood at any of the time points studied, see figure 3.1. 
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Figure 3.1 Bacteraemia following intranasal challenge with D39 and tD39 
Mice were challenged intranasally with 106 CFU D39 wild-type and tD39, a strain that has been 
transformed with plasmid pVA838. Bacterial counts in the blood of infected mice were monitored at pre-
determined time points. The broken line represents the limit of detection. 
To ensure that the bacteria counted in the blood for the tD39 strain were not wild-type D39 
revertants that had lost the plasmid during growth, the blood collected at the 36 hr time point was 
plated onto blood plates in the presence and absence of erythromycin. Viability counts were 
compared and this illustrated that there was no reduction in bacterial counts when the tD39 strain 
was counted in the presence or absence of antibiotic (figure 3.2). Thus tD39 retains its pVA838 
plasmid for up to 36 hr following intranasal challenge and is not impaired in virulence compared 
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to wild-type D39. This provides evidence that the transfonnation protocol used to produce the 
mutants discussed in this thesis does not result in attenuated virulence. 
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Figure 3.2 Stability of tD39 following intranasal challenge 
Mice were challenged intranasally with 106 tD39. At 36 hr post infection cell viability counts were 
performed in the presence (tD39 E) and absence (tD39) of erythromycin (1 !!g mr1). No significant 
difference in bacterial counts were found between the 2 strains. 
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3.2 Insertion-duplication mutagenesis; Basic in vitro analysis 
3.2.1 Creating and confirming mutants in hkOB, rrOB and spOOB2 
Plasmid vectors containing a region of DNA homologous to the target gene for mutagenesis were 
constructed by Lange et at (Hoffmann-La-Roche) and supplied to our laboratory (see appendix). 
Upon transformation into pneumococcal cells the plasmids integrate into the target gene by 
homologous recombination. The constructs contain a gene encoding erythromycin resistance, 
which acts as a selective marker for chromosomal integration of the plasmid. The plasmid 
constructs are suicide vectors that are unable to replicate in S. pneumoniae and are eliminated 
from the cell unless they integrate into the chromosome. 
Constructs designed to integrate into the hk08, rr08 and sp0082 genes were transformed into the 
virulent serotype 2 D39 strain of S. pneumoniae. Transformants were selected on erythromycin 
and each was confirmed using PCR. The resulting mutants were named based on the constructs 
provided by Hoffmann-La-Roche to create the mutants (see appendix). Thus the hk08, rr08 and 
sp0082 mutants will be referred to as iJpRPL7, iJpASl and iJpRPL50, respectively in all 
subsequent work. 
To confirm the individual mutants, the 5' and 3' plasmid integration sites into the target genes 
were confirmed using a chromosome-specific primer and a plasmid-specific primer for each PCR 
(figure 3.3). This resulted in a band present in the mutant but absent in the wild-type parental 
strain for each integration site. For each mutant, the PCR product confirming the 5' integration 
site was sequenced. The chromosome-specific primers, or other primers flanking the target gene, 
can also be used together to amplify a band from the wild-type strain that is absent in the mutant 
(due to the large amount of plasmid DNA inserted between the primer sites) if PCR conditions 
are optimised (data not shown). This PCR also confirms that a lack of band in the wild-type 
strain when confirming the 5' and 3' integrations is not due to poor genomic DNA template. 
All insertion-duplication mutants were confirmed using the PCRs described above. Figure 3.4 
shows confirmation of the iJpRP L 7 mutant only, using PCR to confirm the 5' and 3' integration 
sites only. All other mutants were confirmed in the same way. 
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Figure 3.3 Confirmation of insertion-duplication mutants 
The figure illustrates the insertion of an entire plasmid construct (shown in light blue) into the target gene 
(dark blue) by insertion-duplication mutagenesis. The diagram is modified from figure 1.4 (introduction, 
section 1.7), which should be referred to for a more detailed description of the mutagenesis technique. To 
ensure the integration of the construct into the target site, PCR is used to confirm the 5' and 3' plasmid / 
chromosome junctions. The figure shows the primers used to confirm the iJpRPL7 mutant (mutation within 
hk08), although the same principle was used to confirm all insertion-duplication mutants. Primers HK8PF 
and RPL22 were used to confirm the 5' integration site, with an expected product size of - 540 bp. Primers 
AP70 and HK8PR were used to confirm the 3' integration site, with an expected product size of -782 bp. 
Plasmid-specific primers (RPL2 and AP70) are shown in light blue and chromosome-specific primers 
(HK8PF and RPL22) are shown in black. 
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Figure 3.4 Confirmation of the ApRPL 7 mutant by PCR 
S. pneulIloniae TCS08 Results 
782 bp 
540 bp 
PCR was used to confirm the 5' and 3' integration sites of the iJpRPL7 mutant. The expected PCR 
fi'agments for the 5' and 3' integration sites using the primer sets described in figure 3.3 are 540 bp and 782 
bp, respectively. The absence of these bands in the wild-type genomic DNA is shown (lanes 1 and 4, 
respectively). Lane 1; D39 wild-type with primers specific for 5' integration site. Lane 2; iJpRPL7 mutant 
with primers specific for 5' integration site. Lane 3; iJpRPL7 mutant with primers specific for 3' integration 
site. Lane 4; D39 wild-type with primers specific for 3' integration site. 
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3.2.2 Growth and autolysis ill vitro 
All strains were subject to growth and autolysis determination using a combination of viable cell 
enumeration and optical density readings. None of the mutants displayed growth or autolysis 
characteristics that were significantly different from the wild-type parental strain. Furthermore, 
all mutants retained their erythromycin resistance when grown in culture in the absence of 
antibiotic selection for up to 24 hr, demonstrating that the plasmid insertion is stable under these 
conditions (data not shown). Growth of the i1pASl (rr08) mutant only, as determined by viable 
cell counting, is shown in figure 3.5, and is representative of growth of all the other mutants. The 
stages of growth characteristic of all pneumococcal strains used in this thesis are illustrated in 
figure 3.5. Phases characteristic of S. pneumoniae growth in vitro include exponential phase 
which represents rapid growth where the bacteria divide logarithmically and stationary phase 
where the growth rate is balanced by the number of dying cells. Following stationary phase, 
pneumococci autolyse through activation of the major autolysin LytA (autolysis). 
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Figure 3.5 III vit,.o growth of ApASI 
15 ml BHI was inoculated with 1.0 x 106 CFU D39 or iJpASI mutant. Viable cell enumeration was 
performed every 2 Ill' for 20 hr. The mutant strain was grown in the absence of erythromycin 
selection, being shown to be stable under such conditions in a previous experiment. No difference 
in growth or autolysis was observed with the mutant compared to D39 parental stTain. Exponential 
phase (Ex. phase), stationary phase (St. phase), and autolysis are represented on the curve. The 
broken line represents the limit of detection. 
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3.3 Insertion-duplication mutagenesis; In vivo characterisation 
Prior to all subsequent in vivo work, all bacterial strains were mouse-passaged by intraperitoneal 
injection. 
3.3.1 Survival and bacteraemia following intranasal challenge 
Strains were analysed for their ability to induce disease in a murine model of pneumonia. 
Outbred MFI mice were challenged intranasally with 106 CFU Following challenge, none of the 
mutants were significantly attenuated in virulence compared to the isogenic parental D39 strain, 
as determined by survival and bacterial counts in the blood. Median survival times of mice 
infected with all mutants were all very similar, with the exception of the iJpRPL7 mutant, which 
had a median survival time of 95 hr compared to 54 hr with D39 wild-type (figure 3.6A). 
However, this value was not found to be statistically different to that of wild-type parental strain. 
The median counts within the blood of mice challenged with the iJpRPL7 mutant were also 
consistently lower than those of mice challenged with wild-type bacteria, being> 100-fold lower 
than wild-type at 36 hr post infection (figure 3.6B). Again, these differences were not found to 
be statistically different. 
Following challenge with the iJpASl and iJpRPL50 mutants, the median survival times and 
counts in the blood were no different to those seen with wild-type D39 challenge. Survival and 
bacteraemia for these mutants compared to the isogenic parental strain are shown in figures 3.7 
and 3.8. 
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Figure 3.6 Survival and bacteraemia following intranasal challenge with ApRPL 7 
Mice were challenged intranasally with 1.0 x 106 CFU bacterial strains. Figure 3.6A shows survival of the 
mice. Figure 3.6B shows bacteraemia at 12 hr, 24 hr and 36 hr post infection. No significant differences 
were observed between survival and bacteraemia with the iJpRPL7 mutant compared to mice challenged 
with D39 wild-type. The broken line represents the limit of detection for determination ofbacteraemia. 
164 
Chapter 3 S. pneulI10niae TCS08 Results 
A 
120 --- 039 
100 -o-pAS1 
Iii 
.~ 80 
> 
::; 
(/) 
Q) 60 
C> 
J9 
c 40 Q) u 
cf 20 
0 
0 0 0 0 0 0 0 0 0 N "<t <0 00 0 N "<t <0 
Tirre (Hours) 
B 
8 
7 
6 
~ 5 
::::> 
u.. 4 () 
0 
Cl 3 
0 
...J 2 
1 
0 
12 24 36 
TIrre (Hours) 
Figure 3.7 Survival and bacteraemia following intranasal challenge with LlpASI 
Mice were challenged intranasally with 1.0 x 106 CFU bacterial strains. Figure 3.7A shows survival of the 
mice. Figm-e 3.7B shows bacteraemia at 12 hr, 24 hr and 36 hr post infection. No significant differences 
were observed between sm-vival and bacteraemia with the LJpASI mutant compared to mice challenged with 
D39 wild-type. The broken line represents the limit of detection for determination ofbacteraemia. 
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Figure 3.8 Survival and bacteraemia following intranasal challenge with iJpRPL50 
Mice were challenged intranasally with 1.0 x 106 CFU bacterial strains. Figure 3.8A 
shows survival of the mice. Figure 3.8B shows bacteraemia at 12 hr, 24 hr and 36 hr post 
infection. No significant differences were observed between survival and bacteraemia 
with the !JpRPL50 mutant compared to mice challenged with D39 wild-type. The broken 
line represents the limit of detection for determination ofbacteraemia. 
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3.3.2 Lung counts following intranasal challenge 
Bacterial counts within the lung tissue of mice challenged intranasally with 106 CFU were 
determined 24 hr post challenge. No differences were see between bacterial loads in mice 
infected with all mutants compared to the isogenic parental strain. 
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Figure 3.9 Bacterial load in the lung tissue 24 hr post intranasal infection 
Mice were challenged intranasally with 1.0 x 106 CFU with bacterial strains. 24 hr post infection, bacterial 
counts in the lung tissue were determined. No significant difference was observed in counts of mice 
challenged with any of the mutants compared to D39 wild-type. The broken line represents the limit of 
detection. 
3.3.3 Intranasal challenge with increased challenge dose; Survival and bacteraemia 
Mice were challenged intranasally with 1.0 x 107 CFU, a 10-fold increase in bacterial dose 
administered compared to previous challenges, to determine if this would show any differences 
in virulence of the mutants compared to D39 wild-type. Mice were monitored for survival and 
bacteraemia as described above. 
Following intranasal challenge with the iJpRPL7 mutant, mice survived significantly longer than 
those challenged with the wild-type parental strain (P<0.05). However, no difference in levels of 
bacteraemia were observed between mice infected with wild-type or mutant strains. No 
differences in survival or bacteraemia of the iJpASI or iJpRPL50 mutants were observed 
compared to wild-type D39 following intranasal challenge with 107 CFU. Comparison of the 
iJpRPL7 and iJpRPL50 mutants to D39 wild-type at 36 hr was not possible as many of the mice 
challenged with wild-type bacteria had succumbed to infection by this stage. Similarly, some 
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mice challenged with the iJpASJ mutant had also succumbed to infection by 36 hr. Although the 
median counts in the blood of mice challenged with iJpRPL50 at 36 hr post infection were almost 
2 orders of magnitude higher than bacterial counts in the blood of mice challenged with the 
iJpRP L 7 mutant at the same time point, this difference was not found to be statistically 
significant. Table 3.1 summarises the data from this set of challenges. 
Median Median counts in Median counts in Median counts in the 
survival the blood, 12 hr the blood, 24 hr blood, 36 hr 
(Hours) (LOglO CFU rnI-1) (LoglO CFU rnI-1) (LoglO CFU rnI-1) 
D39 48 2.88 6.52 NID 
LJpRPL7 65* 2.28 5.74 5.86 
LJpASI 49 2.17 6.0 NID 
LJpRPL50 48 1.92 5.4 7.64 
Table 3.1 Survival and bacteraemia following intranasal challenge with 107 CFU 
Mice were challenged intranasally with 1.0 x 107 CFU bacterial strains. The table shows median survival of 
mice and median bacterial counts in the blood at pre-determined time points following infection. A 
statistical difference in survival was found for the LJpRPL7 mutant only, when compared to wild-type D39 
(P<0.05*). No significant differences were found for bacteraemia in mice challenged with any of the 
mutant bacteria compared to mice challenged with D39 wild-type at any time point examined. Counts in 
the blood for wild-type D39 and the LJpASI mutant at 36 hr post challenge have not been included in the 
table as some mice had succumbed to infection by this stage (ND). 
3.4 Allelic-replacement mutagenesis; Type 3 mutants 
Data published by during the course of this work indicated that a mutation in the rrOB gene in a 
serotype 3 pneumococcus resulted in an attenuated phenotype following intranasal challenge 
(Throup et ai., 2000, GlaxoSmithKline). The mutants in this study were created using allelic-
replacement mutagenesis (see introduction, section 1.7.2 for a more detailed description of this 
mutagenesis technique) and were selected using erythromycin. The study used type 3 parental 
strain 0100993, and administered an intranasal challenge dose of 1. 0 x 107 to 5 wk old, male 
CBA/J mice. Following this challenge, CBA/J mice infected with the type 3 rrOB mutant 
(iJ4BBrr) had mean counts in the lung tissue that were> lOOO-fold lower than counts in the lung 
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tissue of mice challenged with wild-type bacteria (Throup et al., 2000). The mutant and parental 
strains used for the above study, together with a mutation in the hk08 gene (iJ488hk) were 
obtained from GlaxoSmithKline for further analysis in our laboratory, and to determine if the 
reported attenuation in virulence could be repeated using our model of infection. Growth, 
autolysis and stability were determined prior to any animal work, and both mutants did not differ 
from the wild-type parental strain for any of these parameters (data not shown). 
3.4.1 Intranasal challenge with type 3 mutants; Survival and bacteraemia 
The parental 0100993 type 3 strain had not been previously assessed in our model of infection so 
a dose response curve was set up to determine the optimum challenge dose for subsequent 
infections. Groups of mice were challenged with 105, 106 and 107 of passaged 0100993 parental 
strain and monitored for bacteraemia and survival (data not shown). Only the latter dose resulted 
in 100 % mortality of mice, and this was the dose chosen for all subsequent in vivo work using 
the type 3 strains. Thus the dose administered to mice in this thesis matches that used in the work 
by Throup et al. 
MF1 mice were infected intranasally with 107 CFU 0100993 wild-type and the iJ488hk and 
iJ488rr mutants, and monitored for survival and bacteraemia. Following challenge, mice infected 
with both mutants had highly significantly increased survival times compared to mice infected 
with wild-type 0100993 (P<0.005 for both mutants). Mice challenged with 0100993 parental 
strain had a median survival time of71 hr. Mice challenged with the iJ488hk and iJ488rr mutants 
had median survival times of 99 and 156 hr respectively. Figure 3.1 0 shows the in vivo data for 
all type 3 strains examined in this work. 
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Figure 3.10 Survival and bacteraemia following intranasal challenge with type 3 A48411k and A484rr 
mutants 
Mice were challenged intranasally with 1.0 x 107 CFU bacterial strains. Figure 3.IOA shows survival of the 
mice. Both mutants resulted in highly significant increases in murine survival time compared to infection 
with the isogenic 0100993 parental strain (P<0.005). Figure 3.1 OB shows bacteraemia at 24 hr and 48 hr 
post challenge. No significant differences were observed with bacteraemia in mice challenged with mutant 
bacteria compared to mice challenged with 0100993 wild-type. The broken line represents the limit of 
detection for determination of bacteraemia. 
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3.4.2 Intranasal challenge with type 3 mutants; Lung counts 
Following intranasal challenge with 107 CFU type 3 strains, bacterial counts within the lung 
tissue were determined 48 hr post challenge. Although the bacterial counts in the lung for the 
L1488hk and L1488rr mutants were shown to be approximately IO-IOO-fold lower than those of 
mice infected with wild-type bacteria, these differences were not found to be statistically 
significant (figure 3.11). 
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Figure 3.11 Bacterial load in the lung tissue 48 hr post intranasal infection with type 3 strains 
Mice were challenged intranasally with 1.0 x 107 CFU with bacterial strains. 48 hr post infection, bacterial 
counts in the lung tissue were determined. No significant difference was observed in counts of mice 
challenged with either of the mutants compared to mice infected with the 0100993 wild-type. The broken 
line represents the limit of detection. 
In the study by Throup and colleagues, intranasal challenge with 107 CFU of the L1488rr mutant 
resulted in mean counts in the lung tissue that were> 1000-fold lower than those found in the 
lungs of mice challenged with the wild-type parental strain, 0100993 (Throup et ai., 2000, no P 
values to determine statistical significance were provided). In this thesis, intranasal challenged 
with the same strains used by Throup and colleagues resulted in mean counts in the lung that 
were only 20-fold lower than those in the lungs of mice challenged with wild-type bacteria. This 
difference was not statistically significant. 
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3.4.3 Intranasal challenge with type 3 mutants; CBAlJ mice 
Data presented in this thesis indicate a role in virulence for RR08 in a type 3 pneumococcal 
background, as shown by increased survival times of mice infected with the mutant compared to 
wild type bacteria. Lower counts of mutant bacteria in lung tissue were also found 48 hr post 
challenge, compared to wild-type although the degree of attenuation did not match that reported 
by Throup and co-workers (Throup et al., 2000), despite using the same bacterial strains and the 
same challenge dose. Thus, the only other factor that was different between the work of Throup 
and co-workers. and the work presented in this thesis was the murine model of infection used. To 
determine if the different strain / age / sex of mice used were responsible for the differences 
observed, CBAlJ mice (age and sex matched to those used by Throup et al., 2000) were used to 
repeat the work described above. Unfortunately, the colony of mice from which this strain was 
derived had respiratory tract infections with Proteus spp., which would have interfered with the 
proposed experiments. Attempts were made to breed a stock of CBAlJs from Proteus-infected 
parents that were treated with antibiotic (Borgal® 0.01 % final concentration) to clear the 
infecting organisms, but the second-generation offspring still showed evidence of swarming 
bacteria representative of Proteus spp. when the lungs were homogenised and plated onto blood 
plates. This work was subsequently abandoned. 
3.5 Allelic-replacement mutagenesis; Type 2 mutants 
3.5.1 Creating and confirming mutants 
A mutation in the rr08 gene was constructed III serotype 2 D39 by allelic-replacement to 
determine if the technique used to create mutants altered the phenotype of the resulting mutants. 
Primers flanking the type 311488rr mutant (484P1 and 484P4) were used to transfer the mutated 
gene from a type 3 background to the D39 type 2 background, by transformation. Potential 
transformants were selected on erythromycin. PCR, using primers 484P1 and 484P4 flanking 
11488rr, were used to confirm the new type 2 mutant. The resulting mutant, where the rr08 gene 
was replaced with a cassette encoding erythromycin resistance, produced a PCR product ~ 300 
bp larger than that of wild-type D39 as expected, see figure 3.12. The PCR product was 
sequenced to further confirm replacement of the rr08 gene This mutation will be referred to as 
l1rr08 from this point onwards. 
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Primers 484P1 and 484P4 were used to confirm the replacement of the rr08 gene in D39 with a gene 
encoding erythromycin resistance. Replacement of the target gene resulted in a PCR product ~ 300 bp 
larger in the mutant than that of the wild-type strain. The figure shows the expected band sizes of 1.7 Kb 
and 1.4 Kb for the mutant and wild-type strains, respectively. Lane 1, genomic DNA from wild-type D39. 
Lane 2, genomic DNA from LJrr08 mutant. Lane 3, genomic DNA from the type 3 LJ484 mutant (used as a 
control). 
3.5.2 Intranasal challenge; Survival and bacteraemia 
MF1 mice were challenged intranasally with 106 CFU of D39 and the confirmed Llrr08 mutant 
and monitored for their ability to survive infection. Bacteraemia at pre-determined time points 
was also monitored. Following challenge, mice infected with the Llrr08 mutant showed increased 
survival (> 2-fold) compared to mice infected with wild-type D39 (median survival times 89 hr 
and 41 hr, respectively), although this difference was not found to be statistically significant 
(figure 3.13A). No significant difference was observed in bacterial counts in the blood between 
the mutant and its isogenic parental strain at 12 hr, 24 hr or 36 hr post infection (figure 3.13B) 
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Figure 3.13 Survival and bacteraemia following intranasal challenge with Arr08 
Mice were challenged intranasally with 1.0 x 106 CFU LJrr08 and D39 wild-type. Figure 3.13A shows 
survival of mice. Figure 3.13B shows bacteraemia at 12 hr, 24 hr and 36 hr post challenge. No significant 
differences were observed between survival or bacteraemia in mice challenged with mutant bacteria 
compared to mice challenged with D39 wild-type. The broken line represents the limit of detection for 
determination ofbacteraemia. 
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3.6 Summary of TCS08 results 
3.6.1 Effect of transformation on virulence 
D39, the parental strain used for much of the work in this section, was transformed with a control 
plasmid, pVA838, conferring erythromycin resistance. The resultant strain, tD39, was not 
impaired in growth in BHI in vitro, nor was it impaired in virulence following intranasal 
challenge, as determined by bacteraemia at 12 hr, 24 hr and 36 hr post challenge, or murine 
survival. Furthermore, viable counts from tD39 obtained from the blood of infected mice, 36 hr 
post challenge showed that the erythromycin resistance was retained at this time point. 
3.6.2 Creating mutants and ill vitro analysis 
Initially mutations in the genes encoding the HK and RR of TCS08, together with the upstream 
putative surface protein, Sp0082, were created by insertion duplication mutagenesis, using D39 
serotype 2 as the parental strain. Mutations in the hk08 and rr08 genes, created by allelic 
replacement mutagenesis in a serotype 3 parental strain, 0100993, were also supplied to our 
laboratory by GlaxoSmithKline. Subsequently a new mutation in the rr08 gene of D39 was 
created by allelic-replacement, by moving the serotype 3 mutant into the serotype 2 D39 by 
transformation. All mutants were selected on erythromycin and confirmed by PCR and 
sequencing. All mutants had no growth or autolysis defects when grown in vitro in BHI 
compared to the isogenic parental strains (data shown for iJpASl mutant only). Furthermore, 
mutants were stable and retained their erythromycin resistance in the absence of antibiotic 
selection for up to 12 hr (data not shown). 
3.6.3 III vivo analysis of virulence; Bacteraemia and survival 
All mutants were analysed in a murine model of infection for bacteraemia and survival following 
intranasal challenge. Some of the mutants were also analysed for their ability to colonise lung 
tissue. Table 3.2 summarises some of the main observations from this work. 
175 
Chapter 3 S. pneu1110niae TCS08 Results 
Gene 
RR08 
(pASl) 
HK08 
(pRPL7) 
sp0082 
------------
RR08 
(pASl) 
HK08 
(pRPL7) 
sp0080 
- --------- --
RR08 
(,14841'1') 
HK08 
(,1484hk) 
------------
RR08 
(,11'1'08) 
Parental Mutagenesis Challenge Median survival Attenuation in virulence 
strain technique Dose (WT) 
D39 Insertion- 10° CFU 60 hr (54 hr) No significant difference for bacteraemia (12, 
(type 2) duplication 1. I-fold lon ger 24 & 36 hr) or survival 
tha n wild -type No significant difference in lung counts at 24 hr 
D39 Insertion- 106 CFU 95 hr (54 hr) No significant difference for bacteraemia (12, 
(type 2) duplication 1.8 fold lon ger 24 & 36 hr) or survival 
than wild -type No significant difference in lung counts at 24 hr 
D39 Insertion- 10° CFU 45 hr (54 hr) No significant difference for bacteraemia (12, 
(type 2) duplication < wild -type 24 & 36 hr) or survival 
No significant difference in lung counts at 24 hr 
------------ -----------------
--i6' -CFU--- --------------.----- ---------------------------------------------- -------D39 Inseltion- 49 hI' (48 hr) No significant difference for bacteraemia (12, 
(type 2) duplication 1.02 fold longe r 24 & 36 hr) or survival 
than wild - type Lung counts not done 
D39 Insertion- 10'CFU 65 hI' (48 hr) No significant difference for bacteraemia (12, 
(type 2) duplication 1.4 fold lon ger 24 & 36 br) 
than wild - type Significant difference in survival * 
Lung counts not done 
D39 Insertion- 10 CFU 48 hI' (48 hI') No significant difference for bacteraemia (12, 
(type 2) duplication No different to 24 & 36 hr) or survival 
wild - type Lung counts not done 
_.--- -------
---- --- ----------
--i6'-CFU--- ----------------- - -- ----------------------.------------------------------0100993 Allelic- 156 hI' (71 hI') No significant differences in bacteraemia (24 & 
(type 3) replacement 2.2 fold lon ge r 48 hr) 
than wild- type Significant difference in survival ** 
No significant difference in lung counts at 48 hr 
0100993 Allelic- 10 CFU 99 hr (71 hr) No significant differences in bacteraemia (24 & 
(type 3) replacement 1.4 fold lon ge r 48 hr) 
than wild-Iype Significant difference in survival ** 
No significant difference in lung counts at 48 hr 
------------
----------------- --i6~-CFU--- -------------------- -----------------------------------------------------D39 Allelic- 89 hr (41 hr) No significant difference in bacteraemia (12,24 
(type 2) replacement 2.2 fold lon ge r & 36 hr) or survival 
Ih :1I1 wild - I~' pe No significant difference in lung counts at 24 hI' 
Table 3.2 Summary of ill vivo work with all TCS08 mutants 
Legend on following page 
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Table 3.2 Summary of ill vivo work with all TCS08 mutants 
The table summarises the main conclusions following intranasal challenge with the TCS08 
mutants. The common gene name is provided along with the name to which mutants are referred 
within this thesis, and the parental strain in which the mutant is created. The method of 
mutagenesis and challenge dose are shown in columns 3 and 4. Column 5 illustrates the median 
survival time of mice infected with the mutants, with the survival time of mice challenged with 
isogenic parental given in brackets for comparison. Although mutants I1pRPL7, I1pASI and 
I1pRPL50 have the same parental strain as mutant 111'1'08, the latter has a slightly different median 
survival time (using the same challenge dose) due to variation between experiments, different 
batches of mice etc. The difference in survival between mice challenged with mutants compared 
to mice challenged with the wild-type strain is shown in bold red typescript. Significant 
differences are given in bold black typescript, where P<O.05 is represented by a single asterix (*) 
and P<O.005 is represented by a double asterix (**). The final column summarises the virulence of 
mutant strains compared with their isogenic parental strains. Significant alterations in virulence 
are highlighted in bold typescript. 
Table 3.2 highlights that the mutants did not appear to be highly attenuated in virulence, as 
determined by levels of bacteria within the blood and lungs at various time points post infection. 
Survival of mice following challenge with most of the mutants (7 out of 9 challenges) increased 
compared to survival of mice infected with the isogenic wild-type strains, although was only 
significant for the 3 of the mutants. 
Intranasal challenge with 106 CFU of the insertion-duplication mutants did not result in 
significant differences for any of the virulence parameters examined. When the challenge dose 
was increased to 107 CFU, in an attempt to reduce variation and identify possible differences, the 
survival of mice challenged with the iJpRPL7 mutant was found to be significantly greater than 
those infected with wild type (P<0.05). The remaining 2 insertion-duplication mutants did not 
differ significantly from wild-type D39 in any ofthe challenges. 
The type 3 allelic-replacement mutants in the hk08 and rr08 genes had significantly longer 
survival than wild-type 0100993 following intranasal challenge with (P<0.005), but did not show 
reduced bacterial counts in the blood. 
The type 2 allelic-replacement did not show any significant difference in survival or bacteraemia. 
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3.6.4 III vivo analysis of virulence; Lung counts 
Of the challenges where bacterial counts within the lung tissue were examined, only mice 
infected with the type 3, allelic-replacement mutants showed lower counts compared to mice 
infected with the wild-type strain. These differences were not significant, however, and do not 
match the high degree of attenuation found by Throup and colleagues using the same challenge 
dose and the same strains in a different model of infection (Throup et ai., 2000). Attempts to 
evaluate these differences using the same model of infection as Throup et ai. (CBNJs) were 
unsuccessful due endemic Proteus infection in the CBNJ colony. 
In summary, none of the mutants were highly attenuated in virulence in the MFI model of 
infection although some did result in significantly longer survival times in infected mice. In a 
type 2 background a mutation in the hk08 gene appears to be more attenuated than a mutation in 
the rr08 gene (insertion-duplication mutants). Mutations in a type 3 background for TCS08 may 
be slightly more attenuated than those in a type 2 background. 
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Chapter 4 Discussion; S. pneumoniae TCS08 
4.1 Creating mutants in S. pneumoniae 
The publication of 2 pneumococcal genomes (R6 and TIGR4) combined with the natural ability 
of S. pneumoniae to take up DNA from the extracellular environment (transformation I 
competence) provides excellent capacity to create mutations in virtually any gene of choice in 
the pneumococcus. Several mutagenesis techniques are available for use, two of which 
(insertion-duplication and allelic-replacement) have been used for this section of work. Both 
techniques rely on transformation of S. pneumoniae cultures with donor DNA (plasmid or peR 
product respectively) to create mutations in the target gene. The donor DNA carries a detectable 
marker, usually a gene encoding antibiotic resistance, allowing for selection of potential 
transformants. As plasmid donors used for this purpose are suicide vectors, failure to integrate 
into the chromosome will result in loss of the plasmid from the cell. Homologous sequences 
from the target gene itself or from regions flanking the target gene are included in the donor 
DNA to promote insertion at the required site. Thus the donor DNA must gain entry into the 
pneumococcal cell and integrate into the bacterial chromosome. Unless this integration results in 
a non-viable phenotype, mutants can be isolated using appropriate antibiotic selection and 
characterised further in comparison with the isogenic parental strain. 
The transformation protocol to create the mutants used in this thesis used a 9.2 Kb plasmid 
vector, pVA838, as a positive control for transformation. This vector is not a suicide vector and 
is able to replicate in S. pneumoniae, conferring erythromycin resistance upon host cells 
(Macrina et at., 1983). As integration into the chromosome is not required for the erythromycin-
resistance phenotype, the transformation efficiency using this plasmid can be up to several 
hundred-fold greater than using donor DNA for mutant construction (which must integrate into 
the chromosome). Thus the protocol for transformation of strain D39 was optimised to allow for 
the construction ofthe mutants described in this thesis (data not shown). 
It is possible that the transformation procedure itself could result in mutants that have altered 
phenotype. Indeed, of the opaque and transparent pneumococcal variants that have been 
described previously (introduction, section 1.5.4), it is thought that the transparent variants have 
increased transformation efficiency. Due to the low levels of transformation obtained using 
donor DNA, it is possible that transparent variants, possessing less capsular material and thus 
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having higher transformation efficiency (Weiser and Kapoor, 1999), are preferentially selected 
for when creating mutants. These variants have reduced virulence in systemic infection (Kim and 
Weiser, 1998) and could thus indicate an attenuated phenotype that is due to the procedure used 
to create the mutant rather than the effects of disrupting the target gene. To investigate this 
possibility, strain D39, used as the parental strain for many of the mutants characterised in this 
thesis, was transformed with control plasmid p V A838, and analysed for in vitro growth, 
virulence and stability, compared to a non-transformed D39 parental strain. Data showed that the 
tD39 was not impaired in growth both in vitro and in vivo and that bacteria retrieved from the 
blood of infected mice at the 36 hr time point still retained their erythromycin resistance. This 
indicates that the presence of this 9.2 Kb plasmid does not exert a large enough metabolic burden 
on host cells to result in rapid elimination. Thus virulence was not compromised by the 
transformation procedure in the murine model of infection used within this thesis. 
Although the aims of this thesis were to identify genes important in the virulence of the 
pneumococcus, all mutants were analysed for their ability to grow and retain their antibiotic 
selection in culture prior to any in vivo characterisation. Growth curve experiments are important 
to ensure that any differences seen in virulence are not due to general growth defects that are also 
present in vitro. Furthermore these basic in vitro characterisations can be used to determine any 
effect antibiotic selection has on the growth and autolysis of mutants, and to determine the 
stability of the mutants in the absence of antibiotic selection (although this must also be checked 
following in vivo infection). None of the TCS08 mutants were found to be impaired in in vitro 
growth or stability. 
4.2 Analysis of virulence of TCS08 mutants using a murine model of infection 
Outbred adult MF1 mice were the murine model used throughout this thesis. This is a well 
characterised model of pneumococcal infection, especially with the serotype 2 D39 strain used to 
make many of the mutants described within this work (Canvin et at., 1995; Kadioglu et at., 
2000). MF1s can be infected through a variety of challenge routes, including intranasal (to study 
nasopharyngeal/airway / lung colonisation, pneumonia and septicaemia), intraperitoneal (to 
passage strains and to study septicaemia) and intravenous (to study septicaemia). Several 
parameters of virulence can subsequently be analysed, such as bacterial counts in different 
tissues, survival of mice following challenge and the host inflammatory response to infection / 
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tissue histology. Being an outbred strain of mouse, this model can be highly variable but has 
been used previously to successfully identify and characterise pneumococcal virulence factors 
(Canvin et at., 1995; Overweg et at., 2000; this thesis, chapters 5 and 7). 
Insertion-duplication TCS08 mutants 
Mutations in the genes encoding HK08, RR08 and Sp0082 were created by insertion-duplication 
mutagenesis, where an entire plasmid construct (> 7 Kb) was inserted into the target gene, 
creating mutants pRPL7, pAS1 and pRPL50, respectively. Normal gene function is disrupted due 
to the integration of such a large piece of DNA, although none of the coding sequence of the 
target gene is removed. Insertion towards the 5' end of the gene should ensure that any region of 
DNA prior to the insert that could result in translation of a truncated protein with some 
functional activity is avoided. Alternatively, a tmRNA tag targeting any translated protein for 
degradation can be included within the plasmid construct, and this technique was used for 
creating the iJpRPL50 (sp0082 gene) mutant (Hoffmann-La-Roche, personal communication). 
tmRNAs can enter a ribosome when it is stalled on a damaged mRNA / mRNA lacking a stop 
codon. Upon entry of the tmRNA molecule, the ribosome can switch from the mRNA to the 
tmRNA and continue translating a short peptide sequence encoded by the latter. This short 
sequence encodes a tag that is a target for proteolysis and subsequent degradation of the 
damaged peptide (Keiler et at., 1996; Molnos et at., 2000). 
Following intranasal challenge with 106 CFU, no significant differences were observed in the 
behaviour of any of the TCS08 insertion-duplication mutants compared to wild-type in any 
parameter of virulence tested (bacteraemia, lung counts or murine survival). All values were very 
similar for the iJpAS1 and iJpRPL50 mutants compared to isogenic wild-type. The iJpRPL50 
mutation (sp0082 gene) even showed slightly increased bacterial counts in the blood at 36 hr 
post infection and mice challenged with this mutant reached the experimental end point prior to 
those challenged with wild-type D39. The iJpRPL7 mutant, however had lower median counts in 
the blood by at least one order of magnitude at 24 and 36 hr post infection, and resulted in 1.8-
fold increased murine survival time compared to infection with isogenic parental strain. These 
differences however, were not found to be significant, although this could be due to the variation 
present using the MF1 model of infection. Lung counts at 24 hr post infection were all very 
similar in all the mutants compared to the D39 wild-type strain. 
In an attempt to decrease the variation seen with the above infections, mice were challenged 
intranasally with a 10-fold increased dose of bacterial strains, and virulence assessed as 
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described above, with the exception of lung counts which were not performed. No difference in 
bacterial counts were observed in the blood of mice challenged with any of the mutants 
compared to wild-type, although infection with the LlpRPL7 mutant again resulted in decreased 
counts by at least one order of magnitude at 24 hr post infection. The difference in survival with 
this mutant was found to be significant compared to infection with D39 wild-type (P<0.05). No 
difference in survival of the remaining 2 mutants was observed. This data suggests that for the 
TCS08 mutants created by insertion-duplication mutagenesis, the only one that appears to be 
attenuated in virulence is the mutant with a disruption in the hk08 gene. This finding is unusual 
as it is generally assumed that mutations in the rr genes of bacteria TCS are more attenuated than 
a mutation in the cognate hk gene (Throup et al., 2000). The LlpASl mutant (rr08 gene) did not 
show any signs of even being slightly attenuated in the infection model used for this work. This 
data indicates that HK08 could have a role in regulating genes or TCS other than rr08 and that it 
is the effect on other genes that is resulting in the slightly attenuated phenotype described above 
for the hk08 mutant. 
Allelic-replacement TCS08 mutants 
During the course of this work, data were published showing that a rr08 mutant in a serotype 3 
strain of the pneumococcus was highly attenuated in virulence as assessed by bacterial counts in 
the lung tissue of CBAlJ mice, 48 hr post intranasal challenge (Throup et al., 2000). This mutant 
(Ll484rr) was created by allelic-replacement mutagenesis. Mean counts in the lungs of mice 
challenged with the Ll484rr mutant were shown to be >lOOO-fold lower than counts in the lungs 
of mice challenged with the isogenic parental strain (Throup et al., 2000). Such an attenuated 
phenotype was not observed using the insertion-duplication LlpASl mutant during the work 
described above, so parental and mutant strains used in the study by Throup et al. were sent to us 
for further characterisation in our MF1 model of infection. The strains (0100993, Ll484hk and 
Ll484rr) were used in an intranasal infection of MF1 mice and virulence was assessed by 
monitoring bacteraemia, survival and lung counts 48 hr post infection. Mice challenged with 
both mutants had significantly increased survival times (P<0.005 for both mutants) compared to 
mice challenged with the isogenic parental strain, although no difference in bacteraemia at any of 
the time points studied was found. Counts within the lung tissue were lower for mice challenged 
with mutant bacteria, being approximately 10-fold lower for the Ll484rr mutant compared to the 
wild-type 0100993 strain. However, such differences were not statistically significant. This data 
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indicates that the mutants are attenuated following intranasal infection, but not as severely 
attenuated as indicated by Throup and colleagues (Throup et ai., 2000). These differences could 
be attributed to the use of different murine models for the study of virulence. Analysis of the type 
3 mutants in the CBAJJ strain of mice used by Throup et ai., was to form a component of this 
thesis but work had to be stopped due to endemic Gram-negative bacterial infection within the 
mouse colony. Significant variation in the susceptibility of 9 different inbred mouse strains to 
pneumococcal infection has been documented previously (Gingles et ai., 2001), so it would not 
be surprising to find that mutants behave differently with different murine genetic backgrounds. 
The iJ484rr mutation was transferred into D39, serotype 2 to create the iJrr08 mutant in this 
parental strain by allelic replacement, to allow for comparison of this mutant with the insertion-
duplication mutant iJpASl. In agreement with the data presented following infection with the 
iJpASl mutant, intranasal challenge with the iJrr08 mutant did not result in significant 
differences in bacteraemia or survival of infected mice compared to the D39 parental strain. This 
suggests that the techniques used to create mutants in the work presented within this section 
result in the same phenotype of the rr08 mutants. 
The variation present using a biological system, such as the MF1 murine model of infection 
described within this thesis, can have a significant impact on the final interpretation of data. For 
example, in the infections described above with all of the TCS08 mutants, statistically significant 
differences were found for survival of mice following intranasal challenge with the type 3 
iJ484hk / iJ484rr mutants and the iJpRPL7 mutant only. A significant difference in murine 
survival was found for the latter mutant only when the challenge dose of mutant and wild-type 
was increased 10-fold (from 106_107 CFU). However, the fold-difference in survival time of 
mice challenged with mutant bacteria compared to that of challenge with the isogenic parental 
strain for all mutants (highlighted in table 3.2), shows that challenges with the iJpRPL7 and 
iJrr08 mutants (both with a challenge dose of 106 CFU) result in differences in survival 
comparable to those of the iJ484hk / iJ484rr and iJpRPL7 (107 CFU), but these differences were 
not found to be statistically significant. The variation present in the model is also illustrated by 
the median survival times of the D39 wild-type strain. The challenges using D39 wild-type with 
the insertion-duplication mutants (iJpRPL7, iJpASl and iJpRPL50) resulted in a median survival 
time of 54 hr for mice challenged with D39 wild-type. However, challenges with D39 and the 
iJrr08 allelic-replacement mutant, gave a median survival time of 41 hr for mice challenged with 
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D39, wild-type. Although the D39 parental strain was the same for both studies, the differences 
in median survival times illustrate the variation that can occur between experiments and when 
using different batches of mice. 
In an attempt to eliminate some of the variation present and to retrieve statistical differences 
between mutants and their wild-type parental strains, several methods were tried. Increasing the 
challenge dose 10-fold did result in a slight reduction in variation, and this allowed significant 
differences in survival following challenge with the iJpRPL7 mutant to be detected. An inbred 
strain of mouse (C57IBI) was also tested using some of the insertion-duplication mutants to 
assess if this could be a suitable alternative to the MFI model, but results were just as variable 
using this inbred strain of mouse as with the outbred MFI mice (data not shown). This was also 
demonstrated in a later study (Gingles et at., 2001). 
Competition experiments, where individual mice are challenged with a 1: 1 mix of mutant and 
wild-type bacteria within the same inoculum, are currently being developed in our laboratory in 
an attempt to overcome some of the variation in murine infections highlighted above. This 
technique may be useful for detecting more subtle differences between strains that can not be 
detected using the conventional infection procedures and will also reduce the number of animal 
models required for individual data sets. Other laboratories have successfully used these 
competition experiments for in vivo studies of pneumococcal mutants (Brown et at., 2001a; Hava 
and Camilli, 2002; Sebert et at., 2002). 
4.3 Summary; involvement of TCS08 in virulence 
This section of work used mutations in genes associated with S. pneumoniae TCS08 in 2 
different serotypes to determine the contribution of this TCS to virulence in a murine model of 
infection. The data suggest the a mutation within the hk08 gene is slightly attenuated in virulence 
following intranasal infection in both type 2 and type 3 parental strains. Mutation of the rr08 
gene appears to be attenuated in virulence in a type 3 strain only, although increased murine 
survival times were observed following challenge with a rr08 mutant created in type 2 by allelic-
replacement, but not in a type 2 rr08 insertion-duplication mutant (differences were not 
significant). Whether this represents a true difference between these mutants or variation within 
the MFI model used for the analysis of virulence remains to be determined. Further work is 
required to determine if the differences in virulence described with the TCS08 mutants are 
significant. Many of the TCS08 mutants described above will be analysed in the competitive 
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experiments described above to further characterise the role of TCS08 in virulence. 
Alternatively, other models of infection could be utilised to examine the aforementioned 
mutants. For example, the nematode Caenorhabditis elegans has been used to assess the 
virulence of many bacterial pathogens (Garsin et al., 2001; Couillault and Ewbank, 2002; Gan et 
al., 2002). Furthermore, virulence factors important for mammalian pathogenesis have also been 
shown to be required for efficient killing of C. elegans (Garsin et al., 2001), indicating that this 
system can be used to identify important virulence factors of pathogens. This model has been 
shown to be susceptible to killing by S. pneumoniae, and zmpB and pneumolysin mutants from 
our laboratory are currently being analysed in a C. elegans model of infection ( Wouter Jansen, 
CX Utrecht, the Netherlands). Such non-vertebrate systems may offer cheaper and simpler 
alternatives to the murine models more commonly used for virulence studies, or could be used in 
combination with other systems to aid in the detection and characterisation of attenuated 
phenotypes. They may also allow for the identification of host factors that contribute to infection, 
as powerful genetic tools are available for some of these models. 
In summary several of the mutants within the hk08 / rr08 genes of type 2 and 3 used within this 
work demonstrated attenuated virulence compared to their isogenic parental strains in a murine 
model of infection. The exact role of the TCS08 genes in virulence is unknown. The contribution 
of TCS08 to virulence may depend on the genetic background of the bacterial strain, as 
differences between the virulence of type 2 and type 3 mutants were observed in this work, 
although variation in the animal model used may also explain such differences. Further work is 
required to determine the role of this TCS in pneumococcal virulence. 
Table 4.1 summarises all current data on the study of S. pneumoniae TCS08 for its role in 
virulence, including data presented in this thesis. 
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Reference Strain I serotype Mutagenesis Murine Strain 
of bacteria technique 
Lange et aI, Sp.l (type 22) Insertion C57BL6/J (I) 
1999 duplication Females 
Lange etaI, Sp.1711 (type 3) Insertion C57BL6/J (I) 
1999 duplication Females 
Throup et 0100993 (type 3) Allelic CBAlJ (I) 
al., 2000 replacement Males, 5 wk 
Sebert et 0100993 (type 3) Allelic Sprague-Dawley 
al.,2002 replacement infant rats (0) 
This work D39 (type 2) Insertion MFI (0) 
duplication Females, 9-13 
wk 
This work D39 (type 2) Allelic MFI (0) 
replacement Females, 9-13 
wk 
This work 0100993 (type 3) Allelic MFI (0) 
replacement Females, 9-13 
wk 
This work D39 (type 2) Allelic MFI (0) 
replacement Females, 9-13 
wk 
Table 4.1 Summary of all in vivo analysis of rr08 mutants 
Legend on following page 
Route of Inoculum Measure of Role in virulence I attenuation 
infection virulence 
i.p. (NP) 4 X 106 Mean survival time No attenuation 
i.p. (NP) 1 X 103 Mean survival time No attenuation 
i.n. (NP) 1 x 10' Mean lung counts at > 1000 fold decrease in lung counts 
48 hr 
i.n. (NP) 4 x 106 - Colonisation of No attenuation 
1.6 x 107 nasopharynx 
i.n. (P) 1 x 106 Bacteraernia, No attenuation 
survival and lung 
counts at 24 hr 
i.n. (P) 1 x 10' Bacteraernia and No attenuation 
survival 
i.n. (P) 1 x 10' Bacteraernia, No attenuation in bacteraernia 
survival and lung Significant increase in murine survival 
counts at 48 hr 10-fold decrease in lung counts (N/S) 
i.n. (P) 1 x 106 Bacteraernia and 2-fold increase in murine survival 
survival (N/S) 
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Table 4.1 Summary of all in vivo analysis of rr08 mutants 
The table summarises all in vivo work available to date with S. pneumoniae TCS08. (I) / (0) designates inbred or outbred strains of mice 
respectively. Route of challenge includes intranasal (i.n.) or intraperitoneal (i.p.). Strains passaged or non-passaged prior to challenge are 
represented by (P) and (NP), respectively. Role in virulence is in comparison with the isogenic wild-type parental strain. (NS) designates data 
that was not found to be statistically significant. The table is modified from that in the introduction (table 1.6) by the addition of work detailed 
in this thesis. 
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SUMMARY OF TCS09 
WORK 
Type 3 strain, 0100993, and 
isogenic LJ488 mutant (GSK) 
7 
I PCR to obtain rr09 mutation from LJ488 
7 
I 
Transformation of type 2, D39, with PCR fragment 
to produce LJ rr09 mutant 
7 
Selection of mutants on erythromycin 
Confirmation of LJ488 and LJrr09 mutants by PCR and sequencing 
I Basic in vitro characterisation 
I in vivo characterisation 
I 
Further in vitro characterisation <~==~> I Microarray analysis 
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5.1 TCS09 basic in vitro analysis 
5.1.1 Creating and confirming mutants 
S. pneul710niae TCS09 Results 
TCS09 was characterised within this thesis based on its close proximity to several genes of 
interest. These include a methionine sulphoxide reductase previously shown to be involved in 
virulence (Wizemann et at., 1996), and a putative zinc metalloprotease, previously not 
extensively characterised for its role in virulence (Novak et at., 2000; Berge et at., 2001). It was 
speculated that TCS09 could be involved in the regulation of these genes. 
S. pneumoniae strain 0100993 (serotype 3) and an isogenic strain with a null mutation in the 
rr09 gene (strain iJ488 I 488) were provided by M. K. Burnham, GlaxoSmithKline (Throup et 
at., 2000). The mutation was created by allelic-replacement mutagenesis as described in section 
1.7.2, and figure 1.5 (introduction). The rr09 gene was replaced with the constitutively 
expressed ermAM gene cassette and care was taken to ensure that insertion of the cassette would 
still allow for the expression of the downstream hk09 gene that appears to be co-transcribed with 
rr09 (http://www.tigr.orgl). Furthermore, to prevent polar effects, the transcription termination 
signals were removed from this cassette prior to insertion. Replacement of the rr09 gene with the 
ermAM cassette results in a PCR fragment approximately 200 bp larger than wild-type gene 
when PCR with primers flanking the region is performed (figure 5.1). 
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Figure 5.1: Allelic-replacement mutagenesis to create a ,.,.09 null mutant 
A cassette encoding erythromycin-resistance was used to replace the rr09 gene as described in the text and 
in section1.7.2. Primers 488PI and 488P4 flanking the region were used to confIrm the mutation, whereby 
the mutated gene results in a slightly larger PCR product compared to wild type. Expression of hk09 should 
not be affected by this method of mutagenesis. Figure S.IA shows the wild-type tcs09 locus. Figure S.lB 
illustrates the tcs09 locus after replacement of the rr09 gene with a cassette encoding erythromycin 
resistance. 
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Primers 488Pl and 488P4 were used to amplify the mutated 1'1'09 gene from strain il488. The 
peR product was excised from the agarose gel, purified and used to transform strain D39 
(serotype 2). Potential mutants were selected by their ability to grow in the presence of 
erythromycin and peR, as described above, was used to confirm potential transformants (figure 
5.2). Resulting peR fragments were sequenced to further ensure cassette insertion into the 
correct target gene. The 1'1'09 null mutation in strain D39 has been designated ilrr09 / 1'1'09. 
1.65 Kb 
1Kb 
Mutant strains Parental strains 
Figure 5.2: Confirmation of Arr09 null mutations by PCR 
Primers 488P1 and 488P2 (see figure 5.1) were used to confirm the ilrr09 mutation in strains D39 and 
0100993. Replacement of the target gene with the ermAM cassette produces a PCR product in the mutant 
strain - 200 bp larger than that of the wild type parental strains (PCR bands l.7 Kb and 1.5 Kb 
respectively). 
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5.1.2 Confirmation of tcs09 locus and surrounding genes in strains used within this work 
The organisation of tcs09 and surrounding genes, as described in section 1.14.4, figure 1.15 
(introduction) is based on the sequenced R6 (type 2) and TIGR4 (type 4) genomes 
(http://www.tigr.orgl). The TCS09 system was identified in both these pneumococcal genomes. 
To determine if the gene organisation in the strains used within this work is the same as the 
sequenced genomes, PCR was performed. Primers were designed against the rr09 (RR09R), 
hk09 (ZmpUp), msrA (MsrAF) and zmpB (ZmpR) genes. Three regions were examined, 
including the whole region spanning from the msrA gene to the zmpB gene (primers MsrAF & 
ZmpR), region 'A' from msrA to rr09 (primers MsrAF & RR09R) and region 'B' from hk09 to 
zmpB (primers ZmpUp & ZmpR). The relative location of primers and expected fragment sizes 
based on the sequenced genomes is illustrated in figure 5.3. 
msrA rr09 hk09 zmpB 
MsrAF RR09R ZmpR 
-+ +- +-
region A region B 
... ~ ... ~ 
1'(, I( h 1.3 I( h 
Whole region 
... ~ 
4.1i I< h 
Figure 5.3: Gene organisation around the tcs09 locus and primers used to examine this region in 
strains D39 and 0100993 
The organisation of tcs09 and surrounding genes shown is based on that of the sequenced strains R6 and 
TIGR4. Primers were designed to bind specifically to all of the indicated genes with the exception of that 
encoding a conserved hypothetical protein situated between hk09 and zmpB. Three PCR reactions were 
performed to amplify up the whole region and regions A and B using genomic DNA isolated from sh'ains 
R6, TIGR4, D39 and 0100993. The expected product size, based on the sequenced genomes is shown (not 
to scale). 
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ZmpB has been shown to exhibit considerable sequence variation between several serotypes with 
homology existing only within the N' terminal region of the gene (Berge et at., 2000). Thus 
primer ZmpR was designed within the homologous region of zmpB to help ensure detection of 
this gene in the strains examined. 
peR using the primers described above resulted in bands of equal size for all three regions 
examined in all strains (figure 5.4). Although this does not indicate sequence homology it shows 
that the organisation of tcs09 and the surrounding genes in strains D39 and 0100993 used within 
this work is the same as that in the sequenced strains (including G54 / type 19F). The protein 
sequences of the 5 genes shown in figure 5.3 are at least 99 % homologous between the R6, 
TIGR4 and G54 genomes based on sequences obtained from PubMed and TIGR, using a BLAST 
alignment tool, [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi and http://www. ncbi.nlm.nih. 
gov:80IBLASTI]). 
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1 2 3 4 
4.6 Kb 
whole region 
1 2 3 4 
1.6 Kb 
region A 
1 2 3 4 
1.3 Kb 
region B 
Figure 5.4: Confirmation of tcs09 and surrounding genes in strains D39 and 0100993 
PCR using the primers described in the text and figure 5.3 was used to confirm that the tcs09 locus and 
sUlTounding genes had the same organisation in the strains used in this work compared to the sequenced 
strains R6 and TIGR4. Three regions were examined, the whole region; upper gel, region A; middle gel and 
region B; lower gel. The expected product sizes for each region based on the published genome sequences 
are shown. For each gel, lane 1; R6, lane 2; TIGR4, lane 3; D39 and lane 4; 0100993. 
The peR reactions described above were perfonned using several other strains, including type 1, 
type 19F and a different type 4 strain. All strains tested produced bands of the same size as R6 
and TIGR4 for all three regions, suggesting the organisation of this region may be conserved 
throughout all pneumococcal serotypes. 
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5.1.3 Growth and autolysis ill vitro 
All strains were subject to growth and autolysis determination using a combination of viable cell 
enumeration and optical density (OD 600 nm) readings over time. The effect of erythromycin on 
the growth and autolysis of mutant strains was also examined. Figure 5.5 illustrates the growth of 
strain D39 and its isogenic iJrr09 mutant. 
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Figure 5.5: III vitro growth and autolysis of D39 and Arr09 
15 m1 BHI was inoculated with 1.0 x 106 CFU bacterial strains. Viable cell enumeration (figure 5.5A) and 
OD 600 om readings (figure 5.5B) were performed every 2 hr for a period of 20 hr. Mutant strains were 
grown in BHI with (rr09E) and without (rr09) erythromycin (1 J.lg mr l ). The broken line represents the 
limit of detection for viable cell counts. 
In the absence of erythromycin, no difference was observed in the growth rate or autolysis of the 
iJrr09 mutant compared to its parental strain, D39, as determined by viable cell enumeration or 
OD 600 nm' Erythromycin did not have any effect on the number of viable cells detected, but did 
appear to result in slightly lower OD 600nm readings for strain iJrr09 (figure 5.5B). In the absence 
of antibiotic selection, OD 600 nm is representative of growth up to stationary phase 
(approximately 7 hours after inoculation of cultures), as judged by viable cell counts. After this 
point readings do not appear to decrease to the same extent as indicated by the viable cell counts. 
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The growth and autolysis of type 3 strain 0100993 and its isogenic mutanLd488 is illustrated in 
figure 5.6. 
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Figure 5.6: In vitro growth and autolysis of strains 0100993 and L1488 
15 m1 BHI was inoculated with 1.0 x 106 CFU bacterial strains. Viable cell enumeration (figure 5.6A) and 
OD 600 nm readings (figure 5.6B) were performed every 2 hr for a period of 20 hr. Mutant strains were 
grown in BHI with (488E) and without (488) erythromycin (1 !!g mr1). The broken line represents the limit 
of detection for viable cell counts. 
Data for the serotype 3 strains shows that there was no difference in growth of mutant L1488 
compared to its isogenic parental strain 0100993. The presence of erythromycin in the media did 
not alter the viable counts or OD 600 nm readings of the mutant. As discussed above for the type 2 
strains, OD 600 nm is representative of growth up to stationary phase (approximately 7 hours after 
inoculation of cultures), after which readings do not appear to decrease to the same extent as the 
viable cell counts. 
Figure 5.7 combines the growth data for wild type D39 and 0100993 strains to illustrate any 
differences observed between the 2 serotypes used for this work. The figure shows that the 2 
strains have similar growth as determined by both viable cell enumeration and OD 600 nm readings 
during exponential phase. Upon reaching stationary growth phase both strains appear to autolyse 
at similar rates as shown by the viable cell counts in figure 5.5B, although strain 0100993 shows 
slightly accelerated autolysis between 16 and 20 hour compared to D39. OD 600 nm readings for 
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cells undergoing autolysis however, are slightly lower for serotype 3 strain 0100993 compared to 
D39 (figure 5.7B). This is possibly due to differences in the relative thickness of the 
polysaccharide capsules surrounding the organisms. Type 3 strains characteristically produce a 
lot of capsular material (Waite et al., 2001) that does not appear to alter OD 600 nm readings of 
live cells but may alter the readings of dead or dying cells. 
A 
0 2 
___ D39 
- 0100993 B 1.6 
1.4 
1.2 
E 1 
I: 
0 0.8 0 
U) 
Q 0.6 
0 
0.4 
.... •...•.... . .... ... 0.2 
0 
4 6 8 10 12 14 16 18 20 o 2 4 6 8 1 0 12 14 16 18 20 
Time (Hours) Tim e (Hours) 
Figure 5.7: Comparison of ill vitro growth and autolysis of strains D39 and 0100993 
15 m1 BHI was inoculated with 1.0 x 106 CFU bacterial strains. Viable cell enumeration (figure 5.7A) and 
OD 600 run readings (figure 5.7B) were performed every 2 hr for a period of 20 hr. The broken line 
represents the limit of detection for viable cell counts. 
The data in figure 5.7 illustrates that cultures of all strains in this work harvested at the same OD 
600 nm reading (during exponential growth phase) will result in equal numbers of viable cells. This 
observation is useful for the design of further experiments where it may be necessary to use 
equal numbers of cells for comparison purposes, but impractical to wait over 16 hr for the results 
of viable cell enumeration analysis. In such instances, cells can be harvested upon reaching a set 
OD 600 nm and used for appropriate experiments. 
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5.1.4 Stability of rr09 mutants ill vitro 
To determine the ability of the rr09 mutants to retain the ermAM cassette during in vitro culture, 
strains were grown in BHI in the absence of antibiotic selection. At pre-determined time points 
the number of viable cells on agar plates without erythromycin and agar plates supplemented 
with antibiotic was compared for each mutant. Mutants Llrr09 and Ll488 did not lose their ability 
to grow in the presence of antibiotic up to 20 hr following culture inoculation (figure 5.8). Time 
points post 20 hr were not examined as pneumococci exhibit autolysis during in vitro growth and 
few CFU can be detected in cultures grown for over 20 hr. 
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Figure 5.8 Stability of 1'1'09 mutants ill vitro 
BRI was inoculated with 1.0 x 106 CFU mutant strains in the absence of erythromycin selection. At 12 hr 
and 20 hr post inoculation cell viability counts were performed to determine if the mutants had lost their 
erythromycin resistance. Figure 5.8A shows the stability of the type 2 mutant L1rr09. Figure 5.8B shows the 
stability of the type 3 mutant L1488. Both L1rr09 and L1488 were stable for up to 20 hr during ill vitro growth. 
Figure 5.8 indicates that in the absence of erythromycin mutants remained stable under the 
conditions used. Furthermore, the growth curves illustrated in figures 5.5 and 5.6 show that the 
mutants are not impaired in growth in the presence or absence of erythromycin. Thus for all 
further work the rr09 mutants were grown in the absence of erythromycin selection unless stated 
otherwise. 
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5.1.5 Expression of rr09 ill vitro 
RT -PCR using primers specific for the rr09 gene was used to determine if it is expressed during 
in vitro growth. RNA was isolated from D39 wild type grown to mid-log phase of growth in BHI 
media. RT-PCR analysis was performed on two independent RNA preparations. Figure 5.9 
shows the in vitro expression ofrr09 transcript from strain D39. 
1 2 3 4 1 2 3 4 
.- 700bp 
281 bp ~ 
response regulator l6S 
Figure 5.9: RT-PCR showing expression of rr09 during ill vitro growth ofD39 
RNA isolated from cells grown to mid-log phase was used to determine the presence of rr09 transcript in 
D39 during in vitro growth. Primers RR09F & RR09R designed within the rr09 gene gave an expected 
band size of 281 bp. Primers 16SF & 16SR specific for 16S RNA were used as a positive control for RNA 
detection and resulted in a band of ~700 bp. For both gels, lane 1; PCR using cDNA template from RNA 
prepared from strain D39, lane 2 PCR using cDNA template prepared from RNA isolated from D39 in the 
absence of reverse transcriptase, lane 3; PCR with no DNA template, lane 4; PCR using D39 genomic 
DNA template. The figure shows that a band of the expected size was present in RNA from D39 using 
primers for 1'1'09 (lane 1). This band was present in the genomic DNA positive control (lane 4) but absent in 
the absence of reverse transcriptase and the no template negative controls (lane 2 and 3 respectively). 
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5.2 In vivo characterisation; Role of RR09 in virulence 
5.2.1 Intraperitoneal challenge 
Prior to any in vivo analysis with our murine model of infection, bacteria are passaged via 
intraperitoneal (i.p.) injection. This generally results in high levels of bacteraemia 24 hr post 
injection. Bacteria are recovered from the blood and used to produce standard inoculum stocks 
for subsequent analysis of virulence. I x 105 CFU of all bacterial strains used for the TCS09 
characterisation were given to MFI mice via i.p. challenge. Survival of mice was monitored as 
described in section 2.5.9 (figure 5.10) . 
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Figure 5.10: Survival ofMF1 mice following intraperitoneal challenge 
Mice were challenged with 1.0 x 105 CFU bacterial strains. Survival was monitored for 1 week. Figure 
5.10A shows survival data for serotype 2 strains. P<0.05 for survival time of mice challenged with Llrr09 
compared to D39 parental strain. Figure 5.10B shows survival data for serotype 3 strains. No significant 
difference in survival was seen for the Ll488 mutant compared to 0100993 parental strain. 
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Intraperitoneal injection resulted in the appearance of moderate to severe disease symptoms in 
mice 24 hr post infection, with high levels of bacteraemia (>log 5 CFU mrl blood) for strains 
D39, 0100993 and Ll488. Such mice all succumbed to infection within 1-3 days and median 
survival times were 24 hr, 28 hr and 28 hr, respectively. However, i.p. injection with Llrr09 failed 
to result in detectable levels of bacteraemia at any time point following infection and all mice 
survived for over 5 days without showing any symptoms of disease (P<0.05), (Figure 5.10A). 
The challenge dose of Llrr09 given to mice was increased up to 1000-fold, but mice remained 
healthy and did not become bacteraemic at any point during the course of infection (data not 
shown). Several independent rr09 null mutations in different D39 stocks (confirmed by PCR and 
sequencing) were evaluated for their virulence following i.p. challenge but none resulted in 
bacteraemia or symptoms of disease. This indicated that RR09 could be essential in the virulence 
ofD39 in our model of infection. 
For all subsequent challenges, passaged bacteria were used for serotype 3 strains 0100993 and 
Ll488 only. Non-passaged glycerol stocks were used for all subsequent challenges with D39 and 
Llrr09 mutant. 
5.2.2 Intranasal challenge 
5.2.2.1 Intranasal challenge; Survival and bacteraemia 
Strains were analysed for their ability to cause disease in a pneumonia model of infection. Mice 
were given 1.0 x 107 CFU intranasally and monitored for their ability to survive infection. The 
doses for serotype 3 were based on previous analysis of optimum bacterial counts required to 
induce 100 % mortality by intranasal (i.n.) challenge, discussed in section 3.4 1, chapter 3. A 10-
fold increase from the usual challenge dose was used for the serotype 2 strains to attempt to 
overcome the decrease in virulence due to the absence of prior i.p. passage discussed above. 
Following challenge with D39, 60 % of mice succumbed to infection by 120 hr (median survival 
time 96 hours), but mice infected with Llrr09 did not succumb to infection and all these mice 
survived the entire course of the experiment (P<0.05 for survival) (Figure 5.11A). These 
observations were matched by the levels of bacteraemia at predetermined time points following 
infection. Levels of bacteria in the blood increased over time with D39 infected mice but no 
bacteraemia was detected in mice infected with strain Llrr09 at any of the time points examined 
(Figure 5.11B). Differences in bacteraemia between wild type and isogenic mutant were 
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statistically significant for all time points after 0 hr (P<0.05). The 100 % mortality usually seen 
with wild-type D39 infection in our laboratory was not obtained in this study and this could be 
attributed to the absence ofi.p. passage of the bacteria prior to infection. 
Intranasal infection of mice with strains in a type 3 background resulted in 100 % mortality with 
the 0100993 strain and 40 % mortality with the isogenic L1488 mutant (P<0.05 for survival of 
L1488 compared to parental strain) (Figure 5.11C). Median survival times of mice were 66 hr and 
168 hr, respectively (based on mice that survived the entire course of infection being assigned an 
arbitrary survival time of 168 hr). Blood counts were similar to those seen for type 2 infection, 
where a steady increase in counts for strain 0100993 was observed but levels of L1488 mutant 
remained very low up to 60 hr post challenge (Figure 5.11D). However, some mice did succumb 
to infection with L1488 so bacterial levels within the blood of such mice must have increased after 
the time points selected for this experiment (when moribund, these mice had counts of 107_109 
CFU mrl in their blood). 
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Figure 5.11 Survival and bacteraemia following intranasal challenge with 1'1'09 mutants and parental 
strains 
Mice were challenged intranasally with 1.0 x 107 CFU bacterial strains. Figure 5.llA shows survival of 
mice following challenge with type 2 strains. P<0.05 for survival of mice infected with LJrr09 compared to 
D39 parental strain. Figure 5.l1B shows bacteraemia in mice challenged with type 2 strains. P<0.05 (*) for 
bacteraemia with LJrr09 compared to D39 parental strain at all time points after 0 hr. Figure 5.llC shows 
survival of mice following challenge with type 3 strains. Figure 5.llD shows bacteraemia in mice 
challenged with type 3 strains. P<0.05(*) for survival and bacteraemia at all time points after 24 hr with 
LJ488 compared to 0100993 parental strain. The broken line represents the limit of detection. 
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5.2.2.2 Intranasal challenge; Lung counts 
Bacterial loads within the lung tissue were determined 24 and 48 hours post infection with 1 x 
107 CFU intranasally. Challenge with type 2 strains resulted in low numbers of bacteria within 
lung tissue both 24 and 48 hr post infection, with median counts of Llrr09 being below the 
detection limit (LOglO 0.40 CFU mg-1 lung tissue) (Figure 5.12A). The difference in counts 
between wild type D39 and isogenic Llrr09 mutant at 24 hr and 48 hr were statistically 
significant (P<0.05). Counts in lung tissue following challenge with type 3 strains were relatively 
high at both time points, showing an increase between 24 hr and 48 hr post infection (Figure 
5.12B). This increase in counts at 48 hours compared to 24 hours was only statistically 
significant for wild type bacteria (P<0.05). No significant difference was observed between 
counts of 0100993 and Ll488 in the lung tissue at either time point studied. 
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Figure 5.12: Bacterial loads in the lung tissue following intranasal challenge with rr09 mutants and 
parental strains 
Mice were challenged intranasally with 1.0 x 107 CFU. Bacterial loads within the lung tissue was 
determined 24 hr and 48 hr post infection. Figure 5.12A represents strains on a type 2 background, where 
filled bars represent D39 wild type and hatched bars represent Llrr09 mutant. P<0.05(*) for wild type values 
compared to mutant at both time points. Figure 5.12B represents strains on a type 3 background, where 
filled bars represent 0100993 wild type and hatched bars represent Ll488 mutant. No differences were found 
between wild type and mutant lung counts at either time point studied. The broken line represents the limit 
of detection. The lower counts in the lungs for the D39 parental strain compared to the 0100993 parental 
strain are likely to be due to absence of passaging in the former strain. 
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5.2.3 Intravenous challenge 
Bacterial strains were inoculated directly into the veins of mice to determine their ability to grow 
in the blood. Counts at 0 hr confirmed the bacterial dose administered and subsequent levels of 
bacteraemia were examined at pre-determined time points. Mice were also monitored for 
survival. 40 % of mice given D39 survived the infection, while all mice injected with iJrr09 
survived (Figure S.l3A). Median survival time for mice given D39 was 84hr. The experiment 
was allowed to proceed for 7 days, after which all surviving animals were given arbitrary 
survival times of 168 hr. On this basis, the difference in survival between D39 wild type and 
isogenic iJrr09 was highly significant (P<O.OOS). 8 hr post infection, counts in the blood of mice 
administered D39 and iJrr09 had fallen significantly. Levels of D39 began to increase after this 
time point, albeit slowly, whilst iJrr09 counts remained below the detection limit (LoglO 1.92 
CFU mr!) at all time points studied (Figure S .l3B). The initial decrease observed in bacteraemia 
is likely to be due to the absence of bacterial passaging prior to infection as passaged wild-type 
D39 bacteria do not display this decrease in the blood following i.v. challenge (chapter 7, section 
7.3.2). Counts of D39 presumably increased within the blood at time points later than those 
examined as 60 % of mice eventually succumbed to infection, and when moribund, these mice 
had counts of 107_109 CFU mr! in their blood. 
All mice infected with strains 0100993 and iJ488 succumbed to infection very quickly and both 
had median survival times of 36 hr (Figure S.l3C). Bacterial counts in the blood of mice 
administered 0100993 and iJ488 were very similar at all time points examined (Figure S.l3D). 
No significant differences were observed between mutant and wild type for bacteraemia or 
murine survival. After 36 hr, no further time points were studied for type 3 strains as many of the 
mice had become moribund by this stage and had to be culled. 
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Figure 5.13: Survival and bacteraemia following intravenous challenge with rr09 mutants and 
parental strains 
Mice were challenged intranasally with 1.0 x 106 CFU bacterial strains. Figure 5.12A shows survival of 
mice following challenge with type 2 strains. P<0.005 for survival of mice infected with ,1rr09 compared to 
D39 parental strain. Figure 5.13B shows bacteraemia in mice challenged with type 2 strains. P<0.05(*) for 
bacteraemia of mice infected with ,1rr09 compared to D39 parental strain at all points after 0 hr. Figure 
5.13C shows survival of mice following challenge with type 3 strains. Figure 5.13D shows bacteraemia in 
mice challenged with type 3 strains. No differences were seen in survival or levels ofbacteraemia between 
mice infected with 0100993 or ,1488 mutant. The broken line represents the limit of detection. 
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5.3 Further in vitro characterisation 
Several assays were perfonned in an attempt to detennine why the rr09 mutants had reduced 
virulence. 
5.3.1 Haemolytic activity 
All strains were characterised for their ability to induce lysis of sheep red blood cells. Complete 
haemolysis was not observed with any of the negative controls, including the pneumolysin null 
mutant, L1pln, treated with deoxycholate (DOC), indicating that any lysis observed was largely 
due to pneumolysin and not other pneumococcal haemolysins. All deoxycholate-lysed cultures, 
including mutants, showed complete haemolysis of sheep red blood cells up to a 1:8 dilution. No 
haemolysis was seen when lysed cultures were diluted 1:32 (table 5.1). The dilutions ranged 
from neat (un-dilute) to 1:128. These data indicate that strains D39, L1rr09, 0100993 andL1488 all 
express similar amounts of active pneumolysin. 
Dilution of culture resulting in haemolysis 
Complete lysis Partial lysis no lysis 
All negative controls No haemolysis No haemolysis All dilutions 
D39 (- DOC) No haemolysis No haemolysis All dilutions 
D39 (+ DOC) Neat-8-fold 8-16-fold 16-32-fold 
L1rr09 (- DOC) No haemolysis No haemolysis All dilutions 
L1rr09 (+ DOC) Neat-8-fold 8-16-fold 16-32-fold 
01009993 (- DOC) No haemolysis No haemolysis All dilutions 
0100993 (+ DOC) Neat-8-fold 8-16-fold 16-32-fold 
L1488 (- DOC) No haemolysis No haemolysis All dilutions 
L1488 (+ DOC) Neat-8-fold 8-16-fold 16-32-fold 
Table 5.1 Haemolytic activity of cultures 
All bacterial strains were analysed for their ability to induce lysis of sheep red blood cells without (- DOC) 
and with (+ DOC) treatment with 0.04 % deoxycholate. Negative controls included a pneumolysin null 
mutant, PBS alone, media alone and media with 0.04 % deoxycholate. 
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5.3.2 Transformation efficiency 
Strains were analysed for their ability to take up DNA from their surroundings using a standard 
transformation protocol. No significant differences were found in the transformation efficiencies 
of either mutant when compared to its parental strain, although the transformation efficiency of 
ilrr09 was lower than its parental stain (table 5.2). A >100-fold increase was seen in the ability 
of encapsulated type 2 strains to take up extracellular DNA compared to encapsulated type 3 
strains (median transformation efficiencies of 69.4 and 0.42 transformants per I!g DNA 
respectively). This is likely to be due to the thick mucoid capsule characteristic of the serotype 3 
strain used, as presence of any capsule is known to greatly reduce transformation efficiency in S. 
pneumoniae (Yother et ai., 1986). 
Transformation Efficiency (Total 
transformants per ug DNA) 
mean med SEM 
D39 69.4 69.4 32.3 
,1rr09 38.7 38.7 24.3 
0100993 0.42 0.04 0.388 
,1488 0.36 0.04 0.322 
Table 5.2 Transformation efficiency of bacterial strains 
Bacterial cultures were grown to OD 600 nm 0.1 and transformed with chromosomal DNA encoding 
streptomycin resistance in the presence of CSP 1. Transformants were selected on streptomycin (150 Ilg mr 
1). All cultures had equal total cell counts following transformation as determined by viable cell counting. 
The table shows mean and median values for experiments performed in duplicate on 3 separate occasions. 
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5.4 Expression analysis 
5.4.1 Optimisation of RNA preparation from bacterial strains 
For all expression analyses, RNA was isolated from cultures grown to mid log phase (OD 600 
nm 0.6-0.7) in BHI media at 37 0 C. Mutant Llrr09 was grown in the absence of erythromycin to 
prevent detection of differentially expressed genes due to the presence of antibiotic alone. 
Previous experiments have shown that the Llrr09 mutant phenotype is stable in the absence of 
erythromycin selection (section 5.1.4). Viable cell counts from cultures from which RNA was 
isolated were determined, although previous experiments comparing in vitro growth of strains 
D39, Llrr09, 0100993 and Ll488 indicated that at any given optical density during exponential 
growth would result in equal cell counts (section 5.1.3). Concentration of isolated RNA was 
determined by agarose gel electrophoresis using an RNA standard. 
The isolation of pure, intact RNA is crucial to the success of gene expression analysis. Bacterial 
RNA is known to be less stable than eukaryotic RNA making isolation relatively more difficult. 
Furthermore, S. pneumoniae, being a Gram-positive organism, has a thick cell wall that must be 
broken down as quickly as possible to avoid RNA degradation. Several commercially available 
kits are available for isolation of bacterial RNA and these include reagents, such as RNA 
Protect® (Qiagen) which has been formulated to help prevent degradation of RNA immediately 
upon harvesting bacterial cultures. However, using this reagent significantly decreased the final 
yield of RNA obtained from individual preparations up to lO-fold (figure 5.14). The reason for 
this loss of RNA yield is unknown. 
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Figure 5.14 Effect of RNA Protect® on pneumococcal RNA yields 
RNA was prepared from 2 independent cultures (1 & 2) of D39 grown to mid-exponential phase in the 
presence and absence of RNA Protect®. Each culture was divided into 2 x 5 m1 volumes, where RNA from 
one x 5 m1 from each was isolated in the presence of RNA Protect® according to manufacturer's 
instmctions (lanes 1 and 2 respectively). RNA was also isolated fi"om the remaining 2 x 5 m1 in the absence 
of RNA Protect® (lanes 1 * and 2 * respectively). The gel shows the greatly increased RNA yield obtained 
in the absence of RNA Protect®. Lane S represents RNA standard from E. coli, with a total of 1.6 Ilg of 
RNA loaded onto the gel. The 2 discrete bands seen for each sample represent 23S (upper band) and 16S 
(lower band) RNA. 
For micro array hybridisations a good RNA yield is required to allow sufficient data analysis with 
appropriate repetitions from each RNA preparation. Isolation of RNA using RNA Protect® or 
other commercially available stabilising reagents was thus avoided. Immediate snap freezing of 
cultures prior to harvesting bacterial cells may help preserve the RNA from degradation, 
although could also have an effect on the final yield of RNA obtained. RNA preparations from 
cultures frozen slowly at - 70 0 C were compared with cultures flash frozen in liquid nitrogen 
(figure 5.15). No difference was observed in RNA yields between the methods of freezing, so an 
RNA isolation protocol was developed using cultures that were flash frozen in liquid nitrogen 
prior to isolation, with the aim of preserving RNA from degradation as much as possible. 
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Figure 5.15: Effect of freezing methods on RNA yields 
RNA was prepared from a culture of D39 grown to mid-exponential phase. The culture was divided into 2 
x 5 m1 volumes, with 1 x 5 m1 being frozen slowly at - 70 0 C and the other being immersed immediately in 
liquid nitrogen. RNA was isolated from both cultures using the same protocol. Lane 1 represents RNA 
isolated from culture frozen at - 70 0 C and lane 2 represents RNA isolated from cultures flash frozen in 
liquid nitrogen. No difference in final yield of RNA was observed. 
5.4.2 Microarray analysis 
Microarray analysis was perfonned using RNA isolated only from D39 and Llrr09 cultures 
grown to mid-exponential phase in BHI. Hybridisations were perfonned using RNA from the 
same preparation but with reverse labelling with Cy3 and Cy5. Thus each RNA preparation was 
analysed in duplicate. Figure 5.16 summarises the protocol used for micro array analysis. 
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D39RNA drr09 RNA 
Direct incorporation of Cy3 and Cy5 dyes 
Convert to eDNA + C~'3 II Convert to eDNA + CyS I I Convert to eDNA + Cy3 II Convert to eDNA + CyS 
Hybridisation to arrays 
ARRAY 1 (SP3-44) ARRAY 2 (SP3-45) 
D39 eDNA + C~'3 D39 eDNA + Cy5 
,11'1'09 eDNA + Cy5 ,1/'1'09 eDNA + Cy3 
Scan in arrays using a laser scanner to 
determine intensity of individual spots 
Data imported into Imagene™ for manipulation 
Data analysis using GenespringTM software 
Figure 5.16: Summary of procedure used for mircoarray analysis of D39 and drr09 
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Prior to analysis, data were imported into Imagene™ (BioDiscovery) to visually inspect the 
computer-generated grid and spot alignment. During this inspection it was noted that many of the 
spots / genes (between 10-20 %) were very poorly expressed or completely absent, although 
there was no way of determining if this was due to lack of expression of absence / loss of RNA 
transcript during preparation. Data were analysed using Genespring™ software. This software 
determines the relative amounts of all gene transcripts from the strains by measuring the 
individual signal intensities of the Cy3 and Cy5 dyes and calculating signal ratios. Data was 
imported into GenespringTM such that a ratio of 1.0 indicates that the intensity of signal is equal 
for both samples, a ratio of <1.0 indicates lower signal intensity in the mutant strain and a ratio 
of >1.0 indicates increased signal intensity in the mutant strain, relative to wild-type. The 
software was also set up to allow spot intensities to be colour co-ordinated to help identify 
differential gene expression. Using this system, gene transcripts present in equal concentrations 
in D39 and iJrr09 (a ratio of 1.0) result in a yellow spot. Blue spots represent genes that have 
reduced expression in the mutant strain (a ratio of <1.0), while red spots represent genes that 
have increased expression in the mutant strain compared to wild-type (a ratio of >1.0). Each 
gene is present on the micro array in duplicate and the intensity of individual replicates of genes 
for both wild-type and mutant can be determined. 
The complete data set generated from one of the micro array experiments is represented in figure 
5.17 as a scatter plot. Wild type genes (x-axis) were plotted against mutant genes (y-axis) and 
this was used to examine the quality of data generated and to identify genes differentially 
expressed in the iJrr09 mutant D39 compared to wild-type D39. Most genes can be seen to 
cluster together around the central green diagonal line which represents a ratio of 1.0, indicating 
that the hybridisations worked well and most genes detected are expressed the same in both 
strains. Diagonal green lines above and below this central line represent two-fold increased and 
decreased gene expression respectively in iJrr09 compared to isogenic D39 parental strain. 
During analysis, genes with an intensity of below 500 were considered too low for reliable 
analysis and intermediate intensities of 500-1000 were considered but with caution. For most 
genes present, the spot intensity was above 1000 which illustrates reliable expression data. Only 
genes with altered expression in both arrays, and those with combined signal intensities of> 500 
were considered for further analysis. 
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Within the data presented as a scatter plot, 2 spots were observed that had greatly reduced 
expression in the mutant compared to D39 wild-type. These spots were coloured blue and were 
located away from the rest of the data and outwith the line representing a two-fold decrease in 
expression. Furthermore, these spots were identified as having reduced expression by > 2-fold in 
both arrays. Other genes with altered expression in the mutant compared to wild-type will be 
discussed below and included in later figures. 
Figure 5.17 Microarray data comparing gene expression in Arr09 mutant with isogenic D39 parental 
strain 
Legend on following page 
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RNA was prepared from bacterial cultures grown to mid-exponential phase in BHI media at 37 0 C. cDNA 
was prepared from the RNA extracts and labelled directly with Cy3 (.11'1'09) or Cy5 (D39). Labelled cDNA 
preparations were combined and hybridised to the array overnight. The scatter plot illustrates the spot 
intensities of all individual genes detected. D39 data (x-axis) is plotted against .11'1'09 data (y-axis). Each 
spot represents the combined intensities of labelled cDNA from mutant and wild-type for any given gene. 
Yellow spots indicate similar expression of individual genes on both bacterial strains, with a ratio of - 1.0. 
These genes lie close to the central, diagonal line. Blue spots represent genes with decreased expression in 
the mutant compared to wild type and red spots are genes with increased expression in .1rr09. If spots lie 
outside the upper and lower diagonal lines they represent genes expressed in .1rr09greater than or less than 
2-fold expression, respectively, compared to wild-type expression l . The further away from the lines, the 
bigger the difference in expression. The scatter plot illustrates that the hybridisations worked well as most 
spots lie within the diagonal lines and within the upper region of the plot, so have reliable spot intensities of 
> 1000. Most of the genes detected have similar levels of expression in both bacterial strains. The arrows 
represent genes of interest that have decreased expression in .1rr09 compared to D39. The red arrow 
represents the /'1'09 gene, further confirming the null mutation within this gene for strain .11'1'09. The white 
arrow represents the gene encoding a subunit (lIB) of a bacterial phosphotransferase (PTS) system 
previously not associated with TCS09. Several other genes lying on or immediately outside the lower 
diagonal line were also characterised and these are discussed in the text. Only genes with altered expression 
in both arrays, and those with combined signal intensities of> 500 were considered for analysis. 
1 As no preliminary experiments were performed to assess the variation in signal intensity associated with a single 
cDNA preparation, the lines used to represent 2-fold increase / decrease in variation are only an approximate 
representation of these values. Thus data lying close to these lines should be regarded with caution. 
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Further analysis of the 2 spots showing decreased expresslOn III ilrr09 indicated that one 
corresponded to the 1'1'09 gene itself (sp0661), further confirming the null mutation. Furthermore, 
this served as a true negative control for subsequent analysis. The second spot was identified as a 
component (lIB) of a bacterial phosphotransferase (PTS) system (sp0061). Within the published 
R6 and TIGR4 sequences, this gene lies within a cluster of other genes encoding PTS 
components or related genes (figure 5.18). In the sequenced TIGR4 genome, this gene was 
annotated as a component of a PTS involved in sorbose uptake (Tettelin et ai., 2001). 
1.8 Kb 0.5 Kb 0.9Kb 0.8 Kb 
B-gal ptsIIB ptsIIC ptsIID 
sp0060 sp0061 sp0062 sp0063 
Figure 5.18 PTS locus and surrounding genes 
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ptsIIA isomerase 
sp0064 sp0065 
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aldose-l-
epimerase 
sp0066 
The figure illush'ates the ptsIIB gene (in dark blue) found to have significantly decreased expression in 
LJrr09 compared to D39. Other genes that are part of the PTS system are shown (light blue), together with 
sUlTounding genes fJ-galactosidase, sugar isomerase domain agaS and aldose-l-epimerase (all in grey) . 
The gene names cOlTesponding to the TIGR4 nomenclature are given in bold and approximate gene lengths 
are given. The fJ-gal & ptsIIB genes overlap by 3 bp, plsIIC & plsIID overlap by 13 bp and ptsIIA & 
isomerase overlap by 1 bp. The regions between genes ptsIIB & ptsIIC, ptsIID & ptsIIA and isomerase and 
aldose-l-epimerase are 28, 7 and1116 bp, respectively, indicating that the genes may fOlTll an operon. All 
gene annotations and lengths are based on those of the TIGR4 genome (http://www.tigr.org). No rho-
independent terminator sites were found following any of the genes shown. 
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The ratio values (figure 5.20) and expression levels (figure 5.21) of genes shown in figure 5.18 
were determined and all showed decreased expression in the mutant compared to wild type (ratio 
<0.1), although the expression levels of some of the genes was below the 500 limit cut off. No 
expression of ptsIID was detected in either D39 or iJrr09, so no data for this gene are available. 
Spots that lay on or just below the lower line, representing a 2-fold decrease in expression in 
iJrr09 were also analysed in further detail2. This highlighted decreased expression of several 
other genes that are located close to one another on the TIGR4 genome sequence and may form 
an operon or functionally related group of genes (figure 5.19). The function of many of these 
genes is unknown, although one has been annotated as a putative general stress protein (sp1804). 
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Figure 5.19 Group of genes of unknown function with decreased expression in Llrr09 compared to 
D39 
The figure illustrates a putative operon comprising largely of genes with unknown function that have lower 
levels of expression in the ilrr09 mutant compared to isogenic parental strain (see figures 5.20 and 5.21). 
Conserved hypothetical proteins (chp) are shown in grey and hypothetical proteins (hp) are shown in white. 
The gene annotated as a putative general stress protein is shown in red. A putative transcriptional activator, 
which mayor may not be involved in regulating the illustrated genes is shown in black. This is the only 
gene shown that is encoded on the complementary DNA strand. The gene names conesponding to the 
TIGR4 nomenclature are given in bold and approximate gene lengths are given. None of the encoding 
regions of the genes overlap, although the regions between genes are relatively small and are provided 
beneath the gene layout. All gene annotations and lengths are based on those of the TIGR4 genome 
(http://www.tigr.org) . The closed circle represents a rho-independent termination site. 
2 See footnote, p217 
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The ratio values and expression levels of all the genes described above was combined and 
analysed statistically to determine if the genes were expressed at lower levels in the iJrr09 
mutant compared to D39 wild-type. Data for all the identified pneumococcal response regulator 
genes was also collected and analysed. The ratio values for each gene are shown in figure 5.20. 
Values close to 1.0 illustrate genes that are expressed at similar levels between wild-type and 
mutant. Expression levels for several genes were too low to be considered so data is not available 
for these (ptsIID, rr07, rrll, rrl2, sp1800, sp1803 and spI806). Genes that had ratio values of 
<1.0 are shown in table 5.3. The 16S and 23S genes also had ratios of significantly <1.0, 
although the mean ratios for both these genes is >0.9 so these genes were not included in the 
table. Of particular interest is the rr14 gene which had a ratio of>1.0 (P=O.Ol), indicating it had 
significantly increased expression in the iJrr09 mutant compared to D39 wild-type. However, 
when intensity values were compared, this increase was not found to be statistically significant 
(figure 5.22). 
Comparisons of intensity between mutant and wild-type cDNA preparations, for all the genes 
discussed above, is provided in figure 5.21. To allow differences in expression of the above 
genes to be appreciated, the expression intensity for each of the response regulator genes is 
shown in a separate figure (figure 5.22). This is due to the comparatively high levels of 
expression of several of the response regulator genes (rr02 and rr05) that are outwith the scale 
used for figure 5.20. All of the genes discussed above (table 5.3) as having a ratio of <1.0, had 
lower levels of intensity of expression in the mutant compared to wild-type (figure 5.21). 
Statistically significant differences in expression were only observed for rr09 (P=0.008), ptsIIB 
(P=O.OOl), isomerase agaS (P=0.016), sp1801 (P=0.048), sp1804 (P=O.OOl) and sp1805 
(P=0.037). For other genes the mean intensity levels may be too low to obtain accurate results or 
the variation between individual values too high to result in statistical significance. None of the 
other pneumococcal response regulator genes have significant differences in expression between 
wild-type and mutant strains. It is interesting that rr07, rr 11 and rr 12 all have expression 
intensities below the 500 threshold in both strains and that the intensity for rr03 is only just 
above this threshold. For the figures displaying expression intensity, data for 16S and 23S genes 
have been omitted as these genes gave very high levels of expression, as expected, (mean wild-
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type values of ~50,000 and 71,000 respectively), which would have been over the scales 
represented. 
Genes surrounding the rr09 gene (msrA, hk09, chp and zmpB) do not appear to have reduced 
expression in the mutant compared to wild-type, although the hk09 and zmpB genes have mean 
intensities only just above the 500 threshold limit. This data indicates that rr09 does not regulate 
genes immediately upstream or downstream of tcs09. Further data and discussion alluding to 
expression of the zmpB gene by TCS09 are presented in chapters 7 and 8. 
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Figure 5.20: Ratio of selected genes in LJrr09 compared to D39 
RNA prepared from bacterial strains grown to mid-exponential phase in BHI media was converted to 
cDNA with the direct incorporation of either of the fluorophores Cy3 or CyS. D39 cDNA labelled with Cy3 
was hybridised on one array with LJr1'09 cDNA labelled with CyS. Hybridisation to a second array was also 
set up using reverse labelling of cDNA (D39 cDNA-CyS, LJrr09 cDNA-Cy3). Arrays were scanned using a 
laser scanner and data was analysed using GenespringTM version software. The figure represents the ratios 
obtained. A ratio of 1.0 indicates that genes had similar levels of expression in D39 and LJrr09. A ratio of 
<1.0 illustrates genes that are expressed at lower levels in the mutant, and the lower the value the greater 
the difference in expression. A ratio of> 1.0 highlights genes that have increased expression in the LJ1'r09 
mutant compared to D39 parental strain. The dashed line represents a ratio of 1.0. Genes that have a ratio 
significantly different from 1.0, as determined by a 2-sample t-test, are indicated by a single asterix (*, 
P<O.OS) or a double asterix (P<0.00S)3. Genes are grouped into colour co-ordinated sets. Those in black 
represent positive controls for gene expression (16S RNA, 23S RNA and DNA gyrase). Genes of the 
TCS09 locus and genes immediately surrounding this region are given in blue. The PTS and surrounding 
genes are shown in red. All response regulator genes (including 1'/'09 for completeness) are coloured 
yellow. Genes from sp1801-sp1805 are shown in green. Genes ptsIID, 1'1'07, 1'1'11, 1'1'12, sp1800, sp1803 
and sp1806 are absent as expression levels were too low to obtain reliable data. 
3 See footnote p217 
223 
13000 
12500 
12000 
11500 
11000 
10500 
10000 
9500 
9000 
8500 P=O.008 
8000 
7500 
£ 7000 en 
c 6500 
.$ 
.£ 6000 
5500 
5000 
4500 
4000 
3500 
3000 
2500 
2000 
1500 
1000 * 
500 I~.~ ••••••• 
0 
Q) <! 
'" ~ ro >-
C1l C1l Q. 
0 ~ .c ~ u ~ 
.c 
0) 
a:l g-
N 
D39 wild type; fIlled! coloured bars 
ilrr09 mutant; white bars 
P=O.OOI 
P=O.016 
** 
ro a:l 0 ~ Q) Q) O) = = 
'" '" cD ~ ~ ~ ro ro ~ ~ 
0 "0. 
"~ Q) 
Gene 
Figure 5.21: Expression of selected genes in "09 compared to D39 
Legend is provided on the following page 
P=O.048 P=O.OOI 
P=O.037 
* * 
C; N "'" U") 0 0 0 
co co co co 
0. 0. 0. 0. 
'" '" '" '" 
224 
Chapter S S. pneumoniae TCS09 Results 
Figure5.21: Expression of selected genes in Lirr09 compared to D39 
RNA prepared from bacterial strains grown to mid-exponential phase in BHI media was converted to cDNA with 
the direct incorporation of either of the fluorophores Cy3 or CyS. D39 cDNA labelled with Cy3 was hybridised on 
one array with .11'1'09 cDNA labelled with CyS. Hybridisation to a second array was also set up using reverse 
labelling of cDNA (D39 cDNA-CyS, .11'1'09 cDNA-Cy3). Arrays were scanned using a laser scanner and data was 
analysed using GenespringTM version software. The figure represents the expression intensity of selected genes 
discussed in the text4• The dashed line represents an intensity of SOO. Expression below this limit is regarded as too 
low for accurate data analysis. Genes in the .11'1'09 mutant that have expression intensities that are significantly 
different from D39 wild-type, as determined by a 2-sample t-test, are indicated by a single asterix (*, P<O.OS) or a 
double asterix (P<O.OOS). Wild-type genes are grouped into colour co-ordinated sets. All mutant genes are shown in 
white but are displayed adjacent to the corresponding wild-type gene. DNA gyrase is shown in black to represent a 
positive control for gene expression. Genes of the TCS09 locus and genes immediately surrounding this region are 
given in blue. The PTS and surrounding genes are shown in red. Genes from sp1801-sp180S are shown in green. 
Genes ptsIID, sp1800, sp1803 and sp1806 are absent as expression levels were too low to obtain reliable data. Data 
for 16S and 23S genes have been omitted as these genes gave very high levels of expression, as expected, (mean 
wild-type values of ~SO,OOO and 71,000 respectively), which would have been over the scale represented. 
4 See footnote p217 
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Genes that had ratios of < 1.0 in the iJrr09 mutant compared to D39 are summarised in table 5.3. 
TIGR4 Other name / gene description P value 
name 
Sp0661 RR09 component ofTCS09, function unknown 0.000** 
Sp0060 B-galactosidase enzyme, hydrolyses lactose 0.009* 
Sp0061 PTSIIB, component of putative sorbose PTS 0.000** 
Sp0062 PTSIIC, component of putative sorbose PTS 0.003** 
Sp0064 PTSIIA, component of putative sorbose PTS 0.000** 
Sp0065 Isomerase agaS enzyme, catalyses isomerisations 0.003** 
Sp0066 Aldose-1 epimerase enzyme, cataslyses isomerisations 0.019* 
Sp1801 None, homology to proteins of unknown function in L. lactis, 0.009* 
E. faecalis, s.pyogenes and B. subtilis 
Sp1802 None, hypothetical protein 0.009* 
Sp1804 Stress protein 0.002** 
Sp1805 None, hypothetical protein 0.000** 
Table 5.3 Genes having a ratio of <1.0 
With the exception of the rr09 gene, all genes that had ratios of <1.0, indicating reduced expression in the 
L1rr09 mutant were clustered at 2 regions of the genome. The first set of genes appears to be components or 
genes related to the functioning of a PTS system for sugar (sorbose) uptake. The remaining genes are 
largely of unknown function, although one encodes a putative stress protein. Gene identifications are based 
on the TIGR4 genome sequence (Tettelin et al., 2001 and http://www.tigr,org/). The P value, as determined 
by 2-sample t-tests, indicates the statistical significance of each gene having a ratio of <1.0 (P<0.05 is 
represented by a single asterix, *. P<0.005 is represented by a double asterix, **). 
226 
Chapter 5 S. pneulI10niae TCS09 Results 
Genes that had lower levels of expression in the iJrr09 mutant compared to D39 are summarised 
in table 5.4. 
TIGR4 Other name Difference in expression P value 
name (represented as fold decrease) 
Sp0661 RR09 31.0-fold 0.008* 
Sp0060 B-gal 2.8-fold 0.140 
Sp0061 PTSIIB 9.0-fold 0.001 ** 
Sp0062 PTSIIC 2.4-fold 0.107 
Sp0064 PTSIIA 2.9-fold 0.117 
Sp0065 Isomerase 3.0-fold 0.016* 
Sp0066 Epimerase 1.7-fold 0.066 
Sp1801 Conserved hypothetical 1.7-fold 0.048* 
Sp1802 Hypothetical 1.9-fold 0.145 
Sp1804 Stress protein 2.0-fold 0.001 ** 
Sp1805 Hypothetical 1.9-fold 0.037* 
Table 5.4: Genes having lower expression intensities in the iJrr09 mutant compared to D39 wild-type 
Genes with expression intensities at least 1.5-fold lower in the mutant strain compared to wild type are 
shown in the table. The P value, as determined by 2-sample t-tests, represents statistical significance in 
expression intensities. A P value of <0.05 is represented by a single asterix (*). Highly significant P values 
of <0.005 are represented by a double asterix (**). Values are based on mean intensity levels. The mean 
expression of /'/'09 is based on a reduction in intensity when compared against background values (as this 
gene is absent in the mutant). 
The table above shows that the ptsIIB and the putative stress protein gene both have expression 
levels that are highly significantly lower in the iJrr09 strain compared to D39 (9-fold and 2-fold 
decreases, respectively). Other genes that have significantly lower expression include isomerase, 
epimerase, sp1801 and sp1805. B-gal, ptsIIC and ptsIIA all demonstrated decreased expression 
levels of>2-fold, but these differences were not found to be statistically significant. 
227 
26000 
25000 
24000 
23000 
22000 
21000 
20000 
19000 
18000 
17000 
16000 
.I 
~ 15000 
·00 14000 
c 13000 Q) 
-
12000 c 
11000 
10000 
9000 
8000 
7000 M 
6000 
5000 
4000 r=r. 
3000 
2000 
1000 
o I. •••••••..•••• ~~ •• ~.~. ~ •• r-f.'l. ·1·1·1·· ~. ~.~ .. m .,.".., .....  
Q) ..... N C'? '<t L() CD f'-. co 
en <2 <2 <2 <2 <2 <2 <2 <2 en 
L.. L.. L.. L.. L.. L.. L.. L.. L.. 
>. 
0> 
Gene 
D39 wild type; filled! coloured bars 
iJrr09 mutant; white bars 
IL 
~ 
.... ~ ..... . .. ~ .. ~ .. ~ ....... . 
(J) 0 N C'? '<t 
<2 ..... ..... ..... ..... ..... L.. L.. I::: L.. L.. L.. L.. L.. L.. L.. 
Figure 5.22: Expression of all response regulator genes in "09 compared to D39 
Legend is provided on the following page 
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Figure 5.22: Expression of all response regulator genes in Arr09 compared to D39 
The figure represents the expression intensity of all 14 pneumococcal response regulator genes in the i1rr09 
mutant compared to D39 wild-type. The dashed line represents an intensity of 500. Expression below this 
limit is regarded as too low for accurate data analysis. Wild-type genes are coloured yellow and mutant 
genes are shown in white. None of the response regulators had significantly different expression intensities 
in the mutant compared to the isogenic parental strain, with the exception of 1'1'09. DNA gyrase is shown in 
black as a positive control for gene expression. 
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Detection of expression of the sorbose-family PTS during in vitro growth of wild-type D39 in 
defined media is somewhat surprising given that such systems would be expected to be 
expressed only when commonly-used sugar sources are limiting. Thus, expression of 
components specific to each individual pneumococcal PTS (Ell components) in D39 grown to 
mid-exponential phase were compared (see figure 5.23). This illustrated that of 21 individual 
PTS systems, only 6 were expressed at intensities above the threshold limit of 500, and of these 
the putative sorbose system had greatest expression. 
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Figure 5.23 Expression of PTS systems in D39 wild-type during ill vit,.o growth 
Following microarray analysis of RNA isolated from wild-type D39 grown to mid-exponential phase in 
BHI media, the expression of Ell components, specific to 21 individual pneumococcal PTS systems were 
compared. The figure shows the 6 PTS systems that had expression intensities greater than the cut-off 
t1n'eshold of 500. The component of each PTS used to examine gene expression in individual systems is 
shown in brackets. The broken line represents the set limit of detection for gene expression. 
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As the iJrr09 mutant was avirulent, expression of several known virulence factors was compared 
between D39 wild-type and the mutant and illustrated in table 5.5. 
Gene D39 Arr09 
(gene intensity) (gene intensity) 
LytA (sp1937) 22954 25058 
PIn (sp1923) 9550 10573 
Cps2L (SPR0320) 4134 5064 
HtrA (sp2239) 3820 5302 
PspC/ CbpA 2025 4719 * 
(spr1995) 
PrtA (sp0641) 1854 2590 
PspA (spOl17) 1409 1343 
CpsO (SPR0323) 1111 1819 
Cps2P 941 1012 
Hya (sp0314) 473 469 
Table 5.5 Expression of several known virulence factors in the Arr09 mutant compared to D39 wild-
type 
The figure shows the mean expression intensity of several genes selected to represent known virulence 
factors in S. pneul11oniae. These are the major autolysin (LytA), the pneumolysin toxin (PIn), 3 genes 
associated with capsule synthesis (Cps2L, CpsO and Cps2P), 2 surface proteins, pneumococcal surface 
protein C (PspC, also known as choline-binding protein A / CbpA) and pneumococcal surface protein A 
(PspA), 2 putative serine proteases (PrtA and HtrA) and the enzyme hyaluronidase (Hya). The genes are 
arranged in descending order of expression intensity. The TIGR4 gene names are given in brackets. Where 
genes are specific to R6 due to absence in TIGR4 (capsule genes) or sequence variation (PspC), the R6 
gene names are given. The only significant difference in expression between the wild-type and mutant was 
with PspC, where significantly higher levels were detected in the mutant (P<0.05, *). 
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The data in table 5.5 is in agreement with prevIOUS experimental analysis that found no 
difference in autolysis (due to LytA) or haemolytic activity (due to PIn) of the mutant compared 
to wild-type. At least 9 capsule-associated genes were analysed (CpsH -CpsP), and of these, only 
3 had expression levels above the 500 threshold intensity. Only these 3 genes (Cps2L, CpsO and 
Cps2P) are shown in the table. These capsule genes comprise genes specific to R6. PspC is the 
only gene identified in the entire micro array analysis that is significantly up-regulated in the 
Llrr09 mutant. 
5.5 Further analysis 
5.5.1 Carbohydrate utilisation assays 
Preliminary micro array analysis identified genes of a putative sorbose-specific PTS system that 
had reduced expression in the Llrr09 mutant compared to D39 wild-type. Previously TCS09 was 
suggested to have a role in nutrient perception based on homology of this system with 
chemotaxis-associated sensors in B. subtilis (Lange et al., 1999). To investigate the role of this 
system in nutrient sensing or uptake an assay was set up (based on a protocol by Ruoff et al., 
1999) to examine the ability of pneumococcal strains to ferment a selection of sugars, including 
the L- and D- forms of sorbose. Bacterial strains were grown overnight in nutrient-replete (THB) 
culture media then transferred to nutrient-deplete media (thioglycollate/purple broth) containing 
a single, defined carbon source. Ability to ferment this carbon source and subsequent acid 
production results in a colour change from purple to yellow due to an indicator present in the 
media. Figure 5.24 shows the ability of parental strains (D39 and 0100993) and mutants (Llrr09 
and Ll488) to ferment 7 different sugars. These sugars represent a selection of monosaccharides 
(glucose, sorbose, mannose and galactose), disaccharides (maltose and sucrose) and a 
trisaccharide (raffinose). All sugars used were the naturally occurring D-forms. Both L- and D-
forms of sorbose were included due to the putative association of TCS09 with this sugar. THB 
medium alone was used as a negative control. In a previous experiment bacterial cultures grown 
in THB were added to thioglycollate/purple broth medium in the absence of carbohydrate to 
show that carbohydrate or acid from the THB medium was not carried over to detectable levels 
in the assay. 
All of the strains, including the mutants, were able to ferment all the carbohydrates tested with 
the exception of sorbose (both Land D forms). 
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Figure 5.24 Carbohydrate fermentation by bacterial strains 
Bacteria strains D39, 0100993, 11'09 and 488 were grown overnight in THB media. Small volumes of 
overnight culture were added to thioglycollate/purple broth media containing various carbon sources (1 % 
final concentration). Following anaerobic growth at 37 0 C for 24 hr, strains capable of fermenting 
individual carbon sources were indicated by a colour change in the media from purple to yellow, due to 
acid production. The figure shows the fermentation of all sugars (shown by clear wells) with the exception 
ofD- and L-sorbose in all strains. The darker wells (THB control and LID-sorbose wells) indicate absence 
of fermentation and hence no colour change. Each strain was tested in duplicate for individual sugars and 
the experiment was repeated twice. 
233 
Chapter 5 S. pneumoniae TCS09 Results 
5.6 Summary of TCS09 Results 
Discussion of mutant phenotypes is in relation to the isogenic parental strains, unless stated 
otherwise 
5.6.1 Basic ill vitro analysis 
Mutations in the rr09 gene of2 pneumococcal strains (D39, serotype 2 and 0100993, serotype 3) 
were constructed by allelic replacement and confirmed by PCR and sequencing. PCR was also 
used to confirm that the organisation of tcs09 and surrounding genes in strains D39 and 0100993 
was the same as that of the sequenced strains R6 (type 2) and TIGR4 (type 4) 
Mutants were not impaired in growth in nutrient-replete BHI media, although RT-PCR indicated 
that rr09 is expressed in mid-exponential phase of growth in D39. Mutants were stable (retain 
erythromycin resistance) in vitro for up to 20 hr in the absence of erythromycin. 
5.6.2 lit vivo characterisation 
Intraperitoneal challenge 
Following intraperitoneal injection, the mutation in a serotype 2 background (L1rr09) was 
completely attenuated (P<0.05). All mice survived infection with no symptoms or bacteraemia. 
The mutation in a serotype 3 background (L1488) was not impaired in virulence. 
Intranasal challenge 
Following intranasal challenge L1rr09 was completely attenuated. All mice survived with no 
symptoms of infection or evidence of bacteraemia. Counts in the lung tissue at 24 and 48 hr post 
challenge were below the detection limit for most mice challenged with this strain. P<0.05 for 
survival, bacteraemia and lung counts. The L1488 mutant was also attenuated in murine survival 
and bacteraemia (P<0.05) but not in lung counts. 
Intravenous challenge 
Following intravenous challenge L1rr09 was again completely attenuated. All mice survived, with 
no symptoms of infection or evidence of bacteraemia after 8 hr post injection. P<0.05 for 
survival and bacteraemia. The L1488 mutant was not impaired in survival or bacteraemia 
following intravenous injection. 
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These data implies that in our model of infection, rr09 is important in virulence in both strains 
but has a different influence depending on the genetic background of the parental strain. In 
serotype 2 D39 it is essential for virulence in all studied routes of infection. In serotype 3, 
0100993, it is not required for virulence following intraperitoneal or intravenous challenge or in 
lung counts following intranasal challenge, but the rr09 mutant is impaired in bacteraemia and 
murine survival following intranasal challenge. 
5.6.3 Further ill vitro characterisation 
The mutants were not significantly impaired III their ability to take up and incorporate 
extracellular DNA during transformation and appear to have equal amounts of functional 
pneumolysin 
5.6.4 Expression analysis 
Microarray analysis was used to compare gene expreSSIOn III D39 and the ilrr09 mutant 
(serotype 2). This identified decreased expression of two groups of genes in the mutant strain. 
One set of genes encodes for various components of a PTS sugar transport system, with a 
possible link with the monosaccharide sorbose. This PTS has the highest levels of expression of 
21 individual systems examined in D39 grown in BHI. The second set of genes are clustered 
together on the genome but their function is unknown, with the exception of one that is a putative 
stress protein. The rr09 gene itself was also identified as being absent in the mutant. Expression 
of all other response regulator genes was not significantly affected in the rr09 mutant. 
Expression of several known virulence was not altered between mutant and wild-type, with the 
exception ofPspC, which was up-regulated in the mutant strain. 
5.6.5 Further analysis 
The ability of all strains to ferment several carbohydrates was investigated in an attempt to 
demonstrate a lillie between TCS09 and sugar fermentation. All strains, including the mutants, 
fermented all sugars tested with the exception of sorbose, which was not fermented by any of the 
strains. 
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6.1 Mutant construction and basic in vitro analysis 
Null mutants were made in the rr09 gene of S. pneumoniae TCS09 in strains D39 (serotype 2) 
and 0100993 (serotype 3). Initially, allelic replacement was used to create the mutation in the 
type 3 background (mutant iJ488). This mutation was subsequently isolated by PCR and the 
product used to transform D39 to create the same mutation in a different strain / serotype (type 2) 
to create the mutant iJrr09. All mutations were confirmed by PCR and sequencing. Prior studies 
using D39 transformed with plasmid pVA838, which does not integrate into the chromosome, 
have shown that virulence in this strain is not compromised by the transformation procedure used 
to create the mutants (chapter 3, section 3.1.2). This observation confirms that published by 
another group (Kadioglu et at., 2001), and illustrates that any phenotypes observed for the 
mutant strains are due to the null mutation and not artefacts of the transformation procedure used 
to create the mutants. 
The 0100993 and D39 strains used for the analysis in the previous chapter have not been 
sequenced, although a sequence for another serotype 2 pneumococcal strain (R6) does exist and 
has been published (Hoskins et at., 2001, http://www.tigr.org/). R6 is a strain derived from D39 
so should be very closely related. The gene organisation of tcs09 and surrounding genes in strain 
R6 is in agreement with that of a second published and annotated sequence, TIGR4 (serotype 4) 
and with the G54 (serotype 19F) sequence (publicly available but not annotated). Furthermore, 
the MsrA, RR09, HK09 and Chp proteins are at least 99 % homologous between R6, TIGR4 and 
G54 (data not shown), indicating that these genes are highly conserved between serotypes / 
strains. PCR using a series of primers designed against genes of tcs09 and the surrounding genes 
(based on the R6 and TIGR4 sequences) were designed and used to confirm that the gene 
organisation for all genes studied was the same in the D39 and 0100993 parental strains used in 
this work as in the R6 and TIGR4 strains. These genes were also found to be present in several 
other strains examined in this work, including serotype 19F, serotype 1 and one other serotype 4 
strain. This indicates that the organisation of the tcs09 region and surrounding genes is conserved 
between serotypes. Sequencing the PCR products would determine if the protein sequence is 
conserved between the 2 strains used in this work. It would be particularly useful to compare the 
rr09 gene sequences in strains D39 and 0100993, given the differences seen in virulence 
( discussed below). 
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In the absence of erythromycin, the mutant strains were not impaired in growth in BHI media 
and autolysed at the same rate as the isogenic parental strains, indicating that the rr09 gene is not 
an essential gene for the growth ofD39 and 0100993 under the conditions used. However, RT-
PCR was used to show that the rr09 gene is expressed during the mid-exponential growth of 
wild-type D39 in BHI. This indicates that the gene may be constitutively expressed or switched 
on at the stage of growth tested, although is not required for growth under the conditions used. 
Expression of the gene at different stages of growth or using different growth media could be 
examined to provide further insight into this finding. Expression of rr09 in strain 0100993 in 
vitro has yet to be examined. 
The presence of erythromycin did not affect the growth or optical density readings of the Ll488 
mutant. However, the presence of erythromycin resulted in lower optical density readings at all 
time points with the Llrr09 mutant, compared to D39 wild-type. As viability counts did not differ 
between the mutant and wild-type strains at any time point, the reduction in optical density 
suggests that there could be differences in capsule expression which subsequently results in 
different light-scattering ability of the strains without altering viability. This could also 
contribute to the differences seen in virulence, both between the Llrr09 mutant and its D39 
parental strain, and in the virulence of rr09 mutants in different pneumococcal serotypes. 
The analysis of in vitro growth demonstrated that optical density during the exponential phase of 
growth could be used as an accurate measurement of cell viability for all the strains examined in 
the absence of erythromycin. This is useful for further experiments where cultures of different 
strains and serotypes can be grown to a set OD 600 nm reading and harvested for experimental 
analysis, with the knowledge that total cell counts isolated should be very similar. The ability of 
mutants to grow well in the absence of antibiotic selection, without losing the selection marker 
and hence their null mutation, is also useful for further work. Cultures required for RNA 
preparation, for example, could be grown in the absence of antibiotic that could otherwise alter 
gene expression, with the knowledge that the mutant genotype will still be retained. 
After progression into stationary phase optical density does not appear to accurately reflect 
viable cell counts so should not be used for such a purpose. Furthermore, the optical density 
between serotypes differed from 8 hour after culture inoculation, such that OD 600 nm values were 
lower for serotype 3, strain 0100993 when compared to D39 (figure 5.7B). This could be related 
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to the presence of the relatively thick mucoid capsule present on type 3 strains, which may 
dissociate from dying or lysed cells and affect the optical density accordingly. 
6.2 Role of RR09 in virulence 
Bacterial strains were initially administered to mIce as an intraperitoneal injection. 
Administration of S. pneu1110niae via this route generally results in high levels of bacteraemia 
(>105 CFU mr!) within 24 hours of injection, even with very low challenge doses of several 
CFU (Aaberge et ai., 1995). Bacteraemia generally correlates with the observation of moderate 
to severe symptoms (hunched stance, piloerection, lethargy) which progress until the mice 
become moribund. This pattern of infection was observed consistently when mice were given 
strains D39, 0100993 and Ll488, but intraperitoneal challenge with the Llrr09 mutant did not 
result in any detectable bacteraemia following infection and mice did not display any signs of 
infection. The mutation was created and confirmed in at least two further, independent 
experiments, using different D39 stocks and groups of mice. However, none of the mutants were 
virulent, even when the challenge dose was increased 1000-fold compared to the initial dose of 
105 CFU. These data indicated that rr09 was important for virulence in a serotype 2 background 
but not in a serotype 3 background when given to MFI mice via intraperitoneal injection. In a 
study by Lange and colleagues, knock out mutations in the rr09 gene of a type 22 and type 3 
pneumococcus were not found to be impaired in virulence compared to the wild type strains 
when given to C57/BI mice i.p. (Lange et ai., 1999). Their data are in agreement with the results 
reported in this thesis for the Ll488 mutant which is also serotype 3, although of a different strain. 
However, the findings of Lange and co-workers do not agree with the data in this thesis for a 
rr09 knock-out in a serotype 2 background, giving the first indication that genetic differences 
between bacteria strains and I or serotypes could exist for the role ofRR09 in infection. 
Mice were subsequently challenged with mutants and their parental strains via an intranasal route 
of infection that allows the evaluation of the virulence of pneumococcal strains at several 
important stages of the infection process. Fully virulent strains that can cause mortality of mice 
via this route must be able to grow within the lung tissue, disseminate into the systemic 
circulation and survive and multiply in the blood, whilst avoiding elimination by the host's 
immune system. Initially, virulence was assessed by murine survival and bacterial load in the 
blood following intranasal challenge. Mice given 107 CFU D39 showed significantly increased 
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levels ofbacteraemia at all time points examined, post infection, compared with those challenged 
with the isogenic Jrr09 mutant. Furthermore, while 60 % of infected mice did not survive 
challenge with D39, all mice given 107 CFU Jrr09 mutant survived the experiment without 
showing any symptoms of infection or bacteraemia. Similarily, with the strains on a type 3 
background, challenge with the wild type 0100993 resulted in levels ofbacteraemia comparable 
to those with D39 infection, resulting in 100 % mortality of infected mice by 120 hours post 
infection. Infection with the J488 mutant did not result in significant levels ofbacteraemia at any 
of the time points examined, although 40 % of mice did eventually succumb to infection. These 
data indicates that rr09 gene is important in virulence via an intranasal route of infection in our 
murine model of pneumonia in both serotype 2 and 3 pneumococcus, with significant differences 
seen between wild type strains and their isogenic mutants in both survival and bacteraemia. 
Prior to intranasal challenge, our laboratory and other groups routinely use i.p. passage to obtain 
a standard inoculum of bacteria that has been prepared directly from the blood of infected mice. 
This increases the virulence of the bacterial strains such that subsequent intranasal challenge 
with a suitable dose of standard inoculum (determined experimentally) will generally result in 
bacteraemia and mortality in all mice challenged intranasally within 48-60 hr post infection. 
However, the D39 and its isogenic /).rr09 mutant used for analysis in the previous chapter were 
not passaged prior to challenge due to the inability to isolate /).rr09 from the blood of mice after 
i.p. injection and the less virulent glycerol stock preparation was used. To compensate for this, 
the dose administered by all routes of infection was increased 10-fold to that usually used in our 
laboratory for D39 standard inoculum challenges. Despite this dose increase, 40 % of mice 
challenged both i.n. and i.v. with wild-type D39 survived the course of infection. This illustrates 
the importance of passaging S. pneul110niae prior to experiments using our model of infection. 
Several studies have examined gene or protein expression following murine peritoneal culture 
with S. pneu71loniae. One study used a type 3 pneumococcus (strain WU2) to demonstrate that 
i.p. culture resulted in increased gene transcripts for pneumolysin and an enzyme involved in 
capsule biosynthesis compared to in vitro growth (Orihuela et at., 2000). Both of these are 
known pneumococcal virulence factors. 2D gel electrophoresis also identified many proteins that 
were unique to in vivo conditions (Orihuela et at., 2000). A second study used quantitative RT-
PCR to compare mRNA levels of 5 known pneumococcal virulence factors (pneumolysin, PspA, 
PsaA, CbpA and capsule genes) from type 2 strains harvested from the blood of infected mice 
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(i.p.) with strains grown in vitro. All virulence factors had increased expression in vivo with the 
exception of CbpA (Ogunniyi et ai., 2002). CbpA is thought to be important in adhesion 
(Rosenow et ai., 1997) so expression of this gene may not be altered following i.p. challenge but 
may be expected to increase should a colonisation model of infection be used. 
The use of non-passaged bacterial stocks for the determination of virulence of certain mutants 
may also have its advantages, as passaging may allow the role of the mutated gene to be 
compensated for by other bacteria factors. For example, with TCS mutants, cross regulation may 
occur and other systems may be able to take over the role of the absent component during 
passage. However, as demonstrated in this work, large bacterial challenge doses may have to be 
given to obtain satisfactory wild-type infection against which mutants can be compared. 
Bacterial loads in the lung tissue following intranasal challenge were determined to see if mutant 
strains were impaired in their ability to grow in the lungs. Significant differences were seen 
between the counts ofD39 and the LJrr09 mutant at 24 hours and 48 hours post challenge, where 
the lung tissue of mice challenged with the I1rr09 mutant failed to yield detectable bacterial 
counts. Nevertheless, bacterial counts in the lung tissue of mice challenged with wild-type D39 
were very low compared to the counts seen using standard inoculum D39 stocks (chapter 7, 
section 7.3.1.3) or the counts seen for the type 3 strains. Again, this is likely to be due to the 
absence of passaging prior to challenge. Furthermore, the median counts in the lungs of mice 
challenged with type 2 D39 wild-type bacteria decrease between 24 and 48 hr, whereas median 
counts in the lungs of mice following challenge with type 3 wild-type 0100993 increase between 
24 and 48 hr. This indicates differences in growth kinetics between the strains used and requires 
further investigation. As the lung environment is one of the first to be encountered by bacteria 
administered to mice intranasally, the inability to detect the I1rr09 mutant in lung tissue may 
indicate clearance by defence mechanisms within this environment. Thus assays could be set up 
to compare the efficiency of alveolar macrophages at phagocytosing both D39 and I1rr09 mutant 
strains, or to evaluate the cytokine profile of these macrophages following stimulation with 
bacterial strains. However, the I1rr09 mutant is also unable to survive following direct 
inoculation into the bloodstream, suggesting a mechanism of host clearance that is not specific to 
the lungs. 
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No significant difference was seen in the lung counts of mice challenged i.n. with type 3 strains. 
This suggests that rr09 null mutants in a type 2 background are unable to colonise lung tissue of 
MF1 mice, while mutants in a type 3 background are not impaired in their ability to grow in the 
lungs. The data using type 3 pneumococcus is in agreement with that of Throup and colleagues, 
who examined lung counts at 48 hours post infection, using the same type 3 strains but in the 
CBAlJ inbred strain of mouse (Throup et at., 2000). This group found a reduction in bacterial 
counts in the lung 48 hour post challenge with the J488 mutant compared to isogenic parental 
strain (approximately reduction of Log lO 1.5 CFU), but the difference was not statistically 
significant (Throup et at., 2000). In this work, a decrease in lung counts of approximately Log lO 
0.5 CFU was observed for the J488 mutant, and this was not statistically different from counts 
with wild-type. As the J488 mutant used in this work is the same strain used in the study by 
Throup and co-workers, the slight difference may be due to experimental variation or the use of a 
different murine model (see table 6.1). Indeed the mean lung counts at 48 hour post infection 
with the wild type strain, 0100993, which is also the same strain used by Throup and colleagues 
were approximately Log lO 2 CFU lower in this work compared to the published study. An 
attempt was made to repeat the lung count data using the CBAlJ strain of mice used by Throup 
and co-workers, but problems were encountered with the sterility of the lungs in these mice so 
work had to be abandoned (chapter 3, section 3.4.3). As no significant differences were seen in 
lung counts between type 3 wild-type and the J488 mutant, it may be useful to examine cytokine 
profiles in the lungs of infected mice to determine if there are any differences in host 
inflammation between strains. Nasopharyngeal colonisation and airway counts could also be 
determined for all strains using the MF1 model of infection. 
Intravenous injection of strains directly into the bloodstream was performed to assess the ability 
of the mutants to grow in the blood. This experiment suggested that the Jrr09 mutant in a 
serotype 2 background was unable to sustain itself in the blood, with bacterial counts falling to 
below the limit of detection within 8 hours of infection and remaining at this level throughout the 
course of the experiment. Subsequently, mice challenged intravenously with Jrr09 all survived, 
whilst 60 % of mice given parental D39 bacteria succumbed to infection. This difference in 
survival was statistically significant. Mice challenged with the type 3 mutant, J488 did not show 
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any statistical difference in survival or bacteraemia from those infected with wild type 0100993 
strain. 
Overall, the in vivo infections suggest that in our murine model of infection RR09 is important in 
virulence in both serotypes examined, but its role in virulence differs between serotypes/strains. 
In a type 2 background RR09 is essential for virulence with null mutants being unable to survive 
all routes of infection examined. These mutants are unable to grow in lung tissue and are cleared 
very rapidly from the blood. As these mutants are not impaired in their ability to grow in culture 
media in vitro, it appears that the loss of the RR09 protein is preventing survival in the blood and 
lungs. It has not been determined if this is due to an increased ability of the host immune system 
to clear mutant bacteria or the inability of the mutants to obtain essential nutrients and growth 
factors required for survival. Further experiments are required to determine this. Classical in 
vitro phagocyte killing assays could be used to determine if the mutants are more susceptible to 
phagocytosis. These assays use freshly isolated PMN cells, which are incubated with bacteria in 
the presence of complement. Following incubation, bacterial cell viability is analysed and the 
susceptibility of the pneumococci to phagocytosis determined (Jansen et at., 2001). Should 
increased levels of phagocytosis be shown for the I1rr09 mutant, Western blot could be used to 
compare the ability of wild-type and mutant strains to deposit host components that promote or 
inhibit opsonophagocytosis onto the bacterial cell surface. Such assays have been performed 
previously to demonstrate the binding of complement factor H and other components to the 
surface of bacteria (Janulczyk et at., 2000; Pandiripally et at., 2002). Alternatively, isolated 
whole human and / or murine blood could be used to determine if this supports the growth of the 
iJrr09 mutant. This could help determine if a component within the blood, or the lack of certain 
nutrients in the blood is preventing the growth of mutant strains, or if this growth defect is due to 
a host component not present in isolated blood. Similar experiments using whole sheep blood 
have been used to examine the virulence of a mutant in a S. suis response regulator, revS (de 
Greeff et at., 2002). Growth of the bacterial strains in nutrient deplete broth could help identify if 
wild-type D39 bacteria are able to grow more efficiently in such conditions compared to the 
iJrr09 mutant strain. This is discussed further with respect to the micro array data below. 
Loss of RR09 in a type 3 background does not result in a loss of virulence in an i.p. route of 
infection and mutants are not impaired in their ability to grow in the blood or within lung tissue. 
243 
Chapter 6 S. pneullloniae TCS09 Discussion 
However, following intranasal challenge much lower counts in the blood are observed compared 
to the parental strain and survival times of mice are increased. It thus appears that the 0100993 
mutant is impaired in its ability to disseminate from the lung tissue into the bloodstream or that 
transition from the lungs to the blood results in the mutants being less well adapted for survival. 
This could result from the inability to detect certain environmental signals that are required for 
the regulation of genes or sets of genes required for systemic virulence and survival following 
transition from the lung tissue into the blood. Certain aspects of the host immune system may be 
activated during this transition, via tissue damage or the inflammatory response, and the mutants 
may have impaired ability to resist such defence mechanisms compared to wild-type bacteria. 
Whatever the cause, the defect appears to be responsible for the lower levels of bacteraemia seen 
at the selected time points and subsequently the difference in survival time of mice following 
intranasal challenge. However, such mutants can induce mortality in 40 % of infected mice, 
albeit at a later stage. This suggests that if TCS09 is involved in dissemination from the lungs in 
serotype 3 pneumococcus and / or bloodstream survival, it is not the sole mediator of this process 
as rr09 null mutants can eventually gain access to the bloodstream, multiply and result in murine 
death. This could also indicate that another TCS could be compensating for the loss of rr09 in 
the mutant on a type 3 background. 
In an effort to identify possible differences in the mutants that could account for the altered 
virulence profiles seen, or to identify the role of RR09 in virulence, several aspects of virulence 
were studied experimentally. Firstly a haemolytic assay was performed to determine the presence 
of functional pneumolysin, an important pneumococcal virulence factor with multiple activities 
thought to be detrimental to the host (Mitchell and Andrew, 2000; Cockeran et at., 2002). No 
differences were seen in the in vitro haemolytic activities for any of the strains, although this 
does not allow us to make inferences to the situation during the infection process. This 
observation was also found when micro array analysis was used to compare the expression of 
several known virulence factors, including pneumolysin, between the mutant and wild-type 
strains (discussed later). 
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The ability to take up DNA from the extracellular environment is also thought to be important 
for virulence. This is highlighted by mutations in components of the competence TCS (ComD/E, 
TCS 12) being identified in several genome wide screens for virulence factors (Lau et al., 2000; 
Camilli and Hava, 2002). Thus the transformation efficiency of the Llrr09 mutants compared 
with their parental strains was examined. The Llrr09 mutant had a transformation efficiency 56 % 
that of D39 wild-type. Although this was not significantly different using a 2-sample t-test, 
Lange and colleagues (Hoffmann-La-Roche) found that a mutation in the rr09 gene in a serotype 
2 strain (R6) also had decreased transformation efficiency of 60 %, relative to the parental strain 
(R. Lange, personal communication). This consistency in reduced competence in the rr09 mutant 
in 2 different serotype 2 strains used in this work and an independent study may indicate that this 
is a phenotype to which further investigation could prove interesting. 
No difference in the transformation efficiency of the serotype 3 Ll488 mutant compared to its 
isogenic parental strain was observed, although the efficiency of both strains was extremely low 
compared to the type 2 strains. No data on transformation of this serotype is available from 
Lange and colleagues. Both type 3 strains had a decrease in mean transformation efficiency of 
greater than 100-fold, when compared to D3 9. This is likely to be related to the thickness of the 
capsule as serotype 3 pneumococci produce a thicker, more mucoid capsule generally not found 
in other serotypes (Yother et al., 1986). Thus a difference in transformation efficiency was found 
between serotypes. Although this may have an effect on virulence it unlikely to account for the 
completely avirulent phenotype of the Llrr09 mutant. 
The capsule has been recognised as an important virulence factor of S. pneumoniae for many 
years now, with un-encapsulated strains being avirulent in humans and the murine model. The 
exact contribution of the capsule to virulence is not fully understood, although it is thought to 
have a role in allowing organisms to avoid phagocytosis, possibly due to the highly charged 
surface. The ability of different capsule structures to avoid complement deposition on the 
bacterial cell surface has been alluded to previously (section 1.6.5, introduction). Serotype 3 
strains produce a much thicker capsule than type 2 strains, and this can be seen by growth on 
blood agar plates, with the former producing large, extremely mucoid colonies (Waite et al., 
2001). Thickness of the capsule may influence virulence to some extent but other factors are also 
important. For example serotypes 3 and 37 both have very thick capsules, but only the former is 
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virulent for both humans and laboratory animals (Paton et ai., 2000). Furthermore, the virulence 
of wild-type type 2 and type 3 standard inoculum preparations are very similar in our model of 
infection, using similar doses, suggesting that capsule composition differences should not 
account for the differences seen between the rr09 mutants of serotype 2 and 3. 
Although polysaccharide capsular material of most pneumococcal serotypes are generally 
thought to be innocuous and will not induce any inflammation or symptoms of disease if given as 
a cell-free preparation (Berry et ai., 1996), the capsules of both serotype 2 and serotype 3 
pneumococci have been shown to induce inflammation. This was shown in a study that measured 
leukocyte influx and protein concentration following intra-tracheal installation of capsular 
material into rabbits (Tuomanen et ai., 1987). 
In relation to the importance of capsule to pneumococcal infection it is possible that the iJrr09 
mutant could be producing less (or no capsule) capsule compared to wild type and this is 
reducing its virulence. The expression of several capsule-associated genes were compared in the 
iJrr09 mutant and D39 wild-type following micro array analysis (see table 5.5) and none were 
significantly different. However, this does not allow inferences to be made on the expression of 
such genes during in vivo infection. It is doubtful that this phenomenon is occurring in the iJ488 
mutant as the capsule of type 3 colonies is clearly visible when cultures are plated onto blood 
agar plates and a reduction in capsule of the type 3 mutant is not observed upon visual 
inspection. This does not, however, confirm that the amount of capsule in the type 3 strains is 
equal. Quellung reaction was performed on all strains to determine if a reduction in capsule 
could be detected, but results were hard to interpret, not reproducible and not quantitative (data 
not shown). A flow cytometry assay is thus being optimised to quantitate the amount of capsule 
present in pneumococcal strains. This procedure involves incubating pneumococcal cells with 
anti-capsular antibody and detecting bound antibody with a secondary antibody conjugated to 
FITC. Cells are sorted by F ACS® analysis to detect polysaccharide capsular material. Studies 
using this technique for the purpose of work presented in this thesis are still preliminary (data not 
shown), although cell sorting has been successfully used by other groups to serotype 
pneumococci (Park et ai., 2000). ELISA may also prove a useful technique for capsule 
quantification and has been used in a previous study for this purpose (Weiser et ai., 1994). 
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In a recently published STM screen, Hava and Camilli (2002) identified a rr09 mutant in a 
serotype 4 background as being highly attenuated in a pneumonia model based on counts within 
lung tissue 44 hours post challenge with 1 x 107 CFU. The same mutant was not highly 
attenuated in a model of bacteraemia on the basis of bacterial counts in the blood 20 hours post 
i.p. challenge (5 x 105 CFU). The challenge doses given in this study were representative of the 
doses used in our work, although Hava and Camilli used a different strain of mice (Swiss 
Webster) and a different pneumococcal serotype. The results of Hava and Camilli is in 
agreement with our findings that RR09 is important in the virulence of the pneumococcus, but its 
exact role in virulence depends on the genetic background of the parental strain and site of 
infection. 
The contribution of the capsule to pneumococcal infection has been studied for many years. 
Although it is generally accepted that virulence of pneumococcal strains in both human and 
mouse differs with capsular serotype (Briles et al., 1992; Kelly et al., 1994), the reasons for this 
are largely unknown. The biochemical composition of the capsule can affect phagocytosis and 
the production of antibodies, and thus can play a role in virulence of a given serotype. For 
example serotypes 3 and 4, which are often isolated from adult infections, are very resistant to 
phagocytosis yet highly immunogenic. In contrast serotypes 6A and 14 are easily phagocytosed 
but are not immunogenic (Hostetter, 2000). However, research by several groups has highlighted 
the importance of both the capsular serotype and the genetic background of the bacterial strain. 
Kelly and colleagues (Kelly et al., 1994) transformed strains of type 2, 5 and 6B pneumococcus 
with genes specific for type 3 capsule production. The resulting strains all grew as thick mucoid 
colonies, characteristic of type 3 pneumococcus, but were otherwise isogenic. The strains were 
analysed for virulence in murine models of infection. The original type 6B strain, which was 
relatively avirulent, increased in virulence when it was expressing the type 3 capsule. In contrast, 
the otherwise highly virulent serotype 5 strain became essentially avirulent with a type 3 capsule. 
Interestingly, the serotype 2 strain did not differ significantly in virulence when it was expressing 
a type 3 capsule. Although serotypes 2 and 3 generally behave very similarly in murine infection 
models, the structure of their capsules differ largely (Kelly et al., 1994). This indicates that 
capsule and genetic background play equally important roles in determining strain virulence. A 
second study found that not only were capsule type and background important in virulence, but 
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the site of infection also determined the virulence of strains (Kadiouglu et al., 2002). This study, 
by Kadioglu and colleagues, used the same serotype 2 pneumococcal strain (D39) as the 
previous study by Kelly and colleagues, and also made a chimeric mutant that expressed a type 3 
capsule. This chimeric mutant, however, was significantly less virulent than the D39 parental 
strain in nasopharyngeal colonisation and lung colonisation and was essentially avirulent with 
respect to survival of mice following intranasal infection. These data highlights that there is an 
optimal combination of capsule type with other factors. 
Very little data have been published highlighting differences m the role of pneumococcal 
virulence determinants in different strains or serotypes. CbpA of pneumococcal strain R6x was 
proposed to bind to the human polymeric immunoglobulin receptor and use this as a mechanism 
of translocation across the nasopharyngeal epithelium (Zhang et al., 2000). However the strain 
used in this study is an avirulent, non-encapsulated strain and a further study has shown that this 
binding effect was specific only to strain R6x when other non-encapsulated laboratory strains 
and encapsulated clinical isolates were examined (Brock et al., 2002). Tomasz and colleagues 
created mutants in the gene for the major autolysin gene, lytA, in serotypes 3 and 6 and found no 
difference in virulence for either mutant when compared to its parental strain (intraperitoneal 
challenge with 3 different challenge doses) (Tomasz et al., 1988). In contrast, another group also 
created a lytA mutant in a serotype 3 strain and showed a significant decrease in virulence 
following intraperitoneal challenge (Berry et al., 1992). The strain of type 3 pneumococcus used 
in both these studies was different, which could suggest that strain differences could exist 
alongside serotype differences. However, as the groups used different mutagenesis techniques 
and different strains of mice an accurate assessment of the reasons for the differences seen 
cannot be made. Thus the data presented in this thesis are the first study in a properly controlled 
manner, as far as we are aware, where the same mutation introduced into the same gene of two 
pneumococcal serotypes has resulted in large differences in virulence between the serotypes. 
PCR has been used to show that the rr091hk09 locus and surrounding genes have the same 
organisation in the strains used in this work to the sequenced strains, TIGR4 and R6. Although 
the serotype 3 sequence is not publicly available, the rr09 genes of strains R6, TIGR4 and G54 
are homologous, so this hypothesis assumes that the rr09 gene does not show significant 
sequence variation between type 2 and 3 and that this does not account for the differences in 
virulence. 
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The data presented in this thesis, combined with that of a recently published study (Hava and 
Camilli, 2002), strongly suggest differences in the way RR09 behaves in different pneumococcal 
strains/serotypes. These data highlight a crucial issue in terms of identification of putative 
vaccine candidates and drug targets, as a cellular component essential for virulence in one strain 
may not have such an important role in virulence in another strain. Additional investigations are 
required to examine the role of the capsule combined with other genetic factors when analysing 
the contribution of certain components to virulence. To characterise this further and determine if 
differences are serotype or strain specific, mutations in the rr09 genes of different serotypes and / 
or strains need to be created using the same mutagenesis techniques and subject to the same 
degree of comprehensive analysis in the same models of infection. Currently a rr09 mutation is 
being constructed in the TIGR4 (serotype 4) strain within our laboratory and will be used for in 
vivo analysis and micro array experiments. Sequencing of the rr09 genes in all the strains 
examined will ensure that any differences observed are due to the genetic background of the 
strains and not subtle differences in RR09 that could result in different functions. It would be 
interesting to create iJrr09 mutations in a D39 background but using a strain ofD39 that has been 
transformed with the capsule genes of strain 0100993. Such a technique has been used in a 
previous group as described above (Kelly et al., 1994), and mutants would easily be identified by 
the presence of a thick capsule which results in large, mucoid colonies on blood agar plates. 
Alternatively, the D39 iJrr09 mutation could be reverted / complemented with the wild-type rr09 
gene from D39 and 0100993 and virulence of the revertant assessed as described previously. 
Expression analysis using micro arrays with rr09 mutations in different strains / serotypes could 
produce data that may help explain the differences in the contribution of RR09 virulence 
between pneumococcal strains. This is explained in detail below. 
Table 6.1 summarises all in vivo analysis, including that from this thesis, available to date for the 
virulence of S. pneumoniae TCS09. 
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Reference Strain I serotype Mutagenesis 
of bacteria technique 
Lange etaI., Sp.1 (type 22) Insertion 
1999 duplication 
Lange et aI., Sp.1711 (type 3) Insertion 
1999 duplication 
Throup et aI., 0100993 (type 3) Allelic 
2000 replacement 
Hava and TIGR4 (type 4) STM 
Camilli, 2002 ( streptomycin-
resistant 
derivative) 
This work D39 (type 2) Allelic 
replacement 
This work 0100993 (type 3) Allelic 
replacement 
~ L--
Table 6.1 In vivo analysis of tcs09 mutants 
Legend on following page 
S. pneumoniae TCS09 Discussion 
Murine Strain Route of Inoculum Measure of virulence Role in Virulence 
infection 
C57BL6/J (I) i.p. (NP) 4 X 106 Mean survival time Fully virulent 
Females 
C57BL6/J (I) i.p. (NP) 1 X 103 Mean survival time Fully virulent 
Females 
CBAlJ (I) i.n. (NP) 1 x 10 Mean lung counts, 48 10-100 fold decrease in lung 
Males, 5 wk hr counts compared to WT, not 
statistically significant 
Swiss Webster (0) i.n. (NP) 2 x 107 Lung counts, 44 hr Highly attenuated in lung counts 
6-10 wk, males (competative index) 
i.p. (NP) 5 x 105 Bacteraemia, 20 hr Not attenuated in bacteraemia 
(competative index) 
MF1 (0) i.p. (NP) 1 X 105 Survival A virulent; all mice survived 
Females, 9-13 wk 
i.n. (NP) 1 x 107 Bacteraemia and A virulent; all mice survived, no 
survival bacteraemia 
i.n. (NP) 1 x 107 A virulent; no counts in lungs 24 
Lung counts hr and 48 hr 
i.v. (NP) 1 X 106 A virulent; all mice survived, no 
Bacteraemia and bacteraemia after 8 hr 
survival 
MF1 (0) i.p. (P) 1 X 105 Survival Fully virulent 
Females, 9 - 13 wk 
i.n. (P) 1 x 107 Bacteraemia and Attenuated in bacteraemia and 
survival survival 
i.n. (P) 1 x 107 Lung counts Fully virulent 
i.v. (P) 1 X 106 Bacteraemia and Fully virulent 
1-. 
survival 
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Table 6.1: In vivo analysis of tcs09 mutants 
The table summarises all in vivo work available to date with S. pneumoniae TCS09. (I) / (0) designates inbred or outbred strains of mice respectively. 
Route of challenge includes intranasal (i.n.), intraperitoneal (i.p.) or intravenous (i.v.). (NP) and (P) illustrate strains that are non-passaged or passaged, 
prior to challenge respectively. Role in virulence is compared to the parental wild-type strain. STM; signature tagged mutagenesis. The table is modified 
from that in the introduction (table 1.6) by the addition of work detailed in this thesis 
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6.3 Expression analysis 
mRNA expression profiles in D39 and iJrr09 only were compared using micro array analysis due 
to time restrictions. The hybridisations worked well and both array replicates identified the rr09 
gene as being significantly down-regulated / absent in the mutant compared to wild-type. Several 
other genes were expressed at significantly lower levels in the mutant. These clustered around 2 
different regions of the genome. The first region is associated with a bacterial phosphotransferase 
system (PTS). These sensory systems transport a large number of carbohydrates into cells with 
concomitant phosphorylation of substrate, and tend to be associated with fermentative organisms 
(Reizer, 1989). The PTS is a phosphorelay system where a phosphoryl group is transferred from 
phosphoenolpyruvate to the incoming sugar via a series of protein intermediates. At least 3 
proteins are required for the PTS systems, enzyme I (EI), histidine protein (HPr) and enzyme II 
(Ell). EI and HPr are usually soluble proteins that phosphorylate all PTS carbohydrates of an 
organism and only one of each of these enzymes is generally present in a bacterial cell (Postma 
et al., 1993). Substrate specificity of any particular chain resides in the membrane-associated Ell 
enzymes of which many different Ell are present in a bacterial cell. The Ell components may be 
present as a single membrane-bound protein with 3 domains (A, B and e) or as 2 or more 
proteins, at least one of which is membrane bound (EUB and ElIe) and one of which is soluble 
(EllA). Of the membrane bound domains, Eue is generally thought to be embedded within the 
membrane and Elm may be associated with the membrane but not embedded within it. EUD 
forms a second membrane bound protein component of some PTSs (Postma et al., 1993). It is a 
group of these EU enzymes that have significantly lower expression in the iJrr09 mutant 
compared to D39 wild-type. The sequencing project using the TIGR4 strain identified 21 PTS 
systems in S. pneumoniae which is more than twice as many as any other sequenced bacterium to 
date, relative to genome size (Tettelin et al., 2001). The authors of this published sequence 
annotated the PTS Ell enzymes showing lower expression in the iJrr09 mutant as belonging to a 
sorbose-family transport system (Tettelin et al., 2001, supplementary information). This was 
based on an identification alignment with a Klebsiella pneumoniae sorbose PTS system 
(Wehmeier and Lengeler, 1994). Sorbose, an intermediate of vitamin e, is a ketose sugar with 6 
carbon atoms and is a monosaccharide (Stryer, 1988). The Ell components of this particular 
pneumococcal PTS have homology to sorbose systems in other bacteria, including Lactobacillus 
casei and E. coli (from the 'gene versus alignment' tool at http://www.tigr.org/ website). 
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Furthennore, when the protein sequence of the PTSIIB component (sp0061) is subjected to a 
BLAST search (http://www.ncbi.nlm.nih.gov:80IBLASTI) which can identify conserved 
domains, it was identified as having a conserved sorbose domain. The PTSIIB component was 
the gene identified as having highly significantly reduced expression in the iJrr09 mutant 
compared to the isogenic D39 parental strain, as indicated in figure 5.17. The PTSIIB proteins of 
the sequenced R6 and TIGR4 strains show 99.4 % similarity and identity (http://www.tigr.org/). 
Following identification of decreased expression of this putative sorbose transport system a 
carbohydrate fennentation assay was used to detennine if the rr09 mutants in both serotype 2 
and 3 had reduced ability to fennent this sugar. Although most sugars occur naturally as the D-
isomer, the L- fonn of sorbose is transported and metabolised by K. pneumoniae and E. coli 
(W6hrl and Lengeler, 1990), although the reason for this is unknown. For this reason, both L-
and D-fonns of sorbose were included in the assay together with several other sugars, selected to 
represent monosaccharides, disaccharides and a trisaccharide. All strains, including the rr09 
mutants fennented all sugars to acid under anaerobic conditions with the exception of both 
sorbose isomers, which were not fennented by any of the strains, including wild-type D39 and 
0100993. There are several possible explanations for this. Firstly, sorbose fennentation may be 
specific to certain strains and absent in the 2 strains used for this work. Indeed, although all 
strains of K. pneumoniae have been found to transport sorbose, only 30 % of E. coli strains can 
transport this sugar (W6hrl and Lengeler, 1990). This could be tested by subjecting a range of 
pneumococcal strains, including the sequenced TIGR4, to the sorbose utilisation assay. The 
media and growth conditions used can also affect bacterial metabolism (Neijssel et ai., 1997), so 
the strains could be tested using several different culture media fonnulations and using different 
growth conditions, such as pH. Should these assays indicate that none of the strains tested 
fennent sorbose then it could be possible that sorbose is transported but not fennented in S. 
pneumoniae. This could be tested by radiolabelled-sorbose uptake assays. Fennentation of sugars 
by streptococci will only occur in anaerobic conditions (Neijssel et ai., 1997) and presumably the 
pneumococcus will encounter aerobic environments during infection so other sugars may be 
taken up by PTS but not fennented. As more data becomes available on bacterial PTSs, it is clear 
that they may have roles distinct from sugar transport, including gene regulation so it is possible 
that the role of this specific PTS system in S. pneumoniae is not solely as a sugar transporter. 
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Alternatively, the identified PTS may function as a sugar transporter but for a sugar other than 
sorbose. Indeed, the PTSIIB component (sp0061) of S pneumoniae also shows identity to non-
sorbose PTS systems, including a mannose-specific PTS in E. faecalis and a fructose-specific 
transporter in L. monocytogenes (BLAST alignment tool, http://www.ncbi.nlm.nih.Gov:80/ 
BLAST/). Although annotated by TIGR as being part of the PTS-sorbose subfamily, this family 
is also known as the mannose/fructose/sorbose family as its permease members exhibit broad 
specificity for a range of sugars including mannose, fructose, sorbose and N-acetylglucosamine 
(http://www.togr.org/tigr-scripts/CMR2/). Of these sugars, all pneumococcal strains used in this 
work have been shown to ferment mannose. The remaining sugars, together with other sugars not 
previously tested could be assayed using the carbohydrate assay described above to determine if 
this system is involved in transport of alternative sugars. It is possible that TCS09 could be 
involved in nutrient perception as Lange and colleagues found that the HK09 sensing domain is 
related to the extracellular regions of the B. subtilis McpA and McpB proteins (Lange et ai., 
1999). These proteins are involved in the control of chemotaxis via sensing environmental 
nutrient concentration (Garrity et ai., 1998). Indeed, of the 3 upper respiratory tract pathogens for 
which genome sequences have been published (S pneumoniae, H injluenzae and N. 
meningitidis), S pneumoniae has the widest substrate utilisation range for sugars (Tettelin et ai., 
2001). Over 30 % of the pneumococcal transporters are thought to be for sugars, representing the 
highest percentage observed to date in any sequenced prokaryote (Tettelin et ai., 2001). It would 
not be surprising to find that genes required for nutrient acquisition were under the control of 
bacterial TCS as nutrient uptake places a huge metabolic burden on bacterial cells (Neijssel et 
ai., 1997). Thus, expression of genes required for nutrient acquisition is likely to be tightly 
regulated. Infection at different sites may require that bacteria can utilise a range of 
carbohydrates depending on the availability, and streptococci are known to exhibit metabolic 
flexibility (Neijssel et ai., 1997). TCS could be involved in sensing nutrient availability at 
various sites of infection. Furthermore, if TCS09 is involved in nutrient perception, then the 
differences presented between the in vivo role of the RR09 protein in type 2 and type 3 could be 
attributed to different nutrient requirements between strains I serotypes. Synthesis of the 
polysaccharide capsule may require uptake of different sugars. Indeed the capsules of type 2 and 
type 3 pneumococci are composed of different sugars, D-glucuronic acid, D-glucose and L-
rhamnose for type 2 (lanelli et ai., 1999) and cellobiuronic acid (a disaccharide of D-glucuronic 
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acid and D-glucose) for type 3 (Garcia et at., 2000). Thus these sugars are obvious candidates for 
the carbohydrate fermentation assay. Alternatively, the structure or thickness of the capsule may 
inhibit the uptake of some sugars. Further work needs to be carried out to determine which 
sugars, if any, the PTS system described transports and if such sugars, or products of these, are 
related to the sugars required for capsule synthesis of the individual strains. It could also be 
possible that in conditions of severe nutrient deprivation, the bacteria could use their own 
capsule polysaccharide as a carbohydrate source, and that the TCS could control this function to 
prevent it become disadvantageous to the bacterial cell. In this situation, a thicker capsule may 
confer an advantage on the invading organism, and could be an explanation for the ability of the 
rr09 mutant in a serotype 3 strain to be more virulent than a serotype 2 mutant due to the thicker 
capsule of the former. Creating null mutations in the pneumococcal PTSIIB (sp0061) component 
(or other Ell PTS components) and comparing the effect of these in different serotypes could 
provide important data to analyse the effect of nutrient acquisition between pneumococcal 
serotypes, if this is indeed the reason for the differences seen in virulence between type 2 and 
type 3. 
Incorrect annotation may also explain the reason that a PTS system in S. pneumoniae has been 
identified as a sorbose uptake system if the bacteria does not ferment sorbose. Such mistakes are 
known to occur, such an example being in S. suis whereby a conserved hypothetical protein had 
homology with a protein in Pseudomonas aeruginosa that was annotated as a macrophage 
infectivity potentiator (mip). However, the P. aeruginosa 'mip' protein was found to be very 
distinct from other, better characterised mip proteins and thus appears to be mis-annotated (King 
et at., 2001). This highlights the caution that must be involved when identifying unknown 
sequences on previously annotated proteins. 
It is intriguing why a putative sorbose uptake system would be expressed during growth of wild-
type bacteria in BHI. The expression of this system was thus compared with expression of other 
PTS. Of 21 individual PTS examined, only 6 had expression levels above the set threshold limit 
of 500, 2 of which had expression intensities of <1 000. This observation is intriguing as the BHI 
medium used to grow the bacteria used for expression analysis contains glucose (0.2 %, see 
appendix). As a glucose-specific PTS is expressed by D39 during in vitro growth, the function of 
the remaining PTS is unknown. Similarily, of the 4 PTS with mean expression intensities of 
>500, the sorbose-family PTS identified in this work as being significantly down-regulated in the 
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iJrr09 mutant, had the highest expression. This is further evidence that it could transport sugars 
other than sorbose or has an entirely different role in bacterial cell function. None of the 6 PTS 
that were expressed during in vitro growth in BHI were identified as being essential 
pneumococcal genes in a recent study by Thanassi and co-workers (Thanassi et al., 2002). This 
study used a bioinformatics approach to identify pneumococcal genes that had 40 % global 
amino acid sequence identity with genes of several other pathogens, on the basis that such genes 
could be targeted for broad-spectrum anti-microbial therapy. All candidate genes were mutated 
and 113 essential genes were subsequently identified (Thanassi et al., 2002). However, this study 
did not aim to identify all essential genes in the pneumococcal genome, only those that were 
conserved between certain bacterial species, so some of the PTS described above may be 
essential for growth and this would require further investigation. 
Given the apparent importance of sugar utilisation in S. pneumoniae discussed above, it is 
possible that pneumococcal PTS could become the target of future therapies or vaccines. 
Although many individual PTS have been identified, there is only one copy of the EI and HPr 
genes (Tettelin et al., 2001). As these proteins perform roles central to and essential for all of the 
pneumococcal PTS, it would be interesting to create null mutations in either of, or both of these 
genes for further in vivo analysis. Furthermore, this work could have significance for other 
bacterial pathogens. Several of the pneumococcal PTS have been identified in genome-wide 
approaches for the identification of virulence factors, illustrating that they are important in 
infection (Polissi et al., 1998; Lau et al., 2001; Marra et al., 2002; Hava and Camilli, 2002). 
Indeed, a study using STM to identify S. pneumoniae virulence factors in a type 4 strain pulled 
out components of 8 different sugar PTS, where mutations in such systems were highly 
attenuated in lung infections, including the ElID component of the sorbose-family PTS discussed 
above (Hava and Camilli, 2002). 
Immediately upstream of the PTS Ell components that were all down-regulated in the iJrr09 
mutant is a gene encoding p-galactosidase, an enzyme often involved in breaking down lactose. 
The expression of this gene was decreased in the iJrr09 mutant compared to the D39 parental 
strain. The association of the fJ-galactosidase gene with the described PTS system is unknown, 
as none of the BLAST alignments of the PTSIIB component (sp0061) had homology to systems 
involved in lactose transport. However, the fJ-galactosidase and ptsIIB genes overlap, indicating 
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that they may form a single transcriptional unit and thus may have related functions. Within the 
R6 and TIGR4 genomes, 2 ~-galactosidase genes have been identified, together with 2 6-
phospho-~-galactosidase genes (table 6.2)(http://www.tigr.org/). The latter enzymes are likely to 
be responsible for cleaving intracellular lactose-6-phosphate and are both located next to putative 
lactose PTSs. The ~-galactosidase genes are also located close to putative PTS (of which the 
sorbose-family PTS described above is one), although the specific sugars associated with these 
systems is yet to be determined. Table 6.2 illustrates the ~-galactosidase and 6-phospho-~­
galactosidase genes found in the sequenced, annotated genomes. As demonstrated in the table, 
the corresponding genes between the different genomes are at least 99 % homologous. However, 
the 2 individual ~-galactosidase genes within each genome do not show any significant 
homology to each other, while the 2 individual 6-phospho-~-galactosidase genes within each 
genome are approximately 47 % identical (68 % similar). 
This thesis has identified sp0060 (R6 spr0059), one of the genes annotated as a ~-galactosidase, 
as having lower expression in the iJrr09 mutant. However, the function of this gene as a true ~­
galactosidase can be questioned based on a study by Zahner and Hakenbeck (Zahner and 
Hakenbeck, 2000). This study created a disruption within the larger ~-galactosidase gene (R6 
spr0565) in strain R6 using allelic replacement, and found that this resulted in a complete loss of 
~-galactosidase activity (Zahner and Hakenbeck, 2000). Surprisingly this gene did not appear to 
be involved in lactose metabolism as growth of the mutant in defined media containing lactose as 
the only carbon source did not result in decreased generation time compared to the parental wild-
type strain (Zahner and Hakenbeck, 2000). As gene spr0565 has a LPXTG motif, used for 
anchoring many Gram positive proteins to the cell surface, it was proposed that this enzyme has 
a role in interactions with host cells rather than for lactose metabolism. Indeed ~-galactosidases 
are able to cleave ~-1 ,4-glycosidic bonds and Gal~ 1-4GlcNAc bonds which are present within 
many polysaccharides on the surface of eukaryote cells (Zeleny et at., 1997). Cleavage of such 
bonds may release sugars for further utilisation by the bacteria. The lack of homology between 
the 2 annotated ~-galactosidases genes of R6 indicates that the study by Zahner and Hakenbeck 
would indeed have disrupted the larger gene only, without having any effect on the ~­
galactosidase gene identified within this work. This indicates that the smaller ~-galactosidase 
gene identified in this work may not have ~-galactosidase activity. However, assay conditions 
used to detect ~-galactosidase activity could affect the ability to detect other ~-galactosidases that 
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may have, for example, different optimum pH for activity, and modification of the assay may 
indeed allow ~-galactosidase activity of other genes to be analysed. Indeed, a second 
neuraminidase enzyme (NanB) present in the pneumococcus was identified and found to 
function at a different pH optimum to that of the known, previously characterised neuraminidase 
(NanA) (Berry et at., 1996). A null mutation in NanA resulted in apparent complete loss of 
neuramidase activity pH6.5, but when the pH was lowered to 4.5, neuraminidase activity due to 
NanB could be detected (Berry et at., 1996). Assays are available to test for both ~-galactosidase 
and phospho-~-galactosidase activity (Zahner and Hakenbeck, 2000 and Chen et at., 2002 
respectively). Mutations in the 4 ~-galactosidase-associated genes could thus be created and 
individual mutants analysed for their ability to cleave the substrates for the respective enzymes, 
using several different assay conditions. This could help determine the role of the putative ~­
galactosidase gene identified in this work. Alternatively, the ability of the ilrr09 mutant to cleave 
the ~-galactosidase substrate 5-bromo-4-chloro-3-indolyl-~-D-galactopyranoside (X-gal) from a 
colourless substrate to a blue product could be compared to that of the isogenic parental strain, 
D39 (Nicholl, 1994). 
The larger ~-galactosidase gene, Spr0565 has an LPXTG motif, and this cell-surface anchor 
motif is absent in spr0059 / sp0060. Thus it may be possible that there are 2 functional ~­
galactosidase genes, one functioning outside the cell and the other acting intracellularly, and that 
the study by Zahner and Hakenbeck only detected activity of the former. Alternatively, the 
smaller spr0059 / sp0060 gene may be mis-annotated and could have other functions that mayor 
may not be related to sugar uptake and utilisation. This concept could be investigated further by 
using mutations in the assays described above. 
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R6 genome Homology between TIGR 4 genome 
Name Gene Common Length corresponding R6 / Name Gene Common Length 
symbol name of TIGR4 gene symbol name of 
protein identity (similarity) protein 
(aa) (aa) 
Spr0059 bga beta- 595 99.3 % (99.7 %) Sp0060 bga beta- 595 
galactosidase galactosidase 
Spr0565 bgaA beta- 2228 98.2 % (99.2 %) Sp0648 bgaA beta- 2233 
galactosidase galactosidase 
Spr0424 lacG 6-phospho- 470 99.8 % (99.8 %) Sp0477 lacG 6-phospho- 470 
beta- beta-
galactosidase galactosidase 
Sprl069 lacG 6-phospho- 468 98.9 % (99.6) Sp1l84 lacG 6-phospho- 468 
beta- beta-
galactosidase galactosidase 
--
Table 6.2 l3-galactosidase-associated genes in R6 and TIGR4 genomes 
Each of the sequenced genomes possess 2 genes annotated as ~-galactosidase and 2 genes annotated as 6-phospho-~-galactosidase. The latter gene 
products are likely to use phosphorylated lactose as their substrate and are located close to lactose-specific PTSs. The function of the ~-galactosidase 
genes has not been fully determined, although the larger gene (spr0565 / sp0648) has been proposed to act on the cell surface to cleave host sugars 
(Zahner and Hakenbeck, 2000). The corresponding genes between genomes are highly homologous (>99 %). 
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Immediately downstream of the pts genes are 2 enzymes, isomerase and aldose-l-epimerase that 
also show reduced expression in the ilrr09 mutant. Isomerases catalyse isomerisations / 
intramolecular rearrangements and this group of enzymes includes epimerases. All genes 
discussed so far are located in relative close proximity to each other suggesting that they may 
form an operon or functional unit. Furthermore, a rho-independent transcription termination site 
was not identified in the region comprising any of the described genes, providing further 
evidence that the genes form an operon (see figure 5.18). If the genes do form an operon, the 
different levels of expression of the genes within this operon seen with both D39 wild-type and 
the mutant strain could indicate post-transcriptional regulation or the presence of rho-dependent 
transcriptional terminator sites between the genes. Although annotated as a sorbose system, 
sorbose is a ketose sugar (has a ketone group in its structure) and the epimerase within this 
cluster of genes is annotated as an aldose-l-epimerase, indicating that it is specific for aldose 
sugars (which contain an aldehyde group in their structure). This provides further evidence 
suggesting that this PTS is involved in the transport of a sugar other than sorbose. Furthermore, 
as discussed above, the link with fJ-galactosidase is intriguing. As the phospho-~-galactosidase 
genes are found close to lactose PTSs, it is unlikely that a third uptake system for lactose exists 
in the genome. Lactose is a disaccharide of galactose and glucose, both of which are aldose 
sugars and both of which were fermented by all the strains used within this work. The sugar that 
is transported and metabolised by these genes therefore remains to be determined. 
The second cluster of genes identified as having lower expression in the ilrr09 mutant 1(spJ800-
spJ805) do not have known functions, with the exception of one, spJ804, which has been 
annotated as a putative stress-related protein (http://www.tigr.org/).This annotation is based on 
some homology with general stress proteins in several other bacteria, although the type of stress 
to which these proteins respond has not been identified. The TIGR4 spJ804 gene is 100 % 
homologous to the equivalent gene in R6. Genes upstream of spJ800 did not appear to be related 
to this cluster and had normal expression levels in the mutant. Downstream genes spJ806-spJ808 
had expression levels in both strains that were too low to be analysed. As for the pts-related 
genes, all of the above genes are situated within close proximity of each other on the 
chromosome, although none of the coding regions overlap. However, only one rho-independent 
I See footnote p217 
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transcription terminator was identified within this set of genes, and was located in the region 
downstream of sp0085. This indicates that the genes may indeed form an operon. As with the 
sorbose PTS-related genes described above, if the genes do form an operon, the different levels 
of expression of the genes within this operon seen with both D39 wild-type and the mutant strain 
(figure 5.21) could indicate post-transcriptional regulation or the presence of rho-dependent 
transcriptional terminator sites between the genes. All genes are encoded on the coding strand, 
with the exception of sp1800, a transcriptional activator, which is found on the complementary 
strand (figure 5.19). This does not, however, exclude the possibility that this activator is involved 
in regulating genes sp1801-1805, as a regulator in the pneumococcus termed RirA has recently 
been shown to regulate 6 divergently transcribed genes (Hava and Camilli, 2002). 
Reduced expression of the genes discussed does not prove that such genes are directly regulated 
by TCS09. It is likely that some genes could be affected indirectly through other regulatory 
networks. Indeed, varying levels of expression of genes that could form an operon and be 
transcribed together (figure 5.21) could indicate a role for TCS09 in post-transcriptional 
regulation of certain genes. DNase I footprinting could be used to identify promoter regions to 
which the active RR09 binds. This technique is used to characterise the targets of sequence-
specific DNA-binding proteins (Galas et al., 1978). Labelled DNA containing a potential binding 
site is mixed with the purified protein or the protein's DNA binding region, and the complex is 
then treated with DNase 1. When compared with a control reaction, target sites on the DNA to 
which the protein has bound will be protected from DNaseI treatment. These sites can be 
identified with subsequent sequence determination. This method has successfully been applied to 
other bacterial TCSs to identify potential regulator-binding sites (Bemish and van de Rijn, 1999; 
Kovacikova and Skorupski, 2001; Dietz et al., 2002), although it depends on the response 
regulator being in its phosphorylated form. If applied to S. pneul110niae RR09, resulting data 
could be used to determine which of the identified genes or sets of genes are controlled directly 
by TCS09. Should a promoter sequence to which RR09 binds to be identified, then this sequence 
can be used to search the genome for other genes potentially regulated by the system that may 
not identified by micro array analysis. 
The array analysis was performed using only one RNA preparation taken from a single time 
point during in vitro growth. Thus, the array work needs to be repeated in duplicate at least one 
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further time using a different RNA preparation, but from the same stage of bacterial growth to 
confirm the data discussed above. Furthermore, the genes discussed above do not provide an 
exhaustive list of all of the genes potentially regulated by S. pneumoniae TCS09 in strain D39 
due to expression analysis using a single time point only. During in vitro growth alone, different 
sets of genes are regulated at different stages of growth and the growth conditions are also likely 
to affect gene expression. Indeed, a study using E. coli estimated that 200 genes are induced 
upon entry into stationary phase during in vitro culture (Tani et al., 2002). During in vivo 
infection, gene expression profiles are likely to change rapidly and frequently as the bacteria 
encounter many different and mixed environmental signals. As an infection progresses, the host 
immune response at various sites of infection will change over time and this is also likely to alter 
bacterial gene expression. It would thus be ideal to compare gene expression in pneumococcal 
strains isolated from different sites of murine infection over a series of time points using TCS 
mutants, as this could help identify differential regulation of virulence-associated genes by TCSs. 
However, several problems may be encountered during such a study. Firstly it is difficult, 
although not impossible, to isolate sufficient concentrations of RNA from in vivo samples for 
microarray analysis. The isolated sample must contain high bacterial loads be processed rapidly 
to prevent significant alteration of bacterial mRNA transcripts. Biological systems are also 
extremely variable so RNA preparations from several animal models must be compared for each 
time point examined with each individual tissue specimen to allow for variation. Problems will 
be encountered where it is desirable to compare gene expression levels in a mutant impaired in 
virulence with its isogenic parental strain, as it will be difficult to isolate sufficient RNA from 
tissue samples containing mutant bacteria due to significantly lower bacterial counts. This is 
highlighted by the in vivo data described for the iJrr09 mutant, where bacterial load in all tissues 
following several routes of infection was generally so low that it was barely detectable. Finally, 
being a human pathogen, many of the environmental signals that are sensed by pneumococcal 
and other bacteria TCSs may be specific to the human host. Therefore, the use of murine models 
of infection may never reveal some of the more important genes regulated by such systems. 
With respect to the decrease in transformation efficiency of the iJrr09 mutant compared to D39 
wild-type, micro array analysis did not reveal any genes involved in competence that had reduced 
expression in the mutant. As expected for the stage of growth from which RNA was isolated, the 
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TCS system largely associated with development of competence (ComD/E) had very low 
expression intensities «200), so could not be analysed. One possible way of investigating gene 
expression differences related to transformation efficiency would be to grow cultures in the 
presence of CSP 1 to induce the genes involved in competence and compare expression of 
competence-related genes in the mutant and wild type. 
Expression data for all of the pneumococcal response regulator genes was included in the 
micro array analysis. None of these genes showed decreased expression in the i1rr09 mutant 
compared to D39 wild-type, indicating that under the conditions used, RR09 does not regulate 
any of the other systems, or if it does, its function can be taken over by another system. A ratio 
of >1.0 was found for the expression ofrr14 in the i1rr09 mutant compared to D39, indicating 
that this response regulator could be up-regulated in the mutant. This increase was statistically 
significant (P<0.05). The expression intensity of this gene, however, was not found to be 
significantly different to that of wild-type. To determine if the differences seen with rr 14 are 
genuine or due to experimental variation, these experiments need to be repeated. 
Figure 5.23 compares the expression intensities of all response regulator genes in both D39 and 
i1rr09. Genes for rr02 and rr05 resulted in very high mean expression intensities indicating that 
the genes are required in high concentrations for cell function, at least during in vitro growth. 
TCS02 has already been identified as being essential for S. pneumoniae viability (Lange et at., 
1999; Throup et at., 2002; Wagner et at., 2002) and homologues of this system in other bacteria 
are also essential (Fabret and Hoch, 1998; Martin et at., 1999). The multifunctional role of 
TCS05/CiaRH has been discussed previously (introduction, section 1.14.3). Many of the 
response regulator genes had intensities that were below the set threshold limit. Whether these 
represent systems that genuinely do have very low expression in pneumococcal growth in culture 
media or whether the RNA isolated for these systems was of poor quality or was rapidly 
degraded is not known. One of the TCS for which expression could not be detected is TCS 12 I 
ComD/E involved in transformation. It is of interest that TCS05 I CiaRIH, which negatively 
regulates the comC/D/E operon (Echenique et at., 2000), has very high expression when 
expression of the comD/E system is too low to detect. Thus comparison of expression levels of 
these two systems following treatment of cultures with CSP-1, which induces expression of the 
comD/E system, would be expected to result in increased expression of the ComD/E system and 
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possibly reduced expreSSIOn of the CiaRIH system. However, caution must be taken when 
comparing expression levels of different genes, as different probe lengths combined with 
problems encountered in direct labelling with Cy dyes may result in inaccurate data 
interpretation. Problems associated with isolation / detection of RNA transcripts and comparing 
expression intensities in micro array analysis are discussed below. 
As the ilrr09 mutant was completely avirulent following all routes of infection, the expression of 
7 known virulence factors, together with several capsule-related genes, was compared between 
the wild-type and mutant strains. None of the genes had reduced expression in the mutant 
compared to D39 wild-type (table 5.5). The genes for the major autolysin, LytA, and 
pneumolysin had the greatest levels of expression, which may be expected as the RNA analysis 
was performed on cultures in mid-late exponential phase, where the autolysin is known to 
become active and lyse cells, releasing the toxin pneumolysin. At least 9 capsule-associated 
genes were compared but only 3 of these had expression intensities above the set threshold limit 
of detection (500). One of these capsule-associated genes is a UDP-glucose dehydrogenase and 
the remaining 2 are dTDP-rhamnose biosynthesis genes (rhamnose is one of the 3 sugars 
required for type 2 capsule biosynthesis) (Ianelli et at., 1999). The finding that a completely 
avirulent phenotype is not associated with decreased expression of many of the main 
pneumococcal virulence factors identified to date, illustrates the complex nature of virulence in 
this pathogen and highlights that there are important S. pneumoniae virulence factors still to be 
characterised. Expression of one virulence factor, PspC (also known as CbpA, Hic, SpsA and 
PbcA), was shown to be significantly increased in the ilrr09 mutant compared to D39 wild-type. 
This pneumococcal surface protein has several properties thought to be important in virulence. It 
is an adhesin and promotes invasion of epithelial cells (Rosenow et at., 1997; Zhang et at., 
2000), can bind components of complement, including factor H (Janulczyk et at., 2000; Dave et 
at., 2001; Duthy et at., 2002), binds the secretory component of IgA (Hammerschmidt et at., 
1997) and has been shown to be a good vaccine candidate (Briles et at., 2000). Furthermore, 
PspC is one of the few pneumococcal genes that displays extensive sequence variation between 
serotypes (Ianelli et at., 2002). The significance of the up-regulation of this important virulence 
gene in the ilrr09 mutant, which is completely avirulent, is not understood and needs to be 
characterised further. Further micro array work with the ilrr09 mutant should help determine if 
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this observation is a true result of the null mutation in rr09. Microarray analysis with mutations 
in the rr09 gene in other serotypes would be useful to determine if this increased expression of 
PspC is specific to certain pneumococcal strains / serotypes. Furthermore, PspC was not 
identified as being significantly up-regulated in the Llrr09 mutant by examination of the 
Genespring™ scatterplot, and this indicates that analysis of gene expression with micro arrays 
should not depend on one method of analysis and that caution must be taken when presenting 
data from such work. 
A more detailed study based upon micro array analysis is required to enable a full discussion of 
the genes regulated by TCS09 and to correlate these with the role of the system in virulence. The 
experiments done with D39 and the Llrr09 mutant must be repeated to ensure that the genes 
described above are significantly and consistently down regulated in the mutant. Experiments 
must be repeated using RNA isolated under the same conditions from the type 3 strains, 0100993 
and Ll488. Should any differences in gene expression be found between Llrr09 and Ll488, this 
could provide important clues as to why the RR09 proteins in type 2 and type 3 pneumococci 
have different roles in virulence in our model of infection. Examination of mutations in rr09 
genes of other strains / serotypes using in vivo characterisation combined with expression 
analysis may provide further insight into the role of TCS09. Following detailed analysis, genes 
of interest must be investigated further by RT-PCR, Northern blot and / or real time-RT-PCR. 
Indeed, one study has shown that TaqMan RT-PCR (real-time RT-PCR) was more efficient than 
micro arrays at detecting low-abundance transcripts (Graham et at., 2002). Where possible, 
functional assays should be performed as gene transcription does not necessarily correlate with 
protein expression. A study by Kothapalli and colleagues, examining gene expression III 
leukaemia patients, found that 3 genes of interest that were down-regulated according to 
micro array analysis could not be confirmed as having differential expression by Northern blot. 
Similarly, analysis of the up-regulated genes in leukaemia patients compared to healthy controls 
found that only 47 % of those identified by micro array experiments could be confirmed by 
Northern blot (Kothapalli et at., 2002). This study highlights the importance of clarifying all data 
obtained through microarray work. The carbohydrate utilisation and p-galactosidase assays 
described above are examples where altered levels of gene transcripts may be correlated with 
functional protein expression. 
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The mIcro array analysis discussed above was very preliminary and the need for repeat 
experiments has been highlighted. Despite this, several issues regarding microarray analysis 
should be discussed so that future work can be interpreted correctly. Although the hybridisations 
worked well, many gene spots on the array did not show up. The exact number of genes absent 
following hydridisation was not accurately determined, but a visual inspection indicated at least 
10 % of genes were missing. This could indicate a genuine absence of expression under the 
conditions used, or could be due to several other causes. For example, the loss of gene transcripts 
during RNA isolation, the detection limit of the arrays or the failure of certain probes to detect 
cDNA transcripts. Bacterial mRNA is generally regarded to be less stable that eukaryotic RNA 
so samples must be processed rapidly during RNA preparations to prevent degradation of 
transcripts. This procedure is further complicated by the thick cell wall of bacteria, especially 
Gram-positive species, such as S. pneumoniae that must be disrupted by rigorous vortexing or 
under high pressure in the presence of lysozyme. Several commercially available reagents have 
been developed to help 'protect' RNA immediately upon harvesting cells, but use of one of these 
reagents was found to significantly reduce the RNA yield obtained. To try and overcome this, 
cell cultures were flash frozen in liquid nitrogen prior to RNA isolation. 
High density oligonucleotide arrays have the ability to detect gene transcripts as low as one copy 
(Lockhart and Winzeler, 2000). The array probes used for this thesis were obtained by spotting 
PCR products onto a microarray slide and the detection limit for this type of array will not be as 
sensitive as the high density oligonucleotide arrays. For this work, the limit of detection for RNA 
transcripts was not determined but is an important consideration for future work. The intensity 
value of 500 as a threshold for considering gene expression was recommended by the Bacterial 
Microarray Group at St. Georges (http://www.sghms.ac.ukldepts/medmicro/bugs/).However.it 
would be useful to select several genes that have expression levels equal to or below the intensity 
threshold of 500, and use RT-PCR (with the same RNA preparation used for array analysis) to 
determine if RNA transcript can be detected and to assess the accuracy of the assigned threshold 
value. The detection limit for micro array analysis could also be determined by spiking cDNA 
preparations with known concentrations of cDNA for the human genes (p-actin and GAPDH) 
included on the array as negative controls. This would help determine the background levels of 
intensity and allow analysis of the minimum concentrations of RNA expected to be detected by 
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array analysis so a more accurate limit of detection could be set. Such controls should be 
included with all subsequent array analysis to take into account variation between arrays, and 
would have been included had time permitted. 
Probe design and cDNA labelling may also affect the detection of RNA transcripts. For the array 
used, the probes were designed using software that places the probes at regions within the gene 
that will result in high specificity to avoid cross hybridisation. The probes were also designed to 
have similar annealing temperatures. This resulted in probes of different lengths designed against 
different regions of pneumococcal genes. Only one probe per gene was used. Random primers 
were used to produce cDNA from the RNA preparations so all probes should lie within the 
cDNA molecule (probes that lie outwith cDNA may result in false negatives). Cy3 / CyS were 
incorporated directly into the cDNA in the same procedure. The Cy dyes used are coupled to 
dCTP, although non Cy-coupled dCTP is also included in the reaction mixture, albeit at lower 
concentration than the other dNTPs. Thus it may be possible that probes having a higher guanine 
content will have greater dye incorporation. Being large structures, the Cy dyes are not 
incorporated into the growing cDNA as easily as the dCTP molecules and the incorporation of 
such large molecules results in relatively short cDNA molecules that do not usually exceed 300 
bp. Uneven incorporation of the Cy fluorophores also occurs, with Cy3 incorporating easier than 
CyS. Following incorporation, Cy3 and CyS do not fluoresce to the same extent, whereby Cy3 
molecules in close proximity to one another enhance fluorescence, but CyS molecules in close 
proximity to one another quench fluorescence (Molecular Genetics NoAb Diagnostics, Inc; 
http://bfx.kribb.re.kr/gene-array2/0S09.html). CyS is also susceptible to bleaching so arrays must 
be protected from light and scanned as soon as possible following hybridisations, with CyS 
scanning performed first. These problems highlight the amount of error that can be introduced 
into the transcription expression profiles solely by using direct incorporation of Cy3 and CyS 
dyes. Reverse labelling of cDNA is an option that will help overcome some of this error, and this 
procedure was used for the data presented in this thesis. However, aminoallyl indirect labelling 
may be more suitable for future work. This method involves the production of cDNA using 
amino allyl dNTP in the absence of fluorescent dyes. Cy3 / CyS is coupled to the resulting 
aminoallyl-cDNA as a separate stage in the protocol. This results in longer cDNA molecules 
(SOO-1000 bp) which results in a greater signal intensity, allowing detection of transcripts that 
may only be present in low copy number. Longer cDNAs also increase the chances of the 
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sequences complementary to the array probe being present. Incorporation of the Cy3 I Cy5 dyes 
is more uniform and a smaller amount of starting RNA is required. This latter advantage could 
allow RNA preparations to be performed in the presence of RNA Protect™, which results in 
lower yields but could protect more of the RNA transcripts from degradation. Combined with the 
advantages of increased signal intensity obtained using indirect labelling, these techniques could 
greatly increase the number of spots detected on the arrays and would help determine the 
differences between low expression and absence of expression. One study has demonstrated an 
improvement in results using indirect labelling compared to direct labelling, where the former 
produced consistently higher intensity hybridisations with low background signal (Yu et ai., 
2002). 
In summary, mIcro array experiments can yield large volumes of exciting data previously 
unattainable using conventional techniques. However due to the complex nature of micro array 
design, array printing, batch variation, sample preparation I hybridisation, labelling methods and 
data analysis I normalisation there are numerous stages at which error may be introduced 
resulting in inaccurate conclusions and interpretation of data (Hess et ai., 2001). Care must be 
taken that all stages and protocols are optimised and strictly adhered to, appropriate controls are 
included in every experiment and that data is normalised and analysed adequately. 
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7 Results: S. pneumoniae ZmpB 
Based on the observation that the zmpB gene was located in close proximity to TCS09, it was 
hypothesised that this particular TCS could control expression of zmpB. Furthermore as zmpB 
has not been extensively characterised previously for its role in pneumococcal virulence, it was 
the aim of this work to create a mutant in this gene, analyse its role in virulence and determine if 
its expression was influenced by TCS09. 
7.1 ZmpB basic in vitro analysis 
7.1.1 Creating and confirming mutants 
A series of interruptions along the zmpB gene were created by M. Berge I JP. Claverys 
(Toulouse, France) using mariner mutagenesis (Berge et ai., 2001). Briefly, this mutagenesis 
technique is based upon a mini-transposon, mariner, which integrates at random sites resulting in 
a series of truncations within the target gene, as described in chapter 1, section 1.7.3. The 
mariner cassette includes a gene encoding spectinomycin resistance, which acts as a selective 
marker for mutants. The mutations were originally made in S. pneumoniae strain R6, an un-
encapsulated, avirulent derivative ofD39 (Ianelli et ai., 1999). PCR products from 2 independent 
R6 zmpB integration mutants (zmpB738 and zmpB739) were sent to our laboratory and used to 
transform the virulent, type 2, pneumococcal strain, D39. Potential transformants were selected 
on spectinomycin plates and confirmed by PCR. The insertion of the mariner cassette into the 
zmpB gene results in a PCR product approximately 1 Kb larger than wild-type zmpB when using 
primers ZmpUp and ZmpDo flanking the entire zmpB gene (figure 7.1). Mariner insertion into 
zmpB was further confirmed using a primer specific to the mariner cassette (MP128) in 
combination with a primer designed against the chromosomal region flanking the insertion site, 
ZmpUp (figure 7.1). The latter PCR will result in a detectable product for the mutants but not for 
wild-type D39, which does not contain a binding site for the MP128 primer. PCR with this 
primer also determines the site of integration within the zmpB gene. Both zmpB738 and 
zmpB739 mutants were created and confirmed this way. Mutant zmpB739 has a mariner 
integration approximately 600 bp from the start of the gene and is thus more truncated than the 
zmpB738 mutation where the mariner cassette has inserted approximately 1-1.5 Kb from the 
start of the gene. Both mutants were analysed in all in vitro and in vivo experiments presented in 
this chapter, with the exception of the IL-6, IL-I0 and IFN-y ELISA work which was performed 
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using zmpB739 alone. As the mutations behaved similarly in all experiments, only data for the 
more truncated zmpB739 mutant is presented. This mutant will be referred to as L1739 or 739 
from this point onwards, with D39 representing the isogenic wild-type parental strain. peR data 
confirming this mutation is shown in figure 7.2. 
1.7 Kb 
8.0Kb 
Figure 7.1 Mariner mutagenesis to create the A739 mutant 
Mariner cassette 
1.1 Kb 
A mariner mini-transposon cassette (shown as a blue bar), containing a gene for spectinomycin resistance, 
was used to create integrations within the zmpB gene. For mutant L1739 shown in the diagram, the cassette 
integrated approximately 600 bp from the start of the gene, resulting in a PCR product 1.1Kb larger in the 
mutant compared to wild-type when primers ZmpUp and ZmpDo flanking the entire zmpB gene were used. 
The integration was also confirmed using a mariner-specific primer (MPI28) with a primer ZmpUp 
upstream of the insertion site. This results in a 1.7 Kb band for the L1 739 mutant that is absent in the wild-
type strain. PCRs confirming the integration for L1739 are shown in the following figure (figure 7.2). The 
distance between the ZmpUp primer and the start of the zmpB gene is 1.1 Kb. As MP 128 binds to the stmt 
of the mariner cassette, the 1.7 Kb PCR product using these primers indicates that the mini-transposon has 
integrated approximately 600 bp from the start of the zmpB gene. Sizes of zmpB and the surrounding genes 
are indicated above the illustration and are based on the TIGR4 genome sequence (http://www.tigr.org). 
Rho-independent h'anscription termination sites have been indicated in a previous figure (inh'oduction, 
figure 1.17). 
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A 
1 2 
8.0Kb 
6.9Kb 
Figure 7.2 Confirming ,1739 mutant by PCR 
1.7Kb--. 
1 2 3 
B 
Primers ZmpUp and ZmpDo flanking the entire zmpB gene (see figure 7.1) were used to confirm the L1739 
mutation in strain D39. Insertion of the mariner cassette into zmpB results in a PCR product 1.1 Kb larger 
in the mutant compared to wild-type (figure 7.2A). Figure 7.2A shows the expected 6.9 Kb band for D39 
wild-type (lane 1) and the larger 8.0 Kb band with the ,1739 mutant (lane 2). To further confirm the 
presence and position of the mariner cassette, primer MP128, specific for mariner was used with primer 
ZmpUp (figure 7.2B). Lane 1; L1739 mutant. Lane 2; D39 wild-type. Lane 3; negative control for PCR, set 
up in the absence of template DNA. A band would not be expected using D39 DNA due the absence of the 
mariner-specific binding site for primer MP128. 
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7.1.2 Growth and autolysis ill vitro 
Strains were subject to growth and autolysis determination using viable cell enumeration and 
optical density readings (figure 7.4). Comparison of the L/739 mutant grown in the presence and 
absence of spectinomycin indicated that the antibiotic did not adversely affect growth (data not 
shown). The mutants were also shown to be stable for up to 12 hours during in vitro growth in 
the absence of spectinomycin (figure 7.3). Time points after 12 hour were not examined as the 
L/739 mutant strains rapidly autolyse and lose viability from 10 hours post inoculation (figure 
7.4). 
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Figure 7.3 Stability of L1739 ill vitro 
15 m1 BHI was inoculated with 1.0 x 106 CFU mutant strains in the absence of spectinomycin selection. At 
6 hr and 12 hr post inoculation, cell viability counts were performed to determine if the mutants had lost 
their antibiotic resistance. Counts were performed in the presence (739S) and absence (739) of 
spectinomycin (200 /!g mr1). The figure illustrates that the mutant is stable for up to 12 hours during in 
vitro growth. 
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Figure 7.4 III vitro growth and autolysis of L1739 
15 ml BHI was inoculated with 1.0 x 106 bacterial sh·ains. Viable cell enumeration (figure 7.4A) and OD 600 
lUll readings (figure 7.4B) were perfOlmed every 2 hour for a period of 20 hour. Significantly lower counts 
were found for the mutant compared to wild-type from 12 hr onwards. The broken line represents the limit 
of detection for viable cell counts. 
No difference in growth was observed for the mutant compared to D39 parental strain up to 10 
hours following culture inoculation, as measured by viable cell enumeration or optical density. 
However, between 10 and 12 hours, the mutant showed a significant increase in autolysis rate 
compared to wild-type (P<0.05). This resulted in lower viability counts for L/ 739 at all 
subsequent time points. Between 12 and 20 hours of growth, the strains appeared to lyse at 
similar rates, despite the lower viable counts for the mutant at each time point, as the autolysis 
curves became parallel (figure 7.4A). The optical density readings appeared to match viable cell 
counts up to 10 hours, but as described in previous sections, this was not representative of cell 
counts following entry into stationary phase (figure 7.4B). Furthermore, although viable counts 
for the mutant were lower that the wild-type during the autolysis phase, the OD 600 nm readings 
for the mutant were higher than D39 and remained constant for the remainder of the experiment 
(figure 7.4). 
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7.1.3 Expression of zmpB by D39 ill vitro 
RT-PCR was used to detennine if zmpB is expressed by D39 during in vitro growth. RNA was 
isolated from wild-type D39 grown in BHI media to mid-exponential phase. Primers were 
designed against 2 different regions of zmpB to improve the chances of detecting mRNA. RT-
PCR analysis was perfonned on 2 independent D39 RNA preparations. Expression of zmpB in 
D39 could be detected during in vitro growth using this technique (figure 7.5). 
1 2 3 4 
ZmpB 
region 1 
~381 
1 2 3 4 
ZmpB 
region 2 
1 2 3 4 
235 bp 
16S 
Figure 7.5: RT-PCR showing expression of zmpB during ill vitro growth ofD39 
700 bp 
RNA isolated from cells grown to mid-log phase was used to determine the presence of zmpB transcript in 
wild-type D39 during ill vitro growth. Primers ZmplntFl & ZmplntR1 designed to amplify a region 
approximately 1 Kb downstream from the start of the gene (region 1; bp 1062-1442) produced an expected 
band size of 381 bp (left hand side gel). Primers ZmplntF2 & ZmplntR2 were designed towards the 3' end 
of the gene (region 2; bp 4411-4644) and produced an expected band size of 233 bp (central gel). Primers 
16SF & 16SR specific for 16S RNA were used a positive control for RNA detection and resulted in a band 
of 700 bp (right hand side gel). For all gels, lane 1; cDNA template from D39, lane 2 D39 cDNA template 
prepared in the absence of reverse transcriptase, lane 3; No DNA template, lane 4; D39 genomic DNA 
template. Details of primers are provided in the appendix (A3). A band of the expected size was observed 
in lanes 1 and 4 only using both ZmpB primer sets and the 16S primers. No bands were observed for the 
negative controls (lanes 2 and 3). 
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7.2 In vitro analysis; Re-evaluation of published data 
Two independent groups have characterised mutations in zmpB III different pneumococcal 
serotypes, and have found conflicting results (Novak et at., 2000 and Berge et at., 2001). On the 
basis of this, several of the phenotypes were re-evaluated as part of this work. 
7.2.1 Cell morphology 
Microscopic examination by Gram's staining was used to determine if the il73 9 mutant showed 
abnormal chain formation during in vitro growth. As shown in figure 7.6, the il 739 mutant grows 
in pairs or short chains, which is indistinguishable from the appearance of wild-type D39, and 
characteristic of all pneumococcal growth in vitro. Cultures at different stages of growth were 
examined to determine if chain formation was specific to a certain phase of growth, but no 
differences were detected (data not shown), suggesting that the mutant strain was able to undergo 
normal separation of daughter cells. 
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Bacterial strains were grown in BHI media and examined microscopically at various 
stages of growth. Grams staining revealed dark purple, Gram-positive cocci which 
occurred singly, in pairs and in short chains for both wild-type (figure 7.6A) and mutant 
(figure 7.6B) strains. The figure illustrates samples examined at mid-exponential phase of 
growth. No difference in cell morphology was observed at other stages of growth. 
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7.2.2 DOC-induced autolysis of L1739 mutant 
The data shown above (figure 7.4A) illustrates that during in vitro growth the L1739 mutant is 
able to autolyse following entry into stationary phase, demonstrating that the mutant has a 
functional LytA enzyme, which is required for pneumococcal lysis (Tomasz et at., 1988). To 
further confirm the presence of active LytA, the effect of DOC (an allosteric activator of LytA) 
on the viability of cultures was determined. Following addition of DOC to bacterial cultures 
grown to mid-exponential phase, a rapid reduction in viable cell counts was observed for both 
D39 and L1739, with counts being below the detection limit 15 minutes post DOC treatment. This 
provides further evidence that the LytA enzyme responsible for autolysis is fully functional in 
the L1 739 mutant. 
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Figure 7.7 Autolysis following treatment with 0.04 % DOC 
D39 and 11739 cultures were grown to mid-log phase in BHI. Each culture was divided into two equal 
volumes and DOC (0.04 %, fmal concentration) was added to an aliquot of each sh·ain. Untreated aliqouts 
of cultures were used as controls. Viability counts on all cultures were performed at pre-determined 
intervals for 60 min post DOC h·eatment. The black broken / dashed lines represent unh'eated cultures and 
solid lines represent DOC-treated cultures. The broken line represents the limit of detection. 
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7.2.3 Transformation efficiency of L1739 mutant 
To assess the ability of the L1739 mutant to take up DNA from the surrounding environment, 
bacterial strains were transformed with pVA838, a plasmid conferring erythromycin resistance 
with the ability to replicate in S. pneumoniae (Macrina et at., 1982). The transformation 
efficiency of strains was determined by calculating the mean number of transformants (colonies 
exhibiting erythromycin resistance) per l-Lg of sample DNA (pVA838). Although transformation 
efficiencies varied greatly between experiments, the number of transformants obtained for the 
L1739 mutant was consistently greater than for the D39 parent. This suggests that the mutant is 
not impaired in its ability to acquire DNA from the external environment and may even have 
increased transformation efficiency compared to the isogenic wild-type strain. Table 7.1 shows 
the mean transformation efficiencies of both strains from replicates of a single experiment. The 
comparisons between strains in the table are representative of all other experiments. 
Transformation Efficiency (Total 
transformant ner UfT DNA) 
mean SEM 
D39 2207 327 
739 2428 398 
Table 7.1 Transformation efficiency of A 739 mutant 
Bacterial cultures were grown to an OD 600 nm of 0.1 in BHI and induced to undergo transformation by the 
addition of CSP 1. Plasmid p V A83 8 (conferring erythromycin resistance) was used to transform cells. 
Potential transformants were selected by their ability to grow on erythromycin-supplemented blood agar (1 
/!g mt!). The transformation efficiency was calculated based on mean number of transform ants per /!g test 
DNA (pVA838). 
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7.2.4 Haemolytic activity of L1739 mutant 
Although haemolytic activity was not determined in any of the published work with the zmpB 
mutants, D39 and the L1739 mutant were characterised as part of this thesis for their ability to 
induce lysis of sheep red blood cells. Haemolysis was not observed with any of the negative 
controls, including the pneumolysin null mutant, L1pln, treated with deoxycholate (DOC), 
indicating that any lysis observed was largely due to pneumolysin and not other pneumococcal 
haemolysins. All deoxycholate-lysed cultures (with the exception of the L1pln mutant) showed 
complete haemolysis of sheep red blood cells up to a 1:8 dilution. The final dilutions tested 
ranged from neat (undilute) to 1:128. No haemolysis was seen when lysed cultures were diluted 
1:32 and above (table 7.2). These data indicate that the L1739 mutant expresses similar amounts 
of active pneumolysin compared to D39 wild-type during in vitro growth. 
Dilution of culture resulting in haemolysis 
Complete lysis Partial lysis no lysis 
All negative controls No haemolysis No haemolysis All dilutions 
D39 (- DOC) No haemolysis No haemolysis All dilutions 
D39 (+ DOC) neat-8-fold 8-16-fold 16-32-fold 
L1739 (- DOC) No haemolysis No haemolysis All dilutions 
L1739 (+ DOC) neat-8-fold 8-16-fold 16-32-fold 
Table 7.2 Haemolytic activity of J739 mutant 
Bacterial strains grown to mid-exponential phase were analysed for their ability to induce lysis of sheep red 
blood cells without (- DOC) and with (+ DOC) treatment with 0.04 % deoxycholate. Negative controls 
included a pneumolysin null mutant, PBS alone, media alone and media with 0.04 % deoxycholate. 
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7.3 In vivo characterisation 
Prior to all subsequent in vivo work, bacterial strains were passaged by intraperitoneal injection. 
7.3.1 Intranasal challenge 
7.3.1.1 Intranasal challenge; Survival and bacteraemia 
Strains were analysed for their ability to induce disease III a munne infection model of 
pneumonia. Outbred MFI mice were given 106 CFU intranasally and monitored for their ability 
to survive infection. All mice challenged with wild-type D39 had succumbed to infection within 
100 hr following challenge, and had a median survival time of 45 hr. Although 90 % of mice 
challenged with the L1739 mutant succumbed to infection, the progression of infection was much 
slower than wild-type infection with a median murine survival time of 127 hr, nearly 3 times 
longer than survival with D39 challenge. Indeed at 60 hour post infection only 1 of 10 mice 
challenged with D39 had survived the challenge, but 9 of 10 mice infected with L1739 remained 
healthy and were not showing any signs of infection (figure 7.8A). The difference between 
survival of the two groups of mice was highly significant (P<0.005). 
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Figure 7.8 Survival and bacteraemia following intranasal challenge 
Mice were challenged intranasally with 1.0 x 106 CFU bacterial strains. Figure 7.8A shows survival of 
mice. P<0.005 for survival of mice infected withLl 739 compared to D39 parental strain. Figure 7.8B shows 
bacteraemia. Levels of bacteraemia for Ll739 compared to D39 were statistically lower at 24 hour 
(P<0.005 **) and 36 hour (P<0.05 *) post infection. Counts for wild-type bacteria were not included at 48 hr 
as some of the mice had to be culled prior to this time point due to severity of infection. The broken line 
represents the limit of detection for determination of bacteraemia. 
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Bacterial counts for both D39 and the L1739 mutant appear in the bloodstream 12 hours post 
infection, with the mutant having slightly higher counts than wild-type (not significantly 
different). However, for all time points studied after 12 hours, mice challenged with wild-type 
bacteria had significantly higher counts in the blood compared to mice challenged with mutant 
bacteria (P<O.OOS for 24 hour and P<O.OS for 36 hour, figure 7.8B). Indeed at 24 hr post 
challenge, the observed median bacterial count in the blood of mice infected with mutant 
bacteria is O.S % of that seen with wild-type infection. Bacteraemia in the blood of mice infected 
with D39 48 hours post challenge was not determined as over 40 % of mice had been culled by 
this time due to severity of infection. It thus appears that during the early stages of infection the 
mutant bacteria can gain entry into the bloodstream, but are then impaired in their ability to grow 
in the blood showing no significant increase in numbers between 12 and 24 hours. This is in 
contrast to D39 growth in the blood, which increases from 10glO 2.9 CFU mrl at 12 hour to 10glO 
6.3 CFU mrl blood at 24 hours post infection (median values), an increase of over 3 orders of 
magnitude. This increase is statistically significant (P<O.OOS). However, between 24 and 36 
hours, the mutant shows a similar rate of growth in the blood compared to wild-type during the 
same time period, displaying an increase in median counts of over 2 orders of magnitude, 
although this does plateau off slightly after 36 hours for infection with the L1739 mutant (figure 
7.8B). Despite the slower growth of the mutant strain in the bloodstream, counts do eventually 
increase to a level which result in the appearance of severe symptoms and eventual mortality of 
mice as mice in a moribund state have counts of 107_109 CFU mrl blood which is similar to 
levels in moribund mice infected with D39 wild-type. 
An unusual feature observed following intranasal infection with the L1739 mutant was the late 
onset of symptoms which subsequently appeared to persist in the milder stages (starey coat and 
slightly hunched stance) for longer periods of time compared to the progression of symptoms 
characteristic of wild-type D39 infection. A more quantitative analysis of this observation was 
performed following intravenous challenge, see section 7.3.2, table 7.3. Furthermore, mice 
challenged with mutant bacteria often showed mild to moderate signs of infection for up to S 
days, after which the mice often appeared to recover and be free of symptoms. Following this 
recovery a rapid relapse was frequently observed, where mice showed moderate to severe signs 
of infection within 6-12 hr of appearing to be completely healthy. Such mice had to be sacrificed 
soon after the development of the latter symptoms. These observations are unusual for 
pneumococcal infection ofMF1 mice with D39, where, following infection and the onset of mild 
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symptoms, the mice progress through several stages of infection displaying moderate (intense 
piloerection and hunched stance) then severe (lethargy) symptoms of disease until they become 
severely lethargic and eventually moribund. The moribund state is usually reached within 24-48 
hr of the mice showing initial signs of infection, and recovery from even mild symptoms is a rare 
occurrence. 
7.3.1.2 Intranasal challenge; Stability of L/739 
At 36 hour post challenge, counts in the blood of mice were used to determine if the L/739 mutant 
retained its spectinomycin selection marker as a measure of the stability of the mariner mutation 
during in vivo infection. Figure 7.9 shows that the mutant was stable for up to 36 hour in the 
blood of infected mice. This is in agreement with in vitro stability, shown in figure 7.3. 
Furthermore, 10 single colonies that grew on spectinomycin plates following isolation from the 
blood of infected mice at 36 hour were used to re-confirm the mutation using the peR reactions 
described above. The mariner cassette was detected within the zmpB gene of all 10 isolated 
colonies (data not shown). Following this observation, viability counts of the mutant strain were 
determined in the absence of antibiotic selection for all subsequent work. 
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Figure 7.9 Stability of L1739 mutant ;/1 vivo 
Blood taken from mice infected intranasally with 106 CFU L1739, 36 hI post challenge was used to 
determine mutant stability ill vivo. Viable cell counts were performed in the presence (739S) and absence 
(739) of spectinomycin (200 f!g mr1). The figure illustrates that the mutants was stable and had not lost the 
mariner insertion. 
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7.3.1.3 Intranasal challenge; Lung counts 
Bacterial loads within the lung tissue were determined at 12, 24 and 36 hr post challenge. No 
difference in lung counts between mice infected with D39 wild-type and L1 739 mutant were 
observed at any of the time points, indicating that the mutant can grow in murine lung tissue as 
efficiently as wild-type (figure 7.1 0). 
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Figure 7.10 Bacterial loads in the lung tissue 
Mice were challenged inh'anasally with ,1739 mutant and D39 parental strain. Bacterial loads within the 
lung tissue were determined 12, 24 and 36 hr post infection. The broken line represents the limit of 
detection. 
7.3.1.4 Intranasal challenge; Airway counts 
To determine the number of bacteria in the murine airways, mice were challenged intranasally as 
described above, and lavage fluid removed at pre-determined time points. A small aliquot of this 
fluid was used for viable cell enumeration and the remainder was snap frozen for cytokine 
analysis (see later). Figure 7.11 illustrates that counts in the airways for mice challenged with 
wild-type and mutant strains remained equal at all time points with the exception of 36 hr, where 
significantly higher counts were found in the airways of mice infected with D39 wild-type 
(P<0.05). 
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Figure 7.11 Bacterial loads in the BALF following challenge with 11739 mutant 
Mice were challenged intranasally with 106 CFU 11739 mutant and D39 parental strain. Bacterial loads 
within the airways / BALF were determined at 0, 12, 18, 24 and 36 hr post infection. A significant 
difference between counts of mice infected with mutant compared to wild-type were observed at 36 hr post 
infection (P<0.05*). The limit of detection (lOglO 1.92 CFU ml-1) is below the scale used for this figure so is 
not represented. 
7.3.2 Intravenous challenge 
To by-pass the respiratory system, bacterial strains were inoculated directly into the veins of 
mice to determine their ability to grow in the blood. Counts at 0 hr confirmed the bacterial dose 
administered and subsequent levels of bacteraemia were measured at pre-determined time 
intervals. Mice were also monitored for survival. All mice challenged intravenously with D39 
and L1739 succumbed to infection. As described for the intranasal challenges, mice challenged 
with the L1739 mutant survived much longer than those infected with the D39 parental strain 
(P<0.05) with median survival times of 97 hr and 46 hr respectively (figure 7.l2A). This is >2-
fold greater survival for mice challenged with mutant bacteria. Bacterial counts in the blood also 
showed a similar pattern to that described with intranasal challenge where counts of D39 
increased by 1.5 orders of magnitude within the first 12 hour following infection, and continued 
to increase at a steady rate for all time points examined. However, counts within the blood of 
mice challenged with L1739 mutant only increased slightly between 0-30 hr post injection. A 
significant increase in bacteraemia compared to the 0 hr time point for the mutant strain was only 
found at 30 hr post challenge, after which counts decreased again by 36 hour post challenge 
(figure 7.12B). Bacterial counts in the blood of mice challenged with mutant bacteria were 
significantly lower at 24, 30 and 36 hours compared to counts of mice administered wild-type 
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bacteria (figure 7.12B). At 24 hr counts within the blood of mice infected with the mutant were 3 
% of those in the blood of mice challenged with wild-type D39. 
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Figure 7.12 Survival and bacteraemia following intravenous challenge with .1739 mutant 
Mice were challenged intravenously with 1.0 x 104 CFU bacterial strains. Figure 7.12A shows survival of 
mice. P<0.005 for survival of mice infected with ,1739 compared to D39 parental strain. Figure 7.8B shows 
bacteraemia following challenge. Levels of bacteraemia for ,1739 compared to D39 were statistically 
significant at 24 hr (P<0.005**), 30 hr (P<0.05*) and 36 hr (P<0.005**) post infection. The limit of 
detection (logJO 1.92 CFU mI- l ) is below the scale used for this figure so is not represented. 
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Despite showing low counts within the blood at the time points studied the levels of L/739 in the 
blood appear to have increased after the 36 hr time point, as some of the mice started to show 
symptoms between 60 and 80 hr post infection. Furthermore, all mice challenged with the mutant 
had been sacrificed by 100 hr post challenge, and when moribund these mice had high counts, 
representative of wild-type infection, within their blood (107-109 CFU mr! blood). Again, this 
suggests that upon entry into the blood the L/739 is poorly adapted for growth and survival in this 
environment, although given time it is able to cause lethal infection. 
During intranasal challenge, it was noted that the mice challenged with the mutant strains 
showed signs of infection for longer periods of time before finally succumbing to the terminal 
stages of the infection and being sacrificed. This observation was recorded for the intravenous 
challenges and table 7.3 below shows mean and median times from the first appearance of 
symptoms of infection (starey coat and slightly hunched stance) to the terminal stages of 
infection (extreme lethargy and moribund state) in mice infected intravenously. The table clearly 
illustrates that, even when survival is measured from the onset of visible symptoms, the mice 
challenged with mutant bacteria can survive the infection> 2-fold longer than those challenged 
with D39 wild-type. 
n mean median SEM 
D39 21 19.6 17.5 1.88 
,1739 16 47.0** 48.5** 4.9 
Table 7.3 Time between appearance of symptoms of infection and mortality in mice following 
intravenous challenge 
Mice were challenged intravenously with 104 CFU ,1739 and D39 strains and monitored carefully for the 
appearance of mild symptoms (starey coat and slightly hunched stance). The time interval between the 
onset of these symptoms and terminal stages of infection (mice extremely lethargic or moribund) where 
mice were actively culled was recorded. The column labelled 'n' provides the group sizes for the 
experiment. The table shows both mean and median values, to indicate that even with relatively large group 
sizes, these two parameters of measurement do not differ greatly. The error of the mean value is also 
provided (SEM). The time from showing symptoms to succumbing to infection was greater in the mice 
challenged with mutant bacteria compared to wild-type infection, and this increase was highly significant 
(P<0.005**). 
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7.3.3 Role of ZmpB in virulence in complement deficient mice 
The data presented above indicated that ZmpB has a role in the virulence of strain D39 in our 
model of infection. Thus it was the objective of the work discussed below to characterise this 
protein further to gain insight into the possible mechanism of action of ZmpB within the 
pneumococcal cell. As complement is an important host defence mechanism in pneumococcal 
infection, and a region of ZmpB shows homology with another pneumococcal protein able to 
interact with complement, the L/739 mutation was characterised in complement-deficient mice. 
7.3.3.1 Survival and bacteraemiafollowing intranasal challenge 
A BLAST search of the protein sequence from the TIGR4 strain revealed some homology to S. 
pneumoniae surface protein PspC / complement factor H binding inhibitor (see Appendix 6c). 
Based on this homology, the behaviour of the L/739 mutant in complement deficient / C3 knock-
out mice (C3-/- , C571B1 background, Wessels et al., 1995) was characterised to determine if 
ZmpB was able to exert an effect on complement or components of the complement cascade. 
Should interference with normal complement function be a major function of active ZmpB, then 
the virulence of wild-type and mutant bacterial strains in C3-/- mice should not be significantly 
different. C3-/- mice were challenged intranasally with D39 and L/739 strains and monitored for 
survival and bacteraemia. Figure 7.13 illustrates that, as described above for challenges with 
MFI mice, infection of C3-/- with the L/739mutant resulted in greater murine survival times 
(P<0.005, figure 7.13A) and lower levels ofbacteraemia at 24 and 36 hr post infection (P<0.05, 
figure 7.13B) compared to infection with wild-type bacteria. Median survival time for C3-/- mice 
infected with the L/739 mutant was 73 hr. Infection of complement-sufficient, wild-type control 
mice (C3+/+), challenge with the L/739 mutant did not result in bacteraemia at any of the time 
points studied, and all mice survived the challenge. 
Following challenge with D39 parental strain, C3-/- mice quickly succumbed to infection, with 
mice having a median survival time of 36 hr, and only 10 % surviving the challenge by 40 hr 
post infection (figure 7.13A). The counts of D39 in the blood increased rapidly, as expected, and 
reached very high median counts of lOglO 9.54 CFU mrl at 36 hr post challenge (figure 7.13B). 
In C3+/+, infection with D39 bacteria only results in 20 % of the mice succumbing to infection, 
with median counts in the blood barely increasing above the limit of detection (figure 7.l3A&B). 
This illustrates the importance of complement in preventing pneumococcal infection in this 
murine model of infection. 
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The data above indicate that the L1739 mutant is also impaired in virulence in the C3-/- mice 
compared to D39 wild-type. This suggests that interference with the host's complement system 
does not appear to be a major function of active ZmpB in strain D39 when assessed in C3-/- mice 
on a C57IBI background. 
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Figure 7.13 Virulence of 11739 in C3-/- mice 
Complement-sufficient (C3+f+, black dotted lines) and complement knock-out (C3 -f- , black unbroken 
lines) mice were challenged intranasally with 106 CFU D39 and ,1739 mutant bacterial strains. Mice were 
monitored for survival (figure 7.l3A) and bacteraemia at pre-determined time points (figure 7. 13B). No 
difference was observed between bacterial strains in the survival or bacterial counts in the blood of C3+f+ 
mice. In the C3-f- mice, those challenged with mutant bacteria survived longer than mice challenged with 
D39 parental strain, and this difference was highly significant (P<0.005). Similarily, for bacterial counts in 
the blood of mice, no difference was seen between bacterial strains in wild-type C3+f+ mice, but in C3-f-
mice lower bacterial counts were observed at all time points examined following challenge with mutant 
bacteria compared to D39 parental sh·ain. This difference was statistically significant for 24 and 36 hr post 
infection (P<O.05, significance not shown on the figure). The broken red line represents the limit of 
detection for bacterial counts in the blood and has been intenupted to allow visualisation of the low 
bacterial counts in wild-type C3+f+ mice. 
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7.3.3.2 Comparison a/survival between murine challenges 
With all murine challenges described so far in this chapter, mice infected with mutant L1739 
bacteria all survived longer than mice infected with the isogenic parental strain, D39. This 
difference was found to be highly significant in all experiments (P<0.005). Direct comparison of 
survival time between experiments is not possible as mice were challenged with different doses 
of bacteria, so survival of all mice at 60 hr was compared. This time point was chosen to 
represent the mean halfway point for the individual experiments. (Mice were monitored for a 
maximum of 2 weeks [336 hr], but individual experiment end points were based on the point at 
which all mice that succumbed to infection had to be culled). Analysis of this time point showed 
that despite the route of infection or the strain of mice used, at least 90 % of mice challenged 
with wild-type bacteria had been culled 60 hr post infection, while only 10 % of mice infected 
with the L1739 mutant had succumbed to infection (figure 7.14) . 
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Figure 7.14 Comparison of murine survival at 60 hr following three individual challenges 
The survival of infected mice at the mean halfway point (60 hr post challenge) of three individual 
experiments was compared. Experiments included intranasal (i.n.) and intravenous (i.v.) challenges ofMFl 
mice and intranasal challenge of C3-/- mice (C3-/- i.n.). Mice were infected with 106, 104 and 106 CFU, 
respectively. The figure illustrates the difference in survival times between mice infected with the L1739 
mutant and its isogenic parental strain, D39, which is consistent across different challenges. 
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7.4 Role of ZmpB in inflammation 
The work with the C3-/- mice presented above indicates that ZmpB does not have a large 
influence on complement function. Another host defence mechanism important in both clearing 
pneumococcal infection, and also being implied in the pathology of infection is the host 
inflammatory response. It was thus decided to characterise the inflammatory response within the 
respiratory system to determine if ZmpB could act within this environment to either promote or 
inhibit inflammation. The cytokine profiles of several key mediators and regulators previously 
shown to be involved in pneumococcal infection was studied. 
The data presented in figures 7.10 and 7.11 showed that there was no difference in the ability of 
the L1739 mutant to colonise the airways or lung tissue of mice at the time points studied, with the 
exception of 36 hr BALF counts, where higher counts were found for strain D39 (figure 7.11). 
Thus any differences observed in cytokine profiles with these samples can be attributed to the 
zmpB mutation and not differences in bacterial loads. 
7.4.1 TNF production 
TNF -a, being an important mediator of inflammation, was the first cytokine to be characterised 
in this work. A bioassay that measures the activity of both TNF-o. and TNF-~ was used for 
BALF and lung tissue sampled over a range of pre-determine time points following intranasal 
infection. The assay indicated that increased levels of TNF were present in lung tissue isolated 
from mice infected with D39 parental strain compared to infection with the L1739 mutant at 12 
and 24 hr post infection. This difference was statistically significant for the 24 hr time point only 
(P<O.OS) Figure 7.1SA shows the mean values obtained for TNF in the lung tissue 24 hr post 
infection using the bioassay to measure TNF activity. However, this experiment was an 
exception from all other data discussed in this thesis because the mean and median values for the 
data do not correlate well. The mean and median values for lung tissue isolated from mice 24 hr 
post infection with wild-type D39 are 487 U and 200 U units respectively. Similarly for lungs 
isolated from mice infected with the L1739 mutant, mean and median counts were 41 U and 0.6 U 
respectively. Thus the median values for both lung samples from both bacterial strains are 
actually significantly lower that those shown in the figure. Nevertheless, statistical analysis based 
on both mean (student t-tests) and median (Mann-Whitney tests) values for the data sets obtained 
indicated that the differences observed between D39 and the L1739 mutant are statistically 
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significant (P<0.05). No TNF within the BALF at any time point studied was detected using the 
bioassay. 
To confirm the results from the bioassay, an ELISA specific for TNF-a was used. This assay 
confirmed the increased concentrations of TNF -a within lung tissue at 24 hr post infection with 
D39 wild-type compared to the L1739 mutant (P<0.05). In contrast to the bioassay, mean and 
median values for the ELISA data were in agreement with each other (304 & 295 pg mr! for 
D39 infection, and 94 & 95 pg mr! for the mutant, respectively). Thus for all subsequent 
analysis and discussion, ELISA values will be used as a measure of TNF -a activity in lung 
tissue. This method is also more suited to TNF -a measurement as the bioassay measures 
combined activities of TNF- a and TNF-~. As for the TNF bioassay, the ELISA did not detect 
TNF- a in the BALF at any of the time points studied (12, 18,24 or 36hr). Figure 7.15 shows the 
increased TNF- a concentration in lung tissue following challenge with D39, as determined by 
both bioassay (figure 7.15A) and ELISA (figure 7.15B). 
Controls were set up for all bioassays and cytokine ELISAs using lung and BALF samples taken 
from uninfected mice and from mice immediately following challenge with both D39 and L1739. 
Subsequent analysis showed that there was no significant differences between the cytokine 
concentrations in uninfected mice and infected mice immediately following challenge (data not 
shown), so all subsequent cytokine data sets will show the uninfected value as the control. This 
control therefore represents both a 0 hr time point and un-infected mice. 
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Figure 7.15 TNF in lung tissue, 24 hr post challenge 
Total TNF activity in lung tissue 24 hr post inh'anasal infection with D39 and the L1 739 mutant was 
determined by a bioassay. This assay measures the specific killing of L929 fibroblasts due to TNF. The 
bioassay measures both TNF-a and TNF-P activity (figure 7.15A). Total TNF-a concentration was 
determined by ELISA, which is specific for TNF-a (figure 7.15B). Both assays showed that mice 
challenged with D39 had significantly higher levels of TNF( a) compared to mice infected with the L1 739 
mutant (P<O.05*). The difference between the D39-infected samples and the 0 hr control was also 
significant (P<O.05*). The levels ofTNF(a) in the lung tissue from mice challenged with L1 739 were only 
just above the limit of detection for both assays and were not significantly different from the 0 hr conh'ol 
values. The broken line represents the limit of detection for both assays. 
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7.4.2 IFN-y production in BALF and lung tissue 
The concentration of the pro-inflammatory cytokine, IFN-y, in murine BALF and lung samples 
was determined by ELISA. In the lung tissue, IFN-y concentrations increased with each time 
point studied for both bacterial strains (figure 7.16B). No significant difference between IFN-y 
concentrations in lung tissue from mice challenged with wild-type and mutant bacteria was 
observed at any of the time points examined. 
In the BALF, IFN-y concentrations increased at each time point with airway washes from mice 
challenged with D39. Following intranasal challenge with L1739, IFN-y concentrations also 
increased but with a peak at 24 hr post challenge. Concentrations at 36 hr post infection with the 
mutant were similar to those seen at 18 hr (figure 7.16A). The only significant difference 
between IFN-y concentration in the BALF of mice challenged with wild-type and mutant 
bacteria was at 24 hr post challenge where challenge with the L1739 mutant resulted in higher 
IFN-y (P<O.05). The IFN-y concentrations detected in the BALF were much lower than those 
present in the lung tissue at all time points for both bacterial strains. 
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Figure 7.16 IFN-y concentrations in lung tissue and BALF following intranasal challenge 
ELISA was used to determine the concentration ofIFN-y in murine lung tissue (7.16A) and 8ALF (7.168) 
following intranasal challenge with 106 CFU D39 and the L1 739 mutant. The only significant difference 
observed between mutant and wild-type IFN-y levels was within the BALF, 24 hI' post challenge, where 
mice infected with the L/ 739 mutant had increased IFN-y (P<O.05*). The broken line represents the limit of 
detection for the assays 
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7.4.3 IL-6 production in BALF and lung tissue 
The concentration of IL-6 in lung tissue and BALF was determined by ELISA. The IL-6 
concentration increased in both the lung tissue and BALF as the infection progressed following 
challenge with both D39 and the L1739 mutant (figure 7.17). No significant difference was 
observed in IL-6 levels between D39 and L1739-infected tissues at any time point. 
7.4.4 IL-IO production in BALF and lung tissue 
The concentration of IL-10 in lung tissue and BALF was determined by ELISA. The IL-I0 
concentrations increased in both the lung tissue and BALF as the infection progressed following 
challenge with both D39 and the L173 9 mutant, with the exception of BALF from mice infected 
with D39 wild-type which showed a peak in IL-10 concentration at 18 hr post challenge (figure 
7.17). However, concentrations oflL-10 detected in the BALF at all time points were lower than 
those of the control. This could indicate that infection with both strains results in suppression of 
IL-I0 at the time points studied. No significant difference was observed in IL-10 levels between 
D39 and L1739-infected tissues at any time point. 
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Figure 7.17 IL-6 concentrations in lung tissue and BALF following intranasal challenge 
ELISA was used to determine the concentration ofIL-6 in murine lung tissue (7.17 A) and BALF (7.17B) 
following intranasal challenge with 106 CFU D39 and the ,1739 mutant. No significant difference between 
IL-6 concentration in lung or BALF from mice challenged with D39 or the ,1 739 mutant was observed at 
any time point examined. The broken line represents the limit of detection for the assays. 
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Figure 7.18 IL-I0 concentrations in lung tissue and BALF following intranasal challenge 
ELISA was used to determine the concentration ofIL-1O in murine lung tissue (7.1SA) and BALF (7.1SB) 
following intranasal challenge with 106 CFU D39 and the L1739 mutant. No significant difference between 
IL-lO concentration in lung or BALF from mice challenged with D39 or the L1 739 mutant was observed at 
any time point examined. The broken line represents the limit of detection for the assays. 
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7.5 Expression of ZmpB / antibody production 
The availability of pure ZmpB protein would be useful for further characterisation of this 
virulence factor, especially should high affinity antibodies against the protein be available. The 
aim of the following section was to express a region of ZmpB in a pure form and use this protein 
to obtain anti-ZmpB antibodies which could be used in a range of experiments summarised in 
figure 7.19. 
7.5.1 Expression of ZmpB protein 
As ZmpB is such a large gene (>5.5 Kb), it was envisaged that attempts to express the whole 
protein would be difficult, if not impossible. To overcome this, the gene was expressed in 2 
fragments, which would exclude the hydrophobic region at the N-terminal end of the protein 
which could have caused problems during expression. Primers containing BamBI and Sac! 
restriction sites were designed to amplify up the central and C-terminal regions of the gene, as 
illustrated in figure 7.19. The reverse primer for amplification of the central region was designed 
to contain a stop codon to prevent read-through into the downstream sequence once cloned. PCR 
was used to amplify up these regions from zmpB in strain D39 (serotype 2). PCR products were 
cloned into the expression vector pET-33b, transformed into DH5a competent cells and checked 
by restriction digest. Positive clones were selected on kanamycin. The insertions in pET -33b 
were sequenced to ensure that the zmpB regions were in-frame with the T7 promoter for 
expression. PET-33b containing the confirmed zmpB insert was subsequently used to transform 
BL21 cells for protein expression. Cultures of transformed BL21s were grown to mid-
exponential phase and expression of the T7 polymerase was induced by the addition of IPTG. 
Protein expression was determined by SDS-PAGE with Coomassie staining. Only the clones 
containing the central region of ZmpB resulted in satisfactory levels of protein expression, as 
judged by SDS-PAGE, so this region was used for further work to obtain protein for vaccination. 
Following induction of protein expression using the central region of ZmpB, most of the protein 
was within inclusion bodies in the insoluble fraction (figure 7.20). Preparation of protein from 
the inclusion bodies involved disrupting the cells mechanically followed by a series of washes in 
sucrose and Triton-X-100, and re-solubilisation in urea. The protein solution was dialysed to 
remove all traces of urea, but following this procedure, a precipitate was formed, with very little 
protein remaining in solution. A decision was made to vaccinate with this precipitate instead of 
soluble protein as had originally been intended. The ZmpB-central region precipitate was re-
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solubilised in urea to detennine the protein concentration and the dialysis procedure was 
repeated. The resulting precipitate was suspended in sterile saline for vaccination studies. Figure 
7.19 summarises the process described above to obtain semi-purified ZmpB protein for 
vaccination. Figure 7.20 illustrates the individual stages of protein purification from the inclusion 
bodies. 
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Figure 7.19 Overview of the production of ZmpB protein for vaccination 
Two regions of zlI1pB were cloned into expression vector pET-33b and used to transform BL21 cells. 
Expression of the protein was induced by the addition ofIPTG to growing cultures. SDS-PAGE indicated 
that the clones expressing the central region of zlI1pB produced the best levels of protein expression. The 
protein was purified from the insoluble inclusion bodies and used to vaccinate MF I mice together with 
Freund's adjuvant. Upon completion of the vaccination schedule, Western blot was used to confum the 
presence of anti-ZmpB antibody, and sera from positive mice were pooled. The red labels on the diagram 
represent possible future work using the purified protein or the murine immune sera. 
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Figure 7.20 Purification of ZmpB-central region from inclusion bodies 
The gel shows the 70 KDa ZmpB-central region protein at various stages during purification. Lane 6 
represents the total cell pellet following induction of expression by IPTG, with lane 5 showing the soluble 
fraction. Although it is not clear from the figure, most of the expressed protein was in insoluble inclusion 
bodies. These were disrupted mechanically and washed in 30 %sucrose and Triton-X- IOO (lanes 4 and 3 
respectively represent the supernatants from these washes), then solubilised twice in 7M urea (lanes 1 and 
2). The figure shows that very little protein was present in the supernatant following the washed with 
sucrose and Triton-x-l 00. Resolubilisation in urea resulted in a substantial band representing crude ZmpB-
central region protein. 
Several mice were vaccinated following the schedule outlined in chapter 2, section 2.92. Prior to 
each vaccination, pre-bleeds were taken, and Western blot was used to determine the presence of 
detectable anti-zmpB antibody at each stage of the vaccination. Antibody could be detected after 
the first boost in some mice, although detection improved with subsequent boosts and antibody 
was detected in the terminal bleed of all mice vaccinated (data not shown). The amount of 
antibody produced by individual mice appeared to vary substantially (data not shown). The 
immune sera from all mice was pooled. Figure 7.21 illustrates the ability of this pooled sera to 
recognise the purified ZmpB central region using a Western blot technique. This immune sera 
will be used for a variety of applications, discussed in the following chapter. 
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Figure 7.21 Westerm blot showing the ability of mouse immune sera to recognise ZmpB 
Mice were vaccinated with partially purified ZmpB protein (central region) following a vaccination 
schedule described previously. Sera from individual mice was tested for anti-ZmpB antibodies and all 
positive samples were pooled. The figure shows the recognition of ZmpB (central region) by this pooled 
sera, with the band being the expected size of 70 KDa. A total of 44 !!g of ZmpB protein was used for 
detection. A marker was used to determine protein size but is not clearly visible from this figure. 
7.S Regulation of zmpB by TCS09 
MicroalTay analysis was used to characterise the expresslOn profile of the iJrr09 mutant 
compared to isogenic parental strain (see chapter 5, section 5.4.2). Although the ratio of zmpB 
expression in D39 wild-type compared to the iJrr09 mutant was close to 1.0 (figure 5.20), 
indicating that the gene is expressed the same in both strains, the actual intensity of expression 
was very close to the threshold for detection of expression (figure 5.21). This low level of 
expression is likely to be due to problems in the design of the probe for the zmpB gene. As 
discussed in the introduction (section 1.6.3), the nucleotide sequence for zmpB between different 
serotypes only shows significant homology within the first 1000 bp, at the 5' end of the gene. 
The only probe on the S. pneumoniae microalTay designed against zmpB includes only a very 
small section of the homologous region and is thus unlikely to hybridise well to sequences that 
are significantly different to the TIGR4 zmpB sequence. Figure 7.22 illustrates the sequence 
variation between the TIGR4 and R6 zmpB genes, together with the position of the zmpB array 
probe, as analysed using the Artemis Comparison Tool (ACT) programme (The Wellcome Trust 
Sanger Institute, http://www.sanger.ac.uklSoftware/ACT/). Figure 7.23 illustrates the BLAST 
alignment of the TIGR4 probe with the cOlTesponding region on the R6 genome sequence. The 
latter figure shows that the probe on the array has very little homology with the R6 sequence, 
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although low levels of hybridisation may still be possible. The regIOns of D39 that were 
sequenced as part of ZmpB expression were homologous with the R6 sequence, indicating that 
significant variation may exist between the zmpB gene of D39 and the TIGR4 strain. Thus it can 
be assumed that zmpB expression in D39 may not be detected by the S. pneumoniae array. This 
further highlights some of the problems, discussed in chapter 6, that may be encountered using 
micro arrays to study gene expression. To overcome this problem, the iJrr09 mutation is currently 
being moved into the TIGR4 parental strain in our laboratory to enable further characterisation of 
this mutant and the genes it regulates. 
However, RT-PCR analysis with primers designed within the zmpB gene, indicated that zmpB 
was expressed during in vitro growth in the iJrr09 mutant. This indicates that TCS09 does not 
prevent expression of zmpB, but does not confirm that TCS09 does not influence zmpB 
regulation. 
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Figure 7.22 Artemis comparison of the zmpB gene sequences in S. pneumoniae strains TIGR4 and R6 
Artemis Comparison Tool (ACT) allows comparison of the sequences of genomes. The figure illustrates a comparison between the region of the S. 
pneumoniae R6 and TIGR4 genomes encoding the gene for zmpB (R6 spr0580, TIGR4 sp0644). Genes / open reading frames within individual genome 
sequences are shown in turquoise / bright blue. The TIGR4 sequence is shown along the top half of the figure and the R6 sequence is along the bottom. 
Red colouring inbetween the 2 genome sequences represent conserved regions. Sequence variation (or absence of sequence) is shown by the white 
regions. The diagram highlights the lack of homology between the zmpB genes of R6 and TIGR4, with the only homologous region being found at the 
start of the gene only. The ZmpB probe on the array, designed against the TIGR4 sequence, is shown as a red bar beneath the TIGR4 zmpB gene, and 
the figure demonstrates that this probe lies mostly within the heterologous region. 
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Figure 7.23 BLAST alignment of the TIGR4 ZmpB probe with the R6 zmpB gene 
The 342 bp probe (shown as a red bar along the top of the figure), designed using the zmpB sequence from 
the type 4 TIGR4 strain was aligned against the R6 genome using the BLAST programme. The figure 
illustrates that the only region of homology of the probe (shown as a short pink bar) with the R6 gene is 
within the first quarter (80 bp) of the probe only, which showed 68 % identity. This low homology may be 
sufficient to detect some expression of zmpB in R6 / D39, but will not result in efficient detection. 
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7.7 Summary of ZmpB Results 
Discussion of mutant phenotypes is in relation to the isogenic parental strain, unless stated 
otherwise. 
7.7.1 Basic ill vitro analysis and analysis of published data 
Two interruptions at different points within the zmpB gene of a serotype 2 pneumococcus, D39, 
were created by mariner transposon mutagenesis, resulting in 2 independent mutants. The 
mutants were confirmed by PCR. Both mutants were characterised in vitro and in vivo for this 
work, and both demonstrated similar phenotypes in all experiments. Thus results for only one 
mutant, ,1739 (the more truncated mutation) were presented in this chapter and are summarised 
in this section. 
The mutant was not impaired in growth in nutrient-replete BHI media, although demonstrated an 
increased initial rate of autolysis upon entry into stationary phase. The mutant was stable and 
retained the spectinomycin resistant phenotype in vitro for up to 12 hr. 
Published data by 2 independent groups found conflicting phenotypes for mutations within the 
pneumococcal zmpB gene. One study found that the zmpB mutant grew in abnormally long 
chains, was unable to autolyse, had significantly decreased transformation efficiency and was 
unable to transport certain proteins to the cell surface (Novak et at., 2000). A second study failed 
to confirm any of these distinct phenotypes (Berge et at., 2001). Several of the reported 
phenotypes were re-examined as part of this work and found to be in complete agreement with 
those reported by Berge et at (2001). The mutant did not demonstrate abnormal colony 
morphology in culture, was able to autolyse in the presence and absence of DOC, an allosteric 
activator of the LytA autolysin enzyme, and did not demonstrate a reduction in transformation 
efficiency. This work also examined the ability of the mutant to lyse sheep red blood cells in 
vitro during mid-exponential growth and found no alteration in the haemolytic activity compared 
to isogenic D39 wild-type. 
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7.7.2 III vivo characterisation 
The mutant was virulent following i.p. challenge and all subsequent in vivo work was performed 
using bacterial strains that had initially been mouse-passaged. The mutant was found to be 
attenuated in virulence following both i.n. and i.v. challenge, demonstrating significantly lower 
levels of bacteraemia and increased murine survival times. Although showing decreased 
virulence in both models of infection, the reduced virulence of the il 73 9 mutant appeared to be 
more attenuated following intranasal infection compared to direct inoculation of the bacteria into 
the bloodstream. This is based on differences in bacteraemia at selected time points and survival 
times following infection in comparison to wild-type values. Table 7.4 summarises some of the 
key observations from the in vivo work carried out with the il 739 mutant. 
Observation Intranasal challenge Intravenous challenge 
Percentage survival No D39 infected mice survived No mice survived infection with D39 
10% L1 73 9 infected mice survived or L1 739 
Experiment endpoint 100 hr for mice infected with D39 80 hr for mice infected with D39 
160 hr for mice infected with L1 7 39 100 hr for mice infected with L173 9 
60 '1.. lon ger than wild - typ e 25 % lon ger than wild - type 
Median survival time 45 hr for mice infected with D39 46 hI.' for mice infected with D39 
127 hr for mice infected with L1 73 9 97 hr for mice infected withL1 739 
2.8- fold lon ger than wild - type 2.1 - fold longer than wild-type 
Survival at the 60 hr 10 % for mice infected with D39 10 % for mice infected with D39 
halfway point 90 % for mice infected withL1 739 90 % for mice infected with L1739 
Bacteraemia at 24 hr 6.28 for mice infected with D39 6.39 for mice infected with D39 
(Log 10 median values) 3.93 hr for mice infected with L1 739 4.91 hr for mice infected withL1 739 
0.5 % t hat of wild-type 3 % that of wild -type 
Table 7.4 Comparison of virulence of L1739 following intranasal and intravenous challenge 
MFI mice were challenged intranasally or intravenously with 106 or 104 CFU, respectively. Bacteraemia 
and survival was monitored. The table highlights some of the main differences seen between mutant and 
wild-type D39 strains for each challenge, and illustrates the more attenuated phenotype of the mutant 
following intranasal challenge compared to intravenous infection (highlighted in bold, red typescript). The 
experimental endpoint is the point at which all mice have been actively culled or the point where infection 
does not progress further (ie. mice remain healthy for the remainder of the experiment). 
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Mutants were stable / retained their spectinomycin resistance up to 36 hr post challenge. No 
significant difference was seen in the ability of the L1739 mutant to colonise lung tissue at 12,24 
or 36 hr post intranasal challenge, compared to the D39 parental strain. Bacterial counts in the 
BALF were also similar for mice challenged with mutant compared to wild-type bacteria at 0, 
12, 18 and 24 hr post intranasal challenge. Significantly higher counts of D39 were found in the 
BALF at 36 hr post infection compared to mutant counts (P<0.05). 
Mice challenged, both intranasally and intravenously with the L1739 mutant often displayed an 
unusual response to infection, where they showed mild signs of infection for up to 5 days but 
then seemed to recover and have a healthy appearance. However, following this recovery phase, 
the mice often relapsed and began to show severe signs of infection, having to be actively culled 
quickly after the re-appearance of symptoms. This prolonged display of symptoms followed by 
recovery with or without relapse is not a common observation following infection with wild-type 
D39 in our murine model. 
7.7.3 Role of ZmpB in complement deficient mice 
A short region within the zmpB sequence showed some homology to other pneumococcal 
proteins previously shown to interfere with complement. Complement deficient mice were thus 
challenged with wild-type and L1739 mutant bacteria to determine if ZmpB is able to interfere 
with complement. Mutants retained their attenuated phenotype in this model of infection 
compared to D39 wild-type, indicating that ZmpB does not interact with complement in any way 
that significantly impairs the host (murine) response to pneumococcal infection. 
7.7.4 Role of ZmpB in inflammation 
The study of selected cytokines in the BALF and lung tissue following intranasal infection with 
bacterial strains indicated that there were no significant alterations in the cytokine profiles of 
IFN-y, IL-6 and IL-IO between infection with D39 wild-type or L1739 mutant bacteria. However, 
significantly higher concentrations of the pro-inflammatory cytokine TNF -u were found in the 
lung tissue of mice infected with wild-type parental strain compared to mice infected with the 
mutant, 24 hr post challenge. This indicates that active ZmpB could have a role in inducing 
inflammation. 
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7.7.5 Expression of ZmpB for vaccination and antibody production 
The central region of the zmpB gene was expressed, semi-purified and used to make anti-ZmpB 
antibodies. Immune sera generated from the vaccination of mice recognised the semi-purified 
ZmpB protein using a Western blot technique and will thus be useful for future applications. 
7.7.6 Regulation of zmpB by TCS09 
RT-PCR data indicates that TCS09 does not prevent expression of zmpB in vitro. Microarray 
analysis could not confirm this observation as the probe on the array does not have sufficient 
homology with the zmpB gene found in strain D39 used for this analysis. 
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Chapter 8; S. pneumoniae ZmpB discussion 
Zinc metalloproteases have previously been shown to have important roles in the virulence of 
several pathogens (Hase and Finkelstein, 1993). The elasatase of Pseudomonas aeruginosa is a 
zinc metalloprotease (Wretlind and Pavlovskis, 1983), as are the tetanus and botulinum 
neurotoxins of Clostridia species (Schiavo et ai., 1992). Bacterial zinc metalloproteases cleave a 
range of substrates and contribute differently to the infection process. S. pneumoniae ZmpB is a 
large gene (>5.5 Kb) and has been detected in several genome-wide approaches for identifying 
potential pneumococcal virulence factors. Such approaches have included differential 
fluorescence induction to identify genes up-regulated in vivo (Marra et ai., 2002) and searches 
based on known cell surface anchoring motifs (S. Koenig, personal communication, based on 
Wizemann et ai., 2001). In the latter study, ZmpB was identified through its LPXTG motif (see 
later). However, the role of ZmpB in virulence has not been investigated in any detail. ZmpB is 
one of the few pneumococcal genes that displays extensive sequence variation between 
serotypes. This suggests that the gene could be important in human infection and that immune 
pressure exists from the host against this gene. It was thus decided to examine the role of this 
putative metalloprotease as part of this thesis and to determine if its expression is regulated by 
TCS09. 
8.1 Mutant construction and in vitro analysis 
Mutations were created in the zmpB gene of S. pneumoniae strain D39 by mariner mutagenesis 
and confirmed by PCR. Although 2 independent mutations were created and analysed throughout 
this work, only data for one of these is presented and will be discussed, as both mutants had very 
similar phenotypes in comparison with one another. 
The mutant, L173 9, was not impaired in growth in vitro indicating that ZmpB is not essential for 
growth in BHI media. However, RT-PCR was used to show that the zmpB gene is expressed by 
D39 during the mid-exponential phase of growth in BHI. This indicates that the gene may be 
constitutively expressed or switched on at the stage of growth tested 
Upon initial entry into the autolysis phase of growth, the mutant appeared to demonstrate a rapid 
reduction in viable cell counts between 10 and 12 hr (figure 7.4A). Although this stage of growth 
is generally attributed to autolysis of pneumococcal cells, it is possible that the mutants may be 
dying without cell lysis. This possibility could also explain why, following stationary phase, the 
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optical density readings of the il739 mutant do not decrease and remain above those of D39 
wild-type, despite the mutant having lower viable cell counts than the parental strain. As cell 
lysis is thought to release the haemolytic toxin pneumolysin, a simple haemolytic assay could 
determine if the mutant bacteria are lysing faster than wild-type D39, and thus releasing more 
pneumolysin into the culture media at this stage of growth. A haemolytic assay was performed as 
part this work and did not indicate greater levels of pneumolysin (described later), but this assay 
was performed at one time point only, where cell viability counts were equal between mutant and 
wild-type bacteria. Furthermore, all cultures were completely lysed in the presence of DOC. The 
haemolytic assay would thus have to be repeated at various time points after the stationary phase 
of growth is reached, and in the absence of DOC. The significance of increased autolysis to in 
vivo infection is not known. Firstly in vivo infection is not likely to represent the batch culture 
growth conditions present during in vitro growth, and consequently it is not known if batches of 
pneumococcal cells undergo autolysis during infection. If, however, pneumococci do autolyse 
during infection, an increased rate of autolysis in the il73 9 mutant could result in a slower overall 
increase in bacterial load and could thus contribute to the attenuated phenotype described for the 
mutant. However, based on the observation that wild-type bacteria induce greater inflammation 
in the lungs early in infection (described later), it is doubtful whether increased autolysis of the 
il739 mutant is occurring in vivo, as this would presumably result in increased release of 
pneumolysin which is itself a potent mediator of inflammation (Mitchell and Andrew, 2000). 
The il7 39 mutant retained its spectinomycin resistance for up to 12 hr in the absence of antibiotic 
selection, demonstrating that the mariner cassette remains integrated within the genome during 
this period of time. 
Two studies have published data on the in vitro phenotypes of mutations in the pneumococcal 
zmpB gene, although the findings from these studies are conflicting. In one study, a zmpB 
knock-out mutation was created in a virulent, encapsulated serotype 4 TIGR4 strain using 
insertion-duplication mutagenesis, and resulting mutants were found to possess a distinct 
phenotype (Novak et at., 2000). The zmpB insertion-duplication mutant grew in very long 
chains of 2000-3000 cells in culture, had lost the ability to express several choline binding 
proteins on the cell surface, was unable to autolyse in the presence of DOC and penicillin and 
had significantly reduced transformation ability (99 % reduction compared to wild-type). The 
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mutants were also deficient in the translocation of competence proteins CinA and RecA to the 
cell membrane. This led the authors to propose that active ZmpB regulates translocation of Cbps, 
CinA and RecA to the surface of the cell where they can perform functions such as lysis / 
separation of daughter cells and transformation. 
A second study created a series of integrations III zmpB in the avirulent, un-encapsulated 
serotype 2 R6 strain, using mariner mutagenesis (Berge et al., 2001, described in the 
introduction, section 1.7.3). None of the phenotypes found by Novak et al could be confirmed 
using the zmpB mutants created in the second study. Table 8.1 summarises the conflicting data 
published from the 2 studies. 
Novak et al., 2000, serotype 4 Berge et al., 2001, serotype 2 (R6) 
(TIGR4) 
Abnormal chain formation Normal chain formation 
Autolysis defect ( even with excess Retained ability to auto lyse in the 
deoxycholate and penicillin) presence of deoxycholate 
LytA trapped in cytoplasm complexed LytA and CinA complexes not 
with CinA; No trafficking of CinA and detected. Individual proteins detected 
RecA to the cell surface by Western blot 
99 % decrease in transformation Transformed at normal frequency 
efficiency 
Proposed a role for ZmpB in the Found no evidence for the role of 
control of translocation of Cbp to the ZmpB in controlling translocation of 
cell surface Cbps to the cell surface 
Table 8.1 Conflicting data published on ZmpB 
Two independent studies have characterised the in vitro phenotype of zmpB mutants, with conflicting 
results. The table summarises some of the phenotypes of the mutants found by the individual studies. 
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Due to the contrasting sets of data published with respect to zmpB mutants, several of the 
phenotypes above were re-examined as part of this thesis and were in complete agreement with 
the data of Berge and co-workers (Berge et at., 2001). The L1739 mutant exhibited cell 
morphology identical to that of the wild-type parental strain, with cells growing singly, in pairs 
or in very short chains. This indicates the presence of functional LytB, a Cbp required for 
daughter cell separation. Upon treatment with DOC, an allosteric activator of the LytA autolytic 
enzyme, all strains were completely lysed within 15 min of treatment, indicating the presence of 
functional LytA, also a Cbp. Western blot, performed within the laboratory, was used to detect a 
single band of the expected size for LytA alone, indicating that this protein was not complexed 
with any other proteins (data not shown). Furthermore, the mutant transformed at the same 
frequency as wild-type. These data highlights that the absence of capsule in the R6 strain used in 
the study by Berge and colleagues (Berge et at., 2001) does not account for the differences 
observed in the mutant strains. The contribution of different genetic backgrounds of the strains 
used for the above studies could indeed result in very distinct phenotypes, a phenomenon that 
was discussed in chapter 6. However, the mutant strain used in the study by Novak and 
colleagues (Novak et at., 2000) was independently analysed in an identification laboratory and, 
in contrast to the wild-type parental strain, was subsequently classified as Streptococcus viridans 
based on its resistance to optochin and the absence of a capsule. Thus it appears that 
contamination occurred during the work of Novak and co-workers (Novak et at., 2000) that 
resulted in the unusual phenotype documented for the zmpB mutant strain used in this study. This 
highlights the requirement for continuous evaluation of all pneumococcal strains used during any 
study. Furthermore, several different identification techniques should be employed to allow for 
accurate S. pneumoniae identification, as pneumococcal colony morphology and haemolysis on 
blood plates is often indistinguishable from that of other Streptococcal species. 
8.2 Role of ZmpB in virulence 
To assess if ZmpB contributed to the virulence of S. pneumoniae, mIce were initially 
administered the L1739 mutant and its isogenic parental strain intranasally. This infection resulted 
in significantly longer survival times and lower bacterial counts in the blood of mice 24 and 36 
hr post challenge with the mutant compared to D39 wild-type, demonstrating that ZmpB is 
required for virulence. To assess the stages of virulence where ZmpB has a significant influence, 
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bacterial counts in the lung tissue post challenge were determined. This indicated that the L1739 
mutant was not impaired in its ability to colonise the lungs at any of the time points studied. 
Mutant bacteria were detected in the bloodstream of mice 12 hr post infection and the counts 
detected were slightly higher than those of wild-type bacteria, indicating that the L1739 mutant is 
not impaired in its ability to disseminate from the lungs to the bloodstream, early in the 
infectious process. However, once in the blood, the bacterial counts for the mutant remain 
significantly lower than those for wild-type strain. This reduction in levels of bacteraemia is also 
observed when the strains are inoculated directly into the bloodstream of mice and demonstrates 
that the mutants are less adapted for survival within this environment. The data from infections 
with the L1739 mutant, summarised in table 7.4, indicates that intranasal challenge may result in a 
more attenuated phenotype than intravenous challenge, as the former results in increased murine 
survival times and a greater difference in bacterial counts in the blood 24 hr post infection 
compared to wild type. This could indicate that at later time points (post 12 hr) wild-type 
bacteria can disseminate more efficiently from the lungs to the bloodstream, or that during the 
transition from the lungs to the blood, the mutants are altered in such a way that reduces their 
ability to survive or replicate in the blood. Regardless of the challenge route, the L1739 mutant 
does not start showing a significant increase in bacterial counts until at least 12 hr after its entry 
into the blood. This is in contrast to the wild-type D39 strain, which demonstrates increased 
bacterial counts as soon as it enters the systemic circulation. The L1739 mutant is not, however, 
essential for virulence as mice do eventually succumb to infection with this strain. Furthermore, 
when moribund, such mice have high levels of bacterial counts in their blood, which are 
indistinguishable from counts in moribund mice following challenge with D39 wild-type. The 
mutant was shown to be stable for up to 36 hr post challenge and bacteria isolated from selected 
mice infected with L1739 at the time of culling (ie. when moribund) were also shown to retain the 
mariner insertion within the zmpB gene as determined by peR (data not shown). This illustrates 
that the high bacterial counts in moribund mice are due to the L1739 and not due to reversion to 
wild-type. The attenuated phenotype with regards to survival in the blood can thus be overcome 
eventually. 
The levels of bacteraemia in the blood of mice infected with the mutant appear to correlate with 
the unusual progression of symptoms observed with such mice. During the earlier stages of 
infection, bacteria are able to gain entry to the systemic circulation and this correlates with the 
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appearance of mild symptoms. Following challenge with the L1739 mutant, bacterial counts 
remain low, particularly following intravenous infection, at several subsequent time points. This 
could explain the prolonged time of mice displaying milder symptoms, and the apparent recovery 
of some mice. However, bacterial counts are known to increase at time points later than those 
selected, due to the high counts present in moribund mice. This delayed increase in bacteraemia 
may explain the sudden relapse seen with some mice, where mice showing very mild symptoms, 
or appear to have recovered, quickly progress to more severe and terminal stages of infection. 
This could suggest that early in infection the immune system is more effective at controlling 
infection with the mutant strain but is unable to completely eliminate infection in the majority of 
infected mice. During the later stages of infection, mutant bacteria are able to overcome their 
attenuation, possibly through reaching high enough numbers to resist the host immune response 
and subsequently can cause severe infection and mortality of the infected mice. Host defence 
mechanisms that may have a role in this response are discussed below. 
8.3 Interaction of ZmpB with complement 
The in vivo data discussed above suggested that the ZmpB mutant was highly attenuated within 
the systemic circulation, but was able to grow in the lung tissue. This indicates that components 
of the blood are able to prevent growth of the L1739 mutant. During systemic infection with S. 
pneumoniae, splenic phagocytic cells play an important role in clearing the invading microbes. 
Complement plays a major role in this clearance by acting as an opsonin, coating the surface of 
the bacteria which enhances phagocytosis (Hostetter, 2000). A BLAST search 
(http://www.ncbi.nlm.nih.gov:80IBLAST/) of the ZmpB protein of TIGR4 and R6 revealed a 
region that had 35 % identity (47 % positive residues) with another pneumococcal protein, Hic 
(also known as PspC and CbpA). This protein has been shown to bind complement factor H 
(Neeleman et at., 1999; Janulczyk et at., 2000; Jarva et at., 2002), which is a host protein that 
acts to inhibit complement activation. The binding of factor H to pneumococcal cells is thought 
to inihbit the activation of complement near the cell surface and prevent subsequent deposition of 
opsonic complement components. The region of ZmpB showing homology to HiclPspC is found 
within the first 400 amino acid residues, which comprises the homologous region between 
pneumococcal serotypes. An alignment showing the homology of ZmpB from strains R6, TIGR4 
and G54 with Hic/PspC is provided in the appendix (A6c). HiclPspC itself displays extensive 
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sequence variation between serotypes (Ianelli et at., 2000), although the region found to bind 
factor H is situated towards the more conserved N-terminus part of the protein (Janulczyk et at., 
2000). A fragment of Hic that covered this homologous region was cloned and expressed and 
was shown to bind factor H, within the short consensus repeats 8-11, and to inhibit the binding of 
this component to the pneumococcal cell surface (Janulczyk et at., 2000; Jarva et at., 2002). The 
region encoding this fragment (Hic residues 39-261) is located immediately upstream of the 
region found to have homology with ZmpB (Hic residues 268-526), indicating that ZmpB itself 
may also be capable of binding small amounts of factor H. On the basis of this homology and 
the importance of complement in clearing pneumococcal infection, it was hypothesised that 
ZmpB had a role in inhibiting complement activity during murine infection and that loss of this 
function results in the attenuated phenotype described. To test this, the Ll739 mutant and its 
isogenic parental strain were analysed in complement deficient (C3-/-) mice (C57Bl/6 
background, Wessels et at., 1995). These mice are unable to produce complement component 
C3, a crucial part of both the alternative and classical complement pathways, and are thus unable 
to mount any complement-associated response to infection. Wild-type C57Bl/6 control mice 
(C3+/+) of equal age and gender were also infected with the same dose of bacteria. C3-/- mice 
challenged with wild-type bacteria succumbed to infection quicker and had significantly higher 
levels ofbacteraemia at pre-selected time points compared to C3-/- mice challenged with Ll739 
mutant. When compared to wild type bacteria, the LlzmpB mutants showed the same attenuated 
phenotype in C3-/- as observed in MF1 mice suggesting that complement is important in clearing 
both D39 wild-type and the Ll739 mutant. Thus a factor other than complement appears to be 
responsible for the impaired growth in the blood and increased murine survival following 
challenge with such mutants. If the hypothesis of ZmpB interacting significantly with 
complement had been correct, similar levels of virulence between the wild-type and mutant 
bacteria in C3-/- mice would have been observed. The indication from these data that ZmpB does 
not bind factor H could be confirmed by Western blot using anti-factor H antibody, and 
comparing the binding of factor H to D39 wild-type and the Ll739 mutant (Pandiripally et at., 
2002). 
Although ZmpB was not shown to interact with complement, the work with the C3-/- mice 
highlighted the importance of complement in the response to pneumococcal infection in C57IBI 
mice. Following intranasal challenge with wild-type bacteria, 80 % of complement-sufficient 
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C3+/+ mice survived the challenge and did not have any detectable bacterial counts in the blood 
at all time points examined. However, in the absence of complement, all mice (C3-/-) infected 
with D39 quickly succumbed to infection and had extremely high bacterial counts in their blood 
within 24 - 36 hr post infection. By 40 hr post infection, 90 % of C3-/- mice infected with D39 
had been culled due to the severity of their symptoms. Complement is known to be important in 
the human host defence system against S. pneumoniae, as complement deficiencies predispose 
patients to pneumococcal infection (Figueroa and Densen, 1991). Thus this is an example where 
the use of animal models can be highly relevant to understanding the infection process in the 
human host. 
8.4 Role of ZmpB in inflammation 
Pathology of pneumococcal pneumonia and meningitis is thought to result from an exaggerated 
host inflammatory response to bacterial components (Tuomanen et at., 1995). Overwhelming 
inflammation can contribute to tissue injury and shock. This is supported by the observation that 
death may occur days after the initiation of antibiotic therapy when tissue culture is sterile but a 
strong inflammatory response still persists (Bergeron et at., 1998). The ability of pneumococcal 
cell wall and toxin pneumolysin to induce inflammation has been described (introduction 1.6.3), 
but little is known about other bacterial factors that could influence the inflammatory response. 
The host inflammatory response to pneumococcal pneumonia is complex and involves a range of 
pro and anti-inflammatory cytokines, the balance of which is crucial in determining outcome of 
infection. TNF- a is a well-established early mediator of inflammation and is critical for the 
ability of the host to control microbial infections (Blanchard et ai., 1988; Steinshamn et ai., 
1996; Lima et ai., 1997 and). Many groups have identified a protective role for TNF-a in 
pneumococcal infection in vivo (Takashima et ai., 1997; O'Brien et at., 1999; Kerr et ai., 2002). 
However, TNF-a can also be detrimental by inducing tissue injury within the lung. Such injury 
could impair tissue integrity and enhance passage of bacteria from the lungs to the bloodstream 
(Bergeron et at. 1998). 
The reduced levels of bacteraemia in the blood of mice challenged with the L1739 mutant 
compared to wild-type from 24 hr post challenge could indicate that wild-type are more able to 
survive in the blood. Alternatively, it could suggest that at later time points more wild-type 
bacteria are able to disseminate from the lung tissue into the blood stream. As the inflammatory 
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response is thought to result in tissue damage (Bergeron et at., 1998), it was hypothesised that a 
more vigorous host response in the lungs tissue during wild-type infection could impair tissue 
integrity and allow bacteria to gain further entry into the bloodstream. To test this hypothesis, 
levels of TNF-a within the respiratory tract were compared following challenge with wild-type 
and mutant bacteria. TNF-a was chosen based on its role as a potent pro-inflammatory cytokine 
that has been characterised previously with regards to its role in pneumococcal pneumonia. It is 
also one of the first inflammatory mediators to be produced following pneumococcal infection 
(O'Brien et at., 1999). 
Significantly increased levels of TNF-a were found in the lung tissue 24 hr post challenge with 
the wild-type bacteria compared to the /).739 mutant. TNF-a, at this time point, was only detected 
in the lungs of 20 % of mice infected with the mutant, compared to 90 % of lungs following 
challenged with wild-type D39 (data not shown). When detected in the lung tissue of mice 
following challenge with the L1739 mutant, TNF-a concentrations were extremely low and did 
not differ significantly from those in the uninfected / control mice. TNF -a could not be detected 
significantly within the lungs at any other time point studied, nor could it be detected in the 
BALF. However, visual inspection of the bioassay, using lung tissue 12 hr post infection, 
indicated that TNF-a was present in the lung tissue of mice infected with D39 wild-type but 
absent in mice infected with the mutant (data not shown). In this assay, the presence of TNF kills 
the L929 fibroblasts, and the dead cells are subsequently unable to metabolise added MTT to its 
purple-coloured formazan product. The absence of a colour change was visible by eye for the 90 
% of the lung samples from mice challenged with wild-type bacteria, although the levels of TNF 
were too low to be detected using the conventional measurements of the assay. No colour change 
was seen for any of the lung samples taken from mice infected with the L1739 mutant, indicating 
the absence of detectable TNF-a. These data indicated that ZmpB is involved in generating a 
host inflammatory response through the production ofTNF-a, 12-24 hr into the infection. 
To further analyse the inflammatory response in the respiratory tract of mice, the profiles of 
several other cytokines were studied. These cytokines were chosen based on previous data that 
indicated a role for such cytokines during pneumococcal infection (see introduction, section 
1.5.3.2). IFN-y and IL-6 were chosen to represent further pro-inflammatory cytokines and IL-I 0 
was chosen to represent an anti-inflammatory cytokine. 
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The concentration of the above cytokines was detennined at 12, 18,24 and 36 hr post infection 
in the BALF and the lung tissue. Bacterial counts from the BALF samples were also detennined 
to ensure that any differences in cytokine concentration were not due to different bacterial 
counts. These data showed that as infection progressed, bacterial counts in the BALF decreased, 
indicating that infection from the airways was being eliminated by the host response or had 
progressed into the lower respiratory tract. No difference was observed for BALF counts 
between the wild-type and mutant strain, with the exception of the 36 hr time point, where mice 
challenged with wild-type bacteria had increased bacterial counts in the BALF. These counts 
were significantly higher than those seen in mice infected with the L1739 mutant. It is not known 
if this increase is characteristic of D39 infection as previous studies of cytokine profiles 
following pneumococcal infection have used different mouse models. To assess this further, the 
experiment would have to be repeated as challenges for cytokine detennination were perfonned 
with 5 mice only for each time point examined (with the exception of the TNF-a studies where 
n=10 and where experiments were perfonned on two separate occasions). Bacterial counts in the 
lung tissue samples used for cytokine detennination could not be assessed because the snap 
freezing procedure used to preserve the cytokines from degradation in the lung tissue would kill 
any bacteria present. However, previous data measuring the bacterial loads in lung tissue at 12, 
24 and 36 hr post infection did not detect any significant difference in counts between wild-type 
and the L1739 mutant, indicating that the bacterial counts in the lung tissue used for cytokine 
analysis should also remain the same. 
The only significant difference in cytokine profile between the wild-type and mutant bacterial 
strains was for IFN-y, in the BALF, 24 hr post infection, where higher levels of this cytokine 
were present in mice infected with mutant bacteria. The relevance of this finding to the infection 
is not clear as IFN-y is a pro-inflammatory cytokine and thus would indicate more inflammation 
in the airways of mice challenged with the L1739 mutant compared to wild-type infection. This 
would not be in agreement with the findings based on TNF -a levels within the lung tissue at the 
same time point. A similar increase in the level of IFN-y is not observed in the lung tissue at 24 
hr post infection. Furthermore, the level of IFN -y in the BALF at this time point is much higher 
than any of the other time points observed following infection with L1739, suggesting that 
abnonnally high levels of this cytokine in the airways of one or two of the mice may have 
skewed the data for this experiment. The concentration of cytokines within the BALF tissue was 
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consistently much lower than concentrations III the lung tissue, indicating that the latter 
environment is more important in terms of generating an inflammatory response, and further 
discussion will thus only be based on cytokine profiles in the lung tissue. One point of interest 
with respect to the cytokine profile in the BALF is the observation that lower IL-I0 levels are 
seen in the lung tissue following infection with both bacterial strains compared to the uninfected 
/ control mice. This could indicate that infection with both strains results in inhibition of IL-l 0 
production, although the mechanism by which this occurs is unknown. 
Within the lung tissue the concentrations of all cytokines appeared to increase over time, and this 
may be attributed to the increase in bacterial load up to 24 hr post infection (see figure 7.10). 
However, at 36 hr post infection, bacterial counts in the lung tissue were much lower than 
previous time points for both the wild-type and the mutant. This decrease in bacterial counts was 
not parallelled by a decrease in cytokine levels, as median concentrations of IFN-y, IL-6 and IL-
10 all increased between the 24 hr and 36 hr time points. The increase in IFN-y and IL-6 is in 
agreement with published data suggesting that the inflammatory response can continue long after 
bacterial infection has been eliminated (Bergeron et ai., 1998). Indeed concentrations of the pro-
inflammatory cytokine IFN-y are the highest of the cytokines studied at all time points examined, 
following by IL-6, also proposed to have pro-inflammatory activities. The increase in the 
concentration of the pro-inflammatory cytokines is matched by an increase in the anti-
inflammatory cytokine IL-I0. Presumably as inflammation progresses, higher levels of this 
cytokine are required to control the host response and prevent it from becoming detrimental. It is 
interesting to note that levels of IL-l 0 in the lung tissue of mice challenged with mutant bacteria 
are consistently higher than the lung tissue of mice challenged with D39 wild-type, up to and 
including 24 hr post challenge, although this difference is not statistically significant. At 36 hr, 
levels of1L-10 are not higher following infection with the mutant. 
Due to the pleiotropic effects of TNF -a and the complex nature of the host inflammatory 
response, the level of many cytokines and other mediators may be altered between infection with 
the mutant and wild-type bacteria. For example, it has been shown that TNF-a can induce the 
production of IFN-y from immune cells (Zhang and Tracey, 1998). This would suggest that the 
decreased levels of TNF -a following challenge with mutant bacteria would similarly result in 
decreased levels of IFN-y compared to infection with wild-type bacteria. Although median levels 
of IFN -y in the lungs of mice challenged with mutant bacteria were lower than levels in the lung 
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tissue of mice challenged with wild-type bacteria at 24 hr, this difference was only slight and not 
statistically significant. However IFN -y production can be induced by other factors, including IL-
12, and it can also stimulate its own production (Roitt et al., 1996b). This highlights the caution 
that must be exerted when analysing host immune responses mediated by cytokines and other 
factors. Furthermore different immune cell types will be recruited to or activated at different 
stages of infection, and the presence of such cells will have a huge influence on the immune 
response generated. Thus further characterisation of the immune response following challenge 
with mutant and wild-type bacteria is required, and will be discussed later in this chapter. 
8.5 Proposed series of events following intranasal challenge 
Based on the data presented above, it appears that ZmpB has a role in inducing an inflammatory 
response and this confers an advantage upon wild-type bacteria during the earlier-middle stages 
of infection. The proposed series of events following intranasal infection are highlighted below 
and are based. 
0-12 hr 
During this time an inflammatory response is initiated through the activity of TNF -a, induced by 
wild-type bacteria only (as determined by eye). This inflammation is not strong enough to induce 
tissue damage at this very early stage of infection and both wild-type and mutant strains are able 
to breach the lung tissue and gain access to the blood at this point independent of the intensity of 
inflammation. 
12-36 hr 
Although inflammation is present in the lungs following challenge with the L1739 mutant, as 
evident by the increased concentrations of IFN-y and IL-6, the inflammatory response appears to 
be less severe than that in the lungs of mice infected with D39 wild-type. This is based on 
significantly lower levels of TNF-a and slightly increased levels of IL-I0. The increased 
inflammatory response proposed during D39 infection could impair tissue integrity, allowing 
more bacteria into the bloodstream and this would enhance the ability of bacteria to reach 
sufficient counts to evade the immune response. Furthermore, the balance of cytokines at this 
stage could have a significant influence on the host immune response at later stages. As a result 
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of less inflammation, fewer numbers of mutant bacteria would gain access to the bloodstream, 
allowing host defences to deal with the decreased numbers of mutant bacteria already present in 
the systemic circulation. 
36 hr onwards 
By this stage, inflammation within the lung tissue appears to have reached similar levels in mice 
infected with both the mutant and wild-type strains. Consequently more mutant bacteria will 
have gained access to the bloodstream, and bacterial counts within the blood will have increased. 
This increased bacterial load will eventually reach a level where the immune system is unable to 
control the infection any further and mice become sick, quickly leading to the terminal stages of 
infection relatively quickly, as evident by the sudden relapse of such mice. 
The hypothesis highlighted above is based on the inflammation induced by ZmpB leading to 
tissue destruction and subsequently increasing access to the bloodstream. However, if this 
hypothesis is true, then ZmpB must have other functions important in virulence as direct 
inoculation of the L1739 mutant into the blood also results in lower bacterial counts and increased 
murine survival. This suggests that active ZmpB also functions to evade the host immune 
response or to help bacteria survive in the blood, possibly through the sequestration of essential 
nutrients. 
These data suggests that the role of ZmpB in virulence is multifactorial. Being such a large 
protein, it is possible that ZmpB, like pneumolysin, has separate regions within the protein that 
contribute differently to virulence. Further experiments to examine the role of ZmpB in 
pneumococcal infection, and to provide evidence for the hypothesis described above are 
suggested below. 
With respect to the phenotype of the L1739 mutant discussed above, a similar phenotype has been 
described for mutants in Mycobacterium tuberculosis which lacked the alternative sigma factor, 
SigH (Kaushal et al., 2002). Such mutants persisted within murine lung tissue but had a delayed 
inflammatory response (Kaushal et al., 2002). Thus further insight into the basis of the L1739 
phenotype could also be relevant to other microbial pathogens. 
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8.6 Further determination of the role of ZmpB in virulence 
8.6.1 Inflammation 
To further characterise the inflammatory response other inflammatory mediators could be 
examined, including other cytokines or nitric oxide (NO). The latter is a potent molecule 
produced in response to pneumococcal infection and can be induced by TNF-a (Coleman, 2002). 
NO, like TNF-a, is thought to be beneficial in small amounts but can cause tissue damage when 
present at increased levels (Bergeron et at., 1998). The Greiss reaction can be used to determine 
nitric oxide concentration (Bematowicz et at., 1995). 
Evaluation of the immune cell types present or recruited to the site of infection over time is 
important to determine the extent of inflammation and the potential source of increased TNF-a 
observed during infection with wild-type bacteria (Kerr et at., 2002). A variety of cell types can 
produce TNF -a, including macrophages, neutrophils, lymphocytes and mast cells (Tracey and 
Cerami, 1994). Some of these cell types, such as macrophages and mast cells, will be present in 
the lung tissue. Mast cells in particular are thought to be important in the early release of TNF -a, 
having pre-formed TNF-a (Gordon et at., 1990 and Kerr et at., 2002). Other cells, such as 
neutrophils, will be recruited to the site of infection, with TNF -a itself serving to attract and 
activate neutrophils. These cells are important for their role in pneumococcal killing, although 
overactivity could contribute to tissue pathology. Thus a large influx of inflammatory cells 
would exacerbate the inflammation and result in further tissue damage. hnmunohistochemistry is 
currently being performed on lung samples from several time points following infection with 
D39 and the L1739 mutant to characterise the immune cells present (by A. Kadioglu, Leicester). 
Production of TNF -a by different cells, such as alveolar macrophages and lung cells could also 
be determined using tissue culture assays. 
The nature of the host response to pneumococcal infection is highly complex and is likely to 
involve many components too numerous to study in individual experiments such as those 
described above or used as part of this thesis. A more comprehensive way of studying the 
response to infection would be to use microarray analysis. Mouse arrays comprising 3000 
immune response genes are available and could be used to examine gene profiles in tissue from 
infected mice, or from specific cells stimulated in vitro with bacterial strains. This work could 
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provide important clues to the differences in virulence of mutants compared with the isogenic 
parental strains. 
With respect to the role of ZmpB in generating increased levels of TNF -u, there are several 
possible explanations. The protein itself could function as a chemoattractant to recruit immune 
cells capable of producing TNF -u to the site of infection. Other possible functions that would 
result in increased TNF -u, could depend on the putative protease activity of ZmpB (discussed 
later), whereby host proteins such as cytokines and their receptors or matrix metalloproteases 
(MMPs) could be targets for proteolysis. ZmpB may also act to cleave pneumococcal proteins, 
either within the cell or on the cell surface and serve to activate or inhibit the function of such 
proteins. 
Cytokines and their receptors 
A number of pathogens produce proteases capable of degrading cytokines and are thus thought to 
be important virulence factors. P. aeruginosa produces two distinct proteases both capable of 
degrading cytokines. The elastase enzyme has been shown to degrade IL-2 and TNF-u (Parme1y 
et at., 1990), and the alkaline protease degrades IFN-y (Horvat et at., 1988). A zinc 
metalloprotease from LegioneUa pneumophila can also cleave IL-2 and TNF-u (Hell et al., 1993; 
Mintz et at., 1993) and has been shown to have structural and functional homologies with the P. 
aeruginosa elastase (Black et at., 1990). In contrast, there are examples of bacterial proteases 
that are able to activate cytokines via cleavage of the precursor form into its active form (Kapur 
et at., 1993). 
Similarly, bacterial proteases have been found that can cleave cytokine receptors. This can result 
in the cleaved receptor acting as a competitive inhibitor for the cytokine or the receptor may bind 
to cells that do not usually express it, thus rendering the cells responsive to the cytokine. 
Proteases from a range of organisms, including Staphytocuccus aureus, P. aeruginosa and 
Serratia marcescens, have been shown to cause the release of IL-6 receptor (IL-6R) from human 
monocytes and macrophages (Vollmer et at., 1996). The IL-6R released by the S. marcescens 
protease was found to be biologically active and able to render hepatoma cells, which do not 
usually express IL-6R, responsive to IL-6 (Vollmer et at., 1996). 
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There are several ways in which S. pneumoniae ZmpB could induce high levels of TNF - a based 
on cleavage of cytokines and their receptors. For instance, it could cleave membrane bound pro-
TNF - a to its mature, more active form and thus mimic the activities of the natural host TNF-a 
converting enzyme, which is itself, a zinc metalloprotease. To test this hypothesis, macrophages 
or mast cells could be incubated with live and heat killed wild type and mutant bacteria. 
Following incubation, target cells would be subject to flow cytometry to detect the presence of 
surface bound TNF -a. ZmpB could also cleave cytokines or mediators involved in regulation the 
inflammatory response, rendering them inactive. IL-10 would be an example of such a candidate, 
although levels of this cytokine were not found to be significantly different following infection 
with mutant bacteria compared to wild-type infection. 
Matrix metalloproteases 
ZmpB could also mimic the activity of matrix metalloproteinases (MMPs) or activate MMPs 
themselves. MMPs are a family of zinc metalloprotease that are able to degrade virtually every 
component of the extracellular matrix (ECM) (Leppert et at., 2001). They are generally secreted 
as inactive precursors and activated to their mature form by extracellular cleavage. Many cell 
types, including neutrophils and macrophages, produce MMPs. Other than ECM components, 
MMPs can cleave cytokine precursors, including TNF- a, and their receptors, and pro forms of 
MMPs themselves (Leppert et at., 2001). Cytokines, including TNF- a, can stimulate activation 
ofMMPs. This can result in a massive loop of amplification where MMPs and TNF- a can cause 
activation of each other and themselves. Unsurprisingly, MMPs have potential for massive tissue 
degradation and are thought to play a role in the pathogenesis of several disease states 
(Nakamura et at., 1998; Leppert et at., 2001; Warner et at., 2001). Indeed an increase in MMP9 
and TNF- a in the CSF of experimental pneumococcal meningitis has been shown (Leib et at., 
2000). 
Proteolysis of ECM is a key event in the progression of inflammatory processes and may 
contribute to infection by allowing spread of pathogens. Several bacterial pathogens, including 
P. aeruginosa and Vibrio choterae, have been found to have proteases able to activate different 
MMPs (Okamoto et at., 1997). Such enzymes are likely to be important virulence factors. It is 
feasible that S. pneumoniae ZmpB could also function as an MMP-activating enzyme within the 
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lung environment and thus facilitating the activation of TNF - a indirectly. For example, ZmpB 
could mimic the activity ofMMP-12, which is the predominant metalloelastase of macro phages 
in the lungs. MMP-12 has been linked with damage to lung tissue, recruitment of neutrophils 
into the lungs and ability to shed biologically active TNF-a (Warner et at., 2001). MMP-12 
activity is up-regulated in cigarette smokers, a condition which also predisposes to 
pneumococcal infection (Hautamaki et at., 1997; Ahmer et at., 1999). Although specific MMP 
inhibitors are generally not available, MMP deficient mice (including MMP-12 -1-) have been 
developed (Warner et at., 2001) and would be a useful model in which to study pneumococcal 
infection in general. Furthermore, this model could be used with the L1739 mutant and its 
isogenic parental strain. Proteolytic destruction of ECM components by ZmpB could be one way 
of inducing an inflammatory response that would result in increased TNF - a levels. 
8.6.2 Growth in the blood 
The attenuated ability of the L1739 mutant to grow in the blood of mice indicates an important 
role for ZmpB within this environment. Phagocytosis is an important clearance mechanism for 
systemic pneumococcal infection and increased phagocytosis of mutant bacteria would reduce 
their survival in blood. Although this process is mediated by complement, and data presented in 
this work indicates that ZmpB does not significantly interfere with complement function, 
phagocytosis may also depend on factors other than complement opsonisation. Anticapsular 
antibodies can promote phagocytosis, although a humoral response to pneumococcal infection is 
thought to take at least 11 days to develop (Dallaire et at., 2001) so would not be expected to 
playa role in the acute model of infection used within this work. In Streptococcus pyogenes, 
fibrinogen binding to the surface of bacteria cells has been shown to influence phagocytosis 
(Hortsmann et at., 1992; Pandiripally et at., 2002), suggesting that other host components may 
also influence phagocytosis in pneumococcal infection. Classical in vitro phagocyte killing 
assays could be used to determine if the L1739 mutant is more susceptible to phagocytosis, and 
the activity of phagocytic cells from both the blood and lungs could be compared (Jansen et at., 
2001). These assays have been described previously (chapter 6, section 6.2). 
Alternatively, isolated whole human and I or murine blood could be used to determine if this 
medium supports the growth of the L1739 mutant. This could help determine if a component 
within the blood, or the lack of certain nutrients in the blood is preventing the growth of mutant 
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strains, or if this growth defect is due to a host component not present in isolated blood. 
Comparison of the bacterial strains in nutrient deplete broth could help identify if wild-type D39 
bacteria are able to grow more efficiently in such conditions compared to the Ll739 mutant strain. 
8.6.3 Adhesion 
Pneumococcal colonisation and adhesion to host tissues is a crucial step in initiation of the 
disease process and is thus a potential target of both prophylactic and therapeutic treatment. 
Pneumococci have been proposed to adhere to a range of cell types within the human respiratory 
system, including both resting and activated cells (Anderson, et al., 1983; Gerard et al., 1995; 
Cundell and Tuomanen, 1997). It has also been proposed that inflammatory cytokines induced 
by bacterial factors may up-regulate expression of host proteins that can subsequently be utilised 
by the pneumococcus for adhesion (Sollid et al., 1987; Kelly et al., 1994; Kadioglu et al., 2002). 
It could thus be hypothesised that increased levels of TNF- a induced by wild type D39 may 
promote adhesion by the up-regUlation of host factors used for pneumococcal attachment. ZmpB 
has previously been proposed to playa role in the colonisation of rat and human nasopharyngeal 
tissue, although the mutant strain used within these studies was later shown to be a non-
pneumococcal Streptococcus species (Novak et al., 2000; Berge et al., 2001). Data presented in 
this thesis indicate that the Ll73 9 mutant was not impaired in its ability to colonise murine 
airways or lung tissue. Thus, data from the work in this thesis does not support a link between 
inflammation and increased adhesion, so it is necessary to study this phenomenon in further 
detail. Several differences (other than contaminating bacterial strains) could account for the 
conflicting data in the ability of LlzmpB mutants to adhere. Novak and co-workers used a mutant 
in a serotype 4 pneumococcus and human cell lines or rat nasopharyngeal tissue to examine 
adhesion, whereas our mutants, in a type 2 background, were analysed for their ability to 
colonise murine airway and lung tissue in vivo. The Ll739 mutant could thus be constructed in a 
type 4 pneumococcal strain and used to compare adhesion with its isogenic parental strain. Such 
a mutant would also be useful for characterisation in the murine infection model used for the 
ZmpB analysis. As the sequence of ZmpB between serotypes is so variable, this work could 
determine if ZmpB has similar functions in different serotypes. 
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8.6.4 Immungenicity and potential as a vaccine candidate 
During this work, antibodies recognising the central region of ZmpB were produced following 
vaccination of mice with part of the ZmpB protein. These antibodies (and the purified ZmpB 
protein) can be used in a variety of ways to further characterise ZmpB. For example, the Western 
blot assay developed within this work could be used to determine if the antibody raised against 
ZmpB from a serotype 2 strain can recognise ZmpB in other serotypes. This is important based 
on the described sequence variation in ZmpB between serotypes. Similarily, pure ZmpB protein 
could be used to determine if antibodies to ZmpB are present during infection, both in murine 
sera following experimental infection and in convalescent sera from human infection. This 
would indicate if ZmpB is naturally immunogenic and produced during pneumococcal infection. 
Furthermore, vaccination studies with the ZmpB protein could be performed to determine the 
protection conferred by ZmpB against subsequent pneumococcal challenge. Anti-ZmpB 
antibodies could also be used to determine if passive protection could be achieved. Again, this 
work could be extended to include the protection elicited against different serotypes or strains of 
S. pneumoniae. All such studies would be important if ZmpB was to be considered as a potential 
vaccine candidate. 
8.6.5 Cellular localisation 
It is not known if the pneumococcal ZmpB protein is present on the cell surface or secreted into 
the surrounding medium. Sequence analysis of ZmpB reveals a LPXTG motif located at the N-
terminal (http://www.tigr.org/).InotherGram-positivebacteria.this motif serves to anchor 
proteins to the cell surface, through the action of a sortase enzyme (Pallen et at., 2001). This 
sortase cleaves between the threonine and the glycine residues and transpeptidates the protein to 
the pentaglycine cross-links of the cell wall (Mazmanian et at., 1999). Such evidence indicates 
that ZmpB is exported to the pneumococcal cell surface. The LPXTG motif, however, is 
generally found at the C-terminal region of Gram positive proteins, so its relevance as a cell 
surface anchor for pneumococcal ZmpB is unclear. The LPXTG residues in ZmpB in D39 have 
been selectively deleted using Janus mutagenesis (G. Paterson, our laboratory). This technique is 
based on the Janus cassette constructed by Sung and co-workers (Sung et al., 2001). Using two 
transformations, this cassette can be used to insert stop codons or DNA of arbitary sequence at 
any chosen site in the pneumococcal genome. The technique is extremely versatile, allowing 
335 
Chapter 8 S. pneulIloniae ZmpB Discussion 
complete inactivation of genes, or more subtle mutations such as amino acid changes, or epitope 
tagging. The resulting mutations do not possess any antibiotic-selection markers that may 
interfere with further investigation. This also allows for the construction of multiple mutations in 
different genes without the need for various antibiotic selection markers. The technique allows 
for the transfer of large regions of DNA between different strains. Furthermore, polar effects on 
downstream genes are avoided. To determine cellular localisation, the Janus mutant and its 
isogenic parental strain could be analysed in conjunction with a sortase null mutant that has also 
been constructed (G. Paterson, our laboratory) using cell fractionation and subsequent detection 
of ZmpB with the anti-ZmpB antibodies in the different fractions. The L1739 mutant could be 
used as a negative control in such experiments. 
The Janus mutagenesis technique could also be used to mutate the HEXXH-E region thought to 
be essential for the activity of zinc metalloproteases. Analysis of resulting mutants using the 
same experiments described in this thesis for L1739 would help determine if the putative protease 
activity of ZmpB contributes to its role in virulence. This could also help provide evidence that 
ZmpB does indeed have protease activity. 
8.6.6 Other functions 
A BLAST search (http://www.ncbi.nlm.nih.gov:80IBLASTI) revealed that the ZmpB proteins of 
the TIGR4 and R6 strains both had highest homology with IgA1 proteases (iga) from S. 
pneu1110niae and other bacteria, mainly Streptococcal species. These proteases function to cleave 
IgA1 and are thus thought to function in immune evasion (Plaut, 1983). Unlike the homology 
with Hic/PspC, the homology to IgA1 proteases was present across the whole protein sequence. 
Table 8.2 shows the region of homology of the TIGR4 ZmpB protein with other proteins. The 
homology with Streptococcal IgA1 proteases is intriguing as this group of proteins have other 
features in common with ZmpB. It has been demonstrated that heterogeneity is present within 
the IgA1 proteases, even within the same species (Poulsen et al., 1996). The IgA1 proteases of 
Streptococcal species also have the HEXXH-E motif characteristic of zinc metalloproteases and 
have a LPXTG motif unusually located at the N-terminus region of the protein. It is thought that 
the heterogeniety between the iga genes is the result of horizontal transfer and recombination 
within and between species (Poulsen et al., 1998). Isolates of S. pneu1110niae vary in their IgA1 
protease activity and this has been attributed to the polymorphism within this species (Reinholdt 
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and Kilian, 1997). Although annotated as IgA1 proteases, these proteins may have other 
functions. Indeed in two, independent STM screens set up to identify pneumococcal virulence 
factors in different pneumococcal serotypes, disruptions in iga genes were found to be attenuated 
in virulence (Polissi et at., 1998; Hava and Camilli, 2002). As murine models were used for both 
screens, and bacterial IgA proteases specifically cleave human but not mouse IgA (Plaut, 1983), 
this data suggested that these proteins have other functions (Hava and Camilli, 2002). One of the 
STM screens demonstrated reduced virulence of a pneumococcal iga mutant in models of 
pneumonia and septicaemia (Polissi et at., 1998). As IgA1 acts predominantly at the mucosal 
surface, reduced virulence of the iga mutant in a septicaemia model is further evidence that this 
gene has roles in virulence other than IgA1 cleavage. Furthermore, the IgA1 protease of N 
gonorrhoeae has been shown to cleave LAMPI, a lysosome integral membrane protein (Hauck 
and Meyer, 1997), indicating that other proteins are indeed the target of IgA1 proteolytic activity 
in bacterial pathogens. 
Repeat structures showing variation in number and sequence have been identified in many 
Streptococcal iga genes. Indeed, the zmpB gene of TIGR4 was identified as containing a stretch 
of iterative DNA (CAAAACAAAACAAAA) (Novak et at., 2000; Tettelin et at., 2001). This 
repeat sequence could not be found in the R6 or G54 zmpB nucleotide sequences however. 
Repeated structures are found in many surface exposed and secreted proteins of Streptococci and 
may allow for phase variation and hence immune evasion (Kehoe, 1994). 
Novak and colleagues tested ZmpB for IgA1 and IgA2 proteolytic activity but could not detect 
any (Novak et at., 2000). While it would be interesting to perform further IgA1 / IgA2 
proteolysis assays to determine if ZmpB does possess this activity, this would not explain the 
attenuation in virulence for L1739 in our murine model of infection as pneumococcal IgA1 
proteases are specific for human IgA only (Plaut, 1983). Furthermore, one study deleted the gene 
encoding the IgA1 protease a type 2 pneumococcus (R6) and found that the resulting mutant had 
a complete loss of human IgA1 proteolytic activity (Wani et at., 1996). This indicates that ZmpB 
may not cleave human IgA1, although the assay conditions used for the above study may not 
have been optimal for detecting IgA1 protease activity present in other genes. 
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Protein description Identity Positives ZmpB region of alignment 
ZmpB, Streptococcus pneumoniae, 98% 99% Across fIrst 300 amino acids 
strain R6 
-----------------
------------------ ------------------------------------------------
40% 58 % 
Across remainder of protein 
ZmpB, Streptococcus pneumoniae, 99% 99% Across fIrst 300 amino acids 
strain G54 (type 19F) 
----------------- ------------------ ------------------------------------------------
41 % 59% Across remainder of protein 
IgA1 protease, Streptococcus 28 % 46% Across whole protein 
pneumoniae, strain TIGR4 
IgA1 protease, Streptococcus 26% 45% Across whole protein 
pneu11loniae, strain R6 
IgA1 protease, Streptococcus 26% 44% Across whole protein 
sanguinis 
IgA1 protease, Streptococcus mitis 25 % 44% Across whole protein 
Factor H-binding region, PspC, 35 % 47% Residues 154-396 
Streptococcus pneumoniae, strain 
A66 (type 3) 
Table 8.2 Proteins showing homology to ZmpB (TIGR4) 
A BLAST search was performed to determine proteins showing homology to S. pneu11loniae ZmpB (from 
the TIGR 4 strain). The table shows a selection of the proteins showing highest homology, together with 
the region over which homology was present. 
The L1739 mutant described in this thesis is currently being analysed in a C. elegans model of 
infection to determine if it is attenuated compared to D39 wild-type in this model ( W. Jansen, 
CX Utrecht, the Netherlands). As discussed in chapter 4, the use of such models are a cheaper 
and simpler alternative to murine models and may enhance our understanding of the infection 
process. 
8.7 Regulation of ZmpB expression 
RT-PCR data presented in this work suggests that TCS09 does not prevent the expression of 
ZmpB, at least under the conditions used. This would not be unusual, as close proximity of a 
gene to a TCS does not necessarily imply its regulation by that system. This observation, does 
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not however, preclude the possibility that TCS09 is involved in regulating zmpB as the RT-PCR 
analysis used is not quantitative. It could be possible that TCS09 may up- or down-regulate zmpB 
expression and this could be assessed using a quantitative technique such as real-time RT-PCR. 
Although it was hoped that zmpB regulation by TCS09 could be confirmed by micro array 
analysis using the ilrr09 mutant discussed in chapter 6, the ZmpB probe on the array was 
designed based on the TIGR4 sequence and shows limited homology to the type 2 R6 sequence. 
Thus to overcome this problem a rr09 mutant will be constructed in the type 4 TIGR4 strain and 
re-analysed for ZmpB expression. 
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At. S. pneumoniae strains 
Strain Description 
D39 Obtained from NCTC (7466), Central Public Health Laboratory, London. Encapsulated virulent isolate, related to the non-
encapsulated R6 strain. Serotype 2. MLST type 128 
L1pASI Mutation in rr08. Created by insertion duplication mutagenesis (in this study). 
L1rr08 Mutation in rr08. Created by allelic replacement (in this study). 
L1pRPL7 Mutant in hk08. Created by insertion duplication mutagenesis (in this study). 
L1rRPL50 Mutation in gene immediately upstream ofTCS08, sp0082. Created by insertion duplication mutagenesis (in this study) .. 
I 
L1rr09 Mutation in rr09. Created by allelic replacement (in this study) .. 
! 
L1hk09 Mutation in hk09. Created by allelic replacement (in this study) .. 
L1738 Mutation in zmpB. Created by Mariner mutagenesis (in this study) .. Resistant to spectinomycin. 
L1739 Mutation in zmpB. Created by Mariner mutagenesis (in this study) .. Resistant to spectinomycin. Mutation results in a more 
truncated version of L1zmp738. 
0100993 Encapsulated, clinical isolate, serotype 3.0btained from M.K.R. Burnham, GlaxoSmithKline (NCIMB no. 40794) MLST type 595 
L1484hk Mutation in hk08 gene, created by allelic replacement. Obtained from M.K.R. Burnham, GlaxoSmithKline. 
L1484rr Mutation in rr08 gene, created by allelic replacement. Obtained from M.K.R. Burnham, GlaxoSmithKline. 
L1488 Mutation in rr09 gene, created by allelic replacement. Obtained from M.K.R. Burnham, GlaxoSmithKline. 
TIGR4 Encapsulated, clinical isolate, serotype 4. Used for the TIGR genome sequencing project (Tettelin et aI, 2000). Other names for this 
strain inc1udeJNR.7/87, KNR.7/87 and N4. MLST type 205 
R6 Unencapsulated, avirulent derivative of strain D39. MLST type 128. Obtained from J-P. Claverys, Toulouse, France 
Table Al S. pneumoniae strains 
Parental strains are illustrated in bold. Mutant strains are illustrated in italics. Mutant strains all have cassettes encoding erythromycin resistance, unless stated otherwise. 
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A2: Hoffmann-La Roche Constructs and vector for TCS08 insertion-duplication mutants 
Construct Function 
pRPL7 To knock out hk08 gene 
pAS1RR08 To knock out 1'1'08 gene 
pRPL50 To knock out sp0082surface protein gene 
Table A2 Plasmid constructs and associated mutations 
The table lists the constructs received from Hoffmann-La Roche which, when transformed into growing cultures of 
S. pneul11oniae, create the mutations described upon homologous recombination into the target gene. All constructs 
are based on the 7.4 Kb pAS1 vector, see below (Mortier-Barriere et at., 1998) and produce an erythromycin-
resistant phenotype when integrated into the pneumococcal genome. Failure to integrate into the genome will result 
in loss of the plasmid. The pRPL50 vector includes a tag that will target any translated protein sequence for 
degradation (Keiler et al., 1996 and Molnos et at., 2000). 
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Figure A2; pASt suicide vector used to construct the TCS08 insertion-duplication mutants 
The pAS1 plasmid is a suicide vector unable to replicate in S. pneul110niae (Mortier-Barriere et at., 1998). A region 
homologous to the gene targeted for mutagenesis was inserted into the multi-cloning site (mcs) and the resulting 
construct was used to transform strain D39. Integration into the target gene occurs by homologous recombination. 
Transformants are selected by their resistance to erythromycin, encoded within the pAS 1 vector. Failure to integrate 
into the chromosome results in loss of the plasmid from the host cell. For the LJpRPL50 mutant, the coding sequence 
of a trnRNA molecule was inserted into the pAS 1 vector to target any translated protein for degradation. 
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A3 Primers used 
General primers 
Name Sequence (5'-3') Description 
PlyF CGGGATCCGGCAAATAAAGCAGT Forward primer for pneurnolysin gene 
AAATGACTTT 
PlyR GACGGAGCTCGACTAGTCATTTTC Reverse primer for pneurnolysin gene 
TACCTTATC 
T3 ATTAACCCTCACTAAAGGGA Forward primer for sequencing PCR products 
in pCR®4-TOPO® 
T7 TAATACGACTCACTATAGGG Reverse primer for sequencing PCR products 
in pCR®4-TOPO® and pET33b 
16SF GATAACTATTGGAAACGATAGCT Forward primer for 16S RNA gene. Control for 
AATACCG RT-PCR. 
16SR GCTAATGCGTTAGCTACGGCACT Reverse primer for 16S RNA gene. Control for 
AAACCC RT-PCR. 
--
Primers for TCS08 work 
Name Sequence (5'-3') Description 
AP70 GACCATGATTACGCCAAG Forward primer to isolate 3' end oL1pASl, 
LJpRPL7 andLJpRPL50. Specific for inserted 
plasmid (pAS 1) DNA 
RPL22 GTCACGACGTTGTAAAAC Reverse primer to isolate 3' end of LJpASl, 
LJpRPL7 and LJpRPL50. Specific for inserted 
plasmid (pASl) DNA 
URR8F TGACGACGAGGTAGAAAT Forward primer to isolate 5' end of LJpASl. 
Specific for chromosomal DNA 
RR08Rl TGTCCTCTCGGTTTCTCT Reverse primer to isolate 3' end of LJpASl. 
Specific for chromosomal DNA 
HK8PFW ACTCAAGGAGCATGCCAA Forward primer to isolate 5' end of LJpRPL7. 
Specific for chromosomal DNA 
HK8PR GGGTAAAGGTACTTCCTAG Reverse primer to isolate 3' end of LJpRPL7. 
Specific for chromosomal DNA 
RPLlO2 ** Forward primer to isolate 5' end of LJpRPL50. 
Specific for chromosomal DNA 
RPLlO9 GTGTCCCATCCACATCAGC Reverse primer to isolate 3' end of LJpRPL50. 
Specific for chromosomal DNA 
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RROSF GATGGATAGTGGGCTGAC Forward primer for rrOS gene to confIrm absence 
in L1pASI mutant. 
RROSR AATCCCAGCACCGACAAG Reverse primer for rrOS gene to confIrm absence 
in L1pASI mutant. 
HKOSF ATAGAGAAACCGAGAGGA Forward primer for hkOS gene to confIrm 
absence inL1pRPL7 mutant. 
HKOSR TCTACCATGAATAGCTGG Reverse primer for hkOS gene to confmn 
absence inL1pRPL7 mutant. 
Sp0644F AGACTCTAAGGAGAATCC Forward primer for spOOS2 gene to confIrm 
absence inL1pRPL50 mutant. 
Sp0644R CCTGATTGCTGATTGAGT Reverse primer for spOOS2 gene to confmn 
absence inL1pRPL50 mutant. 
4S4Pl ACGATGGCAGGTGAAAACA Forward primer to isolate rr08 gene for type 3 
and allelic replacement (Throup et aI, 2000) 
4S4P2 GCGACAACTGGGCAATCATCAA Reverse primer to isolate rr08 gene for type 3 
and allelic replacement (Throup et aI, 2000) 
Primers for TCS09 work 
Name Sequence (5'-3') Description 
4SSPI GCGGAGCCGAGTAGGAGATTCTC Forward primer to isolate rr09 gene for type 3 and 
ACC allelic replacement (Throup et aI, 2000) 
4SSP4 TGTAGAAATGACCTGACCAG Reverse primer to isolate rr09 gene for type 3 and 
allelic replacement (Throup et aI, 2000) 
RR09F GCAGCCTACGATATGGAA Forward primer for RT -PCR of rr09 gene, region A 
RR09R CCTCAATATCCTGACGAG Reverse primer for RT-PCR ofrr09 gene, region A 
MsrAF CAGTTAGCCAAGGAGGAA Forward primer within msrA gene 
MsrAR TGACATGGACGGTTTCTG Reverse primer within msr A gene 
ZmpR ACAGATGCTTCTGTCCCT Reverse primer within zmpB gene 
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Primers for ZmpB work 
Name Sequence (5'-3') Description 
ZmpUp AGTCTTACCCAAGCTGGTTCC Forward primer for isolation of zmpB gene 
(Berge et aI, 2001) 
ZmpDo CCCCCAAAGTCCTAAAATCA Reverse primer for isolation of zmpB gene 
(Berge et aI, 2001) 
MP128 TACTAGCGACGCCATCTATGTG Primer specific for Mariner cassette (Berge 
et aI, 2001) 
ZmpIntF1 GTAGTTCCGGATGACACA Forward primer for RT-PCR ofzmpB gene, 
region 1 
ZmpIntR1 TTGAGGTGCTTGGAGAAC Reverse primer for RT-PCR ofzmpB gene, 
region 1 
ZmpIntF2 GAGCGATGGCGAAGATTT Forward primer for RT-PCR ofzmpB gene, 
region 2 
ZmpIntR2 CACCGTATTCACCATTGG Reverse primer for RT-PCR ofzmpB gene, 
region 2 
ForBamZmp GGTCATGGATCCGGCTAATCCA Forward primer for expression of ZmpB 
ATGGGTGAG middle region. Contains BamHI restriction 
site 
RevSacZmp GGTCATGAGCTCCTAATCCTCT Reverse primer for expression of ZmpB 
GTAGTCGTCTC middle region. Contains Sac! restriction site 
and a stop codon 
ZmpseqgF TGGAGATAAAGGCTGGTG Forward primer for internal sequencing of 
expressed ZmpB middle region. 
ZmpseqgR GCTACTGGAGAAAGTACC Reverse primer for internal sequencing of i 
expressed ZmpB middle region. 
ForBamZmp2 GGTCATGGATCCGGAGACGAC Forward primer for expression of ZmpB C-
TACAGAGGAT terminal region. Contains BamHI restriction 
site 
RevSacZmp2 GGTCATGAGCTCCTATGCTTGT Reverse primer for expression of ZmpB C-
GGTGCAGT terminal region. Contains Sac! restriction 
_~te 
-_._-
---
--
Table A3 Primers used 
** RPLl02 primer supplied by Hoffman-La-Roche. Sequence not available. 
345 
Appendix 
A4 Common solutions and buffers 
Extraction Buffer (for genomic DNA preparation) 
10 ruM Tris pH 8.0 (Sigma-Aldrich, UK), 100 ruM EDTA pH 8.0 (Fisher Scientific UK Ltd.), 0.5 % SDS 
(w/v)(Fisher Scientific Ltd.UK). 
TE (Tris-EDTA) Buffer pH7.4 
10 ruM Tris-Cl (pH 7.4, Sigma-Aldrich, U.K.) 
1 ruM EDTA (pH 8.0, Fisher Scientific U.K. Ltd.) 
PBS, pH 7.4 
One tablet (phosphate buffered saline tablets, Dulbecco A, Oxoid Ltd. Basingstoke) was dissolved in 100 ml dH20 
and autoclaved. 
DNA Gel Loading Buffer (6x) 
0.25 % Bromophenol Blue (Sigma-Aldrich) 
0.25 % Xylene cyanole FF 
40 % (w/v) sucrose in dH20 
Protein Gel Sample Buffer (5x) 
60 ruM Tris-HCl (pH 6.8) 
25 % glycerol 
2%SDS 
14.4 ruM 2-mercaptoethanol 
0.1 % bromophenol blue 
Protein Gel Running Buffer (lx) 
25 ruM Tris 
192 ruM glycine 
0.1 % SDS 
1 % Agarose 
1 g agarose (GibcoBRL) 
100 ml T AE buffer 
1 Kb Ladder 
10 III DNA gel loading buffer (6x) 
50 III DNA ladder (GibcoBRL) 
1 x sse 
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0.15 MNaCI 
0.015 M sodium citrate 
Coating buffer for ELISA 
11.8 g Na2HP04 
16.1 g NaH2P04 
Made up to 1 L with dH20 
Wash buffer for ELISA 
PBS + 0.05 % Tween-20 [polyoxyethylene sorbitol monolaurate] (Sigma-Aldrich, UK) 
Assay diluent for ELISA 
PBS + 10 % heat inactivated FCS (Gibco BRL, Life Technologies) 
Working detector for ELISA 
Appendix 
Assay diluent + biotinylated detection antibody + avidin-horseradish peroxidase conjugate (1 :350 dilution, unless 
stated otherwise) 
TMB substrate solution for ELISA 
Equal volumes ofTMP Peroxidase Substrate (containing 3,3',5,5'-tetramethylbenzidine) and Peroxidase Solution B 
(containing H20 2 in citric acid buffer) (KPL Laboratories/Insight Biotechnologies) 
Prepared within 15 min of use 
Stop solution for ELISA 
10 % phosphoric acid (H3P04) 
BHI contents 
Calf brain infusion solids, beef heart infusion solids, protease peptone, glucose, NaCI, disodium phosphate 
Growth media for tissue culture 
(all reagents from Gibco BRL, Life Technologies) 
RPMI1640 
10 % heat inactivated FCS 
50 IU ml- l penicillin 
50 ~g mrl streptomycin 
Coomassie Blue 
250 mg Coomassie Blue R250 (Sigma-Aldrich, UK.) was dissolved in 100 ml ethanol:dH20 (1:1 v/v). 50 ml of 
acetic acid:dH20 (1: 1 v/v) added and the stain filtered through a Whatman No.1 filter. 
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Destain for SDS-PAGE 
500 ml dH20 
400 ml ethanol 
100 ml acetic acid 
Transfer Buffer, pH 8.1-8.4 for Western blot 
25 mM Tris (Sigma-Aldrich, U.K.) 
192 mM glycine 
20 % (v/v) methanol 
Developing solution for Western blot 
30 mg 4-chloro-l-napthol (Sigma-Aldrich, UK.) dissolved in 10 ml methanol. 
50 ml Tris NaCl, pH 7.4 
30 ilL H20 2 (30 % w/w, Sigma-Aldrich) 
Pre-hybridisation solution for microarrays 
(in 50 ml dH20) 
8.75 ml20 x sse 
250 III 20 % SDS 
5 ml BSA (100 mg ml- l) 
Wash A for microarrays 
(in 400 ml dH20) 
20 ml20 x sse 
1 ml20 % SDS 
Wash B for microarrays 
(in 400 ml d H20) 
1.2 ml 20 x sse 
AS U sefnl Web Addresses 
MLST database 
BLAST 
PubMed 
The Institute of Genomic Research 
Bacterial Microarray Group, St. Georges 
Sanger centre, Artemis Software 
http://fi-srvmlstl-ide.sm.med.ic.ac. uk/newl 
http://www.ncbi.nlm.nih.gov:80/BLAST/ 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi 
http://www.tigr.org/ 
http://www.sghms.ac.uk/depts/medmicro/bugs/ 
http://www.sanger.ac . uk/Software/Alienus 
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A6 ZmpB Alignments 
Figures on following pages. Alignments were performed using the ClustalIV programme for multiple alignments 
(DNAStar) and dashes within alignments were introduced by this software programme. 
Figure A6a Alignment of ZmpB from strains G54, R6 and TIGR4 
Protein alignment of ZmpB from strains G54 (top sequence), R6 (middle sequence) and TIGR4 (lower sequence). 
The arrow represents the signal peptidase site and the boxed region shows the LPxTG motif. The thick, unbroken 
black line above the sequence and the black broken line represent the HETTH zinc binding motif with the conserved 
glutamate (E) residue 20 amino acids downstream, respectively. Identical residues between all 3 strains are shaded 
in red. Residues displaying similarity are not shown. The TIGR4 and R6 sequences have 40 % identity, whilst 
TIGR4 and G54 have 41 % identity across the whole protein (excluding the first 300 amino acids / homologous 
region). Identity between strains G54 and R6 is discussed below. 
Figure A6b Alignment of ZmpB from strains G54 and R6 
Protein alignment of ZmpB from strains G54 (top sequence), R6 (lower sequence). Identical residues between the 
strains are shaded in red. Residues displaying similarity are not shown. The sequences show 67 % identity across the 
whole protein (excluding the first 300 amino acids / homologous region). 
Figure A6c Alignment of ZmpB from G54, R6 and TIGR4 with Hie / Pspc from strain A66 
Alignment of regions of ZmpB from different strains showing homology with N-terminal region of PspC of strain 
A66 (type 3). This region in strain A66 is thought to be involved in binding complement factor H, and has been 
designated Hic (factor H inhibitor of £omplement, Janulczk et aI., 2000). The numbers to the left of the figure 
represent actual protein residues of PspC or ZmpB. Identical residues are shaded in red. Residues displaying 
similarity are not shown. All three ZmpB proteins display approximately 35 % identity and 47 % similarity to this 
region ofPspC of A66. 
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